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Abstract 
Resistance to anticancer therapy represents a major barrier in the successful 
management of human breast cancer. The identification of novel biomarkers that 
correlate with treatment response would increase our understanding of the resistance 
mechanisms and may allow therapy to be tailored on an individual patient basis. Those 
patients unlikely to respond to a particular treatment strategy would be spared the 
serious life-threatening side effects for no therapeutic gain. The immediate 
implementation of a more appropriate treatment strategy may also prevent disease 
progression and such biomarkers would also suggest new drug targets and/or sensitising 
agents for future therapeutic intervention. 
The primary aim of this thesis was to establish and optimise two-dimensional gel 
electrophoresis (2DE) and matrix-assisted laser desorption/ ionisation time-of-flight 
mass spectrometry (MALDI-TOF MS) and to exploit this global proteomics approach to 
identify molecular markers associated with resistance to anticancer therapy in human 
breast cancer cells. This technique was applied to compare the MCF7 cell line with 
novel derivatives displaying significant resistance to cisplatin (MCF7CR) and 
radiotherapy (MCF740Gy). Differentially expressed proteins were identified by 
MALDI-TOF MS analysis. Several molecular markers have been identified, which may 
play a role in resistance to anticancer therapy. Western blotting was used to confirm the 
expression of selected targets and to ensure the accuracy of protein identification. 
Examples of those targets which were confirmed by western blotting include GST-M3, 
cytokeratin 17, peroxiredoxin 4 and HSP27 (which were associated with cisplatin- 
resistance) and L-Plastin, GST-M3 and cytokeratin 17 (which were associated with 
radio-resistance). These provide interesting targets and are worthy of further studies. 
Although 2DE-MALDI-TOF MS remains the gold standard for the global analysis of 
protein expression this technique is associated with several drawbacks. The antibody 
microarray is a powerful new technique designed to overcome many of these drawbacks 
and provides complementary information. Antibody microarrays were applied to 
identify further molecular markers associated with resistance to anticancer therapy in 
human breast cancer cells. The MDA-MB-231 cell line and a novel derivative (MDA- 
MB-231DR) displaying significant resistance to doxorubicin were analysed using 
Panorama Cell Signalling antibody microarrays (Sigma-Aldrich) comprised of 224 
antibodies. Several proteins were associated with resistance to doxorubicin and some 
proteins were confirmed by western blotting. These targets included p-ERK, cyclin D2 
and cyclin B 1. The technique was subsequently extended using the Labvision Antibody 
Microarray Kit (Neomarkers) to analyse the MCF7 parental cell line and the derivative 
(MCF740Gy) displaying significant resistance to radiotherapy. The Labvision antibody 
microarrays were comprised of 720 antibodies. Results indicated that this kit requires 
ftu-ther optimisation and a preliminary analysis of the data revealed that further 
developmental and statistical work is required for interpretation of the results. 
This thesis has generated a list of potential candidate proteins, which may play a role in 
the development of resistance to anticancer therapy. Some of these targets overlap 
between different treatment modalities and have been confirmed by western blotting. 
Further work is now required in order to determine the functional relevance of these 
interesting targets. Ultimately, overcoming resistance to both chemotherapy and 
radiotherapy would represent a major advance in the effective management of breast 
cancertoday. 
3 
Contents 
Acknowledgments ....................... ... 2 ......................................... ....... Abstract ................................................................................................ 3 List of Tables ................................................................................. 9 List of Figures ................................................................................... 10 List of Appendices ............................................................................. 12 List of Abbreviations ........................................................................ 12 
CHAPTERI 
A CLINICAL INTRODUCTION TO BREAST CANCER 
1.1 Epidemiology .............................................................................. 19 
1.2 Aetiology .................................................................................... 19 
1.3 Anatomy of the Breast ................................................................. 19 
1.4 Breast Pathology ........................................................................... 21 1.4.1 Ductal Carcinoma In Situ ....................................................... 21 1.4.2 Lobular Carcinoma In Situ ......................................................... 23 1.4.3 Invasive Breast Carcinoma ..................................................... 23 1.4.3.1 Invasive Ductal Carcinoma/ Not Otherwise Specified ............... 24 
1.4.3.2 Carcinomas of Special Type ............................................. 24 
1.5 Staging ................................................................................... 
24 
1.6 Grading .................................................................................. 
25 
1.7 Treatment of Breast Cancer ........................................................... 
25 
1.7.1 Surgery ............................................................................ 
25 
1.7.2 Radiotherapy ........................................................................ 
28 
1.7.3 Systemic Therapy ............................................................... 
28 
1.7.3.1 Chemotherapy ........................................................... 
28 
1.7.3.2 Endocrine Therapy ......................................................... 
30 
1.7.3.3 Antibody Therapy ......................................................... 
31 
CHAPTER 11 
A MOLECULAR INTRODUCTION TO BREAST CANCER 
2.1 The Molecular Basis of Cancer ....................................................... 
34 
2.1.1 Cell Cycle Regulation ........................................................... 
34 
2.1.2 Apoptosis ......................................................................... 
36 
2.2 The Molecular Biology of Breast Cancer ........................................... 
39 
2.2.1 Oncogenes ........................................................................ 
39 
2.2.1.1 Human Epidermal Growth Factor Receptor 2 ...................... 
39 
2.2.1.2 c-myc ..................................................................... 
40 
2.2.2 Tumour Suppressor Genes ......................................................... 
41 
2.2.2.1 P53 ........................................................................ 
41 
2.2.2.2 BRCA Genes ............................................................... 
42 
2.2.3 Steroid Hormone Receptors .................................................... 
43 
2.2.3.1 Oestrogen Receptor ..................................................... 
43 
2.2.3.2 Progesterone Receptor ................................................. 
45 
2.3 Resistance to Anticancer Therapy .................................................... 
45 
2.3.1 Doxorubicin ...................................................................... 
46 
2.3.2 Cisplatin (cis-diamminedichloroplatinum 11) ................................ 
46 
2.3.3 Radiotherapy ........................................................................ 
47 
2.4 Mechanisms of Anticancer Therapy Resistance ....................................... 
47 
2.4.1 DNA Repair Proteins ............................................................... 48 
4 
2.4.1.1 Nucleotide Excision Repair ................................ 48 ........... 2.4.1.2 Mismatch Repair ........................................................ 49 2.4.1.3 Base Excision Repair ....................................... 49 ............... 2.4.1.4 DNA-Dependent Protein Kinase 
.......................... 50 ............ 2.4.2 Cell Cycle and Apoptotic Proteins .............................. 51 .................. 2.4.2.1 p53 .................................................. 51 ...................... 2.4.2.2 The Bcl-2 Family 
................................................ 51 ....... 2 4 3 Detoxification Proteins . . ............................................................ 53 2.4.4 Drug-Transport Proteins 
....................................... 53 ................. 2.4.4.1 P-Glycoprotein 
.................................. 53 ........................ 2.4-4.2 Multidrug Resistance Protein 
............................................. 54 2.4.4.3 Breast Cancer Resistance Protein 55 ....................................... 2.4.5 Drug Targets 
........................................................................ 2.5 Clinical Relevance of Anticancer Therapy Resistance ............................. 
55 
55 
CHAPTER III 
AN INTRODUCTION TO PROTEOME ANALYSIS TECHNIQUES AND THEIR 
USE IN THE STUDY OF RESISTANCE TO ANTICANCER THERAPY 
3.1 Introduction 58 ................................................................................. 3 2 Genomic A roaches . pp ..................................................................... 59 3.3 Transcriptomic Approaches 
........................................................... 60 3.4 Proteomic Approaches 
......................................... 61 ........................ 3.4.1 Two-Dimensional Gel Electrophoresis and Mass Spectrometry .......... 61 3.4.1.1 Matrix-Assisted Laser Desorption/ lonisation (MALDI) 
.......... 62 3.4.1.2 Electrospray Ionisation (ESI) 
............................................. 63 3.4.1.3 ESI or MALDI? .................................. 63 .......................... 3.4.1.4 Mass Spectrometry Instrumentation and Protein Identification ... 63 3.4.1.5 The Study of Resistance to Anticancer Therapy Using 2DE-MS 67 
3.4.2 Difference In-Gel Electrophoresis (DIGE) 
....................................... 70 3.4.3 Quantitative Proteomics using Labelling Techniques ...................... 70 3.4.4 Surface-Enhanced Laser Desorption/ Ionisation-TOF MS ................. 72 3.4.5 Antibody Microarrays 
....................................................... 73 .... 3.5 Discussion and Conclusions .......................................... 75 .................... 3 6 Thesis Aims 78 . ................................................................................. 
CHAPTERIV 
MATERIALS AND METHODS 
4.1 Cell Culture .............................................................................. 80 4.2 Cell Counting .............................................................................. 81 4.3 Survival Assays ......................................................................... 81 
4.3.1 The MTT Assay .................................................................. 82 
4.3.2 The Modified Colony Counting Assay .......................................... 83 4.4 Two-Dimensional Gel Electrophoresis 
.............................................. 84 4.4.1 Protein Extraction .................................................................. 84 
4.4.2 Protein Quantification ........................................................... 85 
4.4.3 Sample Preparation .............................................................. 86 
4.4.4 Isoelectric Focusing ............................................................. 87 
4.4.5 Equilibration ...................................................................... 88 
4.4.6 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
.......... 89 4.4.7 Protein Visualisation ............................................................. 89 
4.4.7.1 Biosafe Coomassie Blue 
............................................... go 
5 
4.4.7.2 Silver Staining .................................... 91 ....................... 4.4.8 Image Acquisition and Data Analysis .............................. 92 ........... 4 5 In-Gel Digestion . ........................................................................... 4 5 1 Reduction and Alkylation 
92 
. . ......................................................... 93 4.5.2 Washing of the Gel Pieces ............................... 93 ....................... 4.5.3 Tryptic Digestion 
........................................ 94 ........................ 4.5.4 Peptide Extraction 
...................................... 94 ............................ 4.6 Matrix-Assisted Laser Desorption/ lonisation Time-Of-Flight MS ............. 95 4.7 Antibody Microarrays 
......................................... . 96 . ....................... 4.7.1 The Sigma-Aldrich PanoramaTm Cell Signalling Antibody Microarray 
Kit 
.................................................................................. 96 4.7.1.1 Protein Extraction 
... * ** ,***"***- 97 **,, '' -*-*, *-*, "' 4.7.1.2 Protein Quantification 
.................................................. 97 4.7.1.3 Fluorescent Labelling of Proteins ..................................... 98 4.7.1.4 Hybridisation 
.................................................. 99 ........... 4.7.1.5 Data Analysis 
............................................................ 100 4.7.2 The Labvision Antibody Microarray Kit ..................................... 101 4.7.2.1 Protein Extraction 
......................................................... 102 4.7.2.2 Protein Quantification 
.................................................. 103 4.7.2.3 Fluorescent Labelling of Proteins ....................................... 104 4.7.2.4 Hybridisation 
............................................................... 105 4.7.2.5 Data Analysis ............................................................ 106 4.8 Western Blotting ........................................................................ 107 4.8.1 Protein Extraction 
.................................................................. 107 4.8.2 Protein Quantification 
........................................................... 107 4.8.3 Immunoblotting 
..................................................................... 108 4.8.4 Detection of House-Keeping Proteins ......................................... III 4.8.5 Image Analysis ................................................................... III 
CHAPTER V 
ESTABLISHMENT AND OPTIMISATION OF 2DE AND MALDI-TOF MS 
5.1 Two-Dimensional Gel Electrophoresis .............................................. 113 
5.1.1 Sample Preparation ................................................................. 113 
5.1.1.1 Chaotropes .................................................................. 115 
5.1.1.2 Detergents .................................................................. 115 
5.1.1.3 Reducing Agents ........................................................ 116 
5.1.1.4 Additional Constituents ................................................ 
116 
5.1.2 Isoelectric Focusing ............................................................. 
116 
5.1.2.1 Protein Load ............................................................. 
121 
5.1.2.2 Rehydration and Sample Application ................................ 
123 
5.1.2.3 IEF Conditions .......................................................... 
124 
5.1.2.4 Removal of Contaminants ................................................ 
125 
5.1.3 Equilibration ...................................................................... 
127 
5.1.4 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis ............. 127 
5.1.5 Protein Visualisation ............................................................... 
128 
5.1.5.1 Coomassie Blue versus Silver Stain .................................. 
129 
5.1.6 Image Acquisition and Analysis ............................................... 132 
5.2 Matrix-Assisted Laser Desorption/ lonisation Time-Of-Flight MS ............. 
134 
5.2.1 In-Gel Digestion .................................................................. 134 
5.2.2 Sample Preparation .............................................................. 136 
5.2.3 Identification of Purified Proteins ................................................ 137 
6 
5.2.3.1 Sensitivity ................................................................ 141 
5.2.3.2 Determining the Source of Contamination .......................... 143 5.2.3.3 ZipTips versus Vivapureg C18 Micro-Spin Columns ............. 145 5.2.3.4 Peptide Losses ........................................................... 145 5.2.3.5 Peptide Modifications 
.................................................. 149 5.3 Conclusion ................................................................................. 152 
CHAPTER VI 
THE PROTEOMIC ANALYSIS OF CISPLATIN RESISTANCE IN HUMAN 
BREAST CANCER CELLS 
6.1 Introduction .............................................................................. 154 6.2 Materials and Methods ................................................................. 155 6.2.1 Cell Lines ......................................................................... 155 6.2.2 Assessment of In- Vitro Cisplatin Resistance ................................. 155 6.2.3 2DE and MALDI-TOF MS ..................................................... 155 6.2.4 Western Blotting ................................................................. 156 6.3 Results .................................................................................... 156 6.3.1 Establishment of the MCF7CR Cell Line ....................................... 156 6.3.2 Two-Dimensional Gel Electrophoresis .......................................... 157 6.3.3 Identification of Differentially Expressed Proteins ......................... 160 6.3.4 Western Blot Analysis ........................................................... 
163 
6.4 Discussion ............................................................................... 
163 
6.4.1 GST-M3 ........................................................................... 
165 
6.4.2 Cytokeratin 17 .................................................................... 
167 
6.4.3 Peroxiredoxin 4 ..................................................................... 
169 
6.4.4 Heat Shock 27-kDa Protein I ................................................... 
170 
6.4.5 Ribosomal Protein PO ............................................................ 
172 
6.4.6 Proteasome Beta 1 Subunit ..................................................... 
172 
6.4.7 Discussion and Conclusion ..................................................... 
175 
CHAPTER VII 
THE PROTEOMIC ANALYSIS OF RADIOTHERAPY RESISTANCE IN HUMAN 
BREAST CANCER CELLS 
7.1 Introduction .............................................................................. 
183 
7.2 Materials and Methods ................................................................. 
184 
7.2.1 Cell Lines ......................................................................... 
184 
7.2.2 Assessment of In- Vitro Radiotherapy Resistance 186 
7.2.3 2DE and MALDI-TOF MS ..................................................... 
186 
7.2.4 Western Blotting ................................................................. 
186 
7.3 Results .................................................................................... 
187 
7.3.1 Establishment of the MCF740Gy Cell Line .................................... 
187 
7.3.2 Two-Dimensional Gel Electrophoresis .......................................... 
187 
7.3.3 Identification of Differentially Expressed Proteins ......................... 
191 
7.3.4 Western Blot Analysis .......................................................... 
191 
7.4 Discussion ............................................................................... 
194 
7.4.1 GST-M3 .............................................................................. 
195 
7.4.2 Keratin 17 ......................................................................... 
198 
3 L-Plastin ........................................................................... 4 7 
199 
. . 
7.4.4 Ribosomal Protein PO ............................................................ 
200 
7.4.5 Proteasome Activator Subunits ................................................ 
201 
7.4.6 Discussion and Conclusion ..................................................... 
203 
7 
CHAPTER VIII 
THE ANALYSIS OF DOXORUBICIN RESISTANCE IN BREAST CANCER 
CELLS USING ANTIBODY MICROARRAYS 
8.1 Introduction .............................................................................. 8.1.1 Antibody Microarray Surface Chemistries and Coupling Schemes ...... 
207 
209 
8.1.1.1 Derivatized Glass Slides ............................................... 209 8.1.1.2 Oriented Surfaces for Tagged Antibodies .............................. 213 8.1.1.3 Three-Dimensional Surfaces ............................................. 213 8.1.2 Antibody Printing ................................................................ 8.1.3 Detection Methods ............................................................... 
214 
215 
8.1.3.1 Labelled Proteins ........................................................ 215 8.1.3.2 Sandwich Assays ........................................................ 216 8.1.3.3 Direct Measurement .................................................... 217 8.1.4 Commercial versus Custom Antibody Microarrays ........................ 218 8.2 Materials and Methods ................................................................. 220 8.2.1 Cell Lines ......................................................................... 220 8.2.2 Assessment of In- Vitro Doxorubicin Resistance ............................ 220 8.2.3 Antibody Microarrays ........................................................... 220 8.2.4 Western Blotting ................................................................. 221 8.3 Results .................................................................................... 221 8.3.1 Establishment of the MDA-MB-23 I DR Cell Line .......................... 221 8.3.2 Antibody Microarrays ........................................................... 221 8.3.3 Western Blot Analysis 
.......................................................... 
224 
8.4 Discussion ............................................................................... 225 8.4.1 Mitogen-Activated Protein Kinase-Activated Monophosphotyro sine .... 228 8.4.2 Cyclins ............................................................................ 231 8.4.2.1 Cyclin D2 ................................................................ 231 8.4.2.2 Cyclin BI................................................................ 231 
8.4.3 Heterogeneous Nuclear Ribonucleoprotein M3-M4 232 
8.4.4 Discussion and Conclusion ..................................................... 233 
CHAPTERIX 
THE ANALYSIS OF RADIO-RESISTANCE IN HUMAN BREAST CANCER 
CELLS USING ANTIBODY MICROARRAYS 
9.1 Introduction .............................................................................. 
237 
9.2 Materials and Methods ................................................................. 
239 
9.2.1 Cell Lines ......................................................................... 
239 
9.2.2 Antibody Microarrays ........................................................... 
239 
9.2.3 Western Blotting ................................................................. 
239 
9.3 Results and Discussion ................................................................. 
240 
9.3.1 Establishment of the MCF740Gy Cell Line .................................... 240 
9.3.2 Antibody Microarrays ........................................................... 
240 
9.3.2.1 Work in Progress ........................................................ 
240 
9.3.2.2 Preliminary Data Analysis ............................................. 
244 
9.3.3 Western Blot Analysis .......................................................... 
246 
9.4 Conclusion ............................................................................... 
247 
CHAPTER X 
CONCLUDING REMARKS 
10.1 Concluding Remarks .................................................................. 
253 
10.2 Future Perspectives ................................................................... 
261 
8 
10.2.1 Unidentified Proteins .......................................................... 261 
10.2.2 The In- Vitro Functional Relevance .......................................... 262 10.2.3 Clinical Samples ............................................................... 262 10.3 Conclusion ............................................................................. 265 
References .................................................................................... 266 Appendix A: Suppliers and contact details ...................................... . 287 ...... .. Appendix B: The calculation used for cell counting .................................... 288 Appendix C: Equations used to calculate the D/P ratio for the Panorama Cell 
Signalling Antibody Microarrays 
.......................................... 288 Appendix D: Equations used to calculate the D/P ratio for the Labvision 
Antibody Microarrays ......................................................... 288 
Appendix E: Result sheets obtained from the successful identification of 
cytochrome C ................................................................. 289 Appendix F: The database of contaminants used to edit the PMFs prior to 
database searching ........................................................... 293 
Appendix G: The potential relevance of those additional targets, which may play 
a role in cisplatin resistance but require confirmation ................. 296 
Appendix H: The potential relevance of those additional targets, which may play 
a role in radio-resistance but require confirmation ..................... 299 
Appendix 1: The complete list of antibodies arrayed upon Panorama Cell 
Signalling Antibody Microarrays .......................................... 
302 
Appendix J: The complete list of antibodies arrayed upon Labvision Antibody 
Microarrays ................................................................... 
302 
List of Tables 
Table I -I A summary of breast cancer risk factors .............................. 
20 
Table 1-2 TNM criteria for breast cancer staging ............................... 
26 
Table 1-3 Stage grouping of TNM subsets ....................................... 
26 
Table 1-4 The modified Bloom and Richardson system for the grading of 
breast turnours ............................................................ 
27 
Table 1-5 The main classes of chemotherapeutic agents used in the 
treatment of breast cancer .............................................. 
30 
Table 3-1 Summary of studies utilising 2DE and MS for the analysis of 
chemotherapy resistance in cancer .................................... 
69 
Table 4-1 The IEF protocol exploited for pH4-7 and pH7- 10 11 cm IPG 
strips using the Protean IEF Cell ....................................... 
89 
Table 5-1 Search parameters used for protein identification ................... 139 
Table 5-2 A summary of results comparing ZipTips with Vivapure(VC18 
micro-spin columns for sample preparation .......................... 
146 
Table 5-3 Effect of the guanidination of BSA at a concentration of 2ýtg 148 
Table 5-4 The use of variable and fixed modifications for database 
searching .................................................................. 
151 
9 
Table 6-1 Proteomics data for all assigned proteins associated with 
cisplatin resistance in human breast cancer cells .................... 162 Table 6-2 Targets were ranked by their level of importance ................... 166 
Table 7-1 Proteomics data for assigned proteins associated with radio- 
resistance in human breast cancer cells ............................... 193 Table 7-2 Targets were ranked by their level of importance ................... 196 
Table 8-1 Types of Protein Microarrays .......................................... 210 Table 8-2 Proteins identified as significantly differentially expressed 
between the MDA-MB-231 and MDA-MB-231DR cell lines 
from the antibody microarray experiments ........................... 225 
Table 10- 1 All targets were ranked by their level of importance ............... 254 
List of Figures 
Figure I -I A Anatomy of the breast ................................................ 22 Figure I-IB Terminal Ductal Lobular Unit (TDLU) 
............................ 22 
Figure 2-1 The cell cycle and regulation of the G, checkpoint ............... 35 Figure 2-2 A schematic representation of apoptosis ........................... 37 
Figure 3-1 Matrix-assisted laser desorption/ ionisation time-of-flight mass 
spectrometer ............................................................ 65 Figure 3-2 Surface-enhanced laser desorption/ ionisation time-of-flight 
mass spectrometry ..................................................... 73 Figure 3-3 The principles of an antibody microarray experiment ............ 74 
Figure 4-1 BSA standard curve ................................................... 86 Figure 4-2 Precision Plus Dual Colour molecular weight standards (Bio- 
Rad) consisting of 10 recombinant pre-stained proteins with 
molecular weights ranging from 10 to 250-kDa .................. 90 Figure 4-3 Cruz Marker molecular weight standards (Santa Cruz) 
consisting of 6 recombinant unstained proteins with molecular 
weights ranging from 23 to 132-kDa ............................... 109 
Figure 4-4 Assembly of the transfer cassette for western blotting ........... 110 
Figure 5-1 Workflow of a typical 2DE experiment ............................ 114 
Figure 5-2 Non-linear IPG strips ................................................. 119 
Figure 5-3 Increased resolution using medium pH range IPG strips ......... 120 
Figure 5-4 Differential protein loads ............................................. 122 
Figure 5-5 Removal of contaminants ............................................. 126 
Figure 5-6 Comparison of protein stains ......................................... 131 
Figure 5-7 Reflectron MALDI-TOF MS ........................................ 138 
Figure 5-8 Peptide mass fingerprints ............................................. 140 
Figure 5-9 Serial dilutions of purified proteins ................................. 142 
Figure 5-10 PMF for a cytochrome C tryptic digest ............................. 144 
Figure 6-1 Dose response curve demonstrating the relative resistance of 
10 
MCF7 and MCF7CR cell lines to cisplatin over the 
concentration range of 0- 1 l7pM ...................... 157 Figure 6-2 .............. Representative 2D guassian patterns for the MCF7 and MCF7CR cell lines in the pH range 4-7 ................... 158 Figure 6-3 ........ Representative gels showing identified proteins that were differentially expressed between the MCF7 parental cell line 
Figure 6-4 
and MCF7CR .......................................................... Relative expression levels of the differentially expressed 
159 
proteins for which identities have been assigned .................. 161 Figure 6-5 Confirmation of 2DE results by western blotting ................. 164 Figure 6-6 The 26S proteasome ........................... 174 Figure 6-7 ........................ The RNA interference pathway ...................................... 179 
Figure 7-1 The experimental set-up required for the irradiation of cell 
populations ............................................................. 185 Figure 7-2 Dose response curve demonstrating the relative resistance of 
MCF7 and MCF740Gy cell lines to single fractions of ionising 
radiation over the range 0- 1 OGy ..................................... 188 Figure 7-3 Representative 2D guassian patterns for the MCF7 and 
MCF740Gy cell lines in the pH range 4-7 ......................... 189 Figure 7-4 Representative gels showing identified proteins that were 
differentially expressed between the MCF7 parental cell line 
and MCF740Gy ........................................................ 190 Figure 7-5 Relative expression levels of the differentially expressed 
proteins for which identities have been assigned .................. 192 Figure 7-6 Confirmation of 2DE results by western blotting ................. 194 
Figure 8-1 The fabrication of an antibody microarray ......................... 210 Figure 8-2 A comparison of the three main surface chemistries for the 
immobilisation of antibodies onto glass-based microscope 
slides ..................................................................... 211 Figure 8-3 Dose response curves demonstrating the relative resistance of 
MDA-MB-231 and MDA-MB-231DR cell lines to 
doxorubicin over the concentration range of 0-400riM ........... 222 Figure 8-4 A representative antibody microarray post-hybridisation with 
fluorescently-labelled protein ........................................ 223 
Figure 8-5 A representative dye-swapped feature .............................. 224 
Figure 8-6 Confirmation of the antibody microarray results by western 
blotting .................................................................. 
226 
Figure 9-1 Poor spot morphology on the Labvision antibody microarrays 
in comparison with the Panorama Cell Signalling antibody 
microarrays ............................................................. 
242 
Figure 9-2 Western blotting revealed that the down-regulation of cyclin C 
or the up-regulation of MyD88 and Bak could not be 
confirmed suggesting that these proteins are false-positive 
targets from the Labvision antibody microarrays ................. 248 
II 
List of Appendices 
Appendix A Suppliers and contact details 
Appendix B The calculation used for cell counting 
Appendix C Equations used to calculate the D/P ratio for the Panorama Cell 
Signalling Antibody Microarrays 
Appendix D Equations used to calculate the D/P ratio for the Labvision 
Antibody Microarrays 
Appendix E Result sheets obtained from the successful identification of 
cytochrome C 
Appendix F The database of contaminants used to edit the PMFs prior to 
database searching 
Appendix G The potential relevance of those additional targets, which may 
play a role in cisplatin resistance but require confirmation 
Appendix H The potential relevance of those additional targets, which may 
play a role in radio-resistance but require confirmation 
Appendix I The complete list of antibodies arrayed upon Panorama Cell 
Signalling Antibody Microarrays 
Appendix J The complete list of antibodies arrayed upon Labvision 
Antibody Microarrays. 
List of Abbreviations 
2DE Two-Dimensional Gel Electrophoresis 
5FU 5-Fluorouracil 
aaRS Aminoacyl-tRNA Synthetases 
ABC ATP-Binding Cassette 
AbMA Antibody Microarray 
ACN Acetonitrile 
ACTN4 Actinin Alpha 4 
ADP Adenine Diphosphate 
AIF Apoptosis Inducing Factor 
ALL Acute Lymphoblastic Leukaemia 
ANN Artificial Neural Network 
ANOVA Analysis of Variance 
AP-1 Activating Protein 1 
APAF-l Apoptotic Protease Activating Factor I 
ARDI Arrest Defective I Protein 
ATM Ataxia Telangiectasia Mutated 
ATP Adenine Triphosphate 
BCL-2 B-Cell CLL/ Lymphoma 2 
BCRP Breast Cancer Resistance Protein 
BCT Breast Conservation Therapy 
BER Base Excision Repair 
BRCAI Breast Cancer Susceptibility Gene 1 
BRCA2 Breast Cancer Susceptibility Gene 2 
BSA Bovine Serum Albumin 
C1 70RF25 Chromosome 17 Open Reading Frame 25 
Caý+ Calcium 
CA4 Combretastatin A4 
12 
CAD Caspase Activated DNase 
CAM Carbamidomethyl 
CDDP Cisplatin 
CDK Cyclin Dependent Kinase 
CDKi Cyclin Dependent Kinase Inhibitor 
cDNA Copy Dioxyribose Nucleic Acid 
CGH Comparative Genomic Hybridisation 
CH Calponin Homology 
CHAPS 3- [(3 -cholamidopropyl)dimethylammonio] -I -propanesulfonate CHCA a-Cyano-4-Hydroxycinnamic Acid 
CID Collision Induced Dissociation 
CK Cytokeratin 
cm Centimetre 
CNS Central Nervous System 
COP9 Constitutive Photomorphogenesis 9 
Cy-3 Cyanine 3 
Cy-5 Cyanine 5 
dATP Deoxy Adenine Triphosphate 
DCIS Ductal Carcinoma In-Situ 
DHB 2,5 Dihydroxybenzoic Acid 
DIGE Difference In-Gel Electrophoresis 
DMSO Dimethylsulfoxide 
DNA Dioxyribose Nucleic Acid 
DNA-PK DNA-Dependent Protein Kinase 
DOX Doxorubicin 
D/P Dye to Protein Molar Ratio 
DSB Double Stranded Break 
DTT Dithiothreitol 
ECL Enhanced Chemiluminescence 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor 
eIF2 Eukaryotic Translation Initiation Factor 2 
eIF3 Eukaryotic Translation Initiation Factor 3 
eIF5 Eukaryotic Translation Initiation Factor 5 
ELISA Enzyme-Linked Immunosorbent Assay 
EMBL European Molecular Biology Laboratory 
ER Oestrogen Receptor 
ERCCI Excision Repair Cross Complementing I 
ERE Oestrogen Receptor Responsive Element 
ERKI Extracellular Signal Regulated Kinase I 
ERK2 Extracellular Signal Regulated Kinase 2 
ESI Electrospray Ionisation 
ETFB Electron Transfer Flavoprotein Beta 
FADD Fas Associated Death Domain 
FCS Foetal Calf Serum 
9 Gram 
9 Gravities 
GAPDH Glyceraldehyde-3 -Phosphate Dehydrogenase 
GI Gastrointestinal 
GIG5 Growth Inhibiting Gene 5 
GLOI Glyoxalase I 
13 
GLOII Glyoxalase II 
GSH Glutathione 
GST Glutathione-S-Transferase 
GSTM3 Glutathione-S-Transferase Mu 3 
GTP Guanosine Triphosphate 
Gy Gray 
H Hydrogen 
H202 Hydrogen Peroxide 
hARD1 Human Arrest Defective 1 Protein 
HER Human Epidermal Growth Factor RecePtor 
HIP Hypoxia Inducible Factor 
HIS Histidine 
HnRNP Heterogeneous Nuclear Ribonucleoprotein 
HPGD Hydroxyprostaglandin Dehydrogenase 15-(NAD) 
HPLC High Performance Liquid Chromatography 
Hr Hour 
HRP Horseradish Peroxidase 
HSP Heat Shock Protein 
HSP27 Heat Shock 27-kDa Protein I 
IAA lodoacetamide 
IAP Inhibitor of Apoptosis Protein 
ICAD Caspase Activated DNase Inhibitor 
ICAT Isotope Coded Affinity Tagging 
ICC Immunocytochernistry 
IDC Invasive Ductal Carcinoma 
IEF Isoelectric Focusing 
IF Intermediate Filament 
IGF Insulin-like Growth Factor 
IGF- IR Insulin-like Growth Factor Receptor I 
IHC Immunohistochemistry 
1KB Nuclear Factor-Kappa B Inhibitor 
IL-8 Interleukin 8 
ILC Invasive Lobular Carcinoma 
INK4 Inhibitor of Cyclin Dependent Kinase 4 
IPG Immobilised pH Gradient 
IR Ionising Radiation 
IRES Internal Ribosome Entry Site 
JNK c-Jun N-Terminal Kinase 
kb, Kilo-base 
kDa. Kilo-daltons 
kv Kilo-volts 
L Linear 
L Litre 
LCIS Lobular Carcinoma In-Situ 
LEF Lymphoid Enhancing Factor 
LHRH Luteinizing Hormone Releasing Hormone 
LRP Lung Resistance Protein 
LRPPRC Leucine Rich Pentatricopeptide Repeat Containing Protein 
LysRS Lysyl-tRNA Synthetase 
M Molar 
MA Microarray 
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A CLINICAL INTRODUCTION TO BREAST CANCER 
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1.1 Epidemiology 
Clinical Introduction to Breast Cancer 
Breast cancer is the most common cancer in females and accounts for 30% of all new 
cancers diagnosed in women. One in twelve women will develop this disease during 
their lifetime. During 2002, there were approximately 41,000 new diagnoses and 13,303 
deaths from the disease in the UK (Globocan 2002). The high incidence can be partly 
attributed to breast screening programmes, which were implemented during the 1980s. 
Most breast cancers detected by screening are early stage I tumours (see section 1.5) 
with 5-year survival rates of >90%. In fact, the average 5-year survival rate for this 
disease is 73% in developed countries, which is reflected by the low rate of mortality. 
As such, breast cancer is a prevalent cancer worldwide with an estimated 4.4 million 
women alive who have had breast cancer diagnosed within the last 5 years. 
1.2 Aetiology 
The aetiology of breast cancer is multifactorial and involves a complex interplay 
between both environmental and genetic factors (summarised in Table I- 1). Age is a 
major risk factor for breast cancer. More than 80% of cases occur in women over the 
age of 50 years and only 2% of patients with breast cancer are 35 years or younger at 
the time of diagnosis (Gonzalez-Angulo et al. 2005). Women who are diagnosed with 
breast cancer at a younger age are more likely to have a genetic mutation that 
predisposes them to the development of breast cancer. BRCAI and BRCA2 are 
examples of such genes in which germline mutations are associated with a genetic 
predisposition to the development of breast cancer. These genes will be discussed 
further in section 2.2.2.2. 
1.3 Anatomy of the Breast 
The breasts are modified sweat glands which extend from below the clavicle to the level 
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Table 1-1 Summary of breast cancer risk factors (from Dumitrescu and Cotarla, 2005) 
Factors that increase breast cancer risk Magnitude of risk 
Well-confirmed Increasing age ++ 
factors Geographical region 
(western countries) 
++ 
Family history of breast cancer ++ 
Mutations in BRCAI and BRCA2 genes ++ 
Mutations in other high penetrance 
genes (e. g. p53, ATM, PTEN) 
++ 
lonising radiation exposure 
(during childhood) 
++ 
History of benign breast disease ++ 
Late age at menopause (>54) ++ 
Early age of menarche (< 12) ++ 
Nulliparity and older age at first birth ++ 
High marnmographic breast density ++ 
Hormone replacement therapy + 
Recent use of oral contraceptives + 
Obesity in postmenopausal women + 
Tall stature + 
Alcohol consumption (-I drink/day) + 
Probable factors High insulin-like growth factor I (IGF-1) 
levels 
++ 
High prolactin levels + 
High-saturated fat and well-done meat 
intake 
+ 
Polymorphisms in low penetrance genes 
(e. g. glutathione-s-transferases) 
+ 
High socioeconomic status + 
Factors tha t decrease breast cancer risk Magnitude of risk 
Well-confirmed 
factors 
Geographical region 
(far-eastern countries) 
Early age of first full-term Pregnancy 
Higher parity 
Breast feeding (longer duration) 
Obesity in premenopausal women 
Fruit and vegetable consumption 
Physical activity 
Chernopreventive agents 
Probable factors Non-steroidal anti-inflammatory drugs 
Polymorphisms in low penetrance genes 
(e. g. progesterone receptor) 
++ (moderate to high increase in risk) 
+ (low to moderate increase in risk) 
(moderate to high decrease in risk) 
(low to moderate decrease in risk) 
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of the 6thor 7 th rib and from the sternum to the axilla (Figure I -I A). The breasts lie over 
the pectoralis muscles of the chest wall and are attached by fibrous strands called 
Cooper's ligaments. Each breast is composed of approximately 15-20 lobes, which are 
embedded in subcutaneous adipose tissue. Each lobe contains many terminal ductal- 
lobular units (TDLU). The TDLU is the functional unit of the breast and is the point at 
which most breast tumours are thought to arise (Mallon et al. 2000). The TDLU 
comprises of terminal secretory lobules composed of several acini (Figure I-IB). 
Epithelial cells secrete milk into each acinus. Myoepithelial cells are interspersed 
between the epithelial cells and in response to hormonal signals, contract and squeeze 
milk into the duct of the acinus. Each lobule is connected by a branching series of ducts, 
each of which converge onto a lactiferous duct. One lactiferous duct drains each lobe, 
thus there are 15-20 of these larger ducts in each breast. Lactiferous ducts expand to 
form the ampullae, which function as reservoirs for milk and eventually open out at the 
apex of the nipple. 
1.4 Breast Pathology 
1.4.1 Ductal Carcinoma In-Situ 
Ductal Carcinoma In-Situ (DCIS) is a pre-invasive lesion resulting from the malignant 
proliferation of epithelial cells, which line the ducts. These malignant cells are confined 
within a duct. The basement membrane remains intact and there is no stromal invasion. 
DCIS accounted for only 2% of breast cancer cases prior to the implementation of 
breast screening programmes. In a screened population however, DCIS may represent 
up to 20% of all diagnosed breast cancers (Mallon et al. 2000). This is because DCIS 
usually presents as asymptomatic microcalcifications, which are tiny deposits of 
calcium in the breast that cannot be felt but are detectable on mammography. DCIS is 
composed of a heterogeneous group of lesions and early classifications relied on 
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Figure 1-1 A. Anatomy of the breast B. Terminal Ductal-Lobular Unit (TDLU). The 
TDLU is the functional unit of the breast and is the point at which most breast tumours 
arise. 
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architectural growth pattems (cribiform, solid, comedo and micropapillary). This 
system was poorly reproducible among histopathologists because in many cases within 
the same lesion there is a mixture of different growth patterns. The Van Nuys system 
was introduced in 1995 and has proved to be more useful in classifying DCIS lesions 
(Silverstein et al. 1995). This grading system is based upon nuclear grade (an evaluation 
of the size and shape of the nucleus in turnour cells and the percentage of cells that are 
actively dividing) and the presence or absence of necrosis. Lesions are classified into 3 
groups (1 -3): non-high grade lesions without necrosis (1), non-high grade lesions with 
necrosis (2) and high grade lesions with or without necrosis (3). Primary diagnosis of 
DCIS results in an 11 -fold increased risk of developing invasive disease (Wamberg et 
al. 1999). 
1.4.2 Lobular Carcinoma In-Situ 
Lobular Carcinoma In-Situ (LCIS) is a non-invasive malignant proliferation of 
epithelial cells lining the TDLU. The malignant cells are contained within the TDLU 
and there is no stromal invasion. LCIS lesions increase the risk of developing invasive 
disease by a factor 6.9-12.0 in comparison with the reference population and the risk is 
equal in both the index and contralateral breast (Anderson, 1977; Page et al. 1991; 
Salvadori et al. 1991). 
1.4.3 Invasive Breast Carcinoma 
Invasive cancers arise as the basement membrane is breached. This allows malignant 
cells to infiltrate the stroma. Invasive breast cancers fall into 2 categories: invasive 
ductal carcinomas (IDQ or carcinomas not otherwise specified (NOS) and carcinomas 
that have special morphological features, which allow the reproducible categorization 
into a special type. 
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1.4.3.1 Invasive Ductal Carcinoma/ Not-Otherwise-Specified (NOS) 
Invasive Ductal Carcinoma (IDC) (carcinoma of no special type) accounts for 60-80% 
of all diagnosed invasive breast cancers (Mallon et al 2000). IDC occurs when cancer 
cells escape the confines of the ducts and invade the surrounding tissues. This cancer is 
diagnosed on the basis of exclusion of other special types and thus this group of 
tumours is heterogeneous in nature. 
1.4.3.2 Carcinomas of Special Type 
Invasive Lobular Carcinoma (ILC) accounts for -10% of all invasive breast cancers and 
is the second most common invasive breast cancer diagnosed after IDC. This cancer has 
the tendency to be multifocal (many cancerous foci in the same breast) and bilateral 
(occurring in both breasts) and has a slightly more favourable prognosis than tumours in 
the NOS category. ILCs tend to metastasise to the central nervous system (CNS) and the 
gastrointestinal (GI) tract. This is unlike IDCs, which more commonly metastasise to 
other sites such as the lungs and brain. Other invasive carcinomas of special type 
include tubular, mucinous, papillary, medullary and inflammatory carcinoma, all of 
which account for only a small percentage (<5%) of all diagnosed breast cancers and 
exhibit their own unique morphological and pathological characteristics. 
1.5 Staging 
Disease stage is one of the most important determinants of survival and also helps the 
physician to select the most appropriate treatment option. The stage is described 
according to the extent of the disease and is based on 3 components of the TNM 
(jumour Node Metastasis) classification system: the size and location of the primary 
Tumour and the extent to which it has invaded the surrounding tissues, the extent of 
involvement of the regional lymph Nodes and Metastases in distant sites such as the 
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lungs, brain or bones (Table 1-2). Subsets of the TNM classifications are subsequently 
grouped into stages to identify those patients with similar prognoses and treatment 
options (Table 1-3). 
1.6 Grading 
Histological grade is also used to provide prognostic information. Pathologists use 
morphological characteristics to establish the degree of differentiation. Differentiation 
refers to how developed the cancer cells are in a turnour. Differentiated tumour cells 
resemble normal cells and tend to grow and spread at a slower rate than undifferentiated 
or poorly differentiated turnours, which lack the structure and function of normal cells 
and grow uncontrollably. When considered with other recognised prognostic factors the 
degree of differentiation provides some indication of how the tumour is likely to behave 
(Elston and Ellis, 199 1). A modified Bloom and Richardson grading system is most 
commonly exploited (Table 1-4). This system is based on the assessment of 3 main 
parameters: the degree of tubule formation, nuclear pleomorphism and mitotic activity. 
One to three points are awarded for each parameter and the overall grade is derived 
from a summation of individual scores. A score of 3-5 indicates Grade 1,6-7 indicates 
Grade 2 and 8-9 indicates Grade 3. Tumour grade correlates with prognosis; patients 
with Grade I tumours have a better rate of survival than patients with Grade 2 or Grade 
tumours. 
1.7 Treatment of Breast Cancer 
1.7.1 Surgery 
The most appropriate treatment option is dependent on a number of factors including 
disease stage, axillary lymph node status and performance status of the patient. Breast 
conservation therapy (BCT) followed by post-operative 
(adjuvant) radiotherapy is one 
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Table 1-2 TNM criteria for breast cancer staL), inL: y (from Durnkernmi Cnvinnlr ')oo,; ) 
Primary Tx Minimum requirement to assess the primary tumour cannot be met 
Tumour TO No evidence of primary tumour 
(T) Tis Carcinoma In-Situ 
TI Tumour <2. Ocm in dimension 
T2 Tumour >2. Ocm-5. Ocm in dimension 
T3 Tumour >5. Ocm in dimension 
T4a Extension to chest wall, not including pectoralis muscles 
T4b Edema (including peau d'orange) or ulceration of the skin of the 
breast, or satellite skin nodules confined to the same breast 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Regional 
Lymph 
Nx Minimum requirement to assess regional lymph nodes cannot be 
met 
Nodes NO No evidence of regional lymph node metastasis 
(N) NI Metastasis in 1-3 axillary lymph nodes 
N2 Metastasis in 4-9 axillary lymph nodes 
N3 Metastasis in >I 0 axillary lymph nodes 
Distant 
Metastases 
Mx Minimum requirement to assess presence of distant metastases 
cannot be met 
(M) MO No evidence of distant metastases 
MI 
mmmmm 
Distant metastases (not including ipsilateral supraclavicular lymph 
nodes) hlý 
Table 1-3 Stage grouping of TNM subsets (adapted from Duraker and Caynak, 2005). 
The 5-yr survival rates were obtained from the American Cancer Society and are based 
on women diaQnosed with breast cancer between 1995 and 1998. 
Stage TNM Subset 5-Year Relative 
Survival Rate 
0 (DCIS/ LCIS) TisNOMO 100 
I TINOMO 98 
IIA TINIMO 88 
T2NOMO 
1113 T2NIMO 76 
T3NOMO 
IIIA TIN2MO 56 
T2N2MO 
T3NIMO 
T3N2MO 
IIIB T4NOMO 49 
T4N1MO 
T4N2MO 
111C Any T, N3MO - 
IV Any T, Any N, M1 16 
*Thefive-year survival rate is not yet availablefor stage HIC as this stage has only recently been defined 
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Table 1-4 The modified Bloom and Richardson system for the grading of breast 
turnours (from Elston and Ellis, 199 1) 
Tubule Formation (% of tumour. showing distinct tubule structures) Score 
>75% 1 
10-75% 2 
<10% 
I 
Nuclear Pleomorphism Score 
Small, uniform cells I 
Moderate increase in the size and variation of cells 2 
M increase in size and variation 3 
Mitotic Activity (per 10 high power fields) Score 
Up to 7 1 
8-14 2 
>15 3 
strategy for the management of early stage disease (Stage I or 11). BCT involves surgical 
removal of the tumour and a margin of the surrounding normal tissue. Affected lymph 
nodes may also be removed. Mastectomy, involving removal of the whole breast with or 
without adjuvant radiotherapy, may be performed in cases where BCT is not possible or 
desirable. Fortunately, 70-75% of patients are eligible for BCT. Patients presenting with 
locally advanced disease (Stage III; see Table 1-3) with lymph node involvement are 
usually treated with mastectomy. In such cases, neoadjuvant chemotherapy is often 
administered in order to down-stage the disease prior to surgery. In addition, surgery is 
followed by the administration of adjuvant radiotherapy to the breast/ axilla and/ or 
systemic therapy (i. e. chemotherapy and/ or hormone therapy) to prevent recurrence. 
Alternatively, the disease may be considered too extensive for surgery (i. e. patients 
suffering from distant metastases). In such cases, the disease may 
be managed with 
radiotherapy and/ or systemic therapy alone. 
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1.7.2 Radiotherapy 
Clinical Introduction to Breast Cancer 
Adjuvant radiotherapy (RT) is administered to the breast and/ or axilla in order to 
remove residual disease. This treatment strategy has been shown to reduce local 
recurrences and recent evidence suggests that survival rates may also be improved 
(Early Breast Cancer Trialists Collaborative Group, 2000; Galper et al. 2000; Jha et al. 
2001; Noguchi, 2002; Malmstrom et al. 2003; Mokbel, 2003). Patients who undergo 
BCT receive adjuvant RT to the breast as a standard issue of care. In addition, patients 
with early-stage disease who opt for mastectomy may also be selected for RE RT is 
usually offered to those patients at high-risk of recurrence such as those patients with 
tumours larger than 5cm (T3) or when 4 or more axillary lymph nodes are involved 
(Brennan et al. 2005). However, evidence is emerging that post-mastectomy RT may 
also improve survival for women with 1-3 involved nodes in the axilla (Pierce, 2005). 
1.7.3 Systemic Therapy 
Randomised trials have shown that survival and risk of metastatic recurrence in breast 
cancer are unrelated to the nature and intensity of local treatment. In 1995, Christian et 
al. reported that long term follow-up has demonstrated that most patients with so-called 
early breast cancer develop metastatic disease, irrespective of local treatment. The only 
plausible explanation for these clinical observations is that blood-bome micrometastases 
must have been present at the time of initial diagnosis, albeit undetectable. Thus, the 
administration Of systemic therapy such as chemotherapy and hormone therapy 
is an 
important factor in reducing mortality in women with breast cancer. 
1.7.3.1 Chemotherapy 
Chemotherapy involves the administration of anti-cancer drugs and may be used in 3 
ways. Adjuvant chemotherapy may be used 
for the treatment of patients <70 years of 
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age with node positive disease or high-risk node negative disease to combat occult 
micrometastatic disease present at the time of resection and to improve survival. 
Currently, several cytotoxic agents are available for use including anthracyclines, 
taxanes, cyclophosphamide, methotrexate and 5-fluorouracil (5FU). The main classes of 
chemotherapeutic agents used in the systemic treatment of breast cancer along with their 
proposed mechanisms of action and some common examples are summarised in Table 
1-5. Combinations of these agents are considered more effective than single-agents. 
Cyclophosphamide, methotrexate and 5FU (CMF) constitute the modem foundation of 
adjuvant chemotherapy for breast cancer. More recently however, regimens containing 
anthracyclines (including doxorubicin or epirubicin) have been shown to be more 
superior to CMF. Examples of such regimens include cyclophosphamide and 
doxorubicin (also known as adriamycin) (AC); cyclophosphamide, doxorubicin and 
5FU (CAF); 5FU, doxorubicin or epirubicin and cyclophosphamide (FAC/FEC); and 
doxorubicin or AC followed by CMF (Hudis, 2005). Anthracycline-containing regimens 
(e. g. AQ may also be followed by sequential treatment with a taxane (e. g. paclitaxel or 
docetaxel). This has been shown to demonstrate superiority and may improve survival 
(Hennessy and Pusztai, 2005). The platinum-containing compound cisplatin is also 
effective and may be used as a single-agent or in combinations with other agents in the 
treatment of advanced breast cancer (Martin, 2001; Vassilomanolakis et al. 2005). In 
addition, cisplatin-based salvage treatment may be used for patients resistant to 
anthracycline-based regimens (Chehal et al. 2004; Park et al. 2005). Neoadjuvant 
chemotherapy may be offered to Patients with early stage breast cancer (Stage I and 11) 
wishing to undergo less radical surgery in order to down-stage or de-bulk the disease 
and improve survival. Chemotherapy is also administered to patients with metastatic 
breast cancer as a palliative treatment for symptomatic relief and to prolong both quality 
and quantity of life. 
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Table 1-5 The main classes of chemotherapeutic agents used in the treatment of breast 
cancer. 
Drug Classification Examples Action 
Cross Linking Agents Cisplatin Distorts the DNA molecule 
(PlatinolS, Platinol-AQV) by forming intra- and inter- 
strand cross links and 
preventing replication. 
Alkylating Agents Cyclophosphamide Alkylates DNA forming 
(CytoxanS, Neosarg) cross links and adducts 
preventing DNA, RNA and 
Antimetabolites 5-Fluorouracil 
(Adrucilg) 
Methotrexate 
(Rheumatrex(g, Trexellg) 
Anthracycline Antibiotics Doxorubicin 
(Adriamycing, Rubexg) 
Epirubicin 
(Ellence(t) 
protein synthesis. 
Antagonise the normal 
function of key enzymes 
involved in DNA synthesis 
inhibiting this process. 
Intercalate between DNA 
base pairs inhibiting DNA 
synthesis and initiating 
DNA cleavage by 
topoisomerase 11. Other 
effects include inhibition of 
key enzymes and 
production of cytotoxic free 
radicals (Epirubicin). 
Taxanes Paclitaxel Stabilise microtubules by 
(Taxol(g, Onxal(V) preventing 
Docetaxel depolymerisation inhibiting 
(Taxotereg) cell cycle progression 
through metaphase. 
Vinca Alkaloids Vinorelbine Bind tubulin and inhibit 
(Navelbineg) mitosis 
Vincristine 
(Oncovin(g, Vincasar 
PFsS) 
Vinblastine 
(Velbang, Alkaban-AQS) 
Epipodophyllotoxins Etoposide Inhibits topoisomerase II 
(Toposarg, VePesidS, preventing the replication 
EtopophosS) of DNA 
1.7.3.2 Endocrine Therapy 
Approximately three quarters of all invasive breast cancers are oestrogen receptor (ER) 
or progesterone receptor (PR) positive (Winer, 2005). These receptors are discussed 
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further in section 2.2.3. ER and PR positive tumours are dependent upon oestrogen for 
growth. Women with such cancers may derive therapeutic benefit from endocrine 
therapy. Endocrine therapy removes the influence of oestrogen on breast cancer cells 
either by blocking the hormone receptor (e. g. tamoxifen) or by reducing the production 
of oestrogen (ovarian ablation and aromatase inhibitors). The choice of endocrine agent 
administered is dependent upon menopausal status because this factor determines the 
source of oestrogen: ovarian or adrenal (Buzdar and Hortobagyi, 1998). In 
premenopausal women the ovaries actively produce high levels of oestrogen. One 
treatment option is ovarian ablation, which can be accomplished by surgery, radiation or 
luteinizing hormone-releasing hormone (LHRH) agonist therapy (e. g. goserelin). 
Tamoxifen, which is a member of a class of drugs called the selective oestrogen 
receptor modulators (SERMs), is also effective. This drug is the first-line endocrine 
treatment for both pre- and postmenopausal women with all stages of breast cancer and 
is also effective as a chernopreventive for women at high risk of developing breast 
cancer. Postmenopausal women may also be treated with aromatase inhibitors. The 
ovaries cease to function in these women and oestrogen is produced in peripheral tissues 
from androgens secreted by the adrenal gland. Aromatase is the enzyme responsible for 
this conversion, thus inhibition of aromatase with drugs including anastrozole and 
letrozole, is an effective therapeutic strategy in postmenopausal women with advanced 
breast cancer (Buzdar and Hortobagyi, 1998). Recent trials have shown that the 
adjuvant use of aromatase inhibitors is more effective than tamoxifen in preventing 
breast cancer relapse in postmenopausal women (Brennan et al. 2005). 
1.7.3.3 Antibody Therapy 
Drugs that target receptors other than hormone receptors are also available for the 
treatment of breast cancer. Herceptin is a monoclonal antibody directed against 
human 
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epidermal growth factor receptor 2 (HER-2). HER-2 is a key regulator of cell growth 
(see section 2.2.1.1). Over-expression of this receptor occurs in 20-30% of invasive 
breast cancers, which increases cell proliferation and often results in more aggressive 
turnour cells (Slamon et al. 1987). Herceptin functions by binding to HER-2 and 
blocking its function thereby slowing the growth and spread of these turnours. This drug 
is approved for the treatment of HER-2 over-expressing metastastic breast cancers 
(stage IV; see table 1-3) and is used as a first-line agent in combination with paclitaxel 
and also as a single-agent for patients who have received one or more chemotherapy 
regimens. Herceptin has also recently been approved as an adjuvant treatment in 
addition to chemotherapy in women with early HER-2 positive disease to improve 
survival. 
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2.1 The Molecular Basis of Cancer 
Molecular Introduction to Breast Cancer 
Cancer is a multi-step process believed to be driven by defects in the genes and/ or 
proteins critical for the control of cell proliferation and cell death. This allows cancer 
cells to evade the normal mechanisms of control of cell growth and proliferation. 
Genetic defects may be present in the germline (such as the inheritance of BRCAI and 
BRCA2 mutations) or may occur sporadically. Alternatively, changes may occur to the 
proteins themselves following the translation of mRNA. 
2.1.1 Cell Cycle Regulation 
The cell cycle, which controls cell growth and division, is tightly controlled by a 
number of regulatory proteins. These proteins direct the progression of cells through a 
sequence of phases: S phase during which the DNA is synthesised, M phase during 
which mitosis occurs, and 2 gap phases (GI and G2) during which RNA and proteins are 
produced and the cell reorganises for the next round of division. Quiescent cells are said 
to be in Go. Three checkpoints (GI, G2 and M) have been identified that must be 
traversed for accurate cell division. G, transition requires a critical level of regulation 
and functions to ensure the accurate transmission of genetic material. It is during this 
phase that future commitment to division, differentiation or death is made (King, 2000). 
The G2 checkpoint ensures the elimination of damaged cells that may have escaped the 
control of GI or have not accurately duplicated their DNA. Chromosomal alignment and 
retraction into daughter cells is monitored at the M checkpoint. Malignant 
transformation is often characterised by changes in the genes and/ or proteins involved 
with regulating the G, checkpoint. A family of proteins called the cyclin dependent 
kinases (cdks) are involved in this primary regulation. Cdks are activated by forming 
holoenzymes in combination with cyclins but are inhibited by cdk inhibitors (cdki) 
(Figure 2-1). A further element of G, regulation involves DNA repair. If DNA is 
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Figure 2-1 The cell cycle and regulation of the G, checkpoint. The retinoblastoma (Rb) 
protein blocks cell proliferation at G1. In its hypophosphorylated state, Rb binds to and 
inactivates the E2F transcription factor. Phosphorylation of the Retinoblastoma (pRb) 
protein by the cyclin D/ cdk4/6 complex releases and activates E2F. E2F migrates to the 
nucleus where it increases the transcription of growth stimulatory genes, including 
cyclin E. Cyclin E/ cdk2 activity is required for transition from Gj to the S phase of the 
cell cycle. Growth is inhibited by repression of the cyclin/ cdk complexes and this 
involves the cdkis. There are 2 families of cdkis. The ink4 (inhibitor of cyclin 
dependent kinase 4) family of proteins (e. g. p16) binds to cdk4 and 6, thus preventing 
attachment of the cyclin. The other family, which includes p2lwAF 1 has a wider 
specificity and binds to the cyclin/ cdk complex rather than the cdk alone. p53 activates 
p2l WAH in response to DNA damage, which prevents G, transition. DNA damage is 
then either repaired or apoptosis is induced. 
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damaged, the cell will arrest at the G, checkpoint. During cell cycle arrest this damage 
is repaired before the DNA is replicated. A major factor in the control of cell cycle 
arrest is the transcription factor p53, which regulates the transcription of p2 IWAFI. 
Under normal circumstances p53 has only a short half-life but DNA damage stabilises 
the protein, resulting in the up-regulation of p2 I 
WAF 1. 
p2 IWAFI inhibits the kinase 
activity of cyclin E/ cdk2 and cyclin D/ cdk4/6, which prevents the phosphorylation of 
Rb. E2F remains bound to Rb and is unable to activate the transcription of growth 
stimulatory genes. Down-regulation of gene transcription and inhibition of existing 
cyclin E/ cdk2 activity by p2l WAR prevents the progression of cells through the G, 
checkpoint allowing the damage to be repaired before DNA replication and cell division 
take place. If the damage is too extensive for repair, p53 is able to direct cells to 
apoptosis (see section 2.1.2) to prevent the damage from being passed to subsequent 
generations of cells. 
2.1.2 Apoptosis 
Apoptosis (programmed cell death) is a physiological mechanism whereby cells, which 
are damaged or have reached the end of their natural lives, are removed. In many cancer 
cells, defects have occurred which decrease the apoptotic potential of the cell. This 
contributes to an increase in cell number and also allows cancer cells to accrue further 
DNA damage. Apoptosis proceeds via a large number of signalling pathways; however 
execution of the process is mediated through the activation of caspases, a family of 
cysteine proteases. Caspases are synthesised as large inactive precursors (procaspases) 
from which the active enzymes are released in a cascade by proteolytic cleavage of 
aspartate residues. The role of specific caspases is discussed below. Caspases may be 
activated extrinsically by ligand-binding at the cell surface or intrinsically by release of 
cytochrome C from mitochondria (Figure 2-2). The extrinsic apoptotic pathway is 
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Figure 2-2 A schematic representation of apoptosis. The caspase cascade is activated by 
caspase 8 following interaction of extrinsic death receptors with death ligands or by 
activation of caspase 9 following the intrinsic release of cytochrome C from the 
mitochondria. Further caspases are activated, culminating in the activation of effector 
caspases, which cleave various regulatory and structural cellular proteins (e. g. actin) 
resulting in cell collapse. Finally, CAD (caspase-activated DNase) is released by 
cleavage of its inhibitor (ICAD), and is able to enter the nucleus and cleave DNA. 
37 
Molecular Introduction to Breast Cancer 
initiated by the binding of extracellular death ligands (e. g. FasL and TNFa) with their 
respective death receptors (Fas and TNFRI). The cytosolic tails of the receptors fonn a 
'death domain', which enables recruitment of the adapter proteins FADD (Fas 
associated death domain) and TRADD (TNFR associated death domain). Adapter 
proteins trigger the caspase cascade by recruiting procaspase 8, which is able to self- 
process to forrn the active caspase 8 (Muzio et al. 1998). Whereas FADD interacts 
directly with procaspase 8, TRADD acts indirectly through FADD. Caspase 8 provides 
a link between extrinsic and intrinsic pathways of apoptosis. The intrinsic pathway is 
activated by signals within the cell in response to damage such as that caused by 
anticancer therapy (see section 1.7). In addition to the activation of the caspase cascade 
caspase 8 also cleaves Bid, a pro-apoptotic member of the Bcl-2 family (discussed 
further in section 2.4.5.2). Truncated Bid (tBid) translocates to the mitochondria and 
induces the Bak- and Bax-dependent release of cytochrome C. Caspase 8 also activates 
caspase 3, which is an important effector caspase of apoptosis. Caspase 3 activates 
further downstream caspases and also promotes cytochrome C release. Cytochrome C 
binds Apaf-I (apoptotic protease activating factor-1). This requires hydrolysis of ATP 
or dATP. The Apaf-l/ cytochrome C complex recruits procaspase 9, which undergoes 
autocatalysis to form active caspase 9. Caspase 9 is an initiator caspase involved with 
the activation of those caspases responsible for the degradation phase; caspase I digests 
actin, caspase 6 digests nuclear lamin and caspase 3 activates caspase-activated DNase 
(CAD) by cleavage of its inhibitor (ICAD) (King, 2000). CAD is able to enter the 
nucleus and digest the DNA. Apoptosis can be inhibited by proteins including anti- 
apoptotic members of the Bcl-2 family (such as Bcl-2 and Bcl-xL) and inhibitors of 
apoptosis (IAPs, such as survivin). Bcl-2 inhibits the release of cytochrome C from the 
mitochondria whereas Bcl-xL interacts with Apaf- I and inhibits caspase 9 activation. 
IAPs exert an anti-apoptotic effect by inhibiting the activity of the caspases. 
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A well established myriad of factors including oncogenes and tumour suppressor genes, 
play a crucial role in malignant transformation of the breast. Many of these factors can 
be exploited to determine the lifetime risk of disease development, prognosis following 
diagnosis and/ or the likelihood of response to specific treatment. Additionally, an 
increased understanding of pathways involved may help to devise targeted approaches 
to prevention or therapy. 
2.2.1 Oncogenes 
Oncogenes encode proteins which promote cell growth. Activation can occur through 
numerous genetic events resulting in an over-expression of the protein product, thus 
enhancing its function. Such events include gene amplification (an increase in copy 
number), point mutations (alterations in base sequences, which alter gene transcription 
or structure of the resulting protein) and chromosomal translocations (transfer of 
chromosomal segments to new positions). Oncogenes act in a dominant manner, 
therefore only one allele requires mutation for the effect to be observed. Several 
oncogenes have been characterised in human cancers, but relatively few are critical for 
the progression of breast cancer. 
2.2.1.1 Human Epidermal Growth Factor Receptor 2 
Human epidermal growth factor receptor (HER) proteins are members of subclass I of 
the receptor tyrosine kinase (RTK) superfamily (Keen and Davidson, 2003). There are 4 
members of this family: HERI (also called EGFR or erbBI), HER2 (also called 
HER2/neu or erbB2), HER3 (also called erbB3) and HER4 (also called erbB4). At least 
25 known ligands show specificity for HER family members including epidermal 
growth factor (EGF) and transforming growth factor (TGF)-a (Olayioye et al. 2000). 
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HER proteins are composed of 3 domains: an extracellular ligand-binding domain, a 
transmembrane lipophilic region and an intracellular protein tyrosine kinase domain. 
Activation occurs through ligand binding. Alternatively, if the receptors are present in 
sufficient density on the cell membrane activation may occur through an autonomous 
mechanism (Osborne et al. 2004). Activation results in dimerisation and receptor 
autophosphorylation. This leads to the subsequent phosphorylation of further proteins 
and transduction of a growth signal through the cell. The expression of HER2 in breast 
cancer varies according to histological subtype and is found almost exclusively in 
cancers of ductal origin. HER2 is over-expressed in 20-30% of invasive breast cancers 
and also in the majority of high-grade DCIS cases (Slamon et al. 1987; van de ViJver et 
al. 1988). Over-expression of this protein is usually the result of gene amplification and 
has been correlated with poor prognosis. HER2 over-expression has been associated 
with higher risk of recurrence and lower response rates to both endocrine and 
chemotherapy (Slamon et al. 1987; Tetu and Brisson, 1994; De Placido et al. 2003). 
However, turnours over-expressing this protein may be treated with the drug Herceptin 
(see section 1.7.3.3. ). 
2.2.1.2 c-myc 
The c-myc oncogene encodes a nuclear phosphoprotein, which is a transcriptional 
regulator of genes involved with cell proliferation, differentiation and apoptosis. This 
protein functions by forming heterodimers with another protein called max. The 
heterodimers have DNA-binding ability and activate gene transcription. In the absence 
of a growth signal max: max homodimers prevent the binding of myc. In the presence of 
a growth signal, phosphorylation disrupts max: max homodimers. This allows 
heterodimer formation, thus promoting gene transcription. The c-myc gene is amplified 
and over-expressed in 15-25% of breast cancers (Nass and Dickson, 1997). Some 
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studies have associated this over-expression with poor prognosis or aggressive 
biological characteristics (Varley et al. 1987). Furthermore, c-myc also appears to play a 
role in hormone responsiveness and chemotherapy-resistance (Carroll et al. 2002). 
2.2.2 Tumour Suppressor Genes 
The protein products of tumour suppressor (TS) genes reversibly inhibit cell 
proliferation. Mutations in these genes are recessive and require the 'knock-out' of both 
alleles so that neither can yield a functional product. According to the 'two-hit' 
hypothesis, 2 genetic events are necessary for the development of cancer (Knudson, 
1987). Hereditary cancer (e. g. retinoblastoma) involves the inheritance of a defect in the 
first allele and a second hit occurs somatically. In contrast, 2 somatic hits are required 
for the development of sporadic cancers, which accounts for a later onset in comparison 
with hereditary forms. In some cases a mutation may not be responsible for loss of 
function. Other mechanisms also interfere with the expression and function of TS genes. 
Such mechanisms include allele loss (loss of heterozygosity), the hypermethylation of 
promoter regions (resulting in gene silencing), increased rate of proteosomal 
degradation or abnormalities in other proteins that interact with the gene product. 
2.2.2.1 p53 
The p53 gene encodes a nuclear phosphoprotein important in cell cycle regulation, 
DNA repair and apoptosis (see section 2.1.1). This gene is a dominant-negative gene 
and although classified as a tumour suppressor, only one mutant allele is sufficient to 
generate a dysfunctional product. Mutations in p53 are estimated to occur in up to half 
of all human cancers and are observed in 20-30% of sporadic breast cancers (Hollstein 
et al. 1991). Also, germline mutations in p53 are a risk factor for breast cancer 
development as part of the rare familial Li-Fraumeni syndrome. Although mutations are 
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found throughout the gene, there is one particular hotspot which is affected. The 
majority of mutations are confined to a 200 amino-acid span, which contains I of 4 
conserved core domains resulting in decreased DNA-binding affinity and reduced gene 
transcription (Kern et al. 1991; Kern et al. 1992; Cho et al. 1994; Keshava et al. 2002). 
Mutations in the p53 gene prevent cell cycle arrest at the GI checkpoint and allow 
damaged cells to progress through the cycle and proliferate leading to the accumulation 
of genetic damage. The induction of apoptosis is also prevented, which allows the 
survival of cells that would otherwise have been instructed to die. Mutations in the p53 
gene have been associated with poor overall outcome and disease-free survival rates and 
many studies have shown a correlation between p53 mutations and response to anti- 
cancer therapy (Aas et al. 1996; Berns et al. 2000; Geisler et al. 2001). 
2.2.2.2 BRCA Genes 
BRCAI and BRCA2 are tumour suppressor genes in which germline mutations are 
associated with a genetic predisposition to the development of both breast and ovarian 
cancers. Such mutations are thought to be responsible for 5-10% of all breast cancers 
and are inherited via an autosomal dominant mechanism. The lifetime risk of breast 
cancer in women who inherit mutations in these genes is -80%. Deleterious mutations 
can occur at almost any position within these genes however, certain mutations occur at 
higher frequencies within particular ethnic groups, e. g. Ashkenazi Jews. Three specific 
founder mutations (BRCAI 185delAG, BRCAI 5382insC and BRCA2 6174deIT) occur 
at a high prevalence within this community (McPherson et al. 2000). It is interesting to 
note that although mutations in these genes are important in the 
development of 
hereditary breast cancer, they are rarely mutated in sporadic breast cancers. However, 
BRCAI hypermethylation has been observed in some sporadic cases and in some 
hereditary cases with a normal sequence (Esteller et al. 2000). 
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The majority of all BRCAI and BRCA2 genetic defects yield abnormal truncated 
protein products. BRCAI and BRCA2 play important roles in the homologous 
recombinatorial repair of chromosomal double-strand breaks (DSBs), regulation of gene 
transcription and control of cell cycle checkpoints. Dysfunctional BRCA proteins allow 
other genetic defects to accumulate and lead to genetic instability. BRCAl turnours are 
usually high grade IDCs but there is also an increased incidence of medullary histology, 
which carries more favourable prognosis (Breast Cancer Linkage Consortium, 1997). 
Combined data from several studies show that -8 3% of BRCA I -related cancers are ER- 
negative (King et al. 2001; see section 2.2.3.1). BRCA2 is usually associated with 
medium-high grade IDCs and ER-positivity is observed in -76% of turnours (King et al. 
2001). Both BRCAI and BRCA2 cancers are also often HER2 negative. Gene 
amplification of c-myc is observed in a higher percentage of both BRCAl- and 
BRCA2-related breast cancers compared with their sporadic counterparts (Palacios et al. 
2003). 
2.2.3 Steroid Hormone Receptors 
2.2.3.1 Oestrogen Receptor 
Oestrogen is a major promoter of cell proliferation and plays a crucial role in the 
development and progression of breast cancer. The effects of oestrogen are mediated via 
interaction with a nuclear ligand-activated transcription factor called the oestrogen 
receptor (ER). Two ERs have been characterised to date: ERa and ERP. These proteins 
are members of the steroid hormone receptor (SHR) family, which in the absence of 
ligand, form an inactive complex with Heat Shock Protein (HSP)-90 (Nicholson et al. 
1999). Upon oestrogen binding, ER becomes activated and dissociates from HSP90. 
The receptor subsequently undergoes a conformational change, which exposes the DNA 
binding domains and the transcription activation domains. Activated ERs dimerize and 
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autophosphorylate through intrinsic tyrosine kinases and bind to palindromic regulatory 
promoter elements called oestrogen receptor-responsive-elements (EREs) within 
specific target genes (Keen and Davidson, 2003). This allows the formation of a 
transcription complex (Beekman et al. 1993), which results in transcription of these 
genes. Such target genes stimulate growth and include c-myc (see section 2.2.1.2). ERs 
can also regulate gene transcription without directly interacting with DNA. This may 
occur via protein-protein interactions with heterologous transcription factors such as the 
Fos/ Jun activating protein- I (AP-1) complex and Sp I (Kushner et al. 2000). 
ERa is the predominant mediator of the mitogenic effects of oestrogen in the breast 
(Hewitt et al. 2005). Approximately 70-80% of all breast cancers demonstrate ERa- 
positivity (Keen and Davidson, 2003), which results in the excessive stimulation of 
ERa-signalling pathways culminating in uncontrolled cell proliferation. ERa-positivity 
is strongly correlated with a good response to endocrine therapy with 60% of ERa- 
positive tumours responding positively to treatment compared with only 5-10% of ERa- 
negative patients (see section 1.7.3.2) (Osbome, 1998). In contrast, ERP regulates a 
separate set of genes and may therefore serve actions distinct from ERa. A decrease in 
the expression of ERP between normal and neoplastic breast, colon and ovarian cancer 
has been reported (Foley et al. 2000; Iwao et al. 2000; Rutherford et al. 2000; Roger et 
al. 200 1) suggesting that this isoform may function as an inhibitor of tumourigenesis 
(Lazennec et al. 2001). However, more recently ERP was shown to be co-expressed 
with ERa in 45% of 147 cases of primary breast cancer. Furthermore, the over- 
expression of ERP was significantly associated with HER2 over-expression (Choi and 
Pinto, 2005). High levels of ERP also correlated with improved disease-free survival 
and overall survival in breast cancer patients treated with adjuvant tarnoxifen therapy 
(Hopp et al. 2004). 
44 
Chapter H 
2.2.3.2 Progesterone Receptor 
Molecular Introduction to Breast Cancer 
The progesterone receptor (PR) is one of the genes, which is regulated by ER. PR is 
also a member of the SHR family and is activated upon binding of progesterone; a 
hormone also involved in the development and progression of breast cancer. PR exists 
naturally as 2 isoforms: PR-A and PR-B, which are encoded by a single gene utilising 
different transcription start sites (Kastner et al. 1990). Such isofonns differ with regard 
to their biological activity and mediate the transcription of different progesterone- 
responsive genes. PR-A and PR-B are co-expressed and the ratio between isoforms is an 
important parameter for progesterone-mediated functions. Expression of the PR-B 
protein is reported to be markedly elevated in breast cancers and this leads to alterations 
in the ratio between isoforms (Bamberger et al. 2000; Ariga et al. 2001). 
PR status is a good predictor of response to endocrine therapy possibly because 
expression may indicate a functioning ER-signalling pathway. Almost 50% of all ER- 
positive turnours also demonstrate PR-positivity and of these, 75% respond positively to 
endocrine therapy. Tumours that are ER-positive but PR-negative are less responsive 
suggesting that PR may be important for therapeutic outcomes with endocrine therapy. 
Alternatively, this may suggest dysfunctional ER-signalling pathways in these turnours. 
Epigenetic modifications, such as hypermethylation and/ or acetylation, are important in 
the regulation of PR expression and can occasionally result in gene silencing. 
2.3 Resistance to Anticancer Therapy 
Despite recent improvements in the treatment of breast cancer, resistance to anti-cancer 
therapy represents a major obstacle to a successful outcome. Tumours may be resistant 
to radiotherapy and/ or systemic therapy from the outset and even those which are 
initially responsive may develop resistance over the course of treatment. This has led to 
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much research into the causes of resistance. In particular, this thesis focuses on 
resistance to chemotherapy (doxorubicin and cisplatin) and radiotherapy in human 
breast cancer cells. The principal mechanism by which chemotherapy and radiotherapy 
exert a cytotoxic effect is by inducing a lethal burden of DNA damage, which results in 
apoptotic cell death. 
2.3.1 Doxorubicin 
Doxorubicin is an anthracycline antibiotic, which intercalates with DNA preventing 
DNA synthesis and transcription. Doxorubicin also inhibits topoisomerase 11. 
Topoisomerase 11 is a nuclear enzyme, which induces transient breaks in the DNA 
allowing DNA strands or double helices to pass through each other. This relieves 
torsional stress in supercoiled DNA and results in the unlinking of intertwined 
chromosomes (Holm, 1994). Topoisomerase 11 also mediates the subsequent religation 
of DNA. The inhibition of this enzyme by doxorubicin blocks this religation function, 
thus leaving the DNA with a pennanent double-stranded break. The release of 
topoisomerase 11 is also blocked and arrests the replication fork, which further 
contributes to the antineoplastic effects of doxorubicin. Ultimately, this agent induces 
irreparable DNA damage, which results in apoptotic cell death. 
2.3.2 Cisplatin (cis-diamminedichloroplatinum 11) 
Cisplatin is a platinum (11)-containing compound, which is hydrolysed within the cell to 
(NH3)2-Pt-(H20)2. Once hydrolysed this agent is highly reactive and interacts with a 
variety of cellular constituents, including DNA. Cisplatin associates with DNA through 
the formation of adducts, preferentially at the N7 positions of guanine and adenine. 
Interactions occur with other bases to form intra- and inter-strand cross links. Intra- 
strand cross links distort the physical structure of 
DNA, which prevents effective repair. 
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Inter-strand cross links prevent the separation of strands so replication is either inhibited 
or abnormal. Adduct formation also affects transcription and causes strand-breakage 
and miscoding. Ultimately, cisplatin creates a lethal burden of DNA damage, which 
results in apoptotic cell death. 
2.3.3 Radiotherapy 
Radiotherapy involves the delivery of high energy x-rays, which exert a cytotoxic effect 
by producing free radicals within target tissues. Such radicals are the source of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS), which create DNA damage 
by forming both single-stranded breaks (SSBs) and double-stranded breaks (DSBs). 
Cellular enzymes are able to perform the efficient repair of SSBs, however DSBs are 
difficult to repair or are irreparable and thus trigger apoptosis. X-rays can also produce 
damage to individual DNA bases, which increases the complexity of SSBs and DSBs 
and their subsequent repair. Damage to individual DNA bases may be repaired by the 
base excision pathway (see section 2.4.1.3). 
2.4 Mechanisms of Anticancer Therapy Resistance 
Although the mechanisms of resistance to anticancer therapy remain unclear, it is 
accepted that the development of resistance to both chemotherapy and radiotherapy is a 
multifactorial phenomenon involving multiple alterations in several different pathways. 
Some proteins are potentially involved with resistance to both chemotherapy and 
radiotherapy. Such proteins are diverse and include, amongst others: 
9 DNA repair proteins 
e Cell-cycle and apoptotic proteins 
e Detoxification Proteins 
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Other proteins are specifically involved with resistance to chemotherapy, examples of 
which include: 
* Drug transport proteins 
9 Drug targets 
Furthermore, in solid tumours the ability of the drug to penetrate the tumour and reach 
all cells has been shown to contribute to a chemotherapy-resistant phenotype (Tannock 
et al. 2002). 
2.4.1 DNA Repair Proteins 
Cisplatin, doxorubicin and ionising radiation (IR) share a common mode of action. 
Ultimately, the aim is to create a lethal burden of DNA damage, which results in 
apoptosis. Many turnour cells are able to efficiently repair such damage and this may 
manifest clinically as resistance to these treatments. A number of pathways exist for the 
repair of different types of DNA damage and these are discussed further below. 
2.4.1.1 Nucleotide Excision Repair 
The nucleotide excision repair (NER) pathway plays a major role in the repair of 
cisplatin-induced DNA damage and involves proteins capable of recognising and 
removing damaged regions. Following damage recognition, incisions are made at the 3' 
and 5' ends of the damage. Xeroderma pigmentosum group G (XPG) is the nuclease 
responsible for 3' incisions and excision repair cross complementating (ERCC)-1 is the 
nuclease responsible for 5' incisions. The excised section is then transcribed from the 
remaining strand of DNA. Enhanced NER activity has been implicated with cisplatin- 
resistance (Levy et al. 1994; Dempke et al. 2000). Furthermore, in a recent study the up- 
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regulation of ERCC I was demonstrated to protect MCF7 breast cancer cells from 
platinum-based anticancer agents (Youn et al. 2004). 
2.4.1.2 Mismatch Repair 
The mismatch repair (MMR) system acts by recognising and repairing inter-strand 
nucleotide mismatches and slippage mistakes at microsatellite sequences. Initial 
recognition of mismatched bases is through binding of an hMSH2: hMSH6 heterodimer. 
PMSI and hMLHI subsequently bind and direct repair by exonuclease cleavage and 
digestion of a limited number of nucleotides. The parental strand is then used as a 
template for re-synthesis. The MMR system can also recognise various drug-induced 
adducts. However, in contrast to the NER system deficient MMR systems may confer 
resistance. This is because the major role of the MMR system appears to be recognition 
rather than repair of such adducts. Thus, cells with deficient MMR systems fail to 
recognise DNA damage and continue to proliferate. In fact, deficiencies in the MMR 
system are observed in -25% of sporadic breast cancers and loss of either hMSH2 or 
hMLHI function has been implicated with resistance to both cisplatin and doxorubicin 
(Fedier et al. 2001). 
2.4.1.3 Base Excision Repair 
The base excision repair (BER) pathway is predominantly responsible for the repair of 
damage to individual bases caused by ionising radiation (IR). BER involves a family of 
enzymes called N-glycosidases. Each enzyme within this family recognises and 
removes a specific modified base(s) from DNA. The base is removed from DNA 
by the 
catalytic cleavage of the glycosylic bond leaving an abasic site 
(AP site). The 
deoxyribosephosphate chain is cleaved 5' to the abasic site by an AP endonuclease and 
the phosphodiesterase of DNA polymerase-P cleaves 3' to this site. 
DNA polymerase-P 
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subsequently fills the single nucleotide gap with a nucleotide determined by the 
sequence of the intact strand. X-ray repair cross complementing (XRCC)- I protein 
plays a key role in the BER pathway. XRCC I functions as a scaffolding protein, which 
binds tightly to at least 3 other proteins involved in BER: DNA polymerase-0, DNA 
ligase-Ill and PARP. Polymorphisms in XRCCl have been associated with an increased 
risk of many cancers including breast cancer (Duell et al. 2001). Functional analysis has 
suggested that many of the XRCC I variants may contribute to hypersensitivity to IR 
due to a deficiency in BER (Hu et al. 2001; Moullan et al. 2003). 
2.4.1.4 DNA-Dependent Protein Kinase 
DNA-dependent protein kinase (DNA-PK) is a key component of the non-homologous 
end joining (NHEJ) pathway for the repair of double-strand breaks (DSBs). DNA-PK is 
composed of a 460-kDa catalytic subunit (DNA-PKc) and a heterodimer of Ku70 and 
Ku80, which acts as a DNA binding and regulatory component for the complex (Lieber 
et al. 1997). This complex is activated by the presence of broken DNA ends, which 
results in DNA binding of the Ku heterodimer. This induces a conformational change 
that allows interaction with DNA-PKcs. The kinase activity of the catalytic subunit is 
required for DNA repair, which involves physically tethering the 2 ends of a DSB (Cary 
et al. 1997). Furthermore, DNA-PK also functions as a sensor and transmits DNA 
damage signals to downstream targets (Lee and Kim, 2002). In-vivo observations have 
indicated that DNA-PK mutant cells exhibited sensitivity to IR as well as specific 
chemotherapeutic agents. Such observations were associated with lower DNA repair 
activity following DNA damage (Britten et al. 1999; Frit et al. 1999). In 2002, Kim et 
al. hypothesised that DNA-PK may play an important role in conferring resistance to 
radiotherapy and/ or chemotherapy in cancer cells. In accordance, the targeted 
inhibition 
of DNA-PK in breast cancer cells 
decreased the level of radiotherapy resistance and 
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also led to growth inhibition in response to cisplatin treatment. This supports the notion 
that DNA-PK may play a major role in resistance to both radiotherapy and 
chemotherapy and may be a useful molecular target for the treatment of such resistant 
cells. 
2.4.2 Cell-Cycle and Apoptotic Proteins 
2.4.2.1 p53 
The transcription factor p53 plays a crucial role not only in the regulation of the cell 
cycle but also in the induction of apoptosis (see section 2.1.1). DNA damage stabilises 
t is protein leading to cell cycle arrest and DNA repair or apoptosis. In-vitro studies 
have clearly shown that p53 is required for the efficient activation of apoptosis 
following treatment with chemotherapy or radiotherapy (Lowe et al. 1993; Lowe et al. 
1994). Loss of function has been demonstrated to enhance resistance to agents including 
cisplatin and doxorubicin (Aas et al. 1996; Berns et al. 2000; Geisler et al. 2001; 
Mandic et al. 2005). Furthermore wild-type p53 but not the mutant form activates 
transcription of the Fas gene in response to cisplatin (Muller et al. 1998). This raises the 
possibility that dysfunctional p53 could lead to cisplatin-resistance by failure to initiate 
apoptosis via the extrinsic apoptotic pathway (see section 2.1.2). Couture et, al. (2002) 
also found that dysfunctional p53 predicted local failure in patients treated with radical 
radiotherapy for head and neck cancer. 
2.4.2.2 The Bcl-2 Family 
The Bcl-2 family of proteins consists of both pro- and anti-apoptotic members. Pro- 
apoptotic proteins include Bad, Bak, Bax, Bid and Bim/Bod, and anti-apoptotic proteins 
include Bcl-2 and Bcl-xL. Whether or not apoptosis is induced is dependent on the 
relative ratios of these family members. Bcl-2 is located within the inner mitochondrial 
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membrane and serves to inhibit apoptosis by maintaining membrane integrity and 
preventing release of cytochrome C. Bcl-xL is present in the cytoplasm and inhibits 
apoptosis by interacting with Apaf- I and preventing caspase-9 activation (Hu et A 
1998). Either Bak or Bax is required for apoptosis to occur. Bak is present in the 
mitochondrial. membrane whereas Bax is present as a monomer in the cytoplasm and 
integrates into the mitochondrial membrane and oligomerises during apoptosis (Cory 
and Adams, 2002). Inactive Bid is usually found in the cytoplasm and becomes 
activated by caspase 8 to fonn tBid, which translocates to the mitochondria and causes 
release of cytochrome C (Luo et al. 1998). Proteins such as Bad and Bim/Bod fonn 
heterodimers with anti-apoptotic members. This prevents the anti-apoptotic proteins 
from inhibiting the activation of Bax and Bak (Cory and Adams, 2002). 
It has been postulated that the over-expression of Bcl-2 and Bcl-xL may confer 
resistance to chemotherapy. In fact, over-expression of Bcl-2 and Bcl-xL is observed in 
70% and 40% of breast cancer cases respectively (Emi et al. 2005). In a recent study, 
anti-sense oligodeoxynucleotides were exploited to down-regulate the expression of 
Bcl-2 and Bcl-xL in human breast cancer cell lines. This was demonstrated to enhance 
sensitivity to doxorubicin, paclitaxel, docetaxel and mitomycin C (Emi et al. 2005). In 
contrast, loss of pro-apoptotic members may also result in resistance to chemotherapy. 
In support of this hypothesis the forced expression of apoptosis-promoting proteins Bak 
and Bik has been shown to reverse chemotherapy-resistance (Radetzki et al. 2002). 
Furthermore, Nix et al. (2005) demonstrated that resistance to radiotherapy in 
largyngeal cancer was associated with expression of the anti-apoptotic markers Bcl-2 
and Bel-xL and with the loss of Bax expression. These observations suggest that an 
inappropriate apoptotic response may manifest clinically as resistance to chemotherapy 
and/ or radiotherapy. 
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2.4.3 Detoxification Proteins 
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Glutathione transferases (GSTs) are a family of phase 11 enzymes that catalyse the 
conjugation of glutathione (GSH) to endogenous and exogenous electrophilic 
substrates. This converts potentially harmful substrates into water soluble less toxic 
metabolites, which can be easily excreted from the cell. GSTs are involved in the 
detoxification of many cytotoxic drugs and some of the toxic carbonyl-, peroxide-, and 
epoxide-containing metabolites produced within the cell in response to radiotherapy 
(Hayes and Pulford, 1995). GSTs have been well charcterised and have been divided 
into a number of subclasses including alpha, pi, mu and theta. Increased expression 
levels of GST subtypes have previously been implicated with resistance to both 
chemotherapy and radiotherapy (Dirven et al. 1994; Miura et al. 1997; Silvestrini et al. 
1997). This is possibly the result of increased detoxification allowing cells to evade the 
cytotoxic effects of anticancer therapy. Furthermore, recent evidence suggests that 
GSTs are also inhibitors of the MAP-kinase pathway; a pathway involved in 
transmitting the apoptotic signal (Townsend and Tew, 2003). 
2.4.4 Drug-Transport Proteins 
Increased drug efflux may result in a reduced intracellular concentration to below that 
which is necessary for a cytotoxic effect to be observed. This is primarily mediated by 
members of the ATP-binding cassette (ABC) superfamily of proteins, some of which 
are described further below. 
2.4.4.1 P-Glycoprotein 
P-Glycoprotein (P-gp; also known as multidrug resistance protein I (MDRI) or 
ABCB 1) is a 170-kDa plasma membrane glycoprotein, which functions as an ATP- 
dependent drug efflux pump. This protein is over-expressed in many chemotherapy- 
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resistant cells and is associated with a multidrug resistant (MDR) phenotype. MDR is 
characterised by resistance to a wide but well-defined spectrum of chemically distinct 
drugs including the anthracyclines, taxanes and vinca alkaloids (Avendano and 
Menendez, 2002; see Table 1-5). According to immunohistochemistry (IHC) studies 40- 
50% of untreated primary breast cancers express P-gp (Leonessa and Clarke, 2003). 
However, the incidence of P-gp expression following exposure to chemotherapy 
increases to 60-70% (Chevillard et al. 1997; Vargas-Roig et al. 1999). 
2.4.4.2 Multidrug Resistance Protein 
The multidrug resistance protein (MRP)-I is often over-expressed in MDR cells that do 
not over-express P-gp. MRP I is involved in the ATP-dependent transport of a variety of 
molecules across cell membranes. This protein functions as a drug efflux pump capable 
of transporting negatively-charged anionic drugs and neutral drugs conjugated to 
glutathione, glucuronate or sulphate (Wijnholds, 2002). Thus, the over-expression of 
MRP I confers resistance to a wide variety of chemotherapeutic agents including 
anthracyclines, vincristine and epipodophyllotoxins (Burger et al. 2003; see Table 1-5). 
A breast cancer meta-analysis revealed that MRP I mRNA was detected in 98% (429 of 
437) of untreated breast cancers. In 5 of the 6 studies from which the data were pooled, 
expression was detected in 100% of cases. Using IHC, MRP I was detected in 49% of 
cases (213/432 across 5 studies) (Leonessa and Clarke, 2003). In addition, MRPI has 
been detected in intracellular vesicles and Golgi apparatus in transfected HeLa cells, 
which resulted in altered subcellular drug distribution (Rajagopal and Simon, 2003). 
This suggests that along with drug efflux, intracellular sequestration and vesicular 
transport of a drug may be an alternative mechanism of MRPI-mediated drug 
resistance. The expression of MRPI has been associated with shorter overall and 
disease-free survival rates (Filipits et al. 1999). 
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2.4.4.3. Breast Cancer Resistance Protein 
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The breast cancer resistance protein (BCRP) was first identified in an MCF7 breast 
cancer cell line, which exhibited the MDR phenotype in absence of the over-expression 
of known MDR transporters such as P-gp or MRP1 (Doyle et al. 1998). Transfection 
studies from various laboratories have confirmed that enforced expression of BCRP 
confers resistance to a variety of agents including mitoxantrone, methotrexate, 
flavopiridol anýd quinazoline ErbBl inhibitors (Bates et at. 2001; Allen et al. 2002; 
Doyle and Ross, 2003). Transport of the anthracyclines is variable and appears to 
depend on the presence of a mutation within the BCRP gene at codon 482 (Mao and 
Unadkat, 2005). BCRP is predominantly localised to the plasma membrane in resistant 
cells and functions as a drug-efflux pump to decrease intracellular drug accumulation. 
Although first identified in the MCF7 breast cancer cell line, there is little evidence to 
suggest that BCRP is highly expressed in breast cancer, thus it is possible that in this 
tumour-type other drug efflux pumps are more important in the development of 
chemotherapy-resistance (Kanzaki et al. 2001; Faneyte et al. 2002; Burger et al. 2003). 
2.4.5 Drug Targets 
For drugs that interact with specific cellular targets, drug resistance may be conferred by 
changes in the target which affect interaction with the drug. Topoisomerase II is a target 
for the anthracyclines (doxorubicin and its analogue epirubicin) (see section 2.3.1). The 
reduced expression of topoisomerase Il has been implicated with resistance to 
both 
doxorubicin. and epirubicin in breast cancer (Harris and Hochhauser, 1992). 
2.5 Clinical Relevance of Anticancer Therapy Resistance 
Unfortunately, resistance to anticancer therapy is common and represents a major 
obstacle to a successful outcome. 
Furthermore, treatment is associated with many 
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unpleasant side effects such as infections (e. g. Pneumocystis carinii), anemia and 
nausea and vomiting. Some of these side effects are serious and potentially life- 
threatening. Failure to respond to a course of treatment may also delay the 
implementation of a more appropriate treatment modality. During this delay tumour 
progression may occur, which can impact significantly on patient survival. The 
identification of novel biomarkers which correlate with treatment response would not 
not only increase our understanding on the mechanisms of resistance but also allow 
therapy to be tailored on an individual patient basis. Ultimately, those patients unlikely 
to respond to a particular treatment strategy would be spared the serious life-threatening 
side effects for no therapeutic gain. Physicians would also be able to select the most 
appropriate strategy from the onset of treatment. Such biomarkers may also provide 
information on new drug targets for future therapeutic intervention or new sensitising 
agents to increase the efficacy of existing treatment modalities. Overcoming resistance 
to anticancer therapy would represent a major advance in the effective management of 
breast cancer today. 
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CHAPTER III 
AN INTRODUCTION TO PROTEOME ANALYSIS 
TECHNIQUES AND THEIR USE IN THE STUDY OF 
RESISTANCE TO ANTICANCER THERAPY 
Aims: 
40 To review the current body of literature relating to the use of proteome analysis 
techniques in the study of resistance to anticancer therapy 
To assess the merits of using proteome analysis techniques for the identification 
of molecular markers, which correlate with response to anticancer therapy in 
human cancers 
Publications: 
Laura Smith, Michael J Lind, Kevin J Welham, Lynn Cawkwell. (2006) Cancer 
proteomics and its application to the discovery of therapy resistance markers in 
human cancer (review). Cancer 107; 232-241; IF. 4.8 
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3.1 Introduction 
Introduction to Proteome Analysis Techniques 
Many studies have been conducted to elucidate the mechanisms of resistance to 
anticancer therapy in human cancers. In the past, these studies have exploited 
techniques such as IHC to implicate the expression of specific proteins with resistance 
to anticancer therapy (Yeh et al. 1998; Condon et al. 2002; Nix et al. 2004; Nix et al. 
2005). Nix et al. (2005) used immunohistochernical assays to analyse the expression of 
apoptotic proteins in 124 patients with laryngeal cancer. Sixty-two patients who failed 
to respond to radiotherapy were matched for T-stage, laryngeal subsite and smoking 
history to a group of 62 patients who were successfully cured by radiotherapy. 
Resistance to radiotherapy was associated with expression of the anti-apoptotic markers 
Bcl-2 and Bcl-xL and with the loss of Bax expression. Although IHC is useful, existing 
knowledge is required in order to select the target protein(s) to analyse. The target is 
selected based on the function of the protein and its association with a specific 
biological process e. g. apoptosis. Standard lHC is unable to identify new targets or 
establish relationships between targets and is not amenable to high-throughput 
screening. In 1998 however, Kononen et al. introduced the "tissue microarray" for the 
rapid and efficient immunohistochernical. analysis of multiple tissue samples 
simultaneously. This method involves obtaining cylindrical cores of tissue from archival 
paraffin-embedded blocks and arraying these specimens in a master block. Sections, 
which can contain up to 1000 tissue samples from individual tumours are then be 
analysed by standard lHC (Kononen et al. 1998). Using this method, an entire cohort of 
cases can be analysed by performing immunohistochernical assays on just I or 2 master 
array slides. Each tissue specimen can then be linked with information such as survival 
data and treatment response data. Although this has improved the throughput of 
standard IHC, only a single target (antibody) per slide can be assessed. 
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The use of global analytical techniques to study complex phenomena, such as resistance 
to anticancer therapy, overcomes many of these limitations. These techniques enable the 
simultaneous analysis of whole genomes and/or proteomes and potentially allow all 
genes and/or proteins which are associated with a specific disease phenotype to be 
identified. The major advantage being that the regulation of previously unknown genes 
and/or proteins can be implicated with a particular disease state. 
3.2 Genomic Approaches 
Cytogenetic techniques, such as multicolour fluorescence in situ hybridisation (mFISH), 
spectral karyotyping (SKY), and comparative genomic hybridisation (CGH) exploit 
advanced fluorescent technology to study the whole chromosomal complement of cells 
(Watson and Cawkwell, 2004). Cytogenetic techniques are invaluable in the study of 
complex disease processes and have been employed to identify the genomic aberrations 
associated with both chemotherapy and radiotherapy resistance (Singh et al 2000; 
Struski et at. 2003). Such techniques however, are compromised by their limited 
resolution and further studies are required in order to confinn the genes that are 
associated with a particular phenotype. Recently, CGH has been applied to the rapidly 
growing field of microarray technology (Albertson and Pinkel, 2003). Thousands of 
probes are printed at a high density onto glass microscope slides and 2 differentially 
labelled DNA pools are hybridised simultaneously to assess DNA copy number. Array- 
based CGH not only offers superior resolution over chromosome-based CGH but also 
improved quantitative accuracy and dynamic range. Additionally, the aberrations can be 
directly mapped to the genome sequence (Albertson and Pinkel, 2003). Wilson et al. 
(2005) used array-based CGH to analyse cisplatin resistance in testicular germ cell 
turnour cell lines. This study revealed that the over-expression of genes on 16q was 
associated with the development of cisplatin resistance. A 
further understanding of the 
59 
III Introduction to Proteome Analysis Techniques 
genes in this chromosomal region may offer novel therapeutic targets and increase 
understanding of the mechanisms of cisplatin resistance. 
3.3 Transcriptomic Approaches 
At present microarray-based technology is more commonly used for gene expression 
profiling, which explores the relative levels of RNA expression from thousands of 
known genes simultaneously. The aim is to identify changes in gene expression, which 
are associated with disease phenotypes. Gene-expression profiling has been used to 
analyse both chemotherapy and radiotherapy resistance in various tumour types (Hanna 
et al. 2001; Wong et al. 2003; Kang et al. 2004; Duan et al. 2005; Tai et al. 2005; 
Tsunoda et al. 2005). Kang et al (2004) exploited the Affymetrix HG-Ul 13A 
microarray to analyse acquired drug resistance in gastric cancer cell lines. Four 5- 
fluorouracil (5FU) resistant cell lines, 3 doxorubicin resistant cell lines and 3 cisplatin 
resistant cell lines were established from 4 different gastric cancer cell lines. The group 
identified 250 genes that were found to be differentially expressed in 5FU-, 
doxorubicin- or cisplatin-induced chemoresistant cell lines when compared with their 
drug-sensitive parent cell lines. In addition, 8 candidate multidrug resistance genes 
including midkine (a heparin-binding growth factor) were associated with resistance to 
2 or more of the chemotherapeutic agents. 
Unfortunately, there is a common drawback to all of the global techniques which are 
based on the genome and the transcriptome. The proteins within a cell are responsible 
for the key biological processes and also make up the bulk of pharmaceutical targets. 
Unfortunately, the expression levels of mRNA and the corresponding protein are often 
not comparable and post-translational modifications and alternative splicing events 
cannot be inferred from genomic or transcriptomic technologies. Therefore, in order to 
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gain a more comprehensive understanding of intricate biological systems, the 
information extracted from the genome and transcriptome must be complemented with 
information on the proteins themselves. Recent technological advances have enhanced 
the analysis of the human proteome. 
3.4 Proteomic Approaches 
Proteomics can be defined as the large-scale characterisation of the complete 
complement of proteins expressed by a given genome (the proteome). This field 
includes the detennination of expression levels, subcellular localisations, interactions, 
modifications, activities, and ultimately the functions of proteins. A number of 
proteome analysis methods have been utilised in cancer research. These are described 
below along with details of their use in identifying factors associated with resistance to 
anticancer therapy. 
3.4.1 Two-Dimensional Gel Electrophoresis and Mass Spectrometry 
Two-dimensional gel electrophoresis (2DE) remains the gold standard for the separation 
of proteins. First dimensional separation is achieved by isoelectric focussing, which 
separates proteins on the basis of their charge. This is coupled with second dimensional 
separation, which exploits polyacrylamide gel electrophoresis (PAGE) to separate 
proteins in accordance with molecular weight. Under optimal conditions, the expression 
pattern of several thousands of individual protein species can be defined simultaneously 
on a single 2D gel. The protein profiles can be compared using sophisticated software 
packages to identify those proteins which are differentially expressed between samples. 
By itself 2DE is purely a descriptive technique and therefore must be coupled with 
analytical methods, such as mass spectrometry (MS) to 
identify those proteins-of- 
interest (POls). MS provides structural information, such as peptide mass and amino 
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acid sequence, which is then used to identify the protein by searching against nucleotide 
and protein databases (Graves and Haystead, 2002). Current MS-based approaches 
involve the digestion and extraction of proteins from 2D gels using a sequence- specific 
protease such as trypsin. These specific proteolytically-derived peptides are then 
characterised for protein identification. Mass spectrometers are capable of forming, 
separating and detecting molecular ions on the basis of the mass-to-charge ratio (m1z). 
This requires that the peptides are ionised. lonisation techniques transfer biomolecules 
f, 
- from the solid or liquid phase to the gas phase making them amenable to MS 
measurement. Two common methods of peptide ionisation for MS analysis are matrix- 
assisted laser desorption/ionisation (MALDI) and electrospray ionisation (ESI). 
lonisation in both of these methods ensues as a result of the addition of one or more 
protons. Thus, a peptide of molecular weight IOOODa will have a m1z value of 1001 
after ionisation by the addition of a single proton and 501 with the addition of 2 protons 
(M+2H/2). 
3.4.1.1 Matrix-Assisted Laser Desorption/ lonisation (MALDI) 
The sample to be analysed is mixed with a small energy-absorbing matrix molecule, 
such as 2,5 dihydroxybenzoic acid (DHB) or a-cyano-4-hydroxycinnamic acid (CHCA), 
which absorbs light at a specific wavelength suited to the laser source (eg 337nm for the 
N2 laser). The sample/matrix mixture is spotted onto steel 384-well microtitre plate and 
allowed to air-dry to form a crystal lattice, in which the peptide sample is integrated. 
The plate is then systematically irradiated with a laser to convert the solid crystalline 
form to gas phase. The matrix chemicals absorb energy, which is subsequently passed to 
the sample peptides. Following excitation, peptide ions are ejected from the target 
surface and are directed into a mass analyser for detection. 
MALDI produces 
predominantly singly-charged ions, which allows the m1z value to 
be determined. 
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3.4.1.2 Electrospray lonisation (ESI) 
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ESI-based MS is generally regarded as the most sensitive technique (sub femtomole 
level). The liquid phase sample enters the system through a microcapillary tube (usually 
from a high performance liquid chromatography (HPLQ system) held at high voltage. 
As the flowstream exits the tube it sprays out in a fine mist of droplets, which contain 
peptide ions along with other components from the HPLC mobile phase (e. g. water and 
acetonitrile). The peptide ions are separated from the solvent components either by 
passing the droplets through a heated capillary or by passing a curtain of nitrogen across 
the spray. Subsequently, the desolvated ions are drawn into a mass analyser. ESI 
produces primarily doubly-charged ions, which allows for the simple calculation of the 
m1z value. 
3.4.1.3 ESI or MALDI? 
Both ionisation sources have their advantages and disadvantages; however the 
ionisation strategy is ultimately dependent on how much sample is available. If the 
sample is limited, ESI is the method of choice. This is because ESI generally offers 
superior sensitivity to MALDI and the mass spectrum can be interpreted to obtain 
amino acid sequences (Graves and Haystead, 2003). On the other hand if the sample is 
not limited, MALDI is often preferred as it is more amenable to automation and high- 
throughput analysis. 
3.4.1.4 Mass Spectrometry Instrumentation and Protein Identification 
MS instruments consist of 3 basic elements; an ionisation source, a mass analyser and a 
detector. The mass analyser uses a physical property, such as an electric or magnetic 
field or time-of-flight (TOF) to separate ions of a particular m1z value (Yates, 2000). 
Ions pass through the mass analyser and are detected by an instrument, such as an 
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electron multiplier, and the magnitude of current produced at the detector is used to 
determine the m1z value of the ion. MS data are recorded as "spectra", which display ion 
intensity versus their m1z value. A robust instrument frequently employed in proteome 
studies combines a MALDI ionisation source with a TOF mass analyser (Figure 3-1). In 
this instrument, gas phase ions from the MALDI ionisation source are directed into a 
flight tube. The m1z value is measured by determining the time required for the ions to 
traverse the length of the flight tube and strike a detector. Mass resolution can be 
increased by including an ion reflector at the end of the flight tube. This is essentially an 
ion mirror that serves to increase the length of the tube and correct for small energy 
differences among ions. In many cases, MALDI-TOF is the method of choice for 
proteome studies because it is a simple and reasonably sensitive technique (to 
ferntomole level). In addition, it offers the full automation of analysis and database 
searching. MS can generate two types of data (peptide mass fingerprinting and 
sequencing data), which can be used for protein identification. A characteristic mass 
spectrum is known as a peptide mass fingerprint (PMF), which is a list of masses for the 
peptides in a sample. The PMF is compared to the predicted masses of peptides from 
the theoretical digestion of all proteins in a database. If enough peptides from the real 
mass spectrum and the theoretical spectrum match in mass, the protein can be identified. 
Unfortunately, one peptide is rarely unique to one protein, thus several peptides (>3) 
derived from the same protein are typically required for identification. PMF analysis is 
currently the method of choice for identification because it combines a simplistic 
approach with robust high-throughput instrumentation (usually MALDI-TOF MS). 
Unfortunately, the ambiguity of protein identification limits the use of PMF analysis. 
This is the result of peptide mass redundancy. A peptide of 5 amino acids can have the 
same mass as a different peptide by a simple rearrangement of the constitutive amino 
acids, e. g. GPLSV will have the same mass as PSGVL and VGPLS and so on (Graves 
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Figure 3-1 Matrix-assisted laser desorption/ ionisation time-of-flight mass 
spectrometry. The sample/matrix mixture is spotted onto steel 384-well microtitre plate 
and allowed to air-dry to fon-n a crystal lattice, in which the peptide sample is 
integrated. The plate is then systematically irradiated with a laser to convert the solid 
crystalline form to gas phase. The matrix chemicals absorb energy, which is 
subsequently passed to the sample peptides. Following excitation, peptide ions are 
ejected from the target surface and are guided into the time-of-flight (TOF) mass 
analyser, which measures the time taken for the ions to traverse through the flight tube 
and strike the detector. 
and Haystead, 2002). Post-translationally modified proteins also reduce the success of 
PMF analysis. The peptides from a modified protein will not match the masses of the 
peptides from the unmodified protein in the database. Also, PMF analysis is not 
effective with protein mixtures and protein identification is hindered when 2 or 3 
proteins are present in a sample. The presence of contaminants such as keratin and 
peptides from the autolysis of trypsin may also be problematic. Moreover, not all 
proteins are amenable to identification by PMF analysis alone. The full lengths of a 
large percentage of human proteins are not represented in databases. In addition, small 
proteins may not yield a sufficient number of peptides from the tryptic digest for 
unambiguous identification. In such cases, it is preferable to subject selected ions to 
further fragmentation, which can provide the amino acid sequence of the peptide. 
The amino acid sequence for a specific peptide can be deduced by a process called 
tandem mass spectrometry (MS/MS). A higher level of confidence can be assigned to 
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protein identification when searching databases with MS/MS data. MS/N4S combines 2 
mass analysers and a collision cell to collect structural information for individual 
peptides. In this method, the first mass analyser acts to scan all the precursor ions from 
the ionisation source. The spectrum is used to select those ions of a particular m1z value. 
Such ions can be isolated and are dissociated by a process known as collision induced 
dissociation (CID). CID energetically activates ions to dissociate. The selected ions 
enter a collision cell and are subjected to low energy collisions with neutral gas atoms, 
such as argon or nitrogen. As the ions become excited, covalent bonds fragment in a 
predictable manner. The fragmentation process predominates primarily along the 
peptide backbone (at or around the amide bond). If the charge is retained on the N- 
terminus, the fragments are designated b-ions. In contrast, if the charge is retained on 
the C-terminus, the fragments are designated y-ions. This results in a collection of b- 
and y-lons, whose m1z values are determined by the 2d mass analyser (Yates, 2000). 
The molecular weight differences between adjacent b- and y-ions correspond to a 
specific amino acid and thus spell a partial amino acid sequence. This sequence can be 
combined with the mass of a peptide to search databases. The sequences in a database 
can be used to predict an expected pattern of fragmentation. This can be compared with 
the pattern observed in the spectrum and matched for identification. 
The amino acid sequence of a peptide may also be determined using a classical 
MALDI-TOF MS equipped with an ion reflector by a process known as Post-Source 
Decay (PSD). After leaving the ion source gas-phase precursor ions enter a field-free 
region. In this field-free region the precursor ions decay to produce PSD ions. These 
PSD ions have the same velocity as their precursors, however have lower kinetic 
energies owing to their lower masses (Spengler, 1997). In linear 
instruments, PSD ions 
strike the detector at the same time as the precursor 
ions and therefore their mass cannot 
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be analysed. In contrast, an ion reflector acts as a mass analyser for the PSD ions and 
separates ions based on differences in their kinetic energies. Unfortunately, the peptide 
fragmentation patterns are much less predictable than competing sequencing methods 
and other MS instruments (such as those combining an ESI source with triple- 
quadrupole and ion-trap mass spectrometers) are more accurate in obtaining the amino- 
acid sequence of a peptide for protein identification. 
3.4.1.5 The Study of Resistance to Anticancer Therapy using 2DE-MS. 
Historically, the use of 2DE to study resistance to anticancer therapy dates back to 1986 
when Shen and colleagues employed this technique to determine the mechanisms of 
multidrug resistance in human cancer cells (Shen et al. 1986). The group analysed 4 cell 
lines derived from the human KB epidermoid carcinoma cell line selected for resistance 
to high levels of colchicine, doxorubicin or vinblastine. All cell lines displayed cross- 
resistance to each of the other agents and various other unrelated drugs. This study was 
conducted prior to the technological advances which have allowed MS to become a 
routine tool in proteome studies and therefore simply reported the descriptive changes 
associated with resistance to chemotherapeutic agents. Nevertheless several specific 
changes were documented, some of which were common to all cell lines and others 
which were unique to specific cell lines. One such change detected by 2DE was the loss 
of a family of proteins in the molecular weight range of 70-80 kDa, with pI values of 
4.8-5.0. Not only were these proteins lost in all resistant cell lines analysed in 
comparison with parental cell lines, but also reappeared in a revertant derived from 
colchicine-resistant cells. This observation strengthened the association of the loss of 
this family of proteins with the development of MDR in KB cell lines. 
More recently however, in a time whereby such proteins can be routinely identified by 
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MS, further studies have been conducted into resistance to chemotherapy using cell 
lines (Table 3-1). Shin et al. (2005) used 2DE-based comparative proteomics to screen 
for proteins responsible for 5FU resistance in human colon cancer cell lines. The data 
obtained from this study showed that expression of the a-subunit of the mitochondrial 
FIFO-ATP synthase was lower in 5FU resistant cells compared with parent cells. Further 
analysis demonstrated decreased expression of other ATP synthase complex subunits, 
reduced ATP synthase activity and reduced intracellular ATP content in 5FU resistant 
cells. This indicated that down-regulation of ATP synthase may lead to cellular events 
responsible for 5FU resistance. One possible explanation is that a reduction in ATP 
synthase results in a lower intracellular ATP level. ATP is required for the execution of 
apoptosis and therefore reduced ATP levels may decrease the apoptotic potential of a 
cell. 
The aforementioned 2DE studies for analysing chemoresistance have exploited cell 
lines as a model system. In a recent study Allal et al. (2004) used this comparative 
proteornics approach with clinical samples to identify proteins associated with 
radiotherapy resistance in rectal cancer. Biopsies were taken from 17 patients prior to 
radiation therapy. All patients received preoperative radiotherapy. Surgery was 
performed after 6 weeks and clinical response was assessed. Protein extracts from 
radiotherapy-sensitive and radiotherapy-resistant tumours were compared by 2DE and 
differential spots were identified using MALDI-TOF MS. Their results indicated that 
the expression of tropomodulin, heat shock protein 42, P-tubulin, annexin V and 
calsenilin were statistically associated with radiotherapy resistance and keratin type 1, 
notch 2 protein homolog and DNA repair protein RAD5 I L3 were associated with radio- 
sensitivity. 
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From the results of such studies, common proteins have been associated with resistance 
to anticancer therapy. Some of these include DNA repair proteins, molecular 
chaperones, signal transduction proteins and detoxification proteins. Other proteins 
which appear to play a role in resistance to therapy include, structural proteins, proteins 
with metabolic functions and proteins exhibiting calcium binding properties. However, 
without functional studies it remains to be seen whether these alterations are the cause 
or the result of resistance to anticancer therapy. 
3.4.2 Difference In-Gel Electrophoresis (DIGE) 
Unfortunately, 2DE remains difficult to perform due to the inherent reproducibility of 
the technique. Each gel runs slightly differently, which makes gel-to-gel comparison an 
arduous task. Recently, two-dimensional difference gel electrophoresis (2D-DIGE) has 
been introduced, which is a technique designed to minimalise gel-to-gel variations. 
Protein extracts from 2 different samples are covalently labelled with a fluorescent dye. 
The labelled extracts are mixed and separated by 2DE on a single gel. Scanning the gel 
at different wavelengths allows differences in expression levels to be observed. This 
reduces the problems associated with gel matching since the 2 samples are run under the 
same conditions. Still in it's infancy, to the best of our knowledge 2D- 
DIGE has not yet been exploited in the analysis of chemotherapy or radiotherapy 
resistance. This technique has however been used in other areas of cancer research. 
Early diagnosis is one such area, which has been explored with 2D-DIGE (Somiari et al. 
2003; Friedman et al. 2004; Alfonso et al. 2005). Unfortunately, cost implications have 
limited the widespread use of this technique. 
3.4.3 Quantitative Proteomics using Labelling Techniques 
Direct protein quantification based on MS signals is challenging because of the non- 
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linear correlation between protein abundance and MS signal intensity (Gu et al. 2004). 
Techniques have since been developed to overcome this problem and involve the 
labelling of proteins prior to MS analysis. In this approach, a protein is labelled with an 
isotopic tag such that the protein from one cell state is labelled with the light variant of 
the tag and the protein from a second cell state is labelled with the heavy variant. The 
samples are combined and digested with a sequence-specific protease, such as trypsin. 
MS assessment of the heavy: light ratio enables a comparison of expression. One 
example of this mass tagging approach was developed in 1999 by Gygi et al. This 
technique is called Isotope-Coded Affinity Tagging (ICAT) and is a MS/MS-based 
approach designed to simultaneously quantitate and identify differentially expressed 
proteins. An ICAT consists of 3 functional elements; a thiol specific group, which binds 
to cystein, e residues of the protein, a light or heavy deuterated linker and a biotin tag. 
Proteins from 2 different samples are labelled with a light or heavy ICAT reagent. 
Following digestion the labelled peptides are isolated by their affinity for avidin and are 
analysed by MS/MS. In full scan mode, ICAT pairs can be identified by looking for 
those peptides that differ in mass by a specific mass unit (as specified by the mass 
difference between stable isotopes) and the relative abundance can be determined by the 
heavylight ratio. Differentially expressed proteins can be identified by searching 
databases with MS/MS data. Such mass tagging approaches involve the chemical 
labelling of proteins, however a variant of this technique exploits the biosynthetic 
incorporation of stable isotopes (usually in the form of amino acids) into protein during 
cell growth. This is known as metabolic labelling and has previously been exploited in 
the analysis of chemotherapy resistance. Gehrmann et al. (2004b) compared the protein 
expression patterns of MCF7 breast cancer cells resistant to 
doxorubicin and to doxorubicin and verapamil with the parental MCF7 cell line. The 
parental MCF7 cell line was grown in 13C6-arginine- and 13C6-lysine- enriched media 
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resulting in the C-terminal labelling of all tryptic peptides. Results showed distinctive 
protein profiles in MCF7 cells resistant to doxorubicin and those selected for resistance 
to both doxorubicin and verapamil. 
3.4.4 Surface-Enhanced Laser Desorption/ lonisation -TOF MS 
In recent years, surface-enhanced laser desorption/ ionisation time-of-flight (SELDI- 
TOF) MS has gained considerable attention. This technique couples array-based 
technology with MALDI-TOF MS (Figure 3-2). Proteins are selectively retained on a 
platform, which has been engineered with a chemical (e. g. anionic, cationic, 
hydrophobic, hydrophilic or immobilised metal affinity) or biological (e. g. antibodies, 
antigen binding fragments (e. g. scFv), or receptor) bait surface. Such varied surfaces 
allow proteins to be selectively retained on the SELDI platform based on the intrinsic 
properties of the proteins themselves and acts as a pre-fractionation step to allow for the 
detection of less abundant proteins. An energy-absorbing molecule, such as a-cyano-4- 
hydroxy-cinaminic acid (CHCA) is added to the array, which crystallises on the array 
surface. lonisation ensues by laser emission and the gas-phase ions are guided into the 
MS. A unique fingerprint results for each sample tested. Initial experiments aimed to 
produce a discriminatory proteornic pattern based on differential mass spectra to 
distinguish between 2 experimental populations. Here it was the pattern rather than 
protein identity that was deemed as the important factor. With the advance of 
technology however, it is now possible to perfonn secondary processing of the proteins 
on the array. SELDI-TOF technology can now be combined with MS/1\4S. A tryptic 
digestion of proteins is performed and the resulting fragments are analysed to obtain 
sequence information, which can be used to identify the protein of interest. Mian et al. 
(2003) used SELDI-TOF MS to confirm that molecular profiling in conjunction with 
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Figure 3-2 Surface-enhanced laser desorption/ ionisation time-of-flight mass 
spectrometry. Proteins are selectively retained on a protein microarray and are mixed 
with an energy-absorbing molecule. Laser emission converts proteins to gas-phase ions,, 
which are separated by a TOF mass analyser to produce a unique mass spectrum for 
each sample. 
artificial neural network (ANN) algorithms can be applied towards predicting the 
biological behaviour of breast cancer cells to particular chemotherapeutic agents. 
Specific proteomic fingerprints that were indicative of chemotherapy-resistant and 
chemotherapy- sensitive cells were established. Isolation and sequencing could result in 
the identification of those proteins that are associated with chemotherapy-resistant and 
chemotherapy- sensitive phenotypes. 
3.4.5 Antibody Microarrays 
Antibody microarrays are a novel proteomic technique and provide a powerful 
technology for analysing the expression of hundreds of proteins simultaneously (Figure 
3-3). A high precision robot is used to print hundreds of monoclonal antibodies at a high 
density on a glass slide in a format that is compatible with existing hardware and 
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Add protein extraction/ 
labelling buffer 
Protein labelling 
Cy-5 Cy-3 
Removal of unbound dye 
6 
6 
a- a Combine and incubate with 
antibody t-nicroarray 
Scan 
Sample A Sample B 
Figure 3-3 The principles of an antibody microarray experiment. The array can be used 
to compare the protein expression profiles of two samples (test versus reference 
samples). The 2 protein samples are labelled with a different fluorescent dyes (e. g. Cy-3 
or Cy-5) and hybridised simultaneously to the array. Protein expression profiles are then 
compared. The relative ratios of red and green fluorescence at each spot allow the 
expression levels of specific proteins in each sample to be determined. 
74 
t-napier m Introduction to Proteome Analysis Techniques 
software tools for DNA microarrays (Kusnezow et al. 2003). The surface of the slide is 
chemically modified to present functional groups for the covalent binding of antibodies 
allowing the antibodies to maintain their activity despite immobilization (see section 
8.1.1). Protein extracts from 2 different samples are differentially labelled with 
fluorescent dyes (see section 8.1.3.1). The labelled extracts are then hybridised 
simultaneously to the antibody microarray. A fluorescence-based detection procedure, 
analogous to that used in gene expression profiling is exploited, in which the 
immobilised antibodies are used to capture fluorescently-labelled antigen (Haab et al. 
200 1). The relative ratios of red and green fluorescence at each spot allow the 
expression levels of specific proteins in each sample to be determined. Although still in 
its infancy, this technique has already been exploited in cancer research (Sreekumar et 
al. 2001; Ghobrial et al. 2005). In 2001, Sreekurnar et al. successfully utilised antibody 
microarrays to monitor alterations of protein levels in LoVo colon cancer cells treated 
with ionising radiation. 
3.5 Discussions and Conclusions 
Most of the proteornic studies described in this chapter have involved the creation of 
chemotherapy- and/or radiotherapy-resistant cell lines, the protein profiles of which 
have been compared with parental cell lines to identify potential biomarkers. Cell lines 
represent good in-vitro models with which to perform initial screening studies 
due to 
their ready availability, ease of culture and manipulation and their well characterised 
genotypes and phenotypes. However, it is acknowledged that results must 
be interpreted 
with caution and do not always transfer to the in-vivo clinical setting. 
This is because 
the microenvironment influences the behaviour of turnour cells and cultured cells are 
not subject to this influence. It is therefore 
important that any potential biomarkers are 
validated in a relevant clinical series. 
The global analysis of primary tumour tissue or 
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serum samples provides an alternative approach but this produces further technical 
problems. The proteomic analysis of samples from cancer patients requires carefully 
designed experiments with adequate sample numbers with relatively homogeneous 
characteristics (McShane et al. 2005). Tumours are heterogeneous and therefore 
microdissection may be required and more replicates must be performed in order to 
draw conclusive results. Clinical tissue samples are often small, especially in the case of 
pre ictive pre-treatment biopsies, resulting in limited amounts of material for analysis. 
MS instruments are becoming increasingly more sensitive and this will allow smaller 
and smaller amounts of protein to be effectively analysed in the future. Serum samples 
(Caprioli, 2005; Honda et al. 2005; Fujii et al. 2005) and fresh tumour samples (Rahman 
et al. 2005; Zhang et al. 2005) have been used in the identification of potential 
biomarkers for cancer screening, but their use in the identification of markers of 
response has not been reported. In recent years, advances in MS technology have 
involved the hybridisation of instruments whereby sections of conventional tandem 
mass spectrometers have been either added or replaced with devices that provide 
different or superior performance characteristics and enhanced sensitivities. These 
advances have opened up the possibility of applying MS analysis directly to turnour 
tissue (Schwartz et al. 2005) and the identification of proteins from formalin-fixed, 
paraffin-embedded archival tumour samples (Crockett et al. 2005; Hood et al. 2005). 
Additional improvements in all existing protocols will also be required, such that 
sample handling, sample preparation and analysis are standardised to allow data 
comparison between laboratories. 
Two-dimensional gel electrophoresis (2DE) was selected as the global proteornic 
approach for use in this thesis. This is because many of the more recent techniques 
(e. g. 
DIGE, ICAT and SELDI) require expensive specialist equipment and/ or software, 
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which was not available in the laboratory at the start of this thesis. MALDI-TOF MS 
was also selected as the analytical instrument with which to identify differentially 
expressed proteins. This is because MALDI-TOF MS offers several advantages over 
ESI-MS/MS including being more robust and user-friendly (see sections 3.4.1.4). 
Furthermore, although less sensitive than ESI-MS/MS, the level of sensitivity offered 
by MALDI-TOF MS (to ferntomole level) was found to be sufficient for this thesis 
because the use of cell lines ensured that the amount of starting material was not 
limited. Antibody microarrays were also tested as a complementary approach for the 
analysis of anticancer therapy. Antibody microarrays overcome many of the drawbacks 
associated with 2DE and therefore provide complementary data for the analysis of 
complex proteomes (see chapter VIII). Furthermore, the laboratory was already 
equipped with existing technology for the analysis of gene expression microarrays. This 
technology was also compatible for the analysis of antibody microarrays. 
The validation of data derived from proteornic studies is also imperative. Global 
approaches using thousands of known targets (e. g. microarray-based techniques) are 
prone to false discovery and over-interpretation (Qian and Huang, 2005; Reis-Filho et 
al. 2006). Protein identification of unknowns derived from proteomic approaches such 
as 2DE-MS adds a further level of potential error and over-fitting, which has resulted in 
guidelines to standardise the quality of future proteomics data (Wilkins et al. 2006). The 
confirmation and validation of targets identified using proteomic screening should be 
performed using a second method such as western blotting or immunocytochemistry 
and this may be combined with a complementary RNA-based transcriptomic screening 
approach (Zheng et al. 2005). Once the identification and significant expression change 
of a target protein has been confirmed then further detailed studies can ensue. 
Functional studies may include the in-vitro manipulation of protein and/or gene 
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expression using specific phannacological inhibitors and/or RNA interference. The 
analysis of the functional pathway which has been implicated may reveal further 
insights into the mechanism of action, cross-talk between cellular pathways and may 
also identify novel therapeutic targets. 
Proteornic techniques have identified novel biornarkers, which have the potential to 
predict response to anticancer therapy, however such markers require substantial further 
validation before being introduced to the clinic. Continuing improvements will also 
increase the use of these techniques in the study of therapy resistance. Anticancer 
therapy resistance is probably a multifactorial phenomenon and the increased 
understanding of the mechanisms involved will potentially pave the way for novel 
therapy regimes, new drug design and the personalisation of cancer treatment. 
3.6 Aims 
The aim of this thesis was to establish and optimise proteornic techniques, including 
2DE in combination with MALDI-TOF MS and antibody microarrays for use in the 
analysis of chemotherapy (cisplatin and doxorubicin) and radiotherapy resistance in 
human breast cancer cells. The identification of novel biomarkers that correlate with 
treatment response would not only increase our understanding on the mechanisms of 
resistance but may also allow therapy to be tailored on an individual patient basis. 
Ultimately, those patients unlikely to respond to a particular treatment strategy would be 
spared from serious life-threatening side effects for no therapeutic gain. These 
biomarkers would also suggest new drug targets for further therapeutic intervention. 
Overcoming resistance to both chemotherapy and radiotherapy would represent a major 
advance in the effective management of breast cancer today. 
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The majority of this thesis was focused on the establishment and optimisation of two- 
dimensional gel electrophoresis (2DE) and matrix-assisted laser desorption/ ionisation 
time-of-flight mass spectrometry (MALDI-TOF MS) and their application to the 
analysis of resistance to anticancer therapy in breast cancer. Chapter V details the 
principles behind these techniques and presents data on the optimisation of the methods. 
The following sections describe the final optimised protocols that were exploited for the 
subsequent analyses conducted in this thesis. 
All chemicals were of the highest quality (or of proteomics-grade) and were purchased 
from Sigma-Aldrich unless otherwise stated. The full addresses of suppliers are listed in 
A-m 
. ppendix 
A. The contamination of samples for proteomic analyses was minimised by 
wearing a lab coat, powder-free gloves and suitable hair protection (see section 5.2.1). 
Furthermore, wherever possible the preparation of samples for 2DE and MALDI-TOF 
MS were undertaken in a laminar flow hood (see chapter V). 
4.1 Cell Culture 
All cell culture reagents were purchased from Invitrogen Life Technologies unless 
otherwise stated. Cell lines were maintained in RPMI 1640 media supplemented with 
10% foetal calf serum (FCS), 2mM glutamine, lOOU/mI penicillin and 100pg/ml 
streptomycin (hereafter designated RPMI(s) for supplemented). A humidified 
atmosphere of 37'C and 5%CO2was provided for cell growth. Cells were harvested 
upon achievement of -70-80% confluence. Cells were detached from T-75cm 
2 tissue 
culture flasks for passage (and some experiments as described below) 
by enzymatic 
dissociation. All medium was aspirated from flasks to remove FCS, which would 
otherwise have saturated the dissociating enzyme. Three ml of 
TrypLETM Select 
(#12565-029) was added and flasks were incubated for approximately 5 mins at 37'C 
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and 5%CO2, Seven ml of RPMI(s) medium was then added to the enzyme/ cell 
suspension to facilitate cell removal and to saturate the enzyme preventing further 
cellular degradation. The cell suspension was transferred to a 30ml conical bottomed 
centrifuge tube and centrifuged at 2009 for 3 mins. The supernatant was discarded and 
the pellet was resuspended by gentle agitation. Cells were passaged at a ratio of I source 
flask to 3 daughter flasks. Thus, the cell pellet was resuspended in 6ml RPMI(s) 
medium and divided equally between the 3 daughter flasks. Subsequently, 8ml of 
RPMI(s) medium was added to each flask. 
4.2 Cell Counting 
Cells were harvested by enzymatic dissociation (see section 4.1) and resuspended in 
4ml RMPI(s) medium. Twenty-five [d of the cell suspension was mixed thoroughly 
with 25ýtl 0.4% (w/v) trypan blue and 10-15pl of the resulting cell suspension was 
applied to a haernocytorneter under a glass coverslip. Cells were counted in the 4 comer 
squares and the central square of the grid and cell concentration per ml was calculated 
(see Appendix B). 
4.3 Survival Assays 
The choice of survival assay with which to measure the level of in-vitro chemotherapy 
resistance was based on the pharmacokinetics of each of the drugs exploited. The MTT 
assay (see section 4.3.1) was selected to measure the relative resistance of in-vitro 
resistance to cisplatin because this assay was found to 
be more informative than the 
modified colony counting assay (see section 4.3.2) over the concentration range 
tested 
and gave accurate IC50 values (the concentration of 
drug required to achieve 50% cell 
death) for each cell line. In contrast, the MTT assay gave no 
kinetic data for 
doxorubicin and gave no indications of IC50 values over the concentration range tested. 
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For this agent, the modified colony counting assay proved more informative. This assay 
is also the standard assay used to measure the level of in-vitro resistance to ionising 
radiation and was therefore exploited for studies of radiotherapy resistance in this thesis. 
4.3.1 The MTT Assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide) assay is a 
cell survival assay based on the ability of a mitochondrial dehydrogenase enzyme from 
the surviving fraction of cells to produce dark blue formazan crystals from pale yellow 
MTT (Mosmann, 1983). These fonnazan crystals are largely impenneable to cell 
membranes and accumulate within viable cells. The subsequent solubilisation of cells 
results in the liberation of these crystals and the number of surviving cells is directly 
proportional to the level of fonnazan produced. 
These assays were performed in collaboration with Dr Mark Watson (University of 
Hull). Cells were harvested by enzymatic dissociation (see section 4.1) and plated in the 
inner 60 wells of triplicate 96-well tissue culture plates at a concentration of 10,000 
cells/ well (in 200[d volumes). An attachment period of 24 hrs was allowed prior to 
treatment with cisplatin. Subsequently, cisplatin was added in columns in replicates of 6 
wells at concentrations of 0,3.3,16.7,33.3,50.0,66.7,83.3,100.0 and 116.7pM. The 
tissue culture plates were incubated for 24 hrs at 37'C and 5%CO2. Following 
treatment, 50ýtl of media was removed from each well (including blanks) and 25ýtl of 
5mg/ml MTT reagent was added to achieve a final concentration of 2ýM Tissue culture 
plates were incubated for 24 hrs at 37'C and 5% C02 after which all the liquid was 
aspirated from the wells. One hundred [il of MTT lysis buffer 
[40% dimethylformamide 
(pH 6.7), 12.5% SDS] was added. Tissue culture plates were wrapped in aluminium foil 
to prevent heat damage and placed on a hot plate to 
facilitate cell lysis (10 mins, 900C). 
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Subsequently, the tissue culture plates were scanned at an excitation wavelength of 
570nm to measure absorbancies on a Multiscan MS plate reader (Thermo Electron). 
4.3.2. The Modified Colony Counting Assay 
The modified colony counting assay measures cell survival based on the ability of a cell 
to establish a single colony following cytotoxic insult. The number of surviving cells is 
directly proportional to the number of colonies formed. 
These assays were performed in collaboration with Dr. Mark Watson (University of 
Hull). Following achievement of -80% confluence, cells were harvested by enzymatic 
dissociation (see section 4.1). For assessment of in-vitro resistance to doxorubicin, cells 
were plated into triplicate wells of 6-well tissue culture plates at a concentration of 1000 
cells/ well. Doxorubicin was added at concentrations of 0,50,100,200 and 400nM 
approximately 3 hrs following cell plating. This allowed treatment to have an immediate 
effect on colony formation. The cells were incubated for 24 hours at 37'C and 5%CO2 
after which drug-containing RPMI(s) medium was removed and replaced with drug-free 
RPMI(s) medium. 
For assessment of in-vitro radiotherapy resistance, IxIO 
6 cells were irradiated with 
single ftactions of 0,2,4,6,8 and I OGy of ionising radiation (see further details see 
section 7.2.1). Post-irradiation, cells were seeded at a concentration of 1000 cells/ well 
in triplicate wells of 6-well tissue culture plates. 
Following treatment the cells were cultured for a 12-day period after which control cells 
reached a critical mass and individual colonies became 
indistinguishable. All medium 
was removed and cells were fixed for 5 mins, 
in ice cold Carnoy's fixative (3: 1 
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methanol: acetic acid). The following day cells were stained with 2ml I% Eosin or 
0.005% Gentian Violet for 2 mins. The residual stain was then removed in slowly 
running tap water. Plates were air-dried and scanned at a resolution of 36.3ýtm using a 
GS-800 laser densitometer (Bio-Rad) to produce a high resolution image. Colonies were 
defined as a group of >50 cells and were counted in each well. 
4.4 Two-Dimensional Gel Electrophoresis 
4.4.1 Protein Extraction 
Twenty-four hours prior to protein extraction, RPMI(s) medium was discarded and 
replaced with serum-free RPMI 1640 medium (supplemented only with 2mM 
glutamine, 10OU/ml penicillin and 100[ig/ml streptomycin). This prevented 
contamination of samples with proteins from FCS. Cells were harvested for protein 
extraction upon achievement of -80% confluence. Cells were washed in PBS, removed 
using a mechanical cell scraper and transferred to an EZ polypropylene microfuge tube 
(#223-9480; Bio-Rad) to prevent polymer contamination. The mechanical cell scraping 
method (rather than enzymatic dissociation) was exploited in order to ensure that 
membrane receptor proteins remained intact. This class of proteins is particularly 
important in the study of chemotherapy resistance (see section 2.4). Cells were washed 
twice in PBS by centrifugation at 200g for 3 mins and were resuspended in Iml of 
Isoelectric Focusing (IEF) buffer [7M Urea, 2M Thiourea, 4% CHAPS, 50mM 
Dithiothreitol (DTT), 1% Protease Inhibitor Mix (#80-6501-23; Amersham 
Biosciences), 0.2% IOOX Bio-Lyte 3/10 Ampholyte (#163-2094; Bio-Rad), 0.002% 
Bromophenol Blue]. Samples were placed on an end-over-end rotator for 15 mins at 
4'C and cellular debris was removed by centrifugation at 13,000g for 15 mins at 40C. 
The supematant was collected, transferred to a fresh chilled 
EZ polypropylene 
microfuge tube and stored at -80'C until further analysis. 
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4.4.2 Protein Quantification 
Materials and Methods 
The 2D Quant Kit (#80-6483-56; Amersham Biosciences) was used to determine the 
concentration of proteins prior to 2DE. This kit allows accurate protein quantification in 
the presence of detergents, reductants, chaotropes and carrier ampholytes. Such reagents 
are commonly used in IEF buffers (see section 5.1.1) and are incompatible with most 
other assays. The 2D Quant Kit quantitatively precipitates proteins whilst leaving the 
contaminants in solution. Copper ions bind specifically to the polypeptide backbone of 
proteins and unbound copper is measured with a colorimetric agent. The colour density 
is inversely related to the concentration of protein in the sample, which can accurately 
be determined using a BSA standard curve (Figure 4-1). 
BSA standards were prepared at protein quantities of 0,10,20,30,40 and 50ýtg. Five ýfl 
of each sample was added to a 1.5ml microfuge tube. Duplicate assays were performed 
for each sample. Five hundred [tl of Precipitant was added to each tube (including the 
BSA standards), vortexed briefly and incubated at room temperature (R7) for 3 mins. 
Five hundred ýLl of Co-precipitant was added and tubes were vortexed briefly. Protein 
was pelleted by centrifugation at 16,000g for 5 mins and the supernatants were 
subsequently discarded. Samples were returned to the centrifuge and following a brief 
pulse any remaining liquid was removed using a micropipette (I - 10 ýt 1). One hundred ýtl 
of the Copper Solution and 400ýtl distilled water were added and vortexed in order to 
dissolve the protein pellet. One ml of Working Colour Reagent (100 parts Colour 
Reagent A and I part Colour Reagent B) was added to each tube and mixed rapidly by 
inversion. Tubes were incubated for 15 mins at RT. Two hundred pI of each sample was 
added to a single well of a 96-well microtiter plate and absorbancies of the BSA 
standards and samples were read at an excitation wavelength of 
492nm on the Multiscan 
MS plate reader using distilled water as a reference. A BSA standard curve was 
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Figure 4-1 BSA Standard Curve. The curve is used to obtain an equation which can be 
used to calculate the quantity of protein (x) from the absorbance at 492nm (y). In this 
example the equation is y= -0.0038x + 0.4316, thus by simple rearrangement x can be 
calculated using the equation x == (y-0.4316) / -0.0038 
constructed and protein quantities were calculated (see Figure 4-1 for an example). 
4.4.3 Sample Preparation 
The ReadyPrep 2D Clean-Up Kit (#163-2130; Bio-Rad) was used for sample 
preparation prior to IEF. Proteins are quantitatively precipitated and concentrated whilst 
leaving behind and washing away contaminants known to interfere with IEF including 
ionic detergents, salts, nucleic acids and lipids. 
Two hundred pg of protein was transferred to a 1.5ml microfuge tube in a final volume 
of 100ýtl. Three hundred ýd of Precipitating Reagent I was added to each protein 
sample, vortexed and incubated on ice for 15 mins. Three hundred pI of Precipitating 
Reagent 2 was added and vortexed briefly. The samples were centrifuged at 16,000g for 
5 mins to form a protein pellet. The supernatants were subsequently 
discarded and 
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samples were returned to the centrifuge. Following a brief pulse any residual liquid was 
removed using a micropipette. Fourty [d of Wash Reagent I was added and samples 
were centrifuged at 16,000g for a further 5 mins. The washes were discarded. Twenty- 
five ýtl of proteornics-grade water (PGW; Bio-Rad) was added and each tube was 
vortexed for 20 secs. One ml of Wash Reagent 2 (chilled for I hr at -20'C prior to use) 
and 5ýil of Wash 2 Additive were added to the samples and vortexed for 1 min. Samples 
were subsequently incubated at -201C for 30 mins. Every 10 mins during this incubation 
period the samples were vortexed for 30 secs. Following incubation, the proteins were 
pelleted by centrifugation at 16,000g for 5 mins. The supernatants were discarded and 
samples were air-dried at RT until protein pellets became translucent in appearance. The 
pellets were resuspended in 200ýtl of IEF buffer (see section 4.3.1) by a series of 
pipetting steps and were subsequently vortexed for I min. Samples were incubated at 
RT for 5 mins and were subsequently sonicated for 5 mins in an ultrasonic waterbath 
(Ultrawave) to ensure protein pellets were fully resuspended in preparation for IEF. 
4.4.4 Isoelectrie Focusing 
Isoelectric Focusing (IEF) was exploited for the first dimensional separation of proteins. 
Within a pH gradient a protein will migrate to the anode or cathode until it reaches a 
point equal to its isoelectric point (pl) value. At this point the protein will have a net 
charge of zero and is said to be focused (see section 5.1.2). Eleven cm ReadyPrep IPG 
Strips (pH4-7 and pH7-10, #163-2015 and #163-2019; Bio-Rad) were passively 
rehydrated in the presence of protein samples. In order to account for any variations in 
expression that were not the result of differential display, 3 biological replicates were 
performed for each cell line. Two hundred [il of each protein sample 
(containing 200ýtg 
protein) was pipetted along the back edge of a channel 
in an II cm Rehydration/ 
Equilibration tray (#165-4025; Bio-Rad). The IPG strips were placed gel-side down 
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onto the samples using forceps (#165-4070; Bio-Rad). Three ml of mineral oil (#163- 
2129; Bio-Rad) was used to overlay each strip to prevent evaporation during the 
rehydration procedure. Rehydration was performed at RT over a 16 hr period. Electrode 
wicks (#165-4071; Bio-Rad) were subsequently placed over the electrodes at each end 
of the channels in an I lcm Protean IEF tray (#165-4020; Bio-Rad). Eight ýtl of PGW 
was pipetted onto each wick. Strips were transferred from the Rehydration/ 
Equilibration tray to the corresponding channel in the Protean IEF tray. The gel-side 
down orientation was maintained. Each strip was covered with 3ml of fresh mineral oil 
prior to IEF. The Protean IEF tray was positioned on the peltier platform of the Protean 
IEF Cell (#165-4001; Bio-Rad) and electrophoresis was initiated using the parameters 
described in Table 4-1 (also see section 5.1.2.4). Subsequently, the IPG strips were 
transferred gel-side upwards to a clean Rehydration/ Equilibration tray, wrapped in 
Saran wrap and stored at -80'C until further analysis. 
4.4.5 Equilibration 
Equilibration allowed the proteins to become fully saturated with sodium dodecyl 
sulphate (SDS), which transformed the proteins into a suitable state for separation in the 
second dimension (see section 5.1.3). IPG strips were thawed until translucent in 
appearance and equilibrated in 4ml of equilibration buffer 1 [50mM Tris-HCI (pH8.8) 
(BDH), 6M Urea, 30% Glycerol, 2% Sodium Dodecyl Sulphate (SDS), 1% 
Dithiothreitol (DTT), trace Bromophenol Blue]. The IPG strips were incubated for 10 
mins at RT on an orbital shaker (shaking at a frequency of -30 rpm). The buffer was 
subsequently decanted and replaced with 4ml equilibration buffer 11 
[50mM Tris-HCI 
(pHg. 8)ý 6M Urea, 30% Glycerol, 2% SDS, 2.5% lodoacetamide (IAA), trace 
Bromophenol Blue]. The IPG strips were incubated for a further 10 mins at RT on an 
orbital shaker following which the buffer was 
decanted. 
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Table 4-1 The IEF protocol exploited for pH4-7 and pH7-1 0 11 cm IPG strips using the 
Protean IEF Cell. IEF was performed at 250V for 20 mins, ramped up to 8000V for 2.30 
hrs and then maintained at 8000V for an additional 20,000 Volt-Hrs (VHRS). The 
voltage was then decreased to 500V to prevent the diffusion of focused proteins until 
user interception. 
STEP VOLTAGE(V) RAMP TIME 
(HRS: MINS) OR 
(VHRS) 
01 250 Linear 0: 20 
02 8000 Linear 2: 30 
03 8000 Rapid 20,000 VHRS 
04 500 Linear 99: 00 
4.4.6 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
exploited for the second dimensional separation of proteins during which the proteins 
were separated in accordance with molecular weight (see section 5.1.4). Equilibrated 
strips were transferred to the top of I lcm Pre-cast Criterion Gels (#345-0105; Bio-Rad) 
with an 8-16% linear gradient and embedded in hot (-80'C) 1% agarose. The agarose 
was allowed to solidify for 5 mins before proceeding. Gels were transferred to a 
Criterion Cell (#165-6001; Bio-Rad) and 1x Running Buffer [25mM Tris, 192mM 
Glycine, 0.1% (w/v) SDS (pH8.3)] (#161-0772; Bio-Rad) was added to the maximum 
fill levels of both upper and lower buffer chambers (60ml and 800ml respectively). 
Precision Plus Dual Colour molecular weight standards (#161-0374; Bio-Rad) were run 
simultaneously on each gel (Figure 4-2). Electrophoresis was performed at 200V 
constant for 65 minutes. 
4.4.7 Protein Visualisation 
Following electrophoresis, the gels were processed in order to visualise separated 
proteins. Numerous methods can be exploited, however the choice of method 
is 
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Figure 4-2 Precision Plus Dual Colour molecular weight standards (Bio-Rad) 
consisting of 10 recombinant pre-stained proteins with molecular weights ranging from 
10 to 250-kDa. There are 3 high-intensity reference bands (25-kDa (pink), 50-kDa 
(blue) and 75-kDa (pink), which allow the molecular weights of unknown proteins to be 
easily estimated. These standards are also useful in assessing the transfer efficiency 
during western blotting (see section 4.8.3). 
dependent on a number of factors including complexity, sensitivity, compatibility with 
mass spectrometry, cost and the availability of specialist equipment (G6rg et al. 2003). 
In this thesis, 2 different protein stains were exploited and are described further in 
section 5.1.5. 
4.4.7.1 Biosafe Coomassic Blue 
Gels were removed from their cassettes and placed in Nalgene Staining Boxes 
(#BOX1042; Scientific Laboratory Supplies). The gels were washed 3 times in distilled 
water for 5 mins per wash. Fifty ml Biosafe coomassie blue (#161-0787; Bio-Rad) was 
added to each gel and incubated for I hr at RT on an orbital shaker (shaking with a 
frequency of -20 rpm). The staining solution was subsequently removed and replaced 
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with -50ml distilled water. Destaining was performed overnight and the gels were 
stored in distilled water at RT until further analysis. 
4.4.7.2 Silver Staining 
The ProteoSilver Plus Silver Stain Kit (#PROTSIL2; Sigma-Aldrich) was used for 
silver staining. Gels were removed from their cassettes and transferred to Nalgene 
Staining Boxes. The proteins were fixed to the gel overnight by the addition of 200ml of 
fixing solution [50% ethanol, 10% acetic acid]. Fixing is the process whereby proteins 
are denatured and precipitated in large insoluble aggregates within the gel matrix. This 
prevents the diffusion of proteins preventing loss of resolution during the staining 
procedure and also removes buffer components (e. g. SDS), which may interfere with 
the efficiency of the stain. A fixing step was not required for Biosafe coomassie blue 
because this stain contains both methanol and phosphoric acid, which fix the proteins to 
the gel during staining. The fixing solution was decanted and the gels were washed in 
200ml of 30% ethanol for 10 mins. A further wash in 400ml of proteornics-grade water 
(PGW) was subsequently performed for 10 mins. The wash was removed and gels were 
incubated for 10 mins in 200ml of 1% ProteoSensitizer Solution. Gels were washed 
twice in 400ml of PGW for 10 mins per wash and equilibrated for 10 mins in 200ml of 
1% Silver Solution. Following removal of the Silver Solution gels were washed for I 
min in 400ml of PGW. The wash was discarded and gels were incubated for 5 mins in 
200ml of the Developer Solution [5% Developer Reagent A, 0.1% Developer Reagent 
B]. Ten ml of Stop Solution was added to each gel for 5 mins for cessation of the 
reaction. The Developer/ Stop Solutions were removed and a final wash was performed 
in 400ml of PGW for 15 mins. Gels were stored at RT in fresh PGW. 
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4.4.8 Image Acquisition and Data Analysis 
Gels were digitised using a specialist scanner in order to create an image, which was 
suitable for analysis. Sophisticated software packages can analyse the resulting images 
in order to assign those protein spots, which are differentially expressed between 
samples (see section 5.1.6). The gels were digitised with the GS-800 laser densitometer 
(#170-7980; Bio-Rad) and image analysis was performed using PDQuest (version 7.2.0; 
Bio-Rad). Protein spot detection and matching were performed automatically, however 
were manually reviewed and edited where necessary in order to remove false spots, 
include missed spots, distinguish spots within clusters and correct any false matches. 
The "Total Quantity in Valid Spots" normalisation method was used to compensate for 
any non-expression related variations in spot intensity. This method normalises by 
dividing the raw quantity of each protein spot in a member set by the total quantity of 
all the protein spots in that gel, which have been included in the master gel and is 
recommended when little is known about the possible source of sample variation. Only 
those protein spots that were reproducible in all 3 biological replicates were included in 
subsequent analyses. The Student's Mest (p<0.05) was used to assign differentially 
expressed protein spots. 
4.5 In-Gel Digestion 
In-gel digestion is the process by which proteins are digested to peptides within gel C; -_ 
pieces (see section 5.2.1). Gels were washed with distilled water for 5 minutes prior to 
the manual excision of selected protein spots. Gels were transferred to sterile gel cutting 
sheets (#165-7057; Bio-Rad). These mats have an inert surface and prevent the polymer 
contamination of protein samples. Excision was performed using a sterile scalpel. The 
cut was made as close to the edge of the spot as possible in order to reduce the volume 
of background gel and/ or the excision of neighbouring spots. In general, spot diameters 
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ranged from -1-3mm. As a control, an area of background gel was also excised and 
processed alongside the spots-of-interest (SOls). Excised spots were cut into small 
(<lmm 3) pieces and transferred to EZ polypropylene microfuge tubes. These tubes were 
exploited in order to prevent polymer contamination. 
4.5.1 Reduction and Alkylation 
A reduction and alkylation step was performed to disrupt any disulphide bonds within 
the proteins, which may reduce accessability of the digesting enzyme to specific 
cleavage sites. Gel particles were washed for 5 mins in distilled water. Samples were 
centrifuged at 13,000g for 30 secs and the wash was removed. One hundred and fifty [d 
of acetonitrile (ACN) was added for 15 mins at RT to dehydrate the gel pieces. ACN 
was discarded following centrifugation at 13,000g for 30 secs. The particles were dried 
down in a vacuum-centrifuge (Uniequip) for 30 mins. Fifty ýd of lOmM dithiothreitol 
(DTT)/ 0.1 M NH4HCO3 was added to each tube and the proteins were reduced by 
incubation at 560C for 30 mins. Gel particles were centrifuged at 13,000g for 30 secs 
and excess liquid was removed. Gel pieces were subsequently dehydrated by the 
addition of 150pl ACN for 15 mins. ACN was replaced with 50pil of 55mM 
iodoacetamide (IAA)/ 0.1 M NH4HC03and proteins were alkylated by incubation at RT 
in the dark (to protect the light-sensitive IAA) for 20 mins. Gel pieces were centrifuged 
at 13,000g for 30 secs and the liquid was discarded. 
4.5.2 Washing of the Gel Pieces 
Following reduction and alkylation, a series of washing steps was conducted in order to 
remove any contaminants including buffer components, protein dye and unpolymerised 
acrylamide. One hundred and fifty ýd of 0.1 M NH4HC03was subsequently added 
for 15 
mins after which 150pl of ACN was added. Samples were vortexed 
for 15 mins and 
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centrifuged at 13,000g for 30 secs prior to removal of the solution. Gel pieces were 
subsequently dehydrated in 150ýtl of ACN. Gel pieces were centrifuged at 13,000g for 
30 secs, the ACN was discarded and particles were dried down in a vacuum-centrifuge 
for 30 mins. One hundred and fifty ýtl of 0.1 M NH4HC03was added to each tube and, 
following an incubation period of 15 mins at RT, 150[d of ACN was added. Samples 
were vortexed for 15 mins, liquid was removed and gel particles were dehydrated with 
150ýtl of ACN for 15 mins at RT. If Biosafe coomassie blue stained gel pieces remained 
blue in appearance 150[tl of OAM NH4HC03 was added for 15 mins after which a 
further 150ýil of ACN was added. Samples were vortexed for an additional 15 mins and, 
following removal of the liquid, gel pieces were dehydrated with 150pl of ACN for 15 
mins. This was repeated until gel pieces were translucent in appearance. Once achieved 
gel pieces were dried down in a vacuum-centrifuge for 30 mins. 
4.5.3 Tryptic Digestion 
Proteins were digested with a sequence-specific enzyme to produce peptides for MS 
analysis. Trypsin was exploited for use in this thesis and is discussed further in section 
5.2.1. Gel pieces were rehydrated in 20ýtl of 25[tg/ml Trypsin Gold (#V5280; Promega) 
in 40rnM NH4HC03/ 10% ACN. Samples were incubated at RT for 1 hr after which any 
residual liquid was removed. An additional 50[tl of 40mM NH4HC03/ 10% ACN was 
added to each tube and samples were incubated overnight at 37'C. 
4.5.4 Peptide Extraction 
Following digestion the peptides were extracted from gel pieces. Fifteen [tl of 25mM 
NH4HC03was added to each tube and samples were incubated at 37'C for 15 mins with 
shaking (low speed vortexing). Gel pieces were centrifuged at 
13,000g for 30 secs and 
50[tl of ACN was added. Samples were incubated at 
37T for a further 15 mins with 
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shaking. Gel pieces were centrifuged at 13,00og for 30 secs and the supernatants were 
collected. Fifty ýtl of 5% formic acid was subsequently added to the gel pieces and 
samples were vortexed at 37'C for 15 mins. A further 50pl of ACN was added to each 
tube following centrifugation at 13,000g for 30 secs. Samples were incubated at 370C 
for 15 mins with shaking. Gel pieces were centrifuged for an additional 30 secs at 
13,, 000g after which the supernatants were pooled. Samples were dried down in a 
vacuum-centrifuge for -1 hr until -I O[LI of each sample remained. Peptides were stored 
at -20'C prior to MALDI-TOF MS analysis. 
4.6 Matrix-Assisted Laser Desorption/ lonisation Time-Of-Flight MS 
Proteins were identified by matrix-assisted laser desorption/ ionisation time-of-flight 
mass spectrometry (MALDI-TOF MS). The peptides from each protein sample were 
reconstituted with 20ýd of 50% ACN/ water and 1% formic acid and sonicated in the 
ultrasonic waterbath for 5 mins. The matrix was prepared by saturating a solution of 
50% acetonitrile/ water and 1% formic acid with 2,5 dihydroxybenzoic acid (DHB) 
(#85707; Sigma-Aldrich). Samples were prepared with the matrix-containing solution at 
2: 1 (sample: matrix) ratios and 3[il of each sample was spotted at a known location on 
an AnchorChipTM MALDI target (#209515; Bruker Daltonics) (see Figure 3-1). Mass 
spectra were recorded in the reflectron mode on a Bruker Daltonics Reflex IV MALDI- 
TOF MS equipped with a 337nm nitrogen laser following an external calibration with a 
peptide calibration standard (#206195; Bruker Daltonics). Ions were accelerated through 
a potential of 20Kv into the TOF mass analyser and those ions within a m1z range of 
900-2500 were detected. Analysis was performed using the Bruker Software Suite. Data 
were acquired using the Flex Control programme (version 1 .0 for chapter VI and 
version 2.4 for chapter VII) and processed with XMASS (version 5.1.1 
for chapter VI) 
or Flex Analysis (version 2.4 for chapter VII) and Biotools 
(version 2.0 for chapter VI 
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and version 3.0 for chapter VII). Peaks were de-isotoped and monoisotopic peptide 
masses were assigned. Contaminating ions from common keratins and background 
peaks, which were present in multiple spectra from unrelated proteins, were removed 
(see section 5.2-3.3). The resultant peptide mass fingerprints (PMFs, a list of all peptide 
masses from the POI; see section 3.4.1.4) were searched against the NCBInr database 
(version 20060216 containing 3292813 sequences; 1128164434 residues for chapter VI 
and version 20060429 containing 3605113 sequences; 1238276235 residues for chapter 
VII) using the MASCOT programme (www. matrixscience. com) for protein 
identification. The search was restricted to human taxonomy (140744 sequences for 
chapter VI and 146398 sequences for chapter VII). Fixed carbamidomethyl 
modifications resulting from the use of IAA for alkylation and variable methionine 
oxidation modifications were considered (see section 5.2.3.5). A maximum of I missed 
tryptic cleavage was considered and the mass tolerance for the monoisotopic peptide 
masses was set at ±0.1%. The MOWSE scoring algorithm was used by MASCOT to 
determined whether protein identifications were significant (p<0.05) (see section 5.2.3). 
MOWSE scores greater than 64 were deemed significant for chapters VI and VII. 
4.7 Antibody Microarrays 
4.7.1 The Sigma-Aldrich Panaroma TM Cell Signalling Antibody Microarray Kit 
The PanoramaTMCell Signalling Antibody Microarray (#CSAAl; Sigma-Aldrich) was 
exploited, which detects a wide variety of proteins representing a broad range of 
biological functions including apoptosis, cell cycle, neurobiology, cytoskeleton, signal 
transduction and nuclear proteins. Each array was composed of 224 highly specific 
antibodies spotted in duplicate on three-dimensional nitrocellulose-coated glass 
microarray slides (see section 8.1.1.3). The microarrays contained 32 sub-arrays with 
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duplicate spots of 7 antibodies as well as a single positive control for Cy-3 and Cy-5 
fluorescent protein detection (see section 8.1.3.1) and a single negative control. 
4.7.1.1 Protein Extraction 
Cells were harvested for protein extraction upon achievement of -80% confluence. 
Protein was extracted from 2 T-75cm 2 tissue culture flasks (-2. OxI 06 cells in total) for 
each cell line yielding ý: I mg/ml of protein extract as follows. Cells were washed twice 
with cold PBS to remove proteins from FCS. One ml of Buffer A (a component of the 
PanoramaTm Cell Signaling Antibody Microarray Kit) was added directly to I flask of 
each cell line and incubated in ice on an orbital shaker (shaking with a frequency of -20 
rpm) for 5 mins. Cells were removed using a mechanical cell scraper to ensure all 
membrane proteins remained intact and the Buffer A/cell mix was transferred to the 
second flask. This flask was also incubated in ice on an orbital shaker for 5 mins. 
Following removal of the remaining cells with a mechanical cell scraper the Buffer 
A/cell mix was transferred to a 1.5ml microfuge tube. Samples were centrifuged at 
-80OOg for 10 secs and the supernatants were transferred to fresh tubes. 
4.7.1.2 Protein Quantification 
Protein concentrations were detennined using the Bradford Assay (#B6916; Sigma- 
Aldrich) as recommended by Sigma-Aldrich (supplier of the Panorama Cell Signalling 
Antibody Microarray Kit). This assay is based on the formation of a complex between 
the dye (Brilliant Blue G) and the proteins in solution. The protein-dye complex causes 
a shift in the absorption maximum of the dye from 465 to 595nm. The amount of 
absorption is proportional to the amount of protein present (Bradford, 1976). BSA 
protein standards were prepared with Buffer A at concentrations of 0.1,0.3,0.6,0.9,1.2 
and 1.4mg1ml. To ensure the concentration of each sample was within this range 
(0.1- 
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1.4mg/ml) unknown protein samples were prepared at 1: 5 and 1: 10 dilutions with 
Buffer A. Five gl of each BSA standard was added to separate wells of a 96-well plate 
and 5ýfl of each dilution for each unknown protein sample was also added to the plate. 
Assays were performed in duplicate for the unknown protein samples. In addition, 5[d 
of Buffer A was added to the reference well. Two hundred and fifty gl of the Bradford 
Reagent was added to every well in use and samples were mixed for 30 sees on the 
Multiscan MS plate reader. Samples were incubated at RT for 5 mins after which 
absorbancies were read on the same plate reader at an excitation wavelength of 595nm. 
A standard curve was plotted for the BSA standards and the unknown concentrations of 
the protein samples were calculated. Samples with protein concentrations >I. Omg/ml 
were used for fluorescent labelling and the range of concentrations used in this study 
was 1.0 to 2.99mg/ml. 
4.7.1.3 Fluorescent Labelling of Proteins 
Protein extracts were diluted to a concentration of I. Omg/ml in Buffer A prior to 
labelling. A dual fluorescent-labelling assay analogous to that exploited in gene 
expression microarray experiments was used. Extracts were labelled separately using 
either NHS-ester activated mono-functional Cy-3 or Cy-5 dyes (#PA23001 and 
#PA25001; Amersham Biosciences) to prevent the cross-linking of protein molecules. 
These dyes were supplied in a Iyophilised form. One ml of the control sample 
(sensitive-phenotype) was added directly to Cy-3 vial and Iml of the test sample 
(resistant-phenotype) was added to the Cy-5 vial. The total volume in each tube was 
therefore Iml. Samples were mixed thoroughly by inversion and incubated for 30 mins 
at RT in the dark (to prevent photo-bleaching of the light-sensitive fluorescent dyes). 
During this period the samples were mixed by inversion every 10 mins. Labelled 
protein samples were removed from free Cy-3/Cy-5 dye using the SigmaSpin 
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purification columns supplied with the kit. Columns were centrifuged for 2 mins at 
750g following which the eluate was discarded. Columns were placed in new collection 
tubes. One hundred and fifty ýil of labelled sample was loaded onto the centre of the 
column and centrifuged at 750g for 4 mins. The eluate was retained and the post- 
labelling protein concentration was determined using the Bradford Assay (see section 
4.7.1.2). This concentration was required to calculate the labelling efficiency (see 
section 4.7.1.4 and appendix Q. Labelled protein was stored at -20'C until 
hybridisation. Four biological replicates were analysed. Two reverse-colour labelled 
(dye-swapped) replicates were also analysed in which the control sample (sensitive- 
phenotype) was labelled with Cy-5 and the test sample (resistant-phenotype) was 
labelled with Cy-3. This allowed compensation for any potential bias in the binding of 
Cy-3 or Cy-5 dyes to protein (see section 8.1.3.1). 
4.7.1.4 Hybridisation 
The absorbancies of Cy-3 and Cy-5 labelled samples were read at excitation 
wavelengths of 552mn and 650mn respectively using a Libra SII Spectrophotometer 
(Biochrom). These absorbance values were used to calculate the dye to protein molar 
ratio (D/P) following the calculations described in Appendix C. The D/P is used to 
assess the labelling efficiency and only those preparations with D/Ps ý! 2 were hybridised 
to the microarrays as instructed by the manufacturer of the kit. The hybridisation of 
preparations with D/Ps <2 reduces the sensitivity of the antibody microarray technique. 
The microarray slide (supplied with the kit) was washed by a brief submersion in PBS. 
Cy-3- and Cy-5-labelled samples were added at equal protein concentrations 
(10ýtg/ml 
each) to 5ml Array Incubation Buffer. The resulting solution was mixed 
by inversion 
and added to well I of the QuadriPERM Cell 
Culture Vessel supplied with the kit. The 
microarray slide was added to the well containing the 
labelled samples. The vessel was 
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subsequently protected from exposure to light with aluminium foil and incubated for 45 
mins at RT on an orbital shaker (shaking with a frequency of -30 rpm). Five ml of 
Washing Buffer was added to wells 2,3 and 4 and the microarray slide was 
subsequently washed on an orbital shaker for 5 mins in each well. Washing Buffer was 
decanted from well 4 and replaced with 5ml of distilled water for a final wash for 2 
mins. The microarray slide was removed from the vessel and air-dried in the dark 
ovemight. 
4.7.1.5 Data Analysis 
Microarray slides were scanned with a GenePix Personal 41 OOA Microarray Scanner 
(Axon Instruments) using 532nm (for the excitation of Cy-3) and 635nin (for the 
excitation of Cy-5) lasers. The laser photomultiplier tube (PMT) gains were manually 
set for each dye to ensure a normal ratio of I (±O. I) across the whole microarray and 
microarrays were scanned at a resolution of 10ýtm/pixel. Primary analyses were 
performed with the GenePix Pro software package (version 4.1; Axon Instruments). 
Images of scanned microarrays were gridded and linked to a protein print array list. 
Results files were generated, which included feature name, individual dye intensities at 
each feature and the dye ratio (635/532) at each feature. These files were imported to 
the Acuity (version 4.0) programme (Axon Instruments) for the identification of 
differentially expressed proteins. The antibody microarray protocol gave little 
information regarding data analysis, therefore differentially expressed proteins were 
identified following the instructions supplied with the Acuity software for the analysis 
of gene expression microarrays (see chapter 
VIII). Antibody microarrays were 
normalised on the basis of the Lowess method 
due to slight skews in the data 
distribution. L09 ratios of Cy-5 to Cy-3 were exploited to estimate the relative 
concentration of each protein in the 
2 independently fluorescently-labelled samples. 
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Unreliable data were removed from analyses by applying strict quality control criteria. 
Such criteria were set to include only those spots with a small percentage (<3%) of 
saturated pixels, spots that were not flagged as absent, spots with relatively uniform 
intensity and uniform background and those spots that were detectable above 
background levels. The Student's t-test (p<0.05) assuming ýequal variances was 
performed to identify those proteins that were successfully dye-swapped and from this 
group, those proteins demonstrating a ý! 2-fold change in expression in >- 50% of 
individual microarrays were deemed significant. A >2-fold change in expression was 
selected because this is the standard cut-off used for the analysis of gene expression 
microarray data (see chapter VIII). 
4.7.2 The Labvision Antibody Microarray Kit 
The Labvision Antibody Microarray Kit (#TAA-00 1; Neornarkers) was exploited, 
which detects a wide variety of proteins representing a broad range of biological 
functions including proteins involved with apoptosis, signal transduction, the regulation 
of transcription, anglogenesis and neurobiology. Each array was composed of 720 
highly specific antibodies spotted in triplicate on glass-derivatized microarray slides 
(see section 8.1.1.1). Unfortunately, the specific surface chemistry was proprietary 
information, however the glass microarray slides were known to be coated with a 
special polymer to facilitate the immobilisation of antibodies. This differed from the 
antibody microarrays purchased from Sigma-Aldrich, which contained only 224 highly 
specific antibodies spotted in duplicate on nitrocellulose-coated glass microarray slides 
(see section 4.7.1). The Labvision antibody microarrays contained 16 sub-arrays as well 
as a number of antibodies for the detection of 
house-keeping proteins (e. g. claudins, 
actins, myosin, tubulin and laminin) for use as positive 
internal controls and a number 
of antibodies for the detection of rabbit, mouse and viral proteins 
for use as negative 
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controls (for protein extracts from human samples). Other differences between the 
antibody microarray kits included differences in the fluorescent labelling and 
hybridisation processes due to variations in the manufacturer's protocols. Such 
differences will be highlighted below. 
4.7.2.1 Protein Extraction 
Cells were harvested for protein extraction upon achievement of -80% confluence. 
Protein was extracted from a single T-75cm 2 tissue culture flask for each cell line. A 
single T-75cm 2 tissue culture flask was found to yield a sufficient quantity of protein 
(0.25 to 2.5mg/ml) for use with the Labvision Antibody Microarray Kit. This is in 
contrast with the Panaroma Cell Signalling Antibody Microarray Kit, which required 
extraction from 2 T-75CM2 tissue culture flasks to yield >I. Omg/ml of protein. This 
difference may have been the result of a more efficient Extraction Buffer supplied with 
the Labvision Antibody Microarray Kit or alternatively the use of different cell lines in 
each study. Cells were washed twice in 5ml of cold PBS to remove proteins from the 
FCS and were detached using a mechanical cell scraper in order to maintain the 
integrity of membrane proteins. Cells were transferred to a 30ml conical bottomed 
centrifuge tube and pelleted by centrifugation at 200g for 3 mins. The cell pellet was 
resuspended in Iml cold PBS and washed by centrifugation at 30OOg for 3 mins at 4'C. 
PBS was discarded and the wash was repeated to ensure all proteins from the FCS were 
removed from the samples. The final wash was removed and the cell pellet was 
incubated on ice for 5 mins. Five hundred pl of Extraction Buffer was added to each 
sample, mixed thoroughly by pipetting and incubated on ice for 10 mins. During this 10 
min incubation period the samples were vortexed briefly every 2 mins. Cellular debris 
was removed by centrifugation at 13,000g for 10 mins at 4'C after which the 
supernatants were transferred to fresh chilled microfage tubes. 
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4.7.2.2. Protein Quantification 
Materials and Methods 
Protein Quantification was performed using the RC-DC Protein Assay Kit (# 500-0122; 
Bio-Rad) as recommended by Neomarkers (supplier of the Labvision Antibody 
Microarray Kit). The RC-DC assay is based on the Lowry assay, which involves the 
reaction of protein with an alkaline copper tartrate solution and a Folin reagent (Lowry 
et al. 1951). Proteins react with copper in the alkaline medium and the copper-treated 
proteins subsequently reduce the Folin reagent. Reduced Folin has a characteristic blue 
colour, the absorbance of which can be read at excitation wavelengths between 650- 
750nm. BSA protein standards were prepared with distilled water at concentrations of 
0.2,0.5,0.8,1.2 and 1.5mg/ml. Each unknown protein sample was prepared at 1: 2 and 
1: 5 dilutions. Unknown protein samples were assayed in duplicate. Twenty-five [d of 
BSA standards and protein samples were added to 1.5ml microfuge tubes. One hundred 
and twenty-five ýtl of RC Reagent I was added to each tube, vortexed and incubated at 
RT for I min. One hundred and twenty-five pl of RC Reagent 11 was added to each tube, 
vortexed and centrifuged at 16,000g for 5 mins. Supernatants were discarded, tubes 
were returned to the centrifuge and following a brief pulse any residual liquid was 
removed. One hundred and twenty-seven ýd of Working Reagent A was added to each 
tube. Working Reagent A was composed of 5ýtl of DC Reagent S for every 250ýd of DC 
Reagent A required for the run. Samples were incubated at RT for 5 mins and were 
subsequently vortexed for I min. One ml of DC Reagent B was added, mixed rapidly 
using the vortex and incubated at RT for 15 mins. Two hundred pI of each sample was 
added to individual wells of a 96-well microtiter plate and absorbancies were read at an 
excitation wavelength of 692nm using distilled water as a reference. A BSA standard 
curve was constructed and the unknown concentrations of protein samples were 
calculated. 
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4.7.2.3 Fluorescent Labelling of Proteins 
Forty [d of each sample containing 10-100[tg of protein was required for fluorescent 
labelling. This equates to 40[d of each sample with protein concentrations between 0.25 
to 2.5mg/ml. This kit therefore allows smaller quantities of protein to be analysed than 
the Panorama Cell Signalling Antibody Microarray Kit (requiring ýJ. Omg/ml for 
fluorescent labelling). For the purpose of this study all replicates were performed using 
I OOgg of protein to maximise the sensitivity of the assay. This was because the protein 
samples were not limited and each extraction yielded >2.5mg/ml of protein. Therefore, 
40ýtl of each sample containing 100ýtg of protein (diluted with Extraction Buffer) was 
transferred to a fresh 1.5ml microfuge tube. Lyophilised NHS-ester activated Cy-3 and 
Cy-5 dyes (#PA23001 and #PA25001; Amersham Biosciences) were each resuspended 
in 45[il dimethylsulfoxide (DMSO). Five [tl of the Cy-3 dye was added to the control 
sample (sensitive-phenotype) and 5ýd of the Cy-5 dye was added to the test sample 
(resistant-phenotype). In contrast, the fluorescent labelling of proteins with the 
Panorama Cell Signalling Antibody Microarray Kit required the addition of 1ml of each 
protein sample directly to the Cy dyes in their Iyophilised form. Five pl of Labelling 
Buffer was added to each tube and mixed thoroughly by pipetting. Samples were 
incubated in the dark for 2 hrs at 4'C. This differed from the fluorescent labelling 
procedure utilised for the Panorama Cell Signalling Antibody Microarray Kit, which 
involved the incubation of protein samples in the dark for 30 mins at RT. 
During the 2 hr incubation period samples were vortexed every 10 mins. Samples were 
incubated for an additional 20 mins at RT after which the labelled proteins were purified 
from free Cy-3/Cy-5 dye using the purification columns supplied with the kit. The 
purification columns were placed in 2ml collection tubes and allowed 
to drain by 
gravity. Buffer was discarded and the columns were returned 
to the collection tubes. 
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The columns were centrifuged at 10OOg for 2 mins to remove the remaining buffer and 
transferred to fresh collection tubes. Samples were applied to the centre of the columns 
and centrifuged at I OOOg for 4 mins. The purified labelled protein samples were 
subsequently collected. Alternatively, the labelled proteins were purified using 
SigmaSpin purification columns (#S5059; Sigma-Aldrich) following the protocol as 
previously described (see section 4.7.1.3). Three biological replicates were created to 
account for any variations in expression that were not the result of differential display 
(see chapter IX). In addition, 2 dye-swapped replicates were also created to account for 
any potential bias in dye incorporation. For such replicates control samples (sensitive- 
phenotype) were labelled with Cy-5 and test samples (resistant-phenotype) were 
labelled with Cy-3. 
4.7.2.4 Hybridisation 
The absorbancies of Cy-3 and Cy-5 labelled samples were read at excitation wave- 
lengths of 552m-n and 650mn respectively using a Libra Sll Spectrophotometer 
(Biochrom). The absorbancies of labelled protein samples were also read at 280nm 
using a Biotech Photometer (UV I 10 1; WPA). These absorbance values were used to 
calculate the D/P ratios according to the manufacturer's instructions (Appendix D). 
Those preparations with D/Ps ý2 were hybridised to the microarrays. Non-specific 
binding sites on the antibody microarray slides were blocked in 5ml blocking buffer 
[3% BSA in PBS] on an orbital shaker (shaking with a frequency of -30 rpm) for 30 
mins. Fifteen ýtl of labelled protein from control and test samples were mixed. Thirty gl 
of Hybridisation Buffer was added to the labelled protein sample. Labelled protein was 
applied to the top of the microarray area under a coverslip and slides were sealed 
in a 
hybridisation chamber (MWG Biotech AG). Hybridisation was allowed to proceed 
for 2 
hrs at RT after which the slides were removed 
from the chamber and submerged in 50ml 
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washing buffer [0.05% Tween 20 in PBS] for removal of the coverslip. Slides were 
washed in -40ml fresh washing buffer on an orbital shaker (shaking with a frequency of 
-30 rpm) for 10 mins at RT. This washing step was repeated a further 3 times. 
Subsequently, the slides were subjected to a final rinse by submersion in distilled water 
and dried by centrifugation using a rotor with swinging buckets at I OOOg for I min (see 
section 9.3.2.1). Antibody microarrays were stored in the dark overnight prior to 
analysis. 
4.7.2.5 Data Analysis 
Antibody microarray slides were scanned and analysed as described in section 4.7.1.5. 
Again, little information regarding data analysis was supplied with the antibody 
microarray kit, thus differentially expressed proteins were identified following 
instructions supplied by the Acuity software. A different quality control procedure than 
that utilised for the analysis of the antibody microarray slides purchased from Sigma- 
Aldrich was adopted for the analysis of these antibody microarray slides. This is 
because >80% of the features represented on these antibody microarrays were excluded 
using the quality control criteria depicted in section 4.7.1.5. This is because of the 
particularly poor quality of spot morphology in comparison to those spots represented 
on antibody microarrays purchased from Sigma-Aldrich (see section 9.3.2.1). The 
quality control procedure exploited for the analysis of these antibody microarrays was 
therefore based on that used for the successful analysis of gene expression microarrays. 
Individual features were reviewed manually in GenePix Pro (version 4.1) and those 
spots that were not found or were of particularly poor quality were 
flagged. Once the 
data for each slide had been imported into the Acuity (version 4.0) programme, a 
dataset 
was created by filtering each array to include only those 
features with the parameter 
"Flags ý! 0". This ensured that only those features which were "found", and not "bad" or 
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44not found", were included in the analyses (Mark Watson et al. personal communication 
and manuscript submitted). This allowed the maximum number of features to be 
analysed, however, it highlights the importance of confirmation techniques. Following 
creation of the dataset, those differentially expressed proteins were identified using the 
standard >2.0 fold cut-off level (see section 9.3.2.2). 
4.8 Western Blotting 
4.8.1 Protein Extraction 
Cells were harvested by enzymatic dissociation as described in section 4.1. This method 
of harvesting (rather than the mechanical method) was found to be suitable since none 
of the antibodies exploited were specific for membrane proteins. Cell pellets were 
resuspended in Iml of PBS and transferred to a microfage tube. Cells were washed by 
centrifugation at 200g for 3 mins. The wash was removed and the cell pellet was 
resuspended in Iml of Laemmli Buffer [62.5mM Tris-HCI (pH6.8), 10% Glycerol, 2% 
SDS, 5% P-mercaptoethanol, 1% Protease Inhibitor Mix (Amersham Biosciences) and 
0.00125% Bromophenol Blue]. Samples were placed on an end-over-end rotator for 15 
mins at 4'C and cellular debris was removed by centrifugation at 13,000g for 15 mins at 
4'C. Supernatants were transferred to fresh chilled microfuge tubes and stored at -800C 
until further analysis. 
4.8.2 Protein Quantification 
Protein concentration was determined using the RC-DC Protein Assay Kit (#500-0122; 
Bio-Rad) as described in section 4.7.2.2. This kit was exploited because it is able to 
tolerate components of the Laemmli Buffer, such as 62.5mM Tris-HCI 
(pH6.8) and 5% 
P-mercaptoethanol, which are compatible with neither the Bradford Assay (Sigma- 
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Aldrich; see section 4.7.1.2) nor the 2D Quant Kit (Amersham Biosciences; see section 
4.4.2). 
4.8.3 Immunoblotting 
Protein samples were thawed slowly on ice and denatured at 95'C for 5 minutes prior to 
immunoblotting. Homogeneous 12% Novex(X Tris-Glycine gels (#EC6005BOX; 
Invitrogen Life Technologies) were assembled into a vertical electrophoresis unit 
(Sigma-Aldrich) and 1x Running Buffer [25mM Tris, 192mM Glycine, 0.1% (w/v) SDS 
(pH8.3)] (# 161-0772; Bio-Rad) was added to the upper (I 20ml) and lower (I 120ml) 
buffer chambers. Homogeneous 12% gels were selected due to the POIs being within 
the recommended size range for such gels. Equal amounts of denatured protein (15- 
25ýtg/well) in a final volume of 20[d were subsequently loaded into individual wells 
using gel-loading pipette tips (Scientific Laboratory Supplies). Five [tl of both Cruz 
Marker molecular weight standards (4SC-2035; Santa Cruz, see Figure 4-3) and 
Precision Plus Dual Colour molecular weight standards (#161-0374; Bio-Rad, see 
Figure 4-2) were also added to individual wells. Precision Plus Dual Colour molecular 
weight markers were used to assess the efficiency of protein transfer from the gel to the 
nitrocellulose membrane. Any remaining wells were filled with 20ýtl of Laemmli Buffer 
to ensure uniform electrical resistance across the gel. SDS-PAGE was performed at 
200V constant for 60 mins. The gels were disassembled from cassettes and were 
equilibrated in chilled transfer buffer [25mM Tris, 192mM Glycine and 20%(v/v) 
methanol) with the appropriate number of Mini Trans-BlotS filter paper pieces (# 170- 
3932; Bio-Rad), Trans-Blotg nitrocellulose membranes (0.45[im (suitable for the 
analysis of proteins larger than 15-kDa), #162-0115; 
Bio-Rad) and fibre pads for 15 
mins at 40C. This step was performed in order to remove contaminating electrophoresis 
buffer salts and neutralisation salts (resulting 
from the denaturation of nucleic acids 
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Figure 4-3 Cruz Marker molecular weight standards (Santa Cruz) consisting of 6 
recombinant unstained proteins with molecular weights ranging from 23 to 132-kDa. 
Such protein standards were detected by enhanced chemiluminescence (ECL) and were 
therefore used to estimate the molecular weights of the unknown protein bands. 
prior to electrophoresis). These salts have the potential to increase conductivity of the 
transfer buffer and the amount of heat generated during transfer. Following 
equilibration, transfer cassettes were set up according to the manufacturer's instructions 
(Figure 4-4). The cassettes were then transferred to the Mini Trans-Blot(X 
Electrophoretic Transfer Cell (#170-3930; Bio-Rad) and the Bio-Ice cooling unit was 
added. The tank was filled with transfer buffer and a stirring bar was added to maintain 
even buffer temperature and ion distribution. Electrophoretic transfer was performed for 
2 hrs at I OOV and 4'C (to prevent sample degradation). Membranes were subsequently 
transferred to clean Nalgene staining boxes (#BOX1040; Scientific Laboratory 
Supplies). Non-specific binding sites were blocked by incubating the membranes in 
20ml blocking buffer [5% non-dry fat milk and 0.05% Tween 20 in Tris-Buffered 
Saline (TBS-T)] for I hr at RT on an orbital shaker (shaking with a frequency of -40 
rpm). Primary antibodies were added to the blocking buffer for 1-2 hrs at R Ton an 
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Figure 4-4 Assembly of the transfer cassette for western blotting 
orbital shaker (see individual chapters for antibodies used and their concentrations). 
Membranes were washed 3 times for 5 mins each in TBS-T following which the 
appropriate HRP-conjugated secondary antibody (anti-mouse or anti-rabbit, #SC-2031 
and #SC2030; Santa Cruz) was added at a concentration of 1: 1000 for I hr at RT. 
Membranes were washed a further 3 times in TBS-T for 5 mins each and proteins were 
detected using the Supersignalk West Pico Chemiluminescence Kit (#34078; Pierce 
Biotechnology) according to the manufacturer's instructions. The two substrate 
components (West Pico Luminol/ Enhancer Solution and West Pico Stable Peroxide 
Solution) were mixed at 1: 1 ratios to prepare the Supersignal(t West Pico Substrate 
Working Solution. Membranes were incubated in the Working Solution for 5 mins with 
gentle agitation, placed in a light-proof developing cassette and covered with a plastic 
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sheet. Membranes were exposed to CL-XPosurefIMTM(#34090; Pierce Biotechnology) 
for an initial 5 min period. Films were developed by sequential gentle agitation in GBX 
Developer (# 190-0943; Kodak), 2% acetic acid and GBX Fixer (# 190-1875; Kodak) for 
30-60 secs in each. Finally films were rinsed under running tap water and allowed to 
air-dry. Additional exposure times were subsequently allowed depending on results 
from the initial exposure. Membranes were stored in PBS at 40C overnight prior to 
detection of the house-keeping proteins GAPDH or beta actin (loading controls). 
4.8.4 Detection of House-Keeping Proteins 
PBS was discarded and membranes were subsequently re-blocked in blocking buffer for 
I hr at RT on an orbital shaker (shaking at a frequency of -40 rpm). Anti-rabbit 
GAPDH (#Ab9485; Abcam. ) or anti-rabbit beta actin (#Ab8227; Abcam) primary 
antibodies were added at a concentration of 1: 1000 and incubated at RT for I hr. 
Membranes were washed in 3 changes of TBS-T for 5 mins each, following which the 
anti-rabbit HRP-conjugated secondary antibody (#SC-2030; Santa Cruz) was added for 
I hr at RT. Membranes were washed in a further 3 changes of TBS-T for 5 mins each 
and expression was detected as described in section 4.8.3. 
4.8.5 Image Analysis 
Films were scanned using the GS-800 laser densitometer (Bio-Rad) ensuring that bands 
were not saturated prior to quantitation. Protein expression was quantitated using the 
Quantity-One software package (version 4.6.1; Bio-Rad). A normalised quantity of each 
protein was obtained after normalisation to the GAPDH or beta actin band for the same 
sample. A ratio of the normalised quantities was obtained for each protein between 
paired samples (sensitive and resistant). Fold-changes were calculated using the average 
ratio from 3 replicates of each cell line to determine the level of differential expression. 
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CHAPTER V 
ESTABLISHMENT AND OPTIMISATION OF 2DE AND 
MALDI-TOF MS 
Aims: 
To establish and optimise two-dimensional gel electrophoresis (2DE) and 
matrix-assisted laser desorption/ ionisation-time-of-flight mass spectrometry 
(MALDI-TOF MS) in a clinical laboratory setting for the analysis of resistance 
to anticancer therapy in an in-vitro breast cancer cell model. 
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5.1 Two-Dimensional Gel Electrophoresis 
Two-dimensional gel electrophoresis (2DE) is the gold-standard for the separation of 
complex protein samples and is often combined with mass spectrometry (MS) to 
identify proteins-of-interest (Figure 5- 1). The technique resolves proteins on the basis of 
two distinct properties: charge (pl) and mass (see section 3.4.1). The array of resulting 
proteins can be visualised with protein-binding dyes and compared using sophisticated 
software packages to identify those proteins that are differentially expressed between 
phenotypes e. g. therapy- sensitive and therapy-resistant. Unfortunately, 2DE is 
recognised to be technically difficult and one of the primary challenges has been to 
achieve high resolution and reproducibility. High resolution ensures that the maximum 
numbers of protein species are separated and must be achieved to maximise the 
visualisation of complex proteomes. Poorly resolved gels are difficult to analyse and 
may result in matching errors during analysis. Also proteins may be masked within 
horizontal and/ or vertical streaks leading to a biased analysis of the more abundant 
proteins. Furthermore, spot quality is essential for accurate spot excision and 
reproducibility, which allows the comparison of gels within a laboratory or between 
research sites (Wilkins et al. 1996). Spot quality is assessed by the visual appearance of 
gels and must be optimised for each sample. This chapter reports the principles and 
rationale behind 2DE and MALDI-TOF MS and presents data on the optimisation of 
these methods building up the final protocol (see chapter IV). 
5.1.1 Sample Preparation 
The preparation of a sample for isoelectric focusing (IEF) is central to obtaining 
high 
quality 2DE results and is one of the more challenging aspects of protein 
characterisation. The intention of sample preparation 
is to transforin a native sample 
into a suitable PhYsicochemical. state for IEF, whilst maintaining the native charge and 
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Figure 5-1 Workflow of a typical 2DE experiment. Proteins are extracted and 
solubilised from samples. Separation is achieved in accordance with pI in the first 
dimension by isoelectric focusing (IEF) and with molecular weight in the second 
dimension by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE). Image analysis is performed to identify spots-of-interest, which are 
subsequently digested and identified by MS. 
molecular weight of constituent proteins so as not to create artefacts in the gel (Shaw et 
al. 2003). In order to resolve as many proteins as possible, proteins must be solubilised, 
disaggregated, denatured and reduced prior to IEF. It is necessary to disrupt disulphide 
bonds and non-covalent interactions (including electrostatic, hydrogen and van der 
Waal bonds) between protein and non-protein compounds to produce a solution of 
distinct polypeptides. Unfortunately, there is no universal sample preparation method 
due to the diverse nature of proteins within a complex sample. Optimisation is essential 
for the analysis of different subclasses of proteins and different sample types. However, 
general solubilisation buffers are available, which are effective over a wide range of 
samples. Two different solubilisation buffers were tested; the urea-based buffer (8M 
urea, 2% CHAPS, 50mM dithiothreitol (DTT), 1% protease inhibitor mix (Amersham 
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Biosciences), 0.2% IOOX Bio-Lyte 3/10 ampholyte (Bio-Rad), 0.002% bromophenol 
blue) and the urea/thiourea-based buffer (7M urea, 2M thiourea, 4% CHAPS, 50mM 
DTTý 1% protease inhibitor mix, 0.2% IOOX Bio-Lyte 3/10 ampholyte, 0.002% 
bromophenol blue). The urea/thiourea-based buffer is strongly chaotropic (see section 
5.1 .1- 1) and therefore suitable for the analysis of highly hydrophobic proteins. A higher 
quality of the more basic spots was observed with this buffer in comparison to the urea- 
based buffer and was therefore selected as the solubilisation buffer exploited for this 
thesis. The roles played by each of these chemicals in protein solubilisation are 
discussed below. 
5.1.1.1 Chaotropes 
Globular proteins are enclosed in water "cages". A cage is composed of water 
molecules attached to each other by hydrogen (H) bonds and surrounds the protein. In 
the presence of chaotropes, H bonds fonn preferably with these agents preventing the 
formation of the water cage. This allows proteins to unfold and expose their 
hydrophobic residues, which are located at the core of the protein and away from the 
water surface (Herbert et al. 1999). Urea is the chaotropic agent of choice for IEF. 
However, urea is less efficient at disrupting hydrophobic interactions, thus 
solubilisation of membrane proteins is particularly challenging (Santoni, et al. 2000). 
Rabilloud et al (1997) introduced the use of thiourea in combination with urea for the 
improved solubilisation of such hydrophobic proteins. Thus, the urea/ thiourea-based 
buffer was exploited for the extraction and solubilisation of proteins for the subsequent 
2DE analyses. 
5.1.1.2 Detergents 
Hydrophobic residues that are exposed by the chaotropes are solubilised by detergents 
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(Herbert, 1999). Detergents employed for use in protein solubilization must have a net 
charge of zero. Sodium dodecyl sulphate (SDS) is the detergent which is most effective 
for the solubilisation of proteins, however it is incompatible for use in IEF. SDS 
molecules are anionic, thus protein-detergent complexes convey a net negative charge. 
This masks the intrinsic charge of the protein, which is exploited by IEF for separation 
(Dunn and G6rg, 2001). Presently, the detergent of choice is the sulfobetaine-type 
zwitterionic detergent 3-[(3-cholamidopropyl)dirnethylammonio]-l-propanesulfonate 
(CHAPS) (Herbert, 1999). 
5.1.1.3 Reducing Agents 
Proteins contain a number of cysteine residues, which are linked in pairs to form 
disulphide bridges (Herbert et al. 2001). For complete protein solubilisation it is 
necessary to break these inter- and intra-chain disulphide bridges by reduction. Free- 
thiol containing reagents such as dithiothreitol (DTT) are typically exploited. 
5.1.1.4 Additional Constituents 
The presence of nucleic acids has a detrimental effect on the separation of proteins and 
these can be removed by two methods. The first involves the inclusion of carrier 
ampholytes, which form complexes with nucleic acids (Walsh and Herbert, 1998). 
These complexes are subsequently removed by centrifugation. Alternatively, an 
endonuclease mix can be added for nucleic acid digestion. It is also often preferable to 
include a protease inhibitor mix in order to inhibit the action of those enzymes, which 
remain active despite the presence of detergents (Shaw and Riederer, 2003). 
5.1.2 Isoelectric Focusing 
Earliest isoelectric focusing (IEF) protocols for first dimension separation involved the 
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use of carrier amPholytes. These are bifunctional amphoteric (both acidic and basic) 
buffer molecules which form a pH gradient in the medium during electrophoresis. 
Within that gradient a protein will migrate towards the anode or cathode until it arrives 
at the point equal to its pl value. At this point it will have a net charge of zero and is 
said to be focused. Several problems were associated with carrier ampholytes. The pH 
gradients were unstable and had the tendency to move towards the cathode over time 
(cathodic drift). This resulted in time-dependent protein patterns (G6rg et al. 2000). The 
gradients were also malformed by high salt concentrations of samples and by high 
protein loads. In addition, such gels were cast in narrow tubes and were thus difficult to 
handle. In 1982, Bjellqvist et al. introduced an alternative method in order to overcome 
many of the problems associated with carrier ampholytes. Immobilised pH gradient 
(IPG) gels are now the method of choice for IEF in the first dimension. IPG gel strips 
consist of a limited number of well defined chemicals (immobilines) that are covalently 
coupled to an acrylamide matrix. Such gradients are stable and do not have a propensity 
to drift towards the cathode with time. Furthermore the gels are cast onto a stiff backing 
film, which is mechanically strong allowing easier gel handling and improved 
reproducibility (Gbrg et al. 2000). 
IPG strips are commercially available in a range of lengths (7cm, II cm, 17cm, 24cm) 
and pH ranges (3-10,3-6,4-7,5-8,7-10). The IPG strip to be exploited is dependent on 
the complexity of the sample or objective of the analysis. Short gels (e. g. 7cm and 
II cm) are effective for a rapid overview of the proteome or when the most abundant 
proteins are those of interest. In contrast, longer gels (I 7cm and 24cm) offer superior 
resolution and loading capacity and allow for the detection of more protein spots. In the 
present analyses II cm IPG strips were selected due to the ease with which such strips 
can be used and the commercial availability of precast gels for separation in the second 
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dimension. Although large format (17cm and 24cm) gels offer superior spatial 
resolution there are several associated problems. Precast gels for separation in the 
second dimension are expensive and therefore must be cast within the laboratory, which 
can be technically difficult to perform. Furthermore, self-cast gels do not offer the same 
level of reproducibility as commercial precast gels and even small differences within 
gels may lead to differences in spot position, which hinders the analysis. Large format 
second dimension gels are also more difficult to handle and significantly increase the 
time required to perform SDS-PAGE (see section 5.1.4). Thus, a lower level of 
resolution was accepted by using 11 cm IPG strips with commercially available precast 
gels in an attempt to maximise reproducibility and to overcome the limitations 
associated with large format gels. Additional strategies were used in combination with 
II cm IPG strips to improve resolution. 
IPG strips are available in a variety of pH ranges (between 3 and 10), with a gradient 
that can be precisely tailored. Linear broad pH range (3-10) IPG strips give an 
impression of the total protein distribution, however can reveal only a small percentage 
of the many proteins present in complex samples. Loss of resolution in such gels is 
common between pH 4-7; the region where the pl values for most proteins lie (Dunn 
and G6rg, 2001). The use of non-linear broad pH range (3-10) IPG strips can be 
exploited, in which the pH gradient is much flatter in the pH 4-7 region. This increases 
the spatial resolution and allows improved separation of crowded areas, whilst still 
separating most basic species (Figure 5-2). Medium pH range (3-6,4-7,5-8,7-10) IPG 
strips are also available. A pH 4-7 strip can therefore be used in combination with other 
mediwn pH range IPG strips allowing a more comprehensive overview of the proteome 
(Figure 5-3). Multiple overlapping narrow IPG gels with a 1-1.5 pH unit isoelectric 
focusing range also provide a powerful alternative. Such gels stretch the protein pattern 
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Figure 5-2 Non-linear IPG strips. Protein was extracted from the MCF7 breast cancer 
cell line (which served as a model with which to optimise this technique) and separated 
on pH 3 -10 linear II cm IPG strips and pH 3- 10 non-linear II cm IPG strips. Separation 
in the 2 nd dimension was performed on Criterion 8-16% gradient gels and proteins were 
visualised with coomassie blue. Results showed that pH 3-10 non-linear IPG strips offer 
increased spatial resolution between pH 4-7 allowing more spots to be visualised. The 
boxed regions highlight the corresponding proteins on each gel and show that within the 
pH 4-7 region a higher degree of separation is achieved with non-linear IPG strips. This 
allows a more accurate spot excision thereby increasing the chance of a successful 
protein identification. 
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Figure 5-3 Increased resolution using medium PH range IPG strips. Protein was 
extracted from the MCF7 breast cancer cell line and separated on the following IPG 
strips: A. Linear broad PH range (3-10) IPG strip. B. Linear medium PH range (5-8) 
IPG strip. C. Linear medium PH range (4-7) IPG strip. A Linear medium PH range (3- 
6) IPG strip. Separation in the second dimension was performed on Criterion 8-16% 
gradient gels and the gels were stained with coomassie blue. The use of multiple over- 
lapping medium PH range IPG strips allowed the detection of more proteins than were 
detected by the broad PH range (3-10) IPG strip allowing a more comprehensive view 
of the proteome. 
in the first dimension, thus offering superior spatial resolution. Furthermore, ultra- 
narrow gels are now available with a 0.1 pH unit focusing range (Walsh and Herbert, 
1998), which further increases the number of protein spots that can be detected. 
Unfortunately, the use of multiple overlapping strips is compromised due to the added 
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complexity of subsequent gel analysis (see section 5.1.6) and the number of gels 
required for full coverage of the proteome. Thus, pH 4-7 strips in combination with pH 
7-10 strips were used as a strategy to improve resolution for the analyses conducted in 
this thesis. The pH range 4-7 was analysed because, as previously described, the 
majority of proteins are visible within this range. The pH 7-10 range was analysed 
because many membrane proteins are visible within this range. Membrane proteins, 
such as drug transport pumps comprise an important class of proteins in the study of 
chemotherapy resistance. This class of proteins may also be important in radiotherapy 
resistance. 
5.1.2.1 Protein Load 
One of the primary challenges of the optimisation process was to determine the optimal 
protein load for IPG strips. Optimal protein load represents a compromise between 
saturation of abundant proteins and the detection of low abundance proteins. If the 
protein load is too high, horizontal and vertical streaking is the result which can mask 
the visualisation of low abundance proteins. In addition, resolution is reduced and 
individual protein species are lost within clusters hindering accurate manual spot 
excision. Comigration of proteins also becomes a problem, which reduces the success of 
identification. In contrast, if the protein load is insufficient many proteins will remain 
undetected. Protein was extracted from the MCF7 breast cancer cell line and protein 
loads of 100pg, 200pg, 300[tg, 400[tg and 500ýtg were submitted to 2DE analysis 
(Figure 5-4). Protein loads between 200-300[tg gave the highest visual quality of gel 
images. Gels loaded with 500ýtg and 400ýLg of protein exhibited high levels of both 
horizontal and vertical streaking thereby masking some of the individual protein 
species. Although gels loaded with 300pg still showed some degree of both horizontal 
and vertical streaking the highest number of individual protein species was observed. 
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Figure 5-4 Differential protein loads. Proteins were extracted from the MCF7 breast 
cancer cell line and separated on linear pH 3 -10 IPG strips in the first dimension and on 
Criterion 8-16% gradient gels in the second dimension. Proteins were visualised with 
coomassie blue. Protein loads of 100ýtg (A), 200ýtg (B), 300ýtg (C), 400pg (D) and 
500gg (E) were analysed. Optimal spot quality was achieved with protein loads 
between 200-300pg. Gels loaded 500pg (E) and 400ptg (D) of protein exhibited high 
levels of both horizontal and vertical streaking and many proteins remained undetected 
with a protein load of I OOpg (A). 
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Gels loaded with 200[tg displayed minimal streaking, however fewer proteins were 
detected than with a 300pg protein load and gels loaded with 100ýtg of protein 
displayed only a fraction of the proteins visualised in comparison with the other protein 
loads. Although 300gg of protein gave a good visual quality of 2D gels, the subsequent 
analysis (see section 5.1.6) was difficult and differentially expressed proteins could not 
be identified. This was attributed to crowded gels and the inaccurate excision of spots 
leading to the presence of more than I protein per spot. Gels loaded with 200pg of 
protein were easier to analyse and allowed for a more accurate spot excision and 
subsequent identification. This confirins that protein load represents a balance between 
being able to visualise as many protein species as possible and being able to effectively 
process these gels for the successful identication of Proteins. As such, 200[ig of protein 
was used for all experimental analyses. 
5.1.2.2 Rehydration and Sample Application 
IPG strips must be rehydrated overnight prior to IEF in a buffer consisting of urea (or, 
alternatively a combination of thiourea and urea), non-ionic (e. g. NP-40, Triton X-100) 
or zwitterionic (e. g. CHAPS) detergent, DTT and synthetic carrier ainpholytes (SCA) 
appropriate to the pH range of the IPG strip (Dunn and G6rg, 2001). Sample application 
may be performed during rehydration, a process called sample in-gel rehydration, or 
alternatively rehydration can occur in the absence of sample, following which the 
sample is applied by a process known as cup loading. Cup-loading involves the 
rehydration of IPG strips in buffer in the absence of sample. Subsequently, samples are 
applied to the gel via an open-bottom loading cup, typically at the pH extremes (G6rg et 
al 2003). In the method of sample in-gel rehydration, the proteins are directly 
solubilised in an appropriate volume of buffer. The IPG strip is subsequently positioned 
gel-side down onto the buffer solution and proteins are absorbed by the strip during 
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rehydration. This approach proffers many advantages over the cup-loading method, 
including reduced sample precipitation, more accurate quantitation (the result of a more 
efficient sample entry) and shorter focusing times. Thus for the 2DE analyses conducted 
in this thesis strips were passively rehydrated in the presence of sample in the 
solubilisation buffer described previously (see section 5.1.1). 
5.1.2.3 IEF Conditions 
The principal driving force of electrophoresis is the voltage applied to the system. The 
voltage program is dependent on the pH gradient and the length of the IPG strip 
exploited. An archetypal IEF protocol involves progression through a succession of 
voltages, which steadily increase until the desired focusing voltage is attained (Stochaj 
et al. 2003). This voltage is held for several hours. The optimum focusing time is 
dependent on numerous factors including protein sample, protein loading and the pH 
range and length of the IPG strip. In order to achieve the highest quality of protein 
separation and reproducibility, sufficient time is required for the IEF pattern to reach 
steady state (G6rg et al. 2000). Inadequate focusing time will result in horizontal and 
vertical streaking. Overfocusing is also detrimental and although seldom a problem 
below 100,000 total volt-hours (VHrs), can lead to an altered protein pattern, horizontal 
streaking at the basic extremity and loss of protein (Dunn and G6rg, 2001). The optimal 
protocol for 11 cm. broad and mediw-n pH range IPG strips was that recommended by 
Bio-Rad; the manufacturer of the Protean IEF cell, with minor modifications (see Table 
4-1). A final step was added in order to prevent diffusion of proteins following the 
cessation of IEF and holds the voltage at 500V until user interception. A further 
parameter to be controlled is the temperature. Temperatures exceeding 37'C can lead to 
the formation of isocyanate; the product of urea degradation. Isocyanate causes protein 
carbamylation, which can alter the pl of proteins. On the other hand, temperatures 
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below I O'C promote urea crystallisation on the IPG gel resulting in loss of protein 
solubility. Thus, the Protean Cell was programmed to perform IEF at 201C. 
5.1.2.4 Removal of Contaminants 
During initial 2DE runs, it was apparent that a prolonged IEF step was required. The 
focusing voltage was never attained and therefore to achieve the specified number of 
total VHrs, a longer focusing time was necessary. This prevented second dimensional 
separation from being performed on the same day and increased the time taken to 
conduct a 2DE experiment. Increased focusing time also often led to the burning of IPG 
strips. This resulted in electrical discontinuities within the Protean IEF Cell leading to 
significant changes in resistance. On detection of erratic resistance, the IEF Cell 
switched to maintenance mode decreasing the voltage to 500V to prevent the diffusion 
of focused proteins. Thus, IEF was further prolonged. In addition, spot quality was poor 
and horizontal streaking was visible (Figure 5-5). It was hypothesised that this was due 
to the presence of contaminants within protein samples. Thus, sample clean-up was 
employed to remove interfering substances. Such substances included salt which 
increases the conductivity of samples, nucleic acids, lipids and detergents. The 
ReadyPrep 2D Clean-up Kit (Bio-Rad; see section 4.4.3) was exploited for sample 
treatment prior to IEF (Figure 5-5) and spot quality was markedly improved following 
clean-up. The removal of contaminants involved the precipitation of proteins, thus it 
was necessary to ensure that the pellet was fully resuspended by a series of pipetting, 
vortexing and sonicating steps. This was performed to enable the correct amount of 
protein to be loaded onto each IPG strip and minimise protein loss. The rehydration of 
IPG strips over a 16 hour period also significantly reduced burning of the strips during 
IEF (see section 4.4-4). 
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Figure 5-5 Removal of contaminants. Protein was extracted from the MCF7 cell line 
and separated on a pH 3 -10 11 cm IPG strip in the first dimension and a Criterion 8-16% 
gradient get in the second dimension. Proteins were visualised with coornassie blue. A. 
Protein sample prior to the removal of contaminants. B. The Zoom Tool (PDQuest, 
Biorad) was used to further analyse spot quality by enlarging the boxed region from gel 
A. Horizonal streaking was visible. C. The protein sample following the removal of 
contaminants using the 2D Clean-up Kit (Bio-Rad). This gel shows improved spot 
quality. A The boxed region from gel C was enlarged and 3 distinct protein spots were 
observed which were previously concealed in the horizontal streak. 
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5.1.3 Equilibration 
Equilibration allows the proteins to become fully saturated with sodium dodecyl 
sulphate (SDS), which transforms the proteins into a suitable state for SDS- 
polyacrylamide gel electrophoresis (see section 5.1.4). It also ensures the maximum 
transfer of protein from first to second dimension by reduction and alkylation to disrupt 
those disulphide bonds, which may have reformed during IEF. The IPG strips were 
incubated in equilibration buffer 1 [50mM Tris buffer (pH 8.8), 2% SDS, 6M urea, 1% 
DTT and 30% glycerol]. Subsequently, strips were incubated in equilibration buffer 11 
containing 2.5% iodoacetamide (IAA) as a substitute for 1% DTT. IAA acts to alkylate 
free -SH groups, which prevents the re-organisation of disulphide bonds. Re- 
organisation of these bonds may lead to entrapment of the polypeptides within 
polyacrylamide gel fibres, which may reduce transfer to the second dimension. In 
addition, disulphide bonds may reform among species that were not originally linked in 
their native conformation leading to artificial spots visible on the final 2D map (Herbert 
et at. 2001). Following equilibration, the strips were applied to the top of SDS-PAGE 
gels for separation in the second dimension and were sealed using hot (-80'C) 1% 
agarose in Ix running buffer. 
5.1.4 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is used for 
protein separation in the second dimension. SDS is a negatively charged denaturing 
agent that binds to proteins at a ratio of -1.4g of SDS per Ig of protein (Stochaj et al. t: ) 
2003). Secondary and tertiary structures are eliminated, resulting in individual 
polypeptides all of which are the same shape. In addition, the SDS molecules confer a 
negative charge on the protein, which is sufficient to mask the intrinsic electrical 
charges of sample proteins. This ensures all SDS-protein complexes have a similar 
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mass: charge ratio and therefore molecular weight is the only factor of migration. 
Polyacrylamide gels are fortned by the co-polymerisation of acrylamide and cross-linker 
molecules such as bisacrylamide into covalently cross-linked chains. The polypeptides 
are forced through the gel by an applied voltage. Larger molecules encounter more 
resistance from the matrix, thus movement through the gel is suppressed more than for 
smaller molecules, resulting in separation in accordance with molecular weight. The 
pore size of the matrix is an important parameter and is determined by altering the 
concentrations of acrylamide and bisacrylamide. The total monomer concentration in 
the gel (acrylamide) is denoted as %T and the percentage of total monomer that is cross- 
linker (bisacrylamide) is represented as %C. The %T is selected by the molecular 
weights of the proteins to be separated (Walsh and Herbert, 1998). If the %T is too high, 
insufficient penetration is achieved whereas if it is too low, insufficient retardation is 
obtained. Polyacrylamide gels of two types can be cast. Homogenous gels consist of a 
constant %T and %C and gradient gels consist of a constant %C and an increasing %T. 
The casting of homogenous gels is more reproducible and such gels offer better 
resolution for a particular molecular weight window (Stochaj, et al. 2003). Although 
more difficult to cast, gradient gels are more suitable when proteins of a wide range of 
molecular weights are to be analysed. Precast Criterion 8-16%T gradient gels (Bio-Rad) 
were employed for the 2DE analyses conducted in this thesis. This gradient was 
selected because it is optimal for the separation of proteins with a wide range of 
molecular weights (6.5-200 kDa) and is recommended by the supplier of the Criterion 
gels (Bio-Rad) for 2DE applications. 
5.1.5 Protein Visualisation 
Following SDS-PAGE, gels must be processed in order to visualise the separated 
proteins. Numerous methods can be exploited, however the choice of method is 
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dependent on a number of factors including complexity, sensitivity, compatibility with 
mass spectrometry, cost and the availability of specialist equipment (G6rg et al. 2003). 
Fluorescent dyes e. g. SYPRO Ruby, are enjoying increasing popularity as the field of 
proteomics expands. This is because such dyes boast a number of advantages including 
sensitivity comparable to that of silver stains (see section 5.1.5.1), MS compatibility. 
simple methodology and a linear dynamic range, which is superior to colorimetric 
methods. Unfortunately, a specialist fluorescence scanner is required for analysis and at 
the initiation of work for this thesis this was not available within the laboratory. 
Therefore, coomassie blue and silver stains were considered for use in this thesis. 
5.1.5.1 Coomassie Blue versus Silver Stain 
Coomassie blue R-250 is a standard post-electrophoretic stain for total protein detection 
in polyacrylamide gels. This dye has a lower detectable limit of 0.1-0.3gg protein/ spot, 
thus is less sensitive than alternative protein dyes. Coomassie blue G-250 (colloidal 
coomassie) is an attractive alternative and requires an order of only I Ong protein/ spot 
for detection. In addition to increased sensitivity, the colloidal properties of this dye also 
allow for minimal non-specific background staining. 
The silver staining procedure developed by Merril and co-workers (1990) is the most 
sensitive non-radioactive method for the visualisation of proteins (Garfin, 2003). This 
method enables spots containing just less than Ing of protein to be visualised (Garfin, 
2003). Two routine staining procedures are recommended for 2DE, each of which 
differs in the reagent used to bind silver to the proteins. The acidic/ silver nitrate method 
involves the oxidation of proteins using potassium dichromate in dilute nitric acid. 
Subsequently, the gel is exposed to silver nitrate. The silver ions bind to the oxidised 
proteins and are reduced to metallic silver at alkaline pH using formaldehyde. In 
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contrast, the alkaline/ silver diamine method exploits a silver-amine complex bound to 
tungstosilicic acid. Ion-exchange or electrophilic processes enable the transfer of silver 
ions from the tungstosilicic acid to proteins. Formaldehyde in an alkaline solution 
reduces silver ions to metallic silver allowing protein visualisation. Regardless of the 
method employed, all silver staining protocols follow the same principles; gel fixation, 
sensitization, silver impregnation, image development and cessation of development 
(Stochaj et al. 2003). Many of the common reagents employed for sensitization, e. g. 
gluteraldehyde, can cross-link proteins and therefore render silver staining incompatible 
with MS. In addition, the oxidation of proteins results in modifications, which may 
interfere with further analysis. Fortunately, MS compatible silver staining kits are now 
commercially available, which use alternative sensitizing agents and do not involve 
oxidation steps (Garfin, 2003). The exploitation of more sensitive protein stains allows 
more of the lower abundance proteins to be detected. The Biosafe colloidal coomassie 
G-250 stain (Bio-Rad) and the MS-compatible ProteoSilver Plus silver stain kit (Sigma- 
Aldrich) were compared during optimisation in order to determine which stain was to be 
used in subsequent 2DE experiments (Figure 5-6). The Biosafe coomassie blue stain 
detects 8ng of protein and is thus less sensitive than the ProteoSilver Plus silver stain 
kit, which has a detection limit of O. lng/mm2. This was confirmed by the PDQuest 
analysis (Bio-Rad) of resulting gels, which was able to detect 1587 protein spots with 
Biosafe coomassie blue compared with 2270 protein spots that were detected with the 
ProteoSilver Plus silver stain kit. However, the spot quality on the silver-stained gel was 
poor (Figure 5-6B). Both horizontal and vertical streaking was visible indicative of a 
high protein load. Thus, protein load is dependent on the sensitivity of the stain and the 
optimal load for coomassie-staining is too high for silver-staining. Silver-staining 
therefore allows less protein to be loaded onto gels, which is beneficial for analysis 
when the sample is limited. However, the protocol for silver-staining was much more 
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Figure 5-6 Comparison of protein stains. Protein was extracted from the MCF7 breast 
cancer cell line and separated on pH 3-10 non-linear IPG strips in the first dimension 
and on Criterion 8-16% gradient gels in the second dimension. Proteins were visualised 
with Biosafe coomassie blue G-250 stain (A) (section 4.4.7.1) and ProteoSilver Plus 
silver stain (B) (section 4.4.7.2). Silver staining offered increased sensitivity and more 
proteins were detected than with the Biosafe coomassie blue stain. PDQuest analysis 
detected 1587 spots on the gel stained with Biosafe coomassie blue (A) compared with 
2270 spots that were detected on the silver stained gel (B). The poor spot quality 
observed on the silver stained gel was indicative of a high protein load. Biosafe 
coomassie blue was selected as the stain of choice for this thesis due to a more user- 
friendly protocol. 
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laborious and time consuming compared with Biosafe coomassie blue, which is an end- 
point stain. This means that the spots remain at their maximum intensity despite 
prolonged incubation with a minimal increase in background staining. In contrast, silver 
stained gels require an exact duration for image development and this may result in 
problems with reproducibility when multiple gels are being processed. Some gels may 
receive slightly different development times and this may result in some gels with 
differing spot intensities (which are not the result of differential display) or visible 
streaking. For subsequent analyses concerning this thesis, Biosafe coomassie blue was 
selected as the stain of choice (see section 4.4.7.1). This is because the samples were not 
limited and the protocol was more user-friendly and less time-consuming compared 
with the ProteoSilver Plus silver stain kit. This should also ensure that enough visible 
protein is present for subsequent identification by MALDI-TOF MS. 
5.1.6 Image Acquisition and Analysis 
Image acquisition of the 2D gel is achieved using devices such as a camera system, 
densitometer, phosphor imager or a fluorescence scanner (Garfin, 2003). A calibrated 
laser densitometer (GS-800, Bio-Rad) was used to acquire images throughout this thesis 
and PDQuest (Bio-Rad) was the software package exploited for the analysis of these 
images. PDQuest allows automatic spot detection and exploits a Gaussian model, which 
helps to resolve areas of overlapping density and streaking (Stochaj et al. 2003). 
Following spot detection, a matchset can be created that allows the comparison and 
analysis of the spots in an experiment. Automatic spot matching is coordinated by the 
manual identification of a number of landmarks or identical spots in the gel series. The 
software formulates best-guess assignments based on the relative positions of such 
landmarks and compares all spots lying in the close vicinity of these fixed points. 
Matched spots are then used to compare further spots until the entire gel surface has 
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been systematically investigated. Unfortunately, gel comparisons are problematic due to 
the innate irreproducibility of the technique. Each gel runs somewhat differently and as 
a result, changes in spot position within an experimental series occur. The software is 
therefore able to detect minimalistic shifts in individual spot position within the series. 
However, although the software enables automatic spot detection and matching it 
became apparent during 2DE analyses that manual intervention was required. All data 
were manually checked and the spots were edited where necessary in order to remove 
false spots, include missed spots and to distinguish between spots within clusters. 
Furthermore, all matches were reviewed manually and mistakes were corrected. The 
reproducibility issue was addressed by performing 3 biological replicates for each 
phenotype. This number of replicates has been used previously in order to overcome 
problems with reproducibility (Sinha et al. 1998; 1999a; 1999b; 2000; 2001; Gehrmann 
et al. 2004a). The data from multiple gels may be combined in PDQuest to create 
replicate groups, which allow spot comparisons to be performed across all gels in an 
experiment. This enabled only those spots that were reproducible across all 3 replicates 
to be included in subsequent statistical analyses. In addition, a normalisation step was 
performed to compensate for any differences in spot intensity that were not the result of 
differential display. This may be the result of differences in sample preparation, loading, 
protein staining or gel imaging. There are 2 main methods that are frequently utilised 
for normalisation. The "Total Quantity In"' method is based on the intensity of house- 
keeping proteins, whose concentrations are known not to change throughout 
experimental treatment. Alternatively, spots can be normalised according to the "Total 
Quantity in Valid SPots" method, which was utilised in this thesis (see section 4.4.8). 
The software is also able to provide the tools to identify those differentially expressed 
spots using analysis sets and thus guide the manual or robotic excision of these spots 
for 
MS identification. 
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5.2 Matrix-Assisted Laser Desorption/ lonisation-Time-Of-Flight MS 
By itself, 2DE is simply descriptive and therefore must be coupled with analytical 
techniques such as MS for protein identification. Proteins-of-interest (POls) are excised 
from the gels and digested with a sequence-specific enzyme to yield peptides. The 
masses of these peptides are subsequently analysed. A Bruker Daltonics Reflex IV 
matrix-assisted laser desorption/ ionisation-time-of-flight mass spectrometer (MALDI- 
TOF MS) equipped with a 337nm nitrogen laser was exploited for the analyses 
conducted in this thesis. The principles of MALDI-TOF MS are described elsewhere 
(see section 3.4.1). 
5.2.1 In-Gel Digestion 
In-gel digestion is the process by which proteins are digested to peptides within gel 
pieces (see section 4.5). This is necessary because peptides are more efficiently 
extracted in comparison to intact proteins, which become entangled within the gel and 
are difficult to extract. During the in-gel digestion procedure there is a possible risk of 
sample contamination. Keratin is a common contaminant that reduces the success of 
protein identification. Keratin is an abundant fibrous protein molecule that serves as a 
structural unit for several living tissues including skin, hair and nails. Contamination of 
swnples results in the digestion of keratin in addition to the POI. The success of protein 
identification is subsequently reduced due to the presence of peptides from 2 proteins 
rather than those from the POI only. Keratin contamination was minimised by wearing a 
lab coat, gloves and suitable hair protection. Furthermore, wherever possible this 
procedure was perfon-ned in a laminar flow hood. Polymer contamination is also 
possible, thus powder-free gloves were wom. In addition, the highest qualities of 
chemicals. and proteornics-grade water were used. Following spot excision, 
contaminants including buffer components, protein dye and unpolymerised acrylamide 
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must be removed from gel pieces. This was achieved by a series of ammonium 
bicarbonate/ acetonitrile washing steps. A further reduction and alkylation step is also 
necessary, especially for the analysis of small amounts of protein. This step is 
performed in order to disrupt any re-formed disulphide bonds, which may reduce 
accessibility of the enzyme to cleavage sites. Dithiothreitol (DTT) and iodoacetamide 
(IAA) were used for reduction and alkylation respectively. Proteins are subsequently 
digested with a sequence-specific protease. Trypsin was the enzyme selected for 
digestion. This enzyme is an endopeptidase, which cleaves within the polypeptide chain 
rather than at the terminal amino acids located at the ends of the chain. Carboxyl sides 
of the basic amino acids lysine and arginine are the targets for trypsin, except when 
either of these amino acids is followed by a proline residue. Trypsin is commonly 
exploited because, in order to become ionised, a peptide must have the ability to trap 
and retain a proton. This can best occur if the peptide contains a strongly basic region. 
Arginine has a strongly basic sidechain and lysine is also weakly basic. Thus, the use of 
trypsin ensures that each peptide has a site capable of retaining a proton for ionisation. 
The optimum pH for tryptic digestion is pH 8 and was controlled by the buffer to which 
the enzyme was added. The trypsin-containing solution (pH 8) exploited in this thesis 
was composed of 40mM ammonium bicarbonate/ 10% acetonitrile containing 25ýtg 
porcine methylated Trypsin Gold as recommended by the supplier of the enzyme 
(Promega). Following absorption into the gel pieces, the remaining trypsin solution was 
removed in order to reduce the amount of self-digested trypsin peptides in the final 
sample. Unfortunately, the autolysis of trypsin remains a common problem with MS 
analyses and contaminating peptides originating from the trypsin enzyme 
itself can 
often reduce the success of identification. The optimal pH 
8 was subsequently 
maintained by the addition of a small amount of 40rnM ammonium 
bicarbonate/ 10% 
acetonitrile. The reaction was allowed to proceed overnight at 
37'C and was quenched 
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by altering the pH using 25mM ammonium bicarbonate. Peptides were subsequently 
extracted with 5% formic acid. Formic acid ionises the peptides and thus facilitates 
extraction from gel pieces. 
5.2.2 Sample Preparation 
One of the most important aspects of MALDI-TOF MS is preparation of the sample. 
Many variables influence the integrity of a sample for analysis and may include the 
concentration of the matrix and analyte, choice of matrix, hydrophobicity and 
hydrophilicity of character, compatibility of matrix and analyte and the presence of 
contaminants. Not all samples work well in every MALDI matrix since each peptide/ 
protein has a unique structure, which must be incorporated into a specific matrix crystal 
lattice. Also, each matrix compound has its own unique physical properties and interacts 
with the analyte in a unique manner. Following the comparison of different matrices 
(e. g. 2,5-dihydroxybenzoic acid (DHB) and a-cyano-4-hydroxycinnamic acid (CHCA); 
see section 5.2.4) DHB was selected as the matrix of choice for subsequent analyses. 
The DHB matrix was prepared by saturating a solution composed of 50% acetonitrile/ 
water and I% formic acid. The addition of formic acid ensured that the pH of the 
matrix-containing solution was maintained below pH 4 to prevent ionisation of the 
matrix. The desalting and concentration of samples prior to analysis is also often 
necessary to obtain high quality MS data. Salts not only suppress signals and interfere 
with ionisation but can also form adducts with the peptides. These sodium adducts can 
create a problem by altering the mass of a peptide by 22 mass units for every attached 
adduct. This reduces the success of protein identification. ZipTips (Millipore) were 
selected as the method with which to desalt and concentrate the samples prior to 
MALDI-TOF MS analysis. A ZipTip is a 10 [il pipette tip, which contains a bed0f C18 
reversed-phase media. The peptides bind to this media and salts are 
discarded following 
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a series of washing steps with 0.05% trifluoroacetic acid (TFA). Subsequently, peptides 
are eluted in a solution composed of 70% methanol and 0.5% formic acid. 
5.2.3 Identification of Purified Proteins 
A protocol recommended by the European Molecular Biology Laboratory (EMBL), 
Heidelberg, Germany was used as a template with which to optimise the in-gel 
digestion procedure. Known purified proteins were initially digested and analysed in 
order to ensure that the protocol was effective for the accurate identification of proteins. 
Twenty ýtg of bovine cytochrome C (12-kDa), human transferrin (77-kDa) and bovine 
insulin (5.8-kDa) were loaded onto a 12% homogenous Novex* gel (Invitrogen Life 
Technologies) and were separated by SDS-PAGE. Proteins were visualised with 
Biosafe coomassie blue (Bio-Rad) and bands were excised and digested for MALDI- 
TOF MS as described above. Prior to analysis samples were prepared using ZipTips- 
DHB and a-cyano-4-hydroxycinnamic acid (CHCA) are common matrix comPounds for 
the analysis of peptide samples and were exploited for these initial analyses. Samples 
were mixed with either DHB or CHCA matrix-containing solutions at 10: 1 (matrix: 
sample) ratios. One ýtl of each sample was spotted at a known location on an 
AnchorChipTM target (Bruker Daltonics) and allowed to air-dry. The AnchorCjjipTM 
boasts a hydrophilic core at the centre of each sample well, which allows peptide 
concentration on the target. Such targets are suitable for the analysis of small amounts 
of sample. Mass spectra were recorded in the reflectron mode of the mass analyser 
(Figure 5-7). The reflectron mode offers increased resolution over linear mode for the 
analysis of peptides/ small proteins and exploits an ion mirror to correct 
for small 
differences in kinetic energy amongst ions of the same m1z value. The ion mirror 
exploits an electric field reflecting ions towards a 
detector. Ions with greater kinetic 
energy arrive at the reflector first but penetrate 
deeper into the field thus travelling a 
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Figure 5-7 Reflectron MALDI-TOF MS. The reflector corrects for small differences in 
kinetic energy amongst ions of the same m1z value. Ions of greater kinetic energy 
penetrate deeper into an electric field travelling a longer flight path than those ions with 
less energy. Thus, the ions reach the detector at the same time increasing the resolution. 
longer flight path than the ions with less kinetic energy. This ensures that the ions arrive 
at the detector at the same time. Use of the reflectron mode is limited to analysis of 
peptides/ small proteins because for proteins larger than -I 0-kDa peak broadening due 
to metastable decay is usually greater than broadening due to the kinetic energy 
distribution. Ions were accelerated through a potential of 20Kv into the TOF mass 
analyser and ions within the m1z range of 900-3500 were detected. A lower cut-off level 
of 900 was specified to reduce the detection of matrix clusters. Matrix clusters result 
from the possible ionisation of matrix molecules rather than the peptides themselves. 
The upper limit of 3500 was selected because most peptide ions are detectable within 
this range. Analyses were perfonned using the Bruker Software Suite. The data were 
acquired using the Flex Control (version 1.0) programme and processed with XMASS 
(version 5.1.1) and Biotools (version 2.0). Monolsotopic peptide masses were assigned 
and the PMFs were searched against the SwissProt database (version 43.2) using the 
MASCOT software (Matrix Science). The search parameters are shown in Table 5-1. 
Field Free Drift Region 
0 
S 
. 
S 
S . . 
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Table 5-1 Search parameters used for protein identification. 
Type Of Search eptide Mass Fingerprint 
Database SwissProt 43.2 (191643 sequences; 87132023 residues) 
Taxonomy Mammalia (mammals) (64471 sequences) 
Enzyme Trypsin 
Mass Values Monoisotopic 
Protein Mass Unrestricted 
Peptide Mass Tolerance 0.1% 
Peptide Charge State I+ 
Maximum Missed Cleavages I 
MASCOT employs a MOWSE scoring algorithm to determine the significance of a 
match between the calculated peptide masses for each entry in a database and the 
experimental data. The threshold is based on the absolute probability that a match is 
random and is dependent on the size of the database searched. Accordingly, for these 
searches MOWSE scores greater than 61 were deemed significant (p<0.05). Thus, there 
was a less than 5% chance that a match was random for a protein with a score greater 
than 61. A spectrum could not be acquired for any sample integrated in a CHCA crystal 
lattice. However, cytochrome C and transferrin were correctly identified with 
probability-based MOWSE scores of 87 and 67 respectively when prepared with the 
DHB matrix. The search results for cytochrome C are shown in Appendix E as an 
example and the PMFs for these proteins are shown in Figure 5-8. This suggested that 
this matrix was more suitable for analysis of these proteins. After several attempts 
however, insulin remained unidentified. A spectrum could not be obtained for this 
protein regardless of the matrix exploited. It is possible that the use of an alternative 
matrix, such as sinapinic acid, may have been more suitable for this protein. 
However 
insulin is only 5.8-kDa in size, thus it is likely that small tryptic digests were produced. 
Such digests may not have been detected due to mass range (900-3500) in which the 
ions were detected. It was therefore concluded that insulin was a poor choice of protein 
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Figure 5-8 Peptide Mass Fingerprints. A. Cytochrome C. B. Transferrin. The spectra 
show the m1z values for the peptides identified in each sample (x axis) and the intensity 
of these peptides (y axis). The proteins were identified by comparing the mass values in 
each spectrum against the calculated mass values of all sequences in the SwissProt 
database (see Appendix E). 
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with which to optimise MALDI-TOF MS and that the successful identification of both 
cytochrome C and transferrin with the DHB matrix was evidence that the EMBL 
protocol was effective for the tryptic digestion and extraction of peptides from 
polyacrylamide gel pieces. 
5.2.3.1 Sensitivity 
In order to determine the minimal amounts of protein that can be identified by MALDI- 
TOF MS serial dilutions of known purified proteins were prepared. Bovine cytochrome 
C and human transferrin were used due to successful identifications from the previous 
analysis (see section 5.2.3). In addition, bovine serum albumin (BSA; 67-kDa) and 
porcine pepsin (35-kDa) were used to provide ftwther evidence of an effective protocol. 
These proteins were loaded onto one-dimensional 12% homogenous Novex(V gels at 
concentrations of 20[ig, 10ýtg, 2[tg, 400ng and 80ng per well. Separation was achieved 
by SDS-PAGE (Figure 5-9) and the proteins were visualised with Biosafe coomassie 
blue. Bands were subsequently excised and the EMBL protocol was followed for 
digestion (see section 4.5). The resulting peptide samples were prepared using ZipTips. 
DHB was the matrix compound exploited for analysis. Spectra were difficult to obtain 
using 10: 1 (matrix: sample) ratios, thus 1: 1 ratios were prepared and the samples were 
re-analysed. Cytochrome C, transferrin and BSA were only successfully identified at 
concentrations of 20gg and I Ogg. At lower concentrations the proteins could not be 
identified. Porcine pepsin could not be identified even at a concentration of 20ýig. The 
full length amino acid sequence for this protein was obtained from the SwissProt protein 
database and was virtually digested with trypsin using the GPMAW (version 3.0) 
programme. This allowed the prediction of those peptides that should have been visible 
in the experimental PMF. The PMF for porcine pepsin at the 20pg concentration was 
composed of a list of masses for 49 peptides. However, the results 
from the virtual 
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10 
12-kDa 
Figure 5-9 Serial dilutions of purified proteins. Proteins were separated by SDS-PAGE 
and visualised using Biosafe coomassie blue. Bands were digested and excised using the 
EMBL protocol and the resulting peptides were prepared for MALDI-TOF MS analysis 
using ZipTips. Lanes 1-5; transferrin (77-kDa) at concentrations 20ýlg (1), 10[tg (2), 
2ýtg (3); 400ng (4), 
' 
80ng (5). Lanes 6-10; cytochrome C (12-kDa) at concentrations 
20[tg (6), 10[tg (7)1) 2[ig (8), 400ng (9), 80ng (10). 
digestion revealed that porcine pepsin yields only 2 tryptic digests (1091.19 and 
1827.33) that are detectable within the m1z range of 900-3500. This indicated that this 
protein may not be amenable to identification by PMF alone because it is unlikely that 
these 2 peptides are unique to this specific protein. This reinforces the fact that not all 
proteins are identifiable by PMF and highlights a potential limitation of the technique. 
The detection of many other peptides in addition to these 2 peptides also indicated a 
contamination problem. The GPMAW (version 3.0) programme was subsequently used 
for the virtual digestion of bovine cytochrome C, human transferrin and BSA. A 
comparison of peptides from the experimental data and the virtual digestion also 
revealed that several peptides ftom the POIs were undetectable in the PMFs. Thus, it 
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was concluded that the lower concentrations of proteins could not be identified due to 
the presence of contamination and a loss of peptides from the POIs themselves. 
5.2.3.2 Determining the Source of Contamination 
It was necessary to determine the source of contamination in order to maximise the 
possibility of a successful identification. Although care was taken throughout the 
procedure it was hypothesised that contamination may have been the result of keratin 
digestion. Keratin 10 is one of the more common keratins, which often causes problems 
for MS analysis. Thus, this protein was virtually digested with the GPMAW (version 
3.0) programme to reveal the predicted tryptic digests. On analysis it became clear that 
although a few of the unmatched peaks in each spectrum may have been attributable to 
this protein, the majority of contaminants were from an unknown source. The 
polyacrylamide gel itself, the intact protein solutions, the plastieware used throughout 
the in-gel digestion procedure, the AnchorChipTM target and use of a vacuum-centrifuge 
for drying down the pePtides were all ruled out as possible sources of contamination. 
However, during analysis of the PMFs it was apparent that many of the spectra were 
composed of peptides that differed in mass by multiples of 22 mass units (mu) (Figure 
5-10). This suggested that sodium adducts were attached to the peptides (see section 
5.2.2). For every attached sodium adduct the mass of a peptide increases by 22 mu. This 
indicated that the desalting step prior to analysis had not been effective leading to the 
hypothesis that perhaps the majority of contaminating peaks were not from an 
alternative source but were actually the result of modifications to peptides 
from the 
POls themselves. In addition, some of the peptides may also have been lost during this 
desalting step decreasing the signal to noise ratio and reducing the possibility of 
successful protein identifications. 
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5.2.3.3 ZipTips versus Vivapure@ C18 Micro-Spin Columns 
Other methods for the desalting and concentrating of peptide samples for MALDI-TOF 
MS were exploited in an attempt to minimise the presence of these sodium adducts. 
ZipTips were compared with Vivapuret CI8 micro-spin columns (Vivascience), which 
exploit a C18 membrane. Peptides flow through and bind to this membrane during 
centrifugation. Desalting was achieved through a series of further centrifugation steps 
with a washing solution composed of 0.1% TFA and peptides were eluted in 50% 
acetonitrile/ water and 0.1% TFA. However, the MOWSE scores obtained for samples 
prepared with ZipTips were higher in comparison to those prepared with Vivapure(A) C18 
micro-spin columns (Table 5-2). In each spectrum sodium adducts remained visible. 
Furthermore, there remained a small number of peptides in each spectrum that were 
neither attributable to sodium adducts nor to the POIs themselves. Thus, a database was 
established to encompass all predicted peptides from the most common contaminating 
proteins (see Appendix F). A list of Predicted peptide masses from the tryptic digestion 
of trypsin, keratins 1,9 and 10 and type I hair keratin was composed and when the 
spectra were revisited some of the umnatched peaks could be matched to peptides from 
these proteins. Despite this, the majority of contaminants with m1z values >2000 were 
not matched to these proteins. Therefore, those unmatched peptides that were present in 
multiple spectra from unrelated proteins were also included in the database. Examples 
include peptides with m1z values of 113 3 and 1794. The database was updated regularly 
and used to edit the PMFs prior to MASCOT searches for all subsequent analyses. 
5.2.3.4 Peptide Losses 
As described previously a comparison of peptides from the experimental data and 
virtual digestions revealed that several peptides from the POls remained undetected in 
the PMFs. It is important that as many peptides from the POls are detected in order to 
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Table 5-2. A summary of results comparing ZipTips with VivapureOC18micro-spin 
columns for sample preparation. MOWSE scores greater than 61 were deemed 
significant (p<0.05). Sequence coverage refers to the percentage of the complete protein 
sequence observed in the PMF. The "peptides searched" refers to the number of 
peptides included in the search and the "peptides matched" refers to the number of 
peptides matching to the identified protein. Although more peptides were searched for 
the samples prepared with VivapurOOC18micro-spin columns a smaller percentage of 
these peptides matched to the POI thereby decreasing the MOWSE scores. 
Desalt Protein MOWSE Sequence Peptides Peptides 
Method Score Coverage Searched Matched 
ZipTip Bovine 92 57 10 7 
C ochrome C 
ZipTip Human 101 28 19 15 
transfeffin 
Vivapureg Bovine 78 68 20 8 
cytochrome C 
I 
Vivapure(& Human 98 28 22 16 
1 transferrin I I I 
maximise the possibility of a successful match with a protein from a database. It was 
initially postulated that perhaps the tryptic digestion was not being fully completed, thus 
leaving traces of undigested protein in the sample. An in-gel digestion was performed 
using cytochrome C and transferrin at 10ýtg concentrations and no intact protein was 
detected by NIALDI-TOF MS analysis suggesting that the digestion was effective. 
Another possibility was that the peptides were not being efficiently extracted from the 
gel pieces. Although peptide extraction was found to be essential for the identification 
of proteins in this thesis (see sections 4.5.4 and 5.2.1), this step is not included in many 
in-gel digestion protocols and is thought to increase peptide yield by only 5%. Thus, 
most peptides should still be detected even in the absence of this step. 
A Guanidination Kit (Sigma-Aldrich) was used in an attempt to increase sequence 
coverage and compensate for peptide loss. A peptide with an arginine residue at the 
C- 
terminus often undergoes preferential ionisation because of the 
higher basicity of the 
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arginine side chain. The Guanidination Kit serves to reduce this bias and enhance 
overall ionisation by converting the F, -amine side chain of lysine-containing peptides to 
a homoarginine group. This results in increased peak intensity for lysine-containing 
peptides and provides a larger number of candidates for PMF analysis. This strategy is 
not suitable to increase the sequence coverage of all proteins as the efficiency of the 
reaction is the result of the amino acid sequence of a protein. Some proteins may yield 
few lysine-containing residues and the peptide sample may be predominantly composed 
o arginine-containing residues. In contrast, the analysis of those proteins yielding 
primarily lysine-containing residues may derive great benefit from the guanidination 
reaction. The guanidination of cytochrome C, transferrin and BSA at concentrations of 
20ýtg, 10[tg, 2ýtg, 400ng and 80ng was achieved following in-gel digestion using 0- 
Methylisourea in accordance with the manufacturer's instruction. Guanidination was 
specified as a variable modification prior to searching the SwissProt protein database 
because the reaction results in a monoisotopic mass increase of 42.0218 Da. Variable 
modifications allow the software to consider modifications, which may or may not 
present. Thus, it was specified that lysine-residues may or not be guanidinated. 
MOWSE scores greater than 64 were deemed significant (p<0.05) for these analyses. 
This is because although the same database was exploited for identification using the 
same search parameters (Table 5-1) the significance threshold is dependent upon the 
size of the database, which is ever increasing in size. Results showed that the MOWSE 
scores for all guanidinated samples were actually lower than for controls despite the fact 
that more peptides were matched to the POI and sequences coverages were improved 
(see Table 5-3). This suggested that the use of variable modifications actually reduce the 
specificity of the search. The search was subsequently repeated using guanidination as a 
fixed modification rather than a variable modification. This specifies that all lysine- 
containing residues are guanidinated and relies on a 100% efficiency rate of the 
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Table 5-3 The effect of the guanidination of BSA at a concentration of 2Vg. The 
MASCOT programme was used to search the SwissProt database using guanidination as 
a variable modification for guanidinated samples. MOWSE scores greater than 64 were 
deemed significant (p<0.05). Despite improved sequence coverage for the guanidinated 
sample the MOWSE score was less than the control sample. 
Protein Guanidination 
State 
MOWSE 
Score 
Peptides 
Searched 
Peptides 
Matched 
Sequence 
Coverage 
BSA Control 64 15: 11: 19 
927.87 927.87 
1001.93 1001.93 
1249.91 1249.91 
1306.00 1306.00 
1419.44 1419.44 
1440.07 1440.07 
1480.03 1480.03 
1533.04 
1567.35 1567.35 
1640.21 1640.21 
1693.23 1693.23 
1724.27 1724.27 
2020.22 
2497.19 
2511.11 
BSA Guanidinated 61 19: 18: 23 
927.85 927.85 
1001.65 1001.65 
1043.63 1043.63 * 
1249.65 1249.65 
1291.52 1291.52* 
1305.65 1305.65 
1348.28 1348.28 
1419.58 1419.58 
1439.66 1439.66 
1461.56 1461.56* 
1479.51 1479.51 
1567.52 1567.52 
1639.60 1639.60 
1681.63 1681.63 * 
1693.54 1693.54 
1696.74 
1724.64 1724.64 
2301.44 2301.44 
2530.34 2530.34* 
* Peptides modified by the guanidination reaction. 
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reaction. However, MOWSE scores decreased indicating that not all the lysine- 
containing residues were modified in the reaction. In summary, the guanidination 
reaction did not increase the chance of successful protein identification. 
Methods to improve sequence coverage were therefore not sufficient to overcome the 
problems associated with peptide loss. Thus, it was hypothesised that perhaps the 
peptides were being washed away with the salts or were not being efficiently eluted 
from the C 18 resin of the ZipTips. Thus, in-gel digests of transferrin and BSA at 
concentrations of 2[tg, 400ng and 80ng were analysed without a desalting step. These 
proteins were significantly identified at 2pg concentrations with MOWSE scores of 78 
and 70 respectively. Scores were increased further following the removal of known 
contaminants from the PMFs (see Appendix F). However, a loss of resolution for 
peptides with m1z values greater than 2500 was observed. The majority of these peptides 
remained unmatched to POls. Thus, the mass range was decreased to detect those 
peptides between 900-2500. This allowed the significant identification of BSA and 
transferrin at 400ng concentrations (with MOWSE scores of 71 and 72 respectively). 
Transferrin was also significantly identified at a concentration of 80ng with a MOWSE 
score of 74. Therefore, a desalting step using ZipTips was found not to be required and 
in fact was found to have a deleterious effect on protein identification. This has also 
been discovered in other MS laboratories (Dr. Jeff Keen, University of Leeds; personal 
communication). 
5.2.3.5 Peptide Modifications 
Peptide modifications are common during sample handling for MS analysis. These 
modifications may occur accidentally, which includes the oxidation of methionine 
residues. Methionine oxidation may occur when samples are exposed to acidic 
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conditions or oxygen during protein processing and in-gel digestions. Methionine can 
be oxidised to methionine-sulfoxide (altering peptide mass by 16-Da), which can be 
oxidised further to methionine-sulfone (altering peptide mass by 32-Da). Alternatively 
modifications may be specifically introduced, such as carbamidomethyl modifications. 
The carbamidomethylation of free cysteine residues results from the use of IAA for 
alkylation during in-gel digestion and alters a peptide mass by 57-Da. Furthermore, free 
cysteine residues can also be modified by acrylamide free radicals, which alters the 
mass of a peptide by 71 -Da. Although both variable and fixed modifications may reduce 
the specificity of the search (see section 5.2.3.4), it was hypothesised that considering 
these specific modifications during searches may further increase the significance of the 
MOWSE scores. Using the GPMAW (version 3.0) programme, the predicted peptides 
with methionine oxidation, carbamidomethyl (CAM) and proprionamide (acrylamide) 
modifications were obtained for BSA and transferrin. Results revealed that the majority 
of peptides that remained unmatched from the PMFs could be attributed to these 
modified forms. The PMFs obtained from the above analysis were re-analysed and these 
modifications were considered as both fixed and variable modifications. This was to 
determine the most appropriate modifications for protein identification. These 
modifications were also considered in isolation and in combination to determine their 
optimal use in the subsequent analyses. The results for BSA and transferrin at 2[tg 
concentrations are documented in Table 5-4. CAM modifications resulted in increased 
MOWSE scores for all samples. The best results were obtained when CAM was 
specified as a fixed modification indicating that treatment with IAA during in-gel 
digestion modified all free cysteine residues. Furthermore, subsequent 2DE analyses 
also demonstrated that variable methionine oxidation modifications often increased the 
MOWSE scores for some of the unknown proteins. Therefore, fixed carbamidomethyl 
and variable methionine oxidation modifications were considered in all subsequent 2DE 
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Table 5-4 The use of variable and fixed modifications for database searching. The use 
of carbamidomethyl modifications resulted in increased MOWSE scores for all samples 
and was most successful when considered as a fixed modification. 
Transferrin at a concentration of 2fLg 
Modification 
(s) 
Fixed/ 
Variable 
MOWSE 
Score 
Sequence 
coverage 
Peptides 
Searched 
Peptides 
Matched 
77 26 31 17 
CAM 
Met. Ox. 
PAM 
Variable 
Variable 
Variable 
116 48 31 30 
CAM Variable 176 48 31 29 
Met. Ox. Variable 70 26 31 18 
PAM* Variable 53 26 31 18 
CAM 
Met. Ox. 
PAM 
Fixed 
Fixed 
Variable 
160 44 31 28 
CAM Fixed 236 48 31 29 
Met. Ox. Fixed 52 20 31 14 
BSA at a concentration of 2fLg 
Modification 
(s) 
Fixed/ 
Variable 
MOWSE 
Score 
Sequence 
coverage 
Peptides 
Searched 
Peptides 
Matched 
78 21 13 11 
CAM 
Met. Ox. 
PAM 
Variable 
Variable 
Variable 
53 28 13 13 
CAM Variable 84 28 13 13 
Met. Ox. Variable 74 21 13 11 
PAM* Variable 56 21 13 11 
CAM 
Met. Ox. 
PAM 
Fixed 
Fixed 
Variable 
84 26 13 13 
CAM Fixed 112 28 13 13 
Met. Ox. Fixed 78 1 21 13 11 
Abbr: CAM; Carbamidomethylation, Met. Ux; Methionine mwation, rAm;, rrOprIonamIae 
* PAM can only be considered as a variable modification. 
analyses (see section 4.6). Success from the use of these modifications also suggested 
that peptides from contaminating proteins may also be modified. Thus, these modified 
peptides were predicted using the GPNIAW (version 3.0) programme and added to the 
growing database of contaminants (see Appendix F). In-gel digestions with cytochrome 
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C, transferrin and BSA at 80ng concentrations were repeated. Duplicate bands were 
pooled for each protein in an attempt to increase the amount of protein in each sample. 
The samples were also prepared at 1: 2 (matrix: sample) ratios (see section 4.6). This 
ratio was not exploited previously because the matrix must be present in a large excess 
for the efficient ionisation of peptides. However, this ratio still allowed for the efficient 
ionisation of peptides and was therefore found suitable for the analysis of small amounts 
of protein in this thesis. Furthermore, volumes of 3ýfl of each sample were spotted onto 
the AnchorChipTM target. This strategy allowed the significant identification of all 
proteins at their lowest concentration (80ng). 
5.3 Conclusion 
Two-dimensional gel electrophoresis (2DE) in combination with MS, remains the gold 
standard for the global analysis of complex proteomes. These techniques were 
established and optimised within the laboratory to enable the analysis of resistance to 
anticancer therapy in human breast cancer cells. The establishment of an effective 
protocol for MALDI-TOF MS was found to be particularly challenging. Many 
experiments were repeated to overcome problems associated with contamination and 
peptide loss. These are common problems associated with MALDI-TOF MS (Graves 
and Haystead, 2002). It became apparent that optimisation is ongoing and is sample- 
and/ or application-dependent. Although a 2DE protocol has been established for broad 
and medium pH range II cm IPG strips modifications will be necessary for different 
samples, strip lengths and/or pH ranges. Also, different MALDI matrices may be 
required for the analysis of different proteins. The protocols established for this thesis 
can therefore serve as a base for future analyses. In summary, the aim of this chapter 
was successfully fulfilled and, with the caveats recognised above, this global profiling 
technique can now be applied to the analysis of anticancer therapy. 
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CHAPTER VI 
THE PROTEOMIC ANALYSIS OF CISPLATIN 
RESISTANCE IN HUMAN BRFAST CANCER CELLS 
Aims: 
To assess the efficacy of using the 2DE-MALDI-TOF MS method developed in 
chapter V for the identification of markers of response to chemotherapy in an in- 
vitro cell culture model. 
To identify molecular markers associated with cisplatin resistance in human 
breast cancer cells using 2DE-MALDI-TOF MS. 
To conduct the first proteomic analysis of a novel cisplatin resistant breast 
cancer cell line. 
To validate the molecular markers identified with 2DE-MALDI-TOF MS using 
western blot analysis 
Publications and Presentations: 
" Laura Smith, Kevin J Welham, Mark B Watson, Philip J Drew, Michael J Lind, 
Lynn Cawkwell. The Proteomic Analysis of Cisplatin Resistance in Breast 
Cancer Cells. Manuscript Submitted 
" Mark B Watson, Laura Smith, Philip J Drew, Michael J Lind, Lynn Cawkwell. 
Expression microarray analysis reveals genes associated with in-vitro resistance 
to cisplatin in a cell line model of advanced breast cancer. Manuscript Submitted 
" Laura Smith, Mark B Watson, Kevin J Welham, Michael J Lind, Lynn 
Cawkwell. Proteins Associated with Cisplatin Resistance Identified using 2D 
Gel Electrophoresis and MALDI-TOF Mass Spectrometry. 74hSiena Meeting: 
From Genome to Proteome. Back to the Future (September 3-7,2006). Poster 
Presentation 
Laura Smith, Mark B Watson, Kevin J Welham, Philip J Drew, Michael J Lind, 
Lynn Cawkwell. The identification of proteins associated with cisplatin 
resistance in human breast cancer cells using 2D gel electrophoresis and 
MALDI-TOF mass spectrometry. 29h Annual San Antonio Breast Cancer 
Symposium, Texas, USA (December 14-17,2006). Poster Presentation 
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6.1 Introduction 
Cisplatin is a cross-linking agent, which exerts a cytotoxic effect by creating a lethal 
burden of DNA damage and inducing apoptotic cell death. This agent is most 
commonly used as a single agent for the treatment of many cancers and is effective as a 
first-line single agent in metastatic breast cancer (stage IV; see section Table 1-3) 
achieving response rates of approximately 50% (Martin, 2001). Cisplatin is also 
effective as a first-line treatment in combination with other agents. Initial results ftom a 
phase 11 study have demonstrated that cisplatin in combination with gemcitabine is 
highly effective in the first-line treatment of patients with metastatic breast cancer 
achieving overall response rates of 81% (Fuentes et al. 2006). Furthermore, cisplatin in 
combination with docetaxel is emerging as a promising therapy for the first-line 
treatment of metastatic breast cancer achieving response rates of 68% in one study 
(Vassilomanolakis et al. 2005). The potential of cisplatin-based therapy for first-line 
treatment was realised after its initial success as a salvage regimen for metastatic breast 
cancers, which have proven unresponsive to anthracycline-based therapy (Rosati et al. 
2000; Vassilomanolakis et al. 2000; Vassilomanolakis et al. 2003; Chehal et al. 2004; 
Park et al. 2005). Combinations of cisplatin have also been employed as neoadjuvant 
chemotherapy (see section 1.7.3.1) in women with locally advanced breast cancer 
(Martin, 2001). Cisplatin in combination with docetaxel and herceptin. resulted in 
excellent survival rates for patients with large (>4cm) HER-2 positive breast tumours 
(Hurley et al. 2006). Unfortunately, resistance to cisplatin is common and represents an 
obstacle in the successful management of human cancers, including metastatic breast 
cancer. Although several pathways (e. g. DNA repair and apoptotic pathways; see 
section 2.4) have previously been implicated with resistance to cisplatin, the 
mechanisms of resistance remain largely obscure. In the present study we sought to gain 
a further understanding of the mechanisms underlying the development of resistance to 
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this agent in an in-vitro cell culture model. The MCF7 breast cancer cell line was 
initially established from a metastatic infiltrating ductal breast cancer and thus serves as 
a good model of metastatic breast cancer for use in this study. The MCF7 breast cancer 
cell line and a novel derivative (MCF7CR) displaying significant resistance to cisplatin 
were analysed using 2DE. The protein profiles were compared and differentially 
expressed spots were identified by MALDI-TOF MS. 
6.2 Materials and Methods 
6.2.1 Cell Lines 
The MCF7CR cell line was established in our laboratory previously from the surviving 
population of parent MCF7 breast cancer cells after treatment of the parent population 
with seven cyclic 24hr doses of 50ýiM cisplatin followed by approximately 30 days of 
drug-free culture (Watson et al. manuscript submitted). The concentration of cisplatin 
used to establish the resistant cell line was based upon reported clinically achievable 
plasma concentrations (Schondorf et al. 2002) as well as our own dose response 
observations in order to apply a degree of clinical relevance to this in-vitro study. 
6.2.2 Assessment of In-Vitro Cisplatin Resistance 
The relative resistance of MCF7 and MCF7CR to cisplatin was determined using the 
MTT assay as described in section 4.3.1 
6.2.3 2DE and MAILDI-TOF MS 
Protein from each cell line was extracted and quantified as described in sections 4.4.1 
and 4.4.2. Samples were prepared using the 2DE Clean-up Kit (Bio-Rad) and 2DE 
experiments were performed as described in sections 4.4.3-4-4.8 using Biosafe 
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coomassie blue as the protein-binding dye. Differentially expressed proteins were 
digested and identified using MALDI-TOF MS (described in sections 4.5-4.6). 
6.2.4 Western Blotting 
Western blotting was exploited for confirmation of results and was performed as 
described in section 4.8. Primary antibodies against GST-M3 (generously donated from 
Professor John Hayes, Biomedical Research Centre, University of Dundee, UK), 
cytokeratin 17 (#Ab2502, Abcam), peroxiredoxin 4 (#Ab 16943, Abcam), HSP27 (#MS- 
101, Neomarkers) and MMP-9 (#RB-1539; Neomarkers) were added at concentrations 
of 1: 2000 (GST-M3 and peroxiredoxin 4), 1: 250 (MMP-9) and 1: 100 (cytokeratin 17 
and HSP27) for 2 hrs at RT. The appropriate HRP-con ugated secondary antibody (anti- i 
mouse or anti-rabbit,, #SC-2031 and SC-2030; Santa Cruz) was added at a concentration 
of 1: 1000 and enhanced chemiluminescence (ECL) was used for detection as described 
in section 4.8.3. Membranes were subsequently reprobed with GAPDH as described in 
section 4.8.4 and image analysis was undertaken as described in section 4.8.5. 
6.3 Results 
6.3.1 Establishment of the MCF7CR Cell Line 
The MTT assay was used to determine the relative resistance of MCF7 and MCF7CR 
cells to cisplatin over the concentration range of 0- 1 17gM (Figure 6- 1). TheIC50values 
were 48pM and 79ptM respectively. The MCF7CR cell line was 1.6-fold more resistant 
to cisplatin than the MCF7 parent. Phenotypic characterisation of MCF7 and MCF7CR 
cells using western blotting and immunocytochemistry revealed similar positive 
expression for ER and PR and no change in the wild-type p53 status. RT-PCR indicated 
no difference in expression of the major drug pumps P-gp (MDRI), MRPI, BCRP, or 
lung resistance protein (LRP) between MCF7 and MCF7CR. 
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CDDP Concentration (pM) 
Figure 6-1 Dose response curve demonstrating the relative resistance of MCF7 and 
MCF7CR cell lines to cisplatin over the concentration range of 0- 1 17[IM. Each point 
represents the mean of at least 3 individual experiments and error bars represent the 
standard error of the mean for each point. The IC50 values of MCF7 and MCF7CR were 
48ýM and 79ýM respectively making MCF7CR approximately 1.6-fold more resistant 
to cisplatin than the MCF7 parent line. The MCF7CR cells were significantly more 
resistant to cisplatin than MCF7 cells over the dose range 50-117ýM (p<0.05 by 
ANOVA). 
6.3.2 Two-Dimensional Gel Electrophoresis 
Proteins from the parental MCF7 cell line and MCF7CR (displaying significant 
resistance to cisplatin) were analysed by 2DE. Proteins were fractionated using medium 
pH range IPG strips (pH 4-7 and pH 7-10) to maximise resolution. The pH range 4-7 
was analysed because the majority of proteins are visible within this range. The pH 
range 7-10 was analysed because many membrane proteins are visible within this range. 
Membrane proteins, such as drug transport pumps, comprise an important class of 
proteins in the study of chemotherapy resistance. Figure 6-2 
demonstrates the 
representative 2D guassian patterns obtained for the MCF7 parent and 
MCF7CR cell 
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Figure 6-2 Representative 2D guassian patterns for the MCF7 and MCF7CR cell lines 
in the pH range 4-7. Spots up-regulated in all 3 biological replicates are highlighteýd with 
arrows on the appropriate gel. Numbered spots indicate those spots for which identities 
have been assigned (refer to Figure 6-3 for numbering system). 
158 
Chapter VI 
8. Isocitralle 
'\4 
m- 
1 \\x 
lqmk 
ml Aw c 
The Proteomic Analysis of Cisplatin Resistance in Breast Cancer 
kogo, - 
40 
r-IW, 
9. BPGD 
c 
##Mow 
10. ADAP9 
Em 
ETFB 
F/ 
Rroteasoine Beta I S-ubwdt 
mc 
*HARNP A3 
m 
to ----A I 
LLJLIW I 
*PPU 
E/), 
mi //* 
1 
*PPIB 
c MI 
I 
Figure 6-3 Representative gels showing identified proteins that were differentially 
expressed between the MCF7 parental cell line (M) and MCF7CR (C). Numbers 
represent the spots shown in Figure 6-2. Five additional spots (*) were identified from 
the pH 7-10 range. Abbr: HSP27; Heat Shock 27-kDa protein 1, GST-M3; Glutathione- 
S-Transferase-mu 3, HPGD; Hydroxyprostaglandin Dehydrogenase, MMP; Matrix 
Metalloproteinase, ETFB; Electron Transfer Flavoprotein Beta, HnRNP A3; 
Heterogeneous Nuclear Ribonucleoprotein A3, PPI; Peptidyl-Prolyl Isomerase 
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lines for the pH range 4-7. Automatic spot detection and matching were performed with 
PDQuest software (Bio-Rad). Matches were reviewed manually and edited where 
necessary in order to remove false spots, include missed spots and to distinguish spots 
wit in c usters. In the parental cell line, approximately 955 spots were recognised in the 
pH range 4-7. Sixteen differentially expressed spots were identified in the MCF7CR 
cell line in comparison with the parental MCF7 cell line. Twelve of these spots were 
down-regulated and 4 spots were up-regulated in the MCF7CR cell line compared with 
the parental MCF7 cell line. In the pH range 7-10, approximately 218 spots were 
detected in the parental MCF7 cell line. Twelve spots were identified with differential 
expression between the cell lines. Eight spots were up-regulated and 4 spots were down- 
regulated in the MCF7CR cell line in comparison with the parent. 
6.3.3 Identification of Differentially Expressed Proteins 
In total, 28 proteins were excised and subjected to tryptic digestion. The resulting 
peptides were extracted and analysed by MALDI-TOF MS. Assignments have been 
obtained for 15 out of these 28 spots (Figure 6-3). The relative expression levels of 
these proteins in each of the replicate gels are represented in Figure 6-4. The MS 
identifications are listed in Table 6-1. Identified proteins can be categorised into several 
functional groups; structural (beta tubulin type 3, cytokeratin. 17, and tropomyosin I- 
alpha), stress response (heat shock 27-kDa protein 1, peroxiredoxin-4, peptidyl-prolyl 
isomerase A isoform I and peptidyl-prolyl isomerase B precursor), protein biosynthesis 
(ribosomal protein PO and heterogeneous nuclear ribonucleoprotein A3), protein 
degradation (proteasome beta I subunit and matrix metal loproteinase 9 (MNIP9)), 
metabolism (glutathione-s-transferase mu 3 (GST-M3) and hydroxyprostaglandin 
dehydrogenase 15-(NAD)) and regulation of ATP production (electron transfer flavo- 
protein beta polypeptide isofon-n I and isocitrate dehydrogenase 3). Although MMP9 
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Figure 6-4 Relative expression levels of the differentially expressed proteins for which 
identities have been assigned. In each box, the first 3 bars represent spot quantity in the 
parental MCF7 replicate gels and the last 3 bars represent spot quantity 
in the MCF7CR 
replicate gels. Refer to Figure 6-3 for numbering system and abbreviations. 
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was identified with a MOWSE score of 73, the pI value differed from that predicted 
from the 2D map (Table 6-1). However, the molecular weight matched the prediction 
therefore modifications during the experimental procedure may have occurred, which 
could have altered the pI of this protein. This result requires further confirmation. 
6.3.4 Western Blot Analysis 
Several targets were selected for western blot analysis to confirm differential expression 
(Figure 6-5). In addition, confirmation by western blotting also provided evidence of an 
accurate method of protein identification. The targets were selected based on the 
availability of an antibody against the specific isoform of the identified protein. Each 
band was normalised to GAPDH and protein expression was quantitated using 
densitometric analysis (Quantity One (version 4.6.1), Bio-Rad). GST-M3 and 
cytokeratin 17 were present in the parental MCF7 cell line but were undetectable in the 
MCF7CR cell line thereby confirming 2DE results. Furthermore, the down-regulation 
of peroxiredoxin 4 (2.6 fold) and HSP27 (1.5 fold) in the MCF7CR cell line was also 
confinned by western blotting. Although a standard >2 fold cut-off level is commonly 
used to identify differentially expressed proteins (see chapter VIII), western blots are 
difficult to accurately quantitate. Therefore, any change in expression that was observed 
in the correct direction was accepted for confirmation and was used simply to increase 
the confidence for highlighting those proteins for further study (see section 6.4.7). 
Initial western blots for the confin-nation of MMP-9 expression proved inconclusive due 
to non-specific binding of the antibody exploited. Further attempts using alternative 
antibodies must therefore be performed for confirmation of differential expression. 
6.4 Discussion 
Resistance to cisplatin represents a major obstacle to the successful treatment of many 
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Figure 6-5 Confirmation of 2DE results by western blotting. GST-M3 (26-kDa) and 
cytokeratin 17 (48-kDa) were present in MCF7 cells but were undetectable in MCF7CR 
cells. The down-regulation of peroxiredoxin 4 (30-kDa; 2.6 fold) and HSP27 (22-kDa; 
1.5 fold) was also observed in MCF7CR cells in comparison to parental cells. Protein 
bands were visible within the correct size ranges in relation to the Cruz Marker 
molecular weight standards (see section 4.8.3). Protein expression was quantitated using 
densitometry following normalisation to GAPDH. 
cancers, including metastatic breast cancer. In this study, the parental MCF7 breast 
cancer cell line and a novel derivative displaying significant resistance to cisplatin 
(MCF7CR) were analysed using 2DE in combination with MALDI-TOF MS. Fifteen 
proteins have been identified, which may play a role in cisplatin resistance. These have 
been categorised into several functional groups; protein degradation, protein 
biosynthesis, structural, stress response, metabolism and regulation of ATP production. 
The induction of apoptosis is the principal mechanism by which cisplatin exerts a 
cytotoxic effect. Therefore, resistance to apoptosis is possibly one of the major 
mechanisms whereby tumour cells can overcome treatment. However, it is also possible 
that a multitude of different mechanisms may contribute to a resistant-phenotype (see 
section 2.4). Due to the large number of targets identified in this chapter it was not 
possible to discuss the potential relevance of each protein. Therefore, targets were 
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resolved by their level of importance (Table 6-2). The properties of the potentially 
important targets and their possible roles in apoptosis and the development of cisplatin- 
resistance are discussed below and the reader is referred to Appendix G for information 
regarding additional targets. It is acknowledged that further work will be required for 
the verification of any hypotheses discussed below (see section 6.4.7). 
6.4.1 GST-M3 
Glutathione transferases (GSTs) are a family of phase 11 metabolic enzymes that 
catalyse the conjugation of glutathione (GSH) to endogenous and exogenous 
electrophilic substrates. This converts these chemicals into water-soluble, less toxic 
metabolites which can be easily excreted from the cell. GSTs therefore play an 
important role in the detoxification of many potentially harmful compounds, including 
cisplatin and other chemotherapeutic agents. GSTs have been well characterised and 
have been divided into a number of subclasses including alpha, pi, mu and theta. In 
particular, the over-expression of GST pi has been implicated with resistance to 
chemotherapy (Whelan et al 1992; Su et al. 2003; Hirano et al. 2005). This may be the 
result of increased detoxification, which allows cells to evade the cytotoxic effects of 
the drug. Furthen-nore, recent evidence suggests that GSTs are also inhibitors of the 
MAP-kinase pathway; a pathway which participates in transmitting the death signal 
(Townsend and Tew, 2003). There is little data on the association of GST-mu enzymes 
with chemotherapy resistance, however it has been reported that the transfection of 
GST-mu into MCF7 breast cancer cells did not result in an increased level of resistance 
to cisplatin (Townsend et al. I ý992). Results from the present study implicate the down- 
regulation of GST-M3 with resistance to cisplatin. Western blot analysis confirmed that 
GST-M3 was undetectable in MCF7CR cells but was present in MCF7 parent cells (see 
Figure 6-5). Coincidentally, an independent analysis using cDNA microarray analysis 
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and RT-QPCR also identified the down-regulation of GST-M3 in the same MCF7CR 
cell line (4.8 fold and 3.6 fold respectively) (Watson et al. manuscript submitted). 
Although this appears to conflict previous reports, Kearns et al. (2003) demonstrated 
that the over-expression of GST-M3 correlated with good prognosis in childhood acute 
lymphoblastic leukaemia (ALL). This was attributed to a better response to 
chemotherapy compared with patients expressing low levels of GST-M3 as measured 
by RT-PCR. The mechanism by which the down-regulation of GST-M3 may confer 
resistance to chemotherapy remains to be established. However, GST-M3 is the most 
distantly related to other members of the GST-M family. The GST-M3 protein shares 
only 70% homology with other isoforms and has atypical catalytical and structural 
properties compared with other GST-M members (Kearns et al. 2003). Thus, it is 
possible that this protein functions in pathways other than those involved with 
detoxification. In support of this hypothesis, GST-M3 has been shown to demonstrate 
prostaglandin E synthase activity in the human brain (Beuckmann et al. 2000) and 
prostaglandins have previously been associated with apoptosis (see the information on 
hydroxyprostaglandin dehydrogenase in Appendix G). 
6.4.2 Cytokeratin 17 
In the present study, the down-regulation of several cytoskeletal proteins was observed 
in the MCF7CR cell line. It is difficult to determine whether changes in the expression 
levels of these proteins contributed to the resistant phenotype or whether they were the 
result of morphological changes, which were observed during the development of the 
MCF7CR cell line (Watson et al. manuscript submitted). MCF7CR cells were smaller 
in comparison to MCF7 parent cells; a decrease in cell area from a mean of 
approximately 942[tm 2 to approximately 552 ýIM2 was observed. In eukaryotic cells, the 
cytoskeleton is composed of 3 morphologically distinct filamentous structures; 
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intermediate filaments, microtubules and microfilaments and is responsible for the 
mechanical integrity of the cell along with cell motility and transport, cell division and 
cell-cell adhesion (Parry and Steinert, 1999). 
The intermediate filament (IF) family of proteins is composed of several hundred 
members, which have been classified into distinct groups. IF types I and 11 are 
composed of the cytokeratins (CKs) (acidic (CKs 9-20) and basic (CKs 1-8) proteins, 
respectively). In the present study, the down-regulation of CK 17 was associated with 
resistance to cisplatin. Western blotting also revealed that CK 17 was undetectable in 
MCF7CR cells but was Present in MCF7 parent cells (see Figure 6-5). The down- 
regulation of several other type I CKs has previously been implicated with resistance to 
chemotherapy (Sommers et al. 1992; Katabami et al. 1993; Parekh et al. 1995). In 19959 
Parekh et al. found that a cisplatin-resistant ovarian cancer cell line (2008/CI3*) 
contained markedly lower levels of CK 18 in comparison with the parental cell line 
(2008). The transfection of full-length CK 18 cDNA into 2008/CI3* cells partially 
restored their sensitivity to cisplatin. This suggests that the down-regulation of specific 
CKs may contribute to cisplatin-resistance. In contrast, the over-expression of CK 17 
has also been correlated with a poor clinical outcome for patients with breast cancer. In 
2002, van de Rijn and colleagues used lHC to analyse the expression of several CKs in 
more than 600 paraffin-embedded breast tumours; in tissues microarrays. Kaplan-Meier 
survival analysis revealed that the absence of detectable CK 17 and CK 5 was 
associated with a significantly better prognosis than the presence of either of these CKs. 
The mechanism(s) by which alterations in the expression levels of specific CKs may 
lead to resistance remain elusive. Katabami et al. 1993 showed that the reduced 
expression of CK 14 was associated with cisplatin resistance in a human lung squamous 
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cell carcinoma cell line and this was attributed to the decreased accumulation of 
cisplatin within the resistant cells. In contrast, changes in the intracellular level of this 
agent have not been observed in other studies implicating the down-regulation of CKs 
with chemotherapy resistance. This suggests other mechanisms may also contribute to a 
resistant Phenotype. Parekh et al. suggested that the formation of CK-DNA cross-links 
may be associated with cisplatin cytotoxicity and that reduced expression of CKs may 
lead to a reduced formation of protein-DNA cross-links and thus decrease sensitivity to 
cisplatin. Also, recent studies have shown that cytoskeleton integrity is critical for the 
regulation of intracellular signalling pathways and many signalling molecules have been 
found to associate with the cytoskeleton (McCartney and Peifer, 2000). It is therefore 
possible that transmission of the death signal may require an intact cytoskeleton. Further 
studies are required to determine the mechanisms by which the down-regulation of such 
proteins may confer resistance to this agent. 
6.4.3 Peroxiredoxin 4 
Peroxiredoxins are a family of antioxidant enzymes, which form a defence system 
against the toxic processes of reactive oxygen species (ROS). These enzymes use 
thioredoxin as an electTon donor for the reduction of H202. H202may interact and 
damage cellular components including DNA and proteins. Several lines of evidence 
suggest that H202also plays a role as a secondary messenger in signalling cascades. 
Transient and intracellular H202production has been shown to accompany membrane 
receptor-dependent signalling (Finkel, 1998; Rhee et al. 2000). Therefore, 
peroxiredoxins have a dual role not only as defenders against oxidative stress 
but also as 
regulators of the H202signal. The over-expression of several members of this 
family 
has previously been associated with resistance to chemotherapy (Chung et al. 
2001; 
Nonn et al. 2003, Urbani et al. 2005). It has been postulated that apoptosis may 
be 
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inhibited due to the protection of cells against oxidative stress. In contrast, the present 
study has implicated the down-regulation of peroxiredoxin-4 with resistance to 
cisplatin. Western blot analysis confirmed the down-regulation of peroxiredoxin 4 (2.6 
fold) in MCF7CR cells (see Figure 6-5). The mechanism by which the down-regulation 
of specific members may result in resistance to chemotherapy remains unknown, 
however it is possible that it may be related to regulation of signalling pathways in 
which the H202 signal is involved. H202 has been shown to activate NF-KB 
transcriptional activity (Schreck et al. 1991). The NF-KB pathway is involved with anti- 
apoptotic signalling and results in the transcription of survival genes including Bcl-2 
(see section 6.4.1.1). Kang et al. (1998) demonstrated that the over-expression of 
peroxiredoxin-I and -2 reduced H202 that was produced in response to growth factors 
and inhibited NF-ic]3 activation induced by H202or tumour necrosis factor-a (TNF-cc). 
This suggests that the over-expression of these peroxiredoxins blocked NF-icB 
activation by reducing the levels of the secondary message (H202) and therefore 
inhibited the transcription of anti-apoptotic genes. This also suggests, that a down- 
regulation of these proteins may not allow for the efficient reduction of H202 thereby 
allowing the activation of the anti-apoptotic NF-Y-B signalling pathway. Furthermore, 
this secondary message may also be involved with as yet unknown signalling pathways, 
which may be associated with apoptosis. This provides a potential mechanism by which 
the down-regulation of peroxiredoxin-4 may increase resistance to cisplatin. 
6.4.4 Heat Shock 27-kDa Protein I 
Heat shock 27 kDa protein I (HSP27) is a small heat shock protein, which functions as 
a molecular chaperone. This protein is essential for protein folding, translocation across 
cellular compartments, assembling and maintaining multiprotein complexes 
in 
activation-comPetent states, preventing self-association and targeting misfolded and 
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short-lived proteins to the proteasome for degradation (Mosser and Morimoto, 2004). 
The balance between cell division and apoptosis is largely dependent upon cell 
signalling pathways. Many key components of these pathways are regulated through 
interactions with the familY of heat shock proteins, including HSP27. It is not surprising 
therefore, that alterations in the expression of HSP27 have previously been implicated 
with resistance to chemotherapy (Berrieman et al. 2006; Yamamoto et al. 2001; Arts et 
al. 1999). In such studies, the over-expression of HSP27 has been associated with 
resistance suggesting that this protein functions as an inhibitor of apoptosis. It has been 
hypothesised that HSP27 can protect cells from apoptosis by refolding damaged 
proteins into their native states. In the present study a down-regulation of HSP27 was 
implicated with resistance to cisplatin. Western blotting also confinned the down- 
regulation of HSP27 (1.5 fold) in MCF7CR cells (see Figure 6-5). In accordance, 
Hettinga et al. (1996) demonstrated that decreased expression levels of the HSP27 
protein were associated with a decreased sensitivity to cisplatin in 3 cell lines derived 
from germ-cell carcinomas. Several proteins including signalling kinases and 
transcription factors are maintained in an activation-competent state by heat shock 
proteins. It is possible that some of these proteins may be involved in transmitting the 
death signal and transcribing the genes required for the execution of apoptosis. The 
down-regulation of HSP27 may therefore prevent the activation of these proteins 
leading to an attenuated cisplatin-induced apoptotic response. Furthermore, molecular 
chaperones provide stabilisation for some of their interacting partners. It is possible that 
the down-regulation of HSP27 may destabilise and enhance proteasomal degradation of 
apoptosis-promoting proteins. This is supported by the fact that an over-expression of 
proteasome beta I subunit was also observed in MCF7CR cells and several pro- 
apoptotic proteins have been identified as substrates for proteasomal degradation (see 
section 6.4.6). Further studies are required to verify these hypotheses, in particular in 
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would be interesting to identify those proteins that interact with HSP27 in this in-vitro 
cell culture model. 
6.4.5 Ribosomal Protein PO 
Ribosomal proteins decorate ribosomal subunits thereby organising and stabilising the 
rRNA tertiary structure. In addition, many of these proteins have a function outside of 
the ribosome. Increasing evidence suggests that a number of ribosomal proteins may 
play a role in apoptosis. In the present study, a down regulation of ribosomal protein PO 
was associated with cisplatin resistance. This suggests that expression of this protein 
may promote apoptosis. In accordance, the expression of several other ribosomal 
proteins has been associated with apoptosis (Wool et al. 1995; Neumann and 
Krawinkel, 1997; Hu et al. 2000; Khanna et al. 2003). Khanna et al. (2003) 
demonstrated that the over-expression of ribosomal protein S29 was able to induce 
apoptosis and augment the effect of cisplatin and etoposide in H520 lung cancer cells. 
In a series of experiments, this group found that the ribosomal protein S29 promoted 
apoptosis by down-regulating the expression of apoptosis inhibitors including Bcl-2, 
Bcl-xL, IAPs and survivin and up-regulating the pro-apoptotic proteins p53 and Bax. A 
reduction in NF-KB transcriptional activity was also observed. It is possible that 
ribosomal protein PO may function in a similar manner. The down-regulation of this 
protein would therefore result in a reduced apoptotic response to cisplatin. 
6.4.6 Proteasome Beta 1 Subunit 
The degradation of cellular proteins is a highly complex, temporally controlled and 
tightly regulated process that plays a major role in a variety of biological pathways, 
including cell proliferation and apoptosis. The ubiquitin/proteasome pathway is the 
main non-lysosomal route for degradation and is responsible for the turnover of >80% 
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of cellular proteins (Dalton, 2004). This involves the conjugation of multiple ubiquitin 
moieties to a substrate followed by the downstream degradation of the tagged protein by 
a proteasome comPlex. The 26S proteasome is a multicatalytic protease, which consists 
of a cylindrical proteolytic particle (the 20S proteasome), in association with I or 2 19S 
regulatory complexes (Figure 6-6). The 20S proteasome is composed of 4 stacked rings. 
Each outer ring contains 7 distinct alpha-subunits (1-7) and each inner ring contains 7 
distinct beta-subunits (1 -7). Each ring of beta subunits contains 3 proteolytic sites, 
which differ in their substrate specificity. The "chymotrypsin-like" site (beta 5 subunit) 
cleaves peptide bonds preferentially after hydrophobic residues, the "trypsin-like" site 
(beta 2 subunit) cleaves mainly after basic residues and the "caspase-like" site (beta I 
subunit) cleaves Preferentially after acidic residues. In the present study, an over- 
expression of the proteasome beta I subunit was associated with resistance to cisplatin 
in MCF7 breast cancer cells. This finding is in accord with previous results which have 
implicated the aberrant expression and dysfunction of 26S proteasome subunits with 
cellular resistance to various chemotherapeutic agents. In one such study, Spataro et al. 
(2002) found that an over-expression of the 26S proteasome subunit Rpnl I (a 
component of the 19S regulatory complex) conferred a moderate level of resistance to 
vinblastine, cisplatin and doxorubicin in a panel of cell lines. A multitude of 
mechanisms have been proposed to elucidate the anti-apoptotic role of the 
26Sproteasome. Several studies have revealed pro-apoptotic proteins as substrates for 
proteasomal degradation. These include p53, Bax, Bik and tBid (Haupt et al. 1997; Li 
and Dou, 2000; Marshansky et al. 2001; Breitschopf et al. 2000, respectively). 
Furthennore, specific caspases are also substrates for the proteasome (Huang et al. 
2000; Suzuki et al 2001). Caspases are a family of proteins that mediate the execution 
of apoptosis. This promotes the hypothesis that an over-expression of the 26S 
proteasome can result in an attenuated apoptotic response due to the rapid degradation 
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Figure 6-6 The 26S proteasome. This multicatalytic protease consists of a cylindrical 
proteolytic particle (the 20S proteasome) in association with I or 2 19S regulatory 
complexes and is responsible for the degradation of polyubiquitinated proteins. The 20S 
proteasome is composed of 4 stacked rings. Each outer ring contains 7 alpha-subunits 
(1-7) and each inner ring contains 7 beta subunits (1-7). The over-expression of the 
proteasome beta I subunit may be associated with resistance to cisplatin. 
of apoptosis-promoting proteins. In addition, there is evidence to suggest that the 26S 
proteasome is involved in the regulation of the NF-KB pathway. NF-KB is a 
transcription factor, which protects cells from apoptosis through the induction of 
survival genes including cIAP 1, cIAP2, XIAP and Bcl-2. In unstimulated cells, an 
inhibitor of NF-KB (ficB) sequesters this protein in the cytoplasm by binding and 
masking the nuclear translocation signal (Karin and Ben-Neriah, 2000). In response to a 
variety of extracellular stimuli, IrB becomes rapidly phosphorylated and 
ubiquitinylated. Ubiquitinylated ficB is degraded by the 26S proteasome allowing NF- 
KB to translocate to the nucleus and induce gene transcription. Thus, it is reasonable to 
speculate that an over-expression of the proteasome would result in excessive 
degradation of IKB, which would allow NF-KB to translocate to the nucleus and 
stimulate the inappropriate transcription of survival genes. In support of this Cusack et 
al. (2001) found that administration of the proteasome inhibitor; PS-341, blocked 
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inducible NF- KB activation, which increased levels of apoptosis in response to 
chemotherapy. This inhibitor (now known as Bortezimib) has since been approved for 
the treatment of multiple myeloma (Chauhan et al. 2005) and is administered to those 
patients who have failed at least one treatment. Ongoing studies are examining the use 
of Bortezimib and other novel proteasome inhibitors for the treatment of other cancers. 
Alternatively, the over-expression of specific proteasome subunits may increase 
resistance to anticancer agents due to enhanced DNA repair. Jelinsky et al. (2000) 
showed that a large number of protein degradation genes and a selection of base 
excision and nucleotide excision repair genes are linked in a transcriptional regulon in 
Saccharomyces cerevisiae cells. This regulon is controlled by Rpn4, which is also a 
proteasome-associated protein. Rpn4 acts as a transcription factor and influences the 
regulation of genes involved in these 3 pathways in response to a wide-range of 
chemical and physical DNA-damage agents including the monofunctional SN2 
alkylating agent (MMS). RAD23 and SSL2 are nucleotide excision repair (NER) genes, 
which are co-regulated with MAGI (a base excision repair (BER) gene) and protein 
degradation genes. The RAD23 protein has an N-terminal ubiquitin-like domain that 
interacts with the 26S proteasome and a C-terminal that interacts with another DNA 
repair protein RAD4. The RAD23-RAD4 complex interacts with TFIIH (which contains 
the SSL2 protein), which is a transcription factor known to be required for NER. 
Enhanced NER activity has previously been associated with resistance to cisplatin (see 
section 2.4.1.1). Thus it is possible that enhanced DNA repair via over-expression of the 
proteasome may reduce the efficacy of this agent. 
6.4.7 Discussion and Conclusion 
In summary, the aims of this chapter were successfully fulfilled. The 2DE-MALDI-TOF 
MS protocols that were developed in chapter V were effectively applied to the analysis 
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of cisplatin resistance in human breast cancer cells. This global profiling approach 
identified several differentially expressed proteins, which may be associated with 
cisplatin resistance in this novel in-vitro breast cancer model. Western blotting was 
exploited to confinn the differential expression of selected proteins and ensured the 
accuracy of protein identification. Such targets represent potential biomarkers and 
require further study. These methods developed in this thesis are therefore suitable for 
the application of biomarker discovery and also many other areas of cancer research. 
One of the drawbacks associated with the use of 2DE is a bias towards the analysis of 
certain proteins. Alterations in the expression levels of less abundant proteins (which 
are often those POls) may have been masked by the more abundant proteins. This issue 
can be addressed by increasing the resolution of the 2DE technique by using large 
format gels (I 7cm or 24cm) and/or by using additional prefractionation strategies such 
as multiple overlapping narrow pH range IPG strips (see section 5.1.2). The complexity 
of proteomes may also be reduced by subcellular fractionation prior to analysis. This is 
commonly achieved by exploiting differential protein solubility using a series of buffers 
with increasing solubility properties. Each fraction can be analysed independently, 
allowing more of the proteome to be visualised and increasing the chance of observing 
less abundant proteins. However, several problems are associated with the use of such 
strategies including the increased complexity of subsequent analysis (see section 5.1.2). 
In the present study the identities of some of the differentially expressed proteins also 
remain unknown. This may have been the result of co-migration or an inaccurate 
manual spot excision leading to the digestion and subsequent analysis of peptides from 
multiple proteins in addition to the POI. Large fortnat gels and/or the use of the 
additional prefractionation strategies discussed above may increase resolution such that 
more accurate manual spot excisions may be allowed. However, some of these 
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unknown proteins may be novel proteins and may therefore have been absent from the 
NCBlnr database. Alternatively, results from the optimisation procedure revealed that 
some proteins are simply not amenable to identification by PMF alone (see section 
5.2.3). The sequences of some of these unknown proteins may have had few specific 
sites for tryptic digestion thereby yielding a small number of peptides within the 
analysed mass range (see section 5.2.3.1). Additionally, some of these proteins may 
have been composed of regions with a high content of lysine and arginine residues. 
These proteins may have undergone extensive cleavage thereby yielding short peptides 
which were undetectable in the analysed mass range. Additional protease enzymes are 
available for use in proteomic analyses. Examples include Glu-C (V8 protease), Lys-C 
and Asp-N. These enzymes cleave at single amino acid residues and generally produce 
fewer, larger fragments which can reduce the success of protein identification. A further 
example includes chymotrypsin. This enzyme cleaves at tyrosine, phenylalanine and 
tryptophan residues and therefore often cleaves too frequently (Liebler, 2002). 
Nevertheless, such enzymes may prove useful for the analysis of those proteins 
unsuitable for tryptic digestion. In the future, the unknown proteins may also be 
analysed using MS/MS. This technique allows peptide sequences to be obtained and 
therefore more confident assignments to be made (see section 3.4.1.4). Thus, further 
proteins associated with cisplatin-resistance may be identified in this in-vitro cell 
culture model. 
Fifteen proteins have been identified, which may be involved with resistance to cisplatin 
in this in-vitro cell culture model. Although the possible roles of these proteins in the 
devýelopment of cisplatin-resistance have been discussed it is important to note that 
these remain hypotheses and further work (both in-vitro and in-vivo) is required to 
verify any potential roles. Of these targets, GST-M3 
is possibly one of the most 
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attractive candidates and is used as an example with which to describe the further 
studies. This is because the down-regulation of this protein was not only confirmed by 
western blotting but was also identified as down-regulated in an independent analysis of 
the same cell lines using cDNA microarray and RT-QPCR techniques (Watson et al. 
manuscript submitted). Functional studies using gene silencing methods (e. g. RNA 
interference) and/or pharmacological inhibitors will determine whether the down- 
regulation of this protein is the cause of cisplatin-resistance or an innocent bystander 
effect. RNA interference (RNAi) is a powerful method for the post-transcriptional 
silencing of specific genes (Figure 6-7). The functional intermediates of the RNAi 
pathway are 21-23 nucleotide short (or small) interfering RNA (siRNA) duplexes, 
which induce the sequence-specific reduction of target mRNA. SiRNA duplexes are 
characterised by symmetrical 3' dinucleotide overhangs and 5'-phosphate and 3')- 
hydroxyl groups. Several methods for siRNA production are available including 
chemical synthesis, in-vitro transcription, in-vitro digestion of a long dsRNA molecule 
by a RNase III-like enzyme called Dicer and the in-vivo expression of siRNA duplexes 
from PCR cassettes or plasmids. These siRNA complexes are subsequently delivered 
into host cells via a number of different methods (the most common being lipid- 
mediated transfection). The siRNA duplexes enter a multiprotein complex called the 
RNA-induced silencing complex (RISC). RISC-associated ATP-dependent helicase 
activity unwinds the duplex enabling either of the strands to guide target mRNA 
recognition. Upon determining a region of complementarity RISC mediates mRNA 
cleavage and consequently post-transcriptional gene silencing. This method may be 
exploited to determine whether the down-regulation of GST-M3 can contribute to a 
cisplatin-resistant phenotype in MCF7 breast cancer cells. SiRNA duplexes with 
sequence-specific homology for GST-M3 mRNA may be delivered into parental MCF7 
cells. Western blotting and/or RT-QPCR may be exploited to assess the efficiency of 
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Figure 6-7. The RNA interference pathway. RNA interference (RNAi) is mediated by 
21-23 nucleotide short (or small) interfering RNA (siRNA) duplexes. The siRNAs are 
incorporated into a multiprotein complex called the RNA-Induced Silencing Complex 
(RISC). RISC is activated by ATP and probes the target mRNA for complementary 
sequences. Upon the identification of a region of complementarity RISC mediates 
mRNA cleavage and post-transcriptional gene silencing. Figure adapted from 
Dykxhoorn et al. (2003). 
gene silencing after which the transfected parental MCF7 cells may be treated with 
cisplatin. Relative in-vitro resistance may be determined using the MTT assay as 
previously described (see section 4.3.1) and a comparison of the dose response curves 
for transfected MCF7 cells, untransfected MCF7 cells and MCF7CR cells may 
detennine whether the down-regulation of GST-M3 plays a functional role in the 
development of ci splatin-resi stance. Although this technique may be suitable to assess 
the functional relevance of GST-M3, RNAi would not be suitable for analysing the 
functional relevance of post-translationallY modified proteins. This is because RNAi 
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results in gene silencing prior to translation. Pharmacological inhibitors provide an 
alternative approach for determining the functional significance of specific targets and 
result in the inhibition of the target proteins themselves. In order for this approach to be 
successful, specific pharmacological inhibitors must be available for the proteins-of- 
interest. Ethacrynic acid and the glutathione analogue TER199 (y-glutamyl-S[benzyl] 
cysteinyl phenyl glycyl diethyl ester) are the best known inhibitors of GST activity. 
Both of these compounds prevent GSH conjugation by depleting the levels of GSH 
(Ouwerkerk-Mahadevan et al. 1995). Thus, these inhibitors are not GST-M3 specific 
and therefore may have more consequences on host cells than the inhibition of GST-M3 
alone. In contrast, many pharmacological inhibitors specifically targeting the 26S 
proteasome are available. In particular, lactacystin specifically binds and inhibits the 
catalytic beta subunits of the 20S proteasome (Imajoh-Ohmi et al. 1995). This approach 
may therefore be useful in determining whether this multiprotein complex plays a 
functional role in the development of cisplatin-resistance. Pretreatment of MCF7CR 
cells with lactacystin followed by cisplatin treatment would determine whether the level 
of in-vitro resistance could be reduced to that of parental MCF7 cells. In addition, 
several kits are commercially available to assay the function of the 26S proteasome. The 
Proteasome-GIOTM Cell-Based Assay (Promega) exploits a luminogenic proteasome 
substrate (succinyl-leucine-leucine-valine-tyrosine-aminoluciferin), which is degraded 
by the proteasome. Such degradation results in the release of aminoluciferin, a substrate 
for the luciferase enzyme. This allows the luciferase reaction to proceed and produce 
light. The level of luminescence is directly proportional to proteasome activity. Thus, it 
may be interesting to determine whether an over-expression of proteasome beta I 
subunit can enhance proteasome acitivity in MCF7CR cells in comparison with parental 
cells. However, the techniques exploited to determine the functional relevance of these 
targets are not infallable and a failed result does not necessarily rule-out specific targets. 
180 
Chapter VI The Proteomic Analysis of Cisplatin Resistance in Breast Cancer 
This is because many targets may work together in concert and therefore silencing one 
target in isolation may not be sufficient to alter the level of resistance. This may be 
addressed by silencing/ inhibiting a combination of genes/ proteins. 
Future work will also involve analysing further cisplatin-resistant cell lines. This will 
include not only additional breast cancer cell lines displaying significant resistance to 
cisplatin but also those cell-lines originating from other tumour types, which are 
commonly treated with cisplatin. Examples include lung, ovarian, cervical and testicular 
tumours. This will allow general markers of cisplatin-resistance to be identified. 
Ultimately, these targets must be clinically relevant and therefore must be validated in a 
relevant series of clinical samples. This is because the microenviromnent influences the 
behaviour of turnour cells and cultured cells are not subject to this influence. Thus, 
although in-vitro cell culture models represent a good starting point they are not truly 
indicative of the in-vivo situation. The identification of novel biornarkers associated 
with cisplatin-resistance may allow treatment to be tailored on an individual patient 
basis and provide novel targets for future therapeutic intervention. 
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Aims: 
To use 2DE-NIALDI-TOF MS for the identification of molecular markers 
associated with radiotherapy resistance in human breast cancer cells. 
To conduct the first proteomic analysis of a novel radiotherapy resistant breast 
cancer cell line. 
To validate the molecular markers identified by 2DE-MALDI-TOF MS using 
western blot analysis 
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7.1 Introduction 
Radiotherapy (RT) is administered to most patients undergoing breast conserving 
surgery and is also considered for women at high risk of recurrence following 
mastectomy (Jameel et al. 2004). RT involves the delivery of high energy X-rays, which 
exert a cytotoxic effect by producing free radicals within target tissues. Such radicals 
are the source of reactive oxygen species (ROS) and reactive nitrogen species (RNS),, 
which create DNA darnage, by both single-stranded (ss) and double-stranded (ds) breaks 
triggering apoptosis. Unfortunately, RT is associated with many unpleasant and 
potentially life-threatening side-effects (e. g. damage to the heart and lungs and risk of a 
second malignancy). Furthermore, not all patients derive therapeutic benefit from 
treatment and failure to respond to a course of RT may delay the implementation of a 
more appropriate treatment modality. During this delay tumour progression may occur, 
which could impact significantly on patient survival. The identification of novel 
biomarkers which correlate with treatment response would allow therapy to be tailored 
on an individual patient basis. In addition, new sensitizing agents may also be 
developed increasing the efficacy of RT. Alterations in DNA repair pathways, apoptotic 
machinery and antioxidant enzymes have previously been implicated with resistance to 
RT (Sun et al. 1998; Liang et al. 2003; Nix et al. 2005). Increased exPression levels of 
several membrane receptors, including insulin like growth factor- I receptor (IGF- I R) 
and human epidermal growth factor receptors (HERS) have also been implicated with 
radio-resistance (Turner et al. 1997; Zhou et al. 2004). Furthermore, the over-expression 
of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) in the 
extracellular fluid has been associated with a reduced cellular response to RT (Wollman 
et al. 1994; Gupta et al. 2002). However, despite this understanding, the mechanisms 
contributing to radio-resistance remain largely elusive. In the present study, we sought 
to identify molecular markers associated with radio-resistance in breast cancer using an 
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in-vitro cell culture model. The protein profiles of the MCF7 cell line and a novel 
derivative (MCF740Gy) displaying significant resistance to RT were compared using 
2DE in combination MALDI-TOF MS. 
7.2 Materials and Methods 
7.2.1 Cell Lines 
A novel derivative displaying significant resistance to RT (MCF740Gy) was established 
from the MCF7 breast cancer cell line in collaboration with Mr Omar Qutob and 
Professor Andrew Beavis. Cells were harvested by enzymatic dissociation as described 
in section 4.2.1 and seeded at a concentration Of IX106 cells in 5ml RPMI(s) media in a 
screw-capped vial with a diameter of 18mm. Irradiation was performed at the Princess 
Royal Hospital, Hull, UK by a radiation physicist (Professor Andrew Bevis) using x- 
rays produced by a Clinical Linear Accelerator treatment machine (Figure 7-1A). 
Different machines were used throughout the course of the study as dictated by 
availability. These machines were "energy-matched" and the 6MV beam on each was 
therefore considered identical for the purpose of this work. A simple cradle was 
manufactured, which allowed the vial to be suspended inside a water filled vessel 
(phantom) (Figure 7- 1 B). This allowed irradiation of the cells to mimic the in-vivo 
situation with the surrounding water representing body tissue. The cradle was designed 
such that the vial containing the cells was mounted precisely at the centre of the 
phantom. Given the depth of the water between the phantom surface and the centre of 
the vial (5.5cm), the size of the irradiation beam used (8cm x 8cm), the distance from 
the radiation source to the centre of the vial (100cm) and the energy of the x-ray beam 
(6MV) it was possible to calculate the irradiation time required to deliver a specific dose 
to that point. It was assumed that the dose given to any cells at the centre of the vial 
represented that imparted to the cells throughout its volume. Using this experimental 
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Figure 7-1 The experimental set-up required for the irradiation of cell populations. A. 
Irradiation was performed at the Princess Royal Hospital, Hull, UK using x-rays 
produced by the Clinical Linear Accelerator treatment machine. The cells were 
suspended within a water-filled vessel called a phantom, which was arranged so that the 
x-rays were delivered to the centre of the phantom. B. A schematic representation of the 
phantom. A simple cradle was manufacturered allowing the vial containing the cell 
suspension to be suspended within the phantom. The cradle was designed such that the 
cells were mounted precisely at the centre of the phantom. lonising radiation was 
delivered to the centre of the vial and it was assumed that the dose given to cells at this 
point was imparted to the cells throughout the volume of the vial. 
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set-up it was possible to deliver consistent doses to the cell samples throughout the 
course of the study. The cells were treated with RT following a protocol similar to that 
exploited within the clinic for the treatment of breast cancer patients. Thus, cells 
received a total dose of 40Gy administered in 20 sequential fractions of 2Gy per week. 
Following each fraction, the surviving cells were allowed to re-establish the cell 
population. 
7.2.2 Assessment of In-Vitro Radiotherapy Resistance 
The relative resistance of MCF7 and MCF740Gy to single fractions of ionising 
radiation (IR) was measured using a modified colony counting assay described in 
section 4.3.2. 
7.2.3 2DE and MALDI-TOF MS 
Protein from each cell line was extracted and quantified as described in sections 4.4.1 
and 4.4.2. Samples were prepared using the 2DE Clean-up Kit (Bio-Rad) and 2DE 
experiments were performed as described in sections 4.4.3-4.4.8 using Biosafe 
coomassie blue as the protein-binding dye. Differentially expressed proteins were 
digested and identified using MALDI-TOF MS (described in sections 4.5-4.6). 
7.2.4 Western Blotting 
Western blotting was exploited for confmnation of results and was performed as 
described in section 4.8. Primary antibodies against GST-M3 (generously donated from 
Professor John Hayes, Biomedical Research Centre, University of Dundee, UK), L- 
Plastin (#MS-1326; Neomarkers) and cytokeratin 17 (#Ab2502; Abcam) were added at 
concentrations of 1: 2000 (GST-M3), 1: 100 (L-Plastin) and 1: 50 (cytokeratin 17) for 2 
hrs at RT. The appropriate HRP-conjugated secondary antibody (anti-mouse or anti- 
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rabbit, #SC-2031 and #SC-2030; Santa Cruz) was added at a concentration of 1: 1000 
and enhanced chemiluminescence (ECL) was used for detection as described in section 
4.8.3. Membranes were subsequently re-probed with GAPDH as described in section 
4.8.4 and image analysis was undertaken as described in section 4.8.5 
7.3 Results 
7.3.1 Establishment of the MCF740Gy Cell Line 
A modified colony counting assay was used to determine the relative resistance of 
MCF7 and MCF740Gy cell lines to single fractions of IR over the range 0-IOGy 
(Figure 7-2). The MCF740Gy cell line was significantly more resistant to IR than the 
MCF7 parent at 4,6,8 and I OGy (p<0.0 1; ANOVA) with the maximal 3 7-fold increase 
in resistance observed at 8Gy. Western blot and RT-QPCR analysis revealed that both 
parent and derivative cells demonstrated similar expression levels of p53, ER and PR 
(Mark Watson, personal communication). 
7.3.2 Two-Dimensional Gel Electrophoresis 
Proteins from the parental MCF7 cell line and the novel derivative MCF740Gy 
displaying significant resistance to RT were analysed by 2DE. Proteins were 
fractionated using medium pH range IPG strips (pH 4-7 and pH 7-10) to maximise 
resolution. The pH range 4-7 was analysed because the majority of proteins are visible 
within this range. The pH 7-10 range was analysed to determine whether any membrane 
proteins, which have previously been implicated with resistance to chemotherapy, may 
also play a role in radio-resistance. Figure 7-3 demonstrates the representative 2D 
guassian patterns obtained for the MCF7 parent and MCF740Gy cell lines for the pH 
range 4-7. Automatic spot detection and matching were performed with PDQuest 
software (Bio-Rad). Matches were reviewed manually and edited where necessary in 
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Figure 7-2 Dose response curve demonstrating the relative resistance of MCF7 and 
MCF740Gy cell lines to single fractions of ionising radiation over the range 0-IOGy. 
Each point represents the mean of 6 replicates and error bars show the standard error of 
the mean. The MCF740Gy cell line was significantly more resistant to IR than the 
MCF7 parent at 4,6,8 and I OGy (p<0.0 1; ANOVA) with the maximal 3 7-fold increase 
in resistance observed at 8Gy. 
order to remove false spots, include missed spots and to distinguish spots within 
clusters. In the parental cell line, approximately 827 spots were recognised in the pH 
range 4-7. Sixteen differentiafly expressed proteins were identified in the MCF740Gy 
cell line in comparison with the parental MCF7 cell line. Eleven of these spots were 
down-regulated and 5 spots were up-regulated in the MCF740Gy cell line compared 
with the parental MCF7 cell line. In the pH range 7-10, approximately 320 spots were 
detected in the parental MCF7 cell line. Two spots were identified with differential 
expression between the cell lines. One of these spots was up-regulated and the other 
spot was down-regulated in the MCF740Gy cell line in comparison with the parent. 
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Figure 7-3 Representative 2D guassian patterns for the MCF7 and MCF740Gy cell 
lines in the pH range 4-7. Spots up-regulated in all 3 biological replicates are 
highlighted with arrows on the appropriate gel. Numbered spots indicate those spots for 
which identities have been assigned (refer to Figure 7-4 for numbering system). 
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7.3.3 Identification of Differentially Expressed Proteins 
In total, 18 proteins were excised and subjected to tryptic digestion. The resulting 
peptides were extracted and analysed by MALDI-TOF MS. Assignments were obtained 
for 15 out of these 18 spots (Figure 7-4). The relative expression levels of these proteins 
in each of the replicate gels are represented in Figure 7-5. The MS identifications are 
listed in Table 7-1. Identified proteins can be categorised into several functional groups; 
structural (L- plastin, keratin 17 and actinin alpha 4), protein degradation (proteasome 
activator subunit I (PSMEI) isoform 2, proteasome activator subunit 2 (PSME2) and 
growth inhibiting gene 5 (GIG5) protein), protein biosynthesis (eukaryotic translation 
initiation factor 3 (eIF3) subunit 2 beta, lysyl-tRNA synthetase, leucine-rich 
pentatricopeptide repeat motif-containing (LRPPRC) protein, ribosomal protein PO and 
N-acetyltransferase) and metabolism (glutathione-s-transferase mu-3 (GST-M3), 
pyrophosphatase (PPase) 1, chromosome 17 open reading frame 25 (C170RF25) and 
START domain-containing protein 10 (STARD 10)). 
7.3.4 Western Blot Analysis 
Three targets were selected for western blot analysis to confirm differential expression 
(Figure 7-6). It was not feasible to confirm the expression levels of all 15 targets as 
specific antibodies were unavailable for several of the targets. Therefore, those targets 
with the highest MOWSE scores (Table 7-1) and for which a specific antibody was 
available were selected for confinnation. Each band was nonnalised to GAPDH and 
protein expression was quantitated using densitometric analysis (Quantity One (version 
4.6.1), Bio-Rad). L-Plastin was present in the parental cell line but was undetectable in 
the MCF740Gy cell line thereby confirming 2DE results. Furthermore, the down- 
regulation of GST-M3 (15.7 fold) and cytokeratin 17 (1.7 fold) was also confirmed by 
western blotting in the MCF740Gy cell line. 
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Figure 7-6 Confirmation of 2DE results by western blotting. L-Plastin (70-kDa) was 
present in MCF7 cells but was undetectable in MCF740Gy cells. The down-regulation 
of GST-M3 (26-kDa; 15.7 fold) and cytokeratin 17 (48-kDa; 1.7 fold) was also 
observed in MCF740Gy cells in comparison to parental cells. Protein bands were 
visible within the expected size ranges in relation to the Cruz Marker molecular weight 
standards. Protein expression was quantitated using densitometly following 
normalisation to GAPDH. 
7.4 Discussion 
Resistance to RT represents a major obstacle to the successful treatment of patients with 
breast cancer. In this study, a novel derivative (MCF740Gy) displaying significant 
resistance to RT was established from the MCF7 parental cell line. The MCF740Gy cell 
line was established using a fractionated treatment regimen similar to that utilised 
within the clinic, which comprised of 2Gy fractions with a total dose of 40Gy. 
Zhongkui et al. (2001) also used this protocol to derive a statistically significant radio- 
resistant MCF7 subpopulation (MCF-IR20). MCF-IR20 cells were subsequently 
compared with MCF7 parental cells using limited gene expression microarrays. 
Although these microarrays were composed of only 588 genes, changes in the 
expression levels of several stress-related genes were observed. In the present study, cell 
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lines were analysed using 2DE in combination with MALDI-TOF MS. Fifteen proteins 
were identified, which may also play a role in radio-resistance. These proteins can be 
categorised into several functional groups; structural, protein degradation, protein 
biosynthesis and metabolism. The induction of apoptosis is the principal mechanism by 
which RT exerts a cytotoxic effect. Therefore, resistance to apoptosis is possibly one 
major mechanism allowing tumour cells to overcome treatment. However, it is possible 
that a multitude of different mechanisms may contribute to the resistant-phenotype. Due 
to the large number of targets identified in this chapter it was not possible to discuss the 
potential relevance of each protein. Therefore, targets were resolved by their level of 
importance (Table 7-2). The properties of the potentially important targets and their 
possible roles in apoptosis and the development of radio-resistance are discussed below 
and the reader is referred to Appendix H for information regarding additional targets. It 
is acknowledged that ftirther studies are required for the verification of any hypotheses 
described below because functional assays to determine the relevance of these targets 
have yet to be conducted (see section 7.4.6). 
7.4.1 GST-M3 
Glutathione transferases (GSTs) are a family of phase 11 enzymes that catalyse the 
conjugation of glutathione (GSH) to endogenous and exogenous electrophilic 
substrates. This converts these substrates into water-soluble, less toxic metabolites 
which can be easily excreted from the cell. GSTs therefore play an important role 
in the 
detoxification of many potentially harmful compounds, including some of the toxic 
carbonyl-, peroxide-, and epoxide-containing metabolites produced within the cell 
in 
response to RT (Hayes and Pulford, 1995). GSTs have been well characterised and 
have 
been divided into a number of subclasses including alpha, pi, mu and theta. The over- 
expression of the GST-pi subtype has previously been 
implicated with a poor response 
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to RT (Miura et al. 1997; Silvestrini et al. 1997). This is possibly the result of increased 
detoxification allowing cells to evade the cytotoxic effects of RE In addition, recent 
evidence suggests that GSTs are also inhibitors of the MAP-kinase pathway; a pathway 
which participates in transmitting the death signal (Townsend and Tew, 2003). 
Furthermore, the use of GST inhibitors in-vitro has been shown to enhance the effects 
of RT in various human carcinoma cell lines (Khil et al. 1996). In contrast, results from 
the present study have implicated the down-regulation of GST-M3 with resistance to 
RT. This finding was confirmed by western blotting, which revealed that the expression 
of GST-M3 was decreased by 15.7 fold in MCF740Gy cells in comparison with 
parental cells (Figure 7-6). An independent analysis using gene expression microarrays 
and RT-QPCR also identified the down-regulation of GST-M3 (3.6 fold and 3.8 fold,, 
respectively) in the same MCF740Gy cell line (Omar Qutob, personal communication). 
Furthermore, the down-regulation of this same isotype was implicated with resistance to 
cisplatin in MCF7 breast cancer cells and this result was confirmed independently by 
western blotting (see chapter VI). This suggests that the down-regulation of GST-M3 
may be associated with resistance to apoptosis. In accordance with the results from our 
study, Rawal et al. (2001) found that a decrease in the activity of GST enzymes was 
associated with poor response to RT in patients with squamous cell carcinoma of buccal 
mucosa. The mechanism by which the down-regulation of GST-M3 may confer 
resistance to RT remains to be established. However, GST-M3 is the most distantly 
related to other members of the GST-M family. The GST-M3 protein shares only 70% 
homology with other isoforms and has atypical catalytical and structural properties 
compared with other GST-M members (Kearns et al. 2003). Thus, it is possible that this 
protein functions in pathways other than those involved with detoxification. 
GST-M3 is 
an interesting target and will be the subject of further studies 
(see section 7.4.5). This is 
because the down-regulation of this protein has been implicated with resistance to both 
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cisplatin and RT in MCF7 breast cancer cells by numerous techniques including 2DE in 
combination with MALDI-TOF MS, western blotting, gene expression microarrays and 
RT-QPCR. 
7.4.2 Keratin 17 
In the present study, alterations in the expression levels of several cytoskeletal proteins 
were observed in the MCF740Gy cell line. The cytoskeletal network functions in 
maintaining the mechanical integrity of the cell and is also involved in cell motility and 
transport, cell division and cell-cell adhesion. It is composed of 3 morphologically 
distinct filamentous structures; intermediate filaments, microtubules and 
microfilaments. The intermediate filament family of proteins is composed of several 
hundred members, which have been classified into distinct groups. Type I intermediate 
filaments are acidic cytokeratins (9-20) and type 11 are basic cytokeratins (1-8). In our 
study, the down-regulation of keratin 17 (also called cytokeratin. 17) was associated 
with resistance to RT. This finding was also confirined by western blotting, which 
revealed the down-regulation of cytokeratin 17 (1.7 fold) in MCF740Gy cells (Figure 7- 
6). The down-regulation of this same isofonn has previously been associated with 
resistance to cisplatin in MCF7 breast cancer cells within our laboratory (see chapter 
VI). Cisplatin and RT induce apoptosis, thus the fact that cytokeratin 17 was associated 
with resistance to both treatment modalities suggests that the down-regulation of this 
protein may correlate with resistance to apoptosis. Furthermore, the down-regulation of 
specific cytokeratins has also previously been associated with radio-resistance. Brodin 
et al. (1995) observed a decrease in cytokeratin content in radio-resistant human small 
cell lung cancer cells (U-1906). The mechanisms of how the decreased expression of 
specific cytokeratins may contribute to radio-resistance remain elusive, however 
cytoskeleton integrity is critical for the regulation of intracellular signalling pathways 
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and many signalling molecules have been found to associate with the cytoskeleton 
(McCartney and Peifer, 2000). It is therefore possible that many critical signalling 
pathways including transmission of the death signal may require an intact cytoskeleton 
to provoke a cellular response. 
7.4.3 L-Plastin 
Actin-binding proteins assist in stabilising and rearranging the organisation of the actin 
cytoskeleton in response to external stimuli or during cell migration and adhesion 
(Delanote et al. 2005). Plastins (fimbrins) belong to a subclass of actin-binding proteins 
known as actin-bundling proteins. These proteins serve to cross-link actin filaments 
promoting the formation of straight rigid bundles in which all actin filaments have the 
same polarity. Three different isoforms exist (L-plastin, T-plastin and I-plastin), which 
are expressed in a tissue-specific manner. L-plastin is expressed predominantly in 
hernatopoietic cells, however has also been described as a marker for many human 
cancer cells of non-hematopoietic origin (Leavitt, 1994). T-plastin is expressed in cells 
from solid tissue and I-plastin is expressed in the small intestine, colon and kidney. To 
the best of our knowledge, this is the first study to implicate the down-regulation of L- 
plastin with radio-resistance. Western blot analysis also revealed that L-Plastin was 
undetectable in MCF740Gy cells but was present in MCF7 parent cells (Figure 7-6). 
The down-regulation of L-plastin has previously been associated with resistance to 
vinblastine in hwnan leukaernia cells (Verrills et al. 2003). Vinblastine and RT both 
induce apoptosis, thus this suggests that the down-regulation of L-Plastin may be 
associated with resistance to apoptosis. The mechanisms remain elusive, however there 
is evidence to suggest that this protein may play a role in signal transduction. L-plastin 
consists of 4 calponin homology (CH) domains, which are shared by both signalling 
proteins and some members of the cytoskeleton family. In addition, this protein 
has 
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been identified as a substrate for protein kinase C (PKC). PKC phosphorylates and 
activates various signalling proteins, including members of the MAP kinase cascade. 
This cascade regulates various cellular functions including gene expression, mitosis, 
differentiation and apoptosis. Thus, the down-regulation of L-plastin may therefore 
attenuate transmission of the death signal. Also, recent work has demonstrated that L- 
plastin is capable of nucleo-cytoplasmic shuffling indicating that perhaps this protein is 
involved in the regulation of nuclear actin. Nuclear actin is an essential component of 
the pre-initiation complex and co-operates with polymerase 1,11 and III in gene 
expression (Hofmann et al. 2004; Hu et al. 2004; Philimonenko et al. 2004). Down- 
regulation of L-plastin may therefore lead to the decreased transcription of genes 
required for the execution of apoptosis. Further work will be required for the 
verification of such hypotheses. 
7.4.4 Ribosomal Protein PO 
Ribosomal proteins decorate ribosomal subunits thereby organising and stabilising the 
rRNA tertiary structure. In addition, many of these proteins have a function outside of 
the ribosome. Increasing evidence suggests that a number of ribosomal proteins may 
play a role in apoptosis. The results from our study suggest that a down regulation of 
ribosomal protein PO may be associated with radio-resistance. This result was not 
confirmed by western blotting because an antibody against this specific target was not 
available. However, the down-regulation of ribosomal protein PO has previously 
been 
associated with resistance to cisplatin in MCF7 breast cancer cells within our 
laboratory 
(see chapter VI). The down-regulation of ribosomal protein PO 
has therefore been 
implicated with resistance to both cisplatin and RT. Apoptosis is the common 
ftinctional 
pathway for both of these treatment modalities suggesting that the 
down-regulation of 
this protein may be associated with resistance to apoptosis. 
In accordance, several 
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ribosomal proteins have previously been associated with the induction of apoptosis 
(Wool et at. 1995; Neumann and Krawinkel, 1997; Hu et al. 2000; Khanna et al. 2003). 
Ribosomal protein S29 was found to promote apoptosis by down-regulating the 
expression of apoptosis inhibitors including NF--KB, Bcl-2, Bcl-xL, IAPs and survivin 
and up-regulating the pro-apoptotic proteins p53 and Bax (Khanna et al. 2003). If this 
result can be verified using an alternative technique, functional studies may be 
performed to determine whether ribosomal protein PO also functions to control gene 
transcription and whether the down-regulation of this target can reduce apoptosis in 
response to RT. 
7.4.5 Proteasome Activator Subunits 
The primary catalytic site of the proteasome is a 20S core; a barrel-shaped complex 
composed of rings of alpha and beta subunits (Voges et al. 1999; see Figure 6-6). In 
isolation, the 20S proteasome is inactive because substrates are unable to access the 
active sites. Thus, the proteasome requires activation by various proteasome activator 
complexes including PA700 and PA28. PA700 (also known as the 19S regulatory 
element) is the best characterised of these complexes and binds to both ends of the 20S 
core to form the 26S proteasome. The 26S proteasome is thought to carry out most of 
the biological functions of the proteasome and recognises and degrades proteins, which 
have been modified by polyubiquitination (see section 6.4.6). PA28 (I IS) is composed 
of 6 or 7 subunits of -28-kDa each, which are encoded by the PSMEI, PSME2 and 
PSME3 genes. PA28 binds to the ends of the 20S core and activates the cleavage of 
peptides for presentation by major histocompatibility complex (MHC) class I molecules 
(Khan et al. 2001). To the best of our knowledge this is the first study to implicate the 
down-regulation of PSMEI and PSME2 with radio-resistance in human breast cancer 
cells. These targets were not selected for western blot confirmation as antibodies 
for 
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these specific subunits were unavailable. However, an independent analysis using gene 
expression microarrays identified the down-regulation of PSME 1 (2.8 fold) in the same 
MCF740Gy cell line (Omar Qutob, personal communication) thereby confirming 
results from the 2DE experiment at the RNA level. RT-QPCR is currently underway 
within the laboratory for confirmation of this result. PSME2 was represented on the 
gene expression microarray, however was not identified as differentially expressed 
using a >2 fold cut-off level. Often RNA levels do not correlate with protein levels due 
to factors including altered protein tum-over rates and post-translational modifications. 
This is one of the several advantages of analysing proteins rather than DNA or RNA 
(see section 3.3) and therefore the expression level of this subunit requires further 
confirmation. The mechanisms of how the down-regulation of these targets may 
contribute to radio-resistance remain unclear, however proteasome activator complexes 
can combine with the 20S core to form a variety of hybrid proteasomes (e. g. PA700- 
20S-PA28) with varying functions (Tanahashi et al. 2000). Within these hybrid 
proteasomes PA28 may function as an adapter molecule recruiting proteasomes to 
specific intracellular locations (Rechsteiner and Hill, 2005). Interactions between the 
proteasome and several nucleotide excision repair (NER) and base excision repair 
(BER) proteins are required for the optimal repair of damaged DNA (Jelinsky et al. 
2000). BER is required for the efficient repair of DNA following treatment with IR and 
involves the recognition and subsequent repair of dwnaged DNA. It is possible that 
targeting proteasomes to areas of insult following RT may allow detection of DNA 
darnage, thus allowing an appropriate cellular response to ensue. The down-regulation 
of PA28 may therefore prevent this targeting and DNA damage may remain undetected 
reducing cellular response to injury. These subunits comprise interesting targets worthy 
of ftirther studies (see section 7.4.6). This is because the proteasome was also 
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implicated with resistance to cisplatin in MCF7 breast cancer cells (see chapter VI) 
indicating a possible link between proteasome function and resistance to apoptosis. 
7.4.6 Discussion and Conclusion 
In summary, the aims of this chapter were successfully fulfilled. The 2DE-MALDI-TOF 
MS approach was effectively applied to identify several proteins, which may be 
associated with RT resistance in this novel in-vitro breast cancer model. Western 
blotting was exploited to confirm the differential expression of selected proteins and 
ensured the accuracy of protein identification. These targets represent potential 
biomarkers and require ftirther study. In the present study, the identities of 3 
differentially expressed proteins remain unknown. This may have been due to several 
reasons (described in section 6.4.7). The exploitation of large fon-nat gels and/ or 
additional prefractionation strategies and/ or different protease enzymes for protein 
digestion (which may increase the number of peptides available for MALDI-TOF MS 
analysis) may increase the chances of obtaining more successful protein identifications 
(see section 6.4.7). Alternatively, in the future these proteins may be analysed using 
MS/MS. This technique allows peptide sequences to be obtained and therefore more 
confident assigm-nents, to be made (see section 3.4.1.4). Thus, further proteins associated 
with radio-resistance may be identified in this in-vitro cell culture model. Fifteen 
proteins have been identified, which may be involved in the development of radio- 
resistance in breast cancer. Although the possible roles played by these proteins in the 
development of radio-resistance have generated many hypotheses, further work is 
required for the verification of such hypotheses. In particular, only 3 proteins were 
confirmed by western blotting. This is because it was difficult to find specific antibodies 
for some of the targets therefore limiting the number of proteins that could be confirmed 
by this technique. The confirmation of proteomics data remains crucial to ensure the 
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accuracy of protein identification. Thus, prior to progressing further to functional 
studies the expression levels of many targets still require confirmation. One possible 
method for the confirmation of those targets for which there is no available antibody is 
RT-QPCR. This technique allows the relative quantification of mRNA expression 
between different samples using primers that are complementary to defined sequences. 
RT-QPCR was able to confirm the down-regulation of GST-M3 in MCF740Gy cells 
(see section 7.4.1). However, since protein levels can be regulated by altered protein 
turnover rates and subsequent post-translational modifications, negative confirmations 
using RT-QPCR do not necessarily equate to inaccurate protein identifications. Targets 
for which confirmation has been achieved will be the subject of further studies. Of these 
targets, GST-M3 poses one of the most attractive candidates because the down- 
regulation of this protein was not only confinned by western blotting but was also 
identified as down-regulated in the independent analysis of the same cell lines using 
gene expression microarrays and RT-QPCR. Furthermore, the PSME subunits may also 
be important because although antibodies were not available for western blot 
confirmation, PSMEI was independently identified as down-regulated in the same 
MCF740Gy cell line using gene expression microarrays. PSME2 was represented on 
the microarray, however was not identified as differentially expressed using a >2 fold 
cut-off value. The RT-QPCR analysis of these targets is currently underway within the 
laboratory in order confirm the expression of PSMEI and to ensure that PSME2 was not 
a false-negative target from the gene expression microarray analysis. In addition, it is 
hoped that antibodies against these targets may become commercially available in the 
near future to enable the confirmation of both PSME subunits at the protein level. 
Functional studies using RNAi and/ or pharmacological inhibitors will determine 
whether the down-regulation of these targets is the cause or the result of radio-resistance 
in this in-vitro cell culture model (see section 6.4.7). Furthermore, the mRNA 
204 
Chapter VII The Proteomic Analysis ofRadio-Resistance in Breast Cancer 
expression of both PSMEI and PSME2 (but not PSME3) can be specifically induced by 
interferon gamma (IFN-7). Thus, the MCF740Gy cells may be treated with IFN-7 prior 
to RT in order to determine whether the level of sensitivity can be restored to a level 
similar to that of parental cells. It may also prove useful to ascertain the level of 
proteasome activity in these cell lines to determine whether the down-regulation of 
PSMEI and PSME2 (which comprise the PA28 proteasome activator complex) has 
altered the function of the proteasome in MCF740Gy cells in comparison to parental 
cells (see section 6.4.7). 
Future work will also involve analysing further radio-resistant cell lines. This will 
include not only additional breast cancer cell lines displaying significant resistance to 
RT but also those cell-lines originating from other tumour types, which are commonly 
treated with RT (e. g. head and neck tumours). This will allow general markers of radio- 
resistance to be identified. Ultimately, these targets must be clinically relevant and 
therefore must be validated in a relevant series of clinical samples due to the reasons 
previously described (see section 6.4.7). The identification of novel biomarkers that are 
associated with radio-resistance may allow treatment to be tailored on an individual 
patient basis and provide novel targets for future therapeutic intervention. 
The 2DE-MALDI-TOF MS protocols that were developed in chapter V have been 
proven to be useful in the identification of potential biomarkers, which may correlate 
with response to anticancer therapy. Such biomarkers will now be the focus of further 
studies in order to determine their functional relevance. Antibody microarrays represent 
a novel recent technological advance, which may provide complementary information 
to 2DE-based proteomics. The potential value of antibody microarrays for the 
ap lication of biomarker discovery will be explored in chapters VIII and IX. 
.Vp 
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CHAPTER VIII 
THE ANALYSIS OF DOXORUBICIN RESISTANCE IN 
HUMAN BREAST CANCER CELLS USING ANTIBODY 
MICROARRAYS 
Aims: 
To optimise a protocol for the recently introduced Panorama Cell Signalling 
Antibody Microarray Kit (#CSAAI; Sigma-Aldrich) for the analysis of 
doxorubicin resistance in human breast cancer cells. 
To establish a suitable data analysis method, including the number of replicates 
and an appropriate cut-off value for the identification of differential expression. 
To assess the efficacy of using the Panorama Cell Signalling antibody 
microarray (Sigma-Aldrich) comprised of 224 different antibodies, to identify 
molecular markers associated with doxorubicin resistance in human breast 
cancer cells. A 
" To conduct the first proteomic analysis of a novel doxorubicin resistant breast 
cancer cell line. 
" To validate the molecular markers identified by antibody microarrays using 
western blot analysis. 
" To produce one of the first published manuscripts in the field of resistance to 
anticancer therapy using this commercially available kit. 
Publications and Presentations: 
Laura Smith, Mark B Watson, Sara L O'Kane, Philip J Drew, Michael J Lind, 
Lynn Cawkwell. (2006). The analysis of doxorubicin resistance in human breast 
cancer cells using antibody microarrays. Molecular Cancer Therapeutics 5; 
2115-2120; IF. 5.1. 
Laura Smith, Sara L O'Kane, Mark B Watson, Michael J Lind, Lynn Cawkwell. 
The analysis of doxorubicin resistance in human breast cancer using antibody 
microarrays. NCRI Cancer Conference, Birmingham, UK (October 2-5,2005) 
Poster Presentation 
Laura Smith, Sara L O'Kane, Mark B Watson, Michael J Lind, Lynn Cawkwell. 
Novel antibody microarray technology in the analysis of doxorubicin-resistant 
breast cancer cells. 7h Siena Meeting From Genome to Proteome, Siena, Italy, 
(September 3- 7,2006). Poster Presentation 
Laura Smith, Mark B Watson, Kevin J Welham, Philip J Drew, Michael J Lind, 
Lynn Cawkwell. Novel antibody microarray technology identifies proteins 
associated with doxorubicin resistance in human breast cancer cells. 291h Annual 
San Antonio Breast Cancer Symposium, Texas, USA (December 14-17,2006) 
Poster Presentation 
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8.1 Introduction 
Doxorubicin is an anthracycline antibiotic, which is widely effective in the treatment of 
breast cancer. Doxorubicin is commonly administered in both the adjuvant and 
neoadjuvant setting often in combination with cyclophosphamide and 5FU (CAF) or in 
combination with cyclophosphamide followed by treatment with paclitaxel (AC-T). 
Unfortunately, resistance to doxorabicin is common and represents a major obstacle in 
the successful management of breast cancer. Anthracycline-based chemotherapy 
regimens achieve response rates of 12-70% in patients with early breast cancer (stage I 
and stage 11; see Table 1-3) (Clahsen et al. 1998; Ring et al. 2004), 14-70% in patients 
with locally advanced breast cancer (stage 111) (Mezi et al. 2003; Pickles et al. 2005) 
and 17-65% in patients with metastatic breast cancer (stage IV) (Robain et al. 2000; 
Dose Schwarz et al. 2005). Furthennore, continuous follow-up has shown that the 
majority of metastatic breast cancer patients initially classified as responders are likely 
to suffer a relapse (Pusztai et al. 1999; Prof M. Lind, personal communication). 
Doxorubicin exerts a cytotoxic effect by creating a lethal burden of DNA darnage and 
inducing apoptotic cell death. Several alterations associated with resistance to this agent 
have been documented including changes in the expression levels of drug transport 
pumps, over-expression of drug detoxification enzymes, increased DNA repair 
mechanisms, altered apoptotic machinery and modifications to the drug target 
(topoisomerase 11). However, the multifactorial mechanisms of resistance remain 
largely obscure. 
Although 2DE in combination with MS remains state-of-the-art for elucidating global 
variations in protein expression (see section 3.4.1), the technique 
is laborious to 
perform. The procedure is time consuming, expensive and reproducibility still remains a 
challenge (Lilley et al. 2002). Membrane proteins are 
difficult to analyse due to their 
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hydrophobicity. Hydrophobic proteins are difficult to solubilise for separating on 2D 
gels. In fact, it has been claimed that -15% of a cell's proteome may never even enter 
the gel due to hydrophobicity (Hochstrasser et al. 2002). Membrane proteins represent 
an important class of proteins because they are the targets of up to 80% of therapeutic 
compounds (Santoni et A 2000). In addition, such proteins are important in this study 
because changes in the expression levels of some of these proteins (e. g. drug pumps; see 
section 2.4.4), have previously been implicated with chemotherapy resistance. 
Furthermore, 2DE also has a limited ability to detect low abundance proteins and is not 
readily amenable to high-throughput applications. Nevertheless, 2DE remains 
unrivalled in its ability to obtain "snapshots" of whole complex proteomes and requires 
no prior knowledge of targets before discovery. Thus, the search for novel 
complementary proteomic technologies continues. 
A microarray is an ordered arrangement (defined rows and columns) of uniformly sized 
and shaped biomolecules upon a solid planar support. A transfer of technology from 
DNA microarrays has led to the development of novel protein microarrays (see section 
3.4.5). However, several fundamental differences exist between DNA and proteins, 
which are reflected in the challenges faced in attempting to produce a robust protein 
microarray. Nucleic acids are composed of 4 nucleotide bases and have hydrophilic, 
negatively charged backbones. In contrast, proteins are made from 20 different amino 
acids and can be hydrophilic, hydrophobic, acidic or basic. This leads to a broad 
diversity of solubilities, tertiary structures and active sites; the characteristics that give 
proteins their individual fimctionality (Mann et al. 2004). Protein-protein interactions 
are dependent on their folded three-dimensional structures. This is unlike the 
hybridisation of DNA microarrays, which involves interactions between linear DNA or 
RNA sequences. Furthermore, many proteins lose their activity when immobilised to 
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solid supports. Nevertheless, the significant challenge of how to cope with the diverse 
nature of proteins has been overcome and several types of protein microarrays are now 
available (Table 8-1). Antibodies make excellent candidates for arraying because they 
are highly tolerant to external perturbations of their structure and the resulting antibody/ 
antigen interactions are highly specific. As such, antibody microarrays are well suited 
for determining the relative abundance of key proteins in different samples. Some of the 
steps pertaining to the fabrication of an antibody microarray are detailed below and are 
illustrated in Figure 8-1. 
8.1.1 Antibody Microarray Surface Chemistries and Coupling Schemes 
The most commonly used antibody microarray support is glass and most microarrays 
conform to the standard glass microscope format (25mm x 75mm) for ease of 
integration into existing microarray technology. The surfaces of glass slides may also be 
modified by a variety of means to facilitate the immobilisation of antibodies. Properties 
of the microarray surface may be tailored to allow the immobilisation. of unmodified 
antibodies (untagged; antibodies in their native form). Alternatively, antibodies may be 
modified with tags e. g. HIS-tags or biotin-tags (see section 8.1.1.2) to effectively anchor 
them to a particular microarray surface. Some of the common surface chemistries are 
discussed below and are summarised in Figure 8-2. 
8.1.1.1 Derivatized Glass Slides 
Derivatized glass slides are appropriate for the immobilisation of untagged antibodies. 
The antibodies bind to the surface of the slide through multiple interacting groups on 
their surfaces. The antibodies are randomly oriented such that different 
faces of the 
protein can interact with their complementary proteins 
in solution. However, this 
random onentation may reduce the number of protein 
interaction sites either through an 
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Table 8-1 Types of protein microarrays (adapted from Mann et al. 2004) 
Protein Microarray Description 
Antibody Antibodies (polyclonal or monoclonal) are arrayed and used to 
detect and quantify specific proteins in biological samples. 
Antigen/ Reverse This array is the reverse of an antibody microarray. Antigens are 
arrayed and used to detect and quantify specific antibodies in 
biological samples. 
Functional Purified proteins are arrayed and used to detect and characterise 
protein-protein, protein-DNA or protein-small molecule 
interactions. 
Capture Non-protein molecules that interact with proteins are arrayed. 
Examples include capture agents based on surface chemistries 
(e. g. ion exchange, hydrophobic or metal affinity) or highly 
specific agents (e. g. molecular imprinted polymers or 
oligonucleotide aptamers). 
-o- Print Head 
The print head moves to each 
shde m turn "printine'antibody 
solutions onto the microarray 
surfaces 
*0 
0 
0 
M[kroaxny Odes 
Antibody 
"Skrotolp \ \, 
/ 
ir Afft 
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Pins are loaded 
with antibody 
solutions 
--* 
Plate contafiting 
Antibody Sulufiejz 
Print lead returns 
to plate and piw 
reload 
WASHING AND DRYING OF PINS 
Figure 8-1 The fabrication of an antibody microarray. This method of fabrication 
involves the physical transfer of antibodies from a microtiter plate to specific locations 
on a glass microscope slide. This involves the use of metal pins, which are 
held together 
in a print head. The print head is positioned over each slide in turn by a 
high-precision 
computer-controlled driving mechanism and each time the pins contact the slides 
defined volumes of antibody solutions are deposited onto the surfaces. This process 
is 
called printing and results in an ordered array of antibody solutions called spots on the 
surfaces of the microarrays. 
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Figure 8-2 A comparison of the three main surface chemistries for the immobilisation 
of antibodies onto glass-based microscope slides. A. Derivatized glass slides (e. g. poly- 
L-lysine-coated glass slides). Unlabelled antibodies bind to the surface of the 
microarray slide through multiple interacting groups on their surfaces. This results in a 
random orientation such that different faces of the antibody can interact with their 
complementary proteins in solution. B. Oriented surfaces for tagged antibodies. 
Antibodies are labelled with tags (e. g. biotin-tags) and are immobilised by binding to 
affinity molecules (e. g. streptavidin) on the surface of the microarray slide. This enables 
site-specific attachment and ensures a maximal surface of antibodies for hybridisation. 
C. Three dimensional surfaces (e. g. nitrocellulose-coated glass slides). Antibodies are 
absorbed into a deep permeable layer, which preserves both structure and function of 
immobilised antibodies. Such slides provide a larger surface area and therefore allow a 
greater antibody density. 
Randomly Onented 
Antibodies 
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inappropriate orientation or inactivation due to conformational changes. Slides may be 
coated with poly-L-lysine (protein constructed from lysine chains). Poly-L-lysine 
carries a net positive charge and therefore binds negatively charged antibodies through 
electrostatic interactions to form salt bridges. Poly-L-lysine-coated slides (also called 
silanated slides) offer several advantages including easy manual preparation, low 
intrinsic fluorescence, good signal uniformity and spot reproducibility (spots can be 
defined as small quantities of specific antibody solutions upon the microarray surface; 
Figure 8-1). Electrostatic interactions are relatively weak and since the immobilisation 
technique is non-specific the slide can also immobilise proteins other than the 
antibodies-of-interest. Poly-L-lysine slides are also not very durable and can easily be 
damaged during the delivery of antibodies onto the slide surface. Slides can also be 
coated with organosilanes with an added reactive aldehyde group. These slides 
immobilise antibodies through the Schiffs base reaction. Amino groups of the 
antibodies attack electropositive aldehyde groups forming stable covalent bonds. 
Covalent bonds are much stronger than electrostatic interactions. These slides are easy 
to prepare, store and handle and also give good signal-to-noise ratios. However, a major 
disadvantage is the low level of spot homogeneity observed for such slides arising from 
the uneven surface produced by the oligomerisation and formation of multiple aldehyde 
layers (Kusnezow and Hoheisel, 2003). Epoxide chemistry is also used for the 
derivatization of glass slides. Such slides are coated with epoxysilane. Antibodies 
covalently attach to the surface of the slide through an epoxide ring-opening reaction 
primarily via their amino, hydroxyl, and thiol groups. Epoxy-coated slides are highly 
durable., however the epoxy ring is susceptible to moisture and such slides therefore 
require storage in a moisture-free environment preventing long-term storage. 
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8.1.1.2 Oriented Surfaces for Tagged Antibodies 
Antibodies may be tagged at their amino or carboxyl termini to enable site-specific 
attachment. This enables the complementarity-determining regions to be oriented away 
from the microarray support ensuring a maximal surface of antibodies available for 
hybridisation. The use of such oriented capture antibodies offers up to aI O-fold increase 
in the binding of proteins in comparison to randomly bound antibodies (Peluso et al. 
2003). Examples include nickel-coated slides for the immobilisation of HIS-tagged 
antibodies and streptavidin-coated slides for the inimobilisation of biotin-tagged 
antibodies. The major disadvantage of such a system is that the tagging of an antibody 
may alter its properties resulting in a decreased affinity for the interacting protein. 
8.1.1.3 Three-Dimensional Surfaces 
The functional properties of antibodies are highly dependent on their structures and 
conformations. It is therefore often advantageous to use three-dimensional surfaces, 
which provide a fluidic envirom-nent for immobilisation. Such slides have a deeper 
coating compared with the planar surfaces discussed above (see sections 8.1.1.1 and 
8.1.1.2) and aim to preserve the structure and fimction of immobilised antibodies. Such 
slides boast a permeable antibody-absorbing layer, which also provides a larger surface 
area, greater antibody density and increased binding capacity. Examples include 
nitrocellulose-, polyacrylamide-, and agarose-coated glass microscope slides. 
Nitrocellulose-coated slides were amongst the first commonly used supports for the 
preparation of protein microarrays (Towbin et al. 1979). These slides possess a sponge- 
like microporous layer of nitrocellulose (-15[tm in thickness). Antibodies are 
subsequently absorbed into this layer and bind through electrostatic 
interactions. 
Nitrocellulose is one of the most effective surfaces at maintaining protein conformation 
and also allows for higher sample loading compared with some of the other surfaces. 
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However, binding through electrostatic interactions is associated with several problems 
(see section 8.1.1.1). The nitrocellulose matrix also tends to have a high level of 
intrinsic fluorescence, however this can be controlled with the correct experimental 
conditions. Polyacrylamide-coated slides possess a microporous layer of gel matrix (20- 
30[im in thickness) into which the antibodies are absorbed. Antibodies are subsequently 
immobilised through electrostatic interactions and as such suffer from several 
drawbacks (see section 8.1.1.1). Agarose-coated slides have also been previously 
exploited (Afanassiev et al. 2000). These slides possess an agarose film, within which 
activated aldehyde groups allow the covalent immobilisation of antibodies. 
8.1.2 Antibody Printing 
Two methods of printing are available for the construction of antibody microarrays; 
contact and non-contact printing. These are also the methods, which are exploited for 
the construction of gene expression microarrays. Contact printing produces spots of the 
highest quality and involves the physical transfer of antibodies from a 96- or 384-well 
microtiter plate to a specific location on a slide using a metal printing pin (Figure 8-1). 
Multiple pins are held in a print head, which is connected to a computer-controlled high 
precision robotic drive mechanism controlling movement in the x, y and z axis. Contact 
printing pins may either be solid pins or split pins. Solid pins require immersion into 
each antibody solution between spotting. In contrast, split pins exploit an orifice at their 
tip. Antibody solutions are drawn into these orifices by capillary action and defined 
volumes (nl quantities) are dispensed each time the pins contact a slide. Split pins hold a 
larger volume of antibody solution and this avoids the need for repeated re-loading 
making printing multiple spots of the same antibody quicker. Alternatively, a non- 
contact method of printing may be exploited. Non-contact printing utilises the same 
principles as contact printing (Figure 8-1), however the method of antibody 
delivery is 
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the same as that employed by ink-jet printers; piezoelectric actuation. This involves the 
use of pressure waves within a liquid filled capillary, which is induced by the action of a 
piezoelectric transducer. This results in the firing of liquid droplets from the end of the 
capillary onto the slide surface. Ink-jet printing is more rapid at multi-dispensing a 
single antibody solution, however is slower than contact printing at changing between 
samples. Furthermore, ink-jet printing has the tendency to smear spots or produce an 
uneven intensity across the spot. The tips are also very delicate and expensive to 
replace. 
8.1.3 Detection Methods 
8.1.3.1 Labelled Proteins 
The most widely used method for the detection of proteins involves chemical labelling 
with fluorescent dyes. The main advantage being that it is analogous to the detection 
method exploited for DNA microarrays and therefore many laboratories already possess 
the appropriate laser scanners for subsequent analysis. The most widespread fluorescent 
dyes used for the labelling of proteins are the cyanine (Cy) dyes. Cy-3 and Cy-5 dyes 
are highly fluorescent, relatively stable to photobleaching, highly water soluble and 
have distinct emission spectra. The emission spectra for Cy-3 and Cy-5 are 532nm and 
635nin with Cy-3 fluorescing the colour green and Cy5 fluorescing the colour red. The 
Cy dyes are supplied as mono-reactive N-hydroxysuccinimide (NHS)-esters, which 
prevent the cross-linking of protein molecules. The NHS-ester is a functional group, 
which reacts with accessible aliphatic arnino groups on the surfaces of proteins. A 
covalent amide group is formed when the NHS-ester reacts with a primary amine 
releasing N-hydroxysuccinimide. Two biological samples can be labelled with a 
different Cy dye and the relative log ratios of red and green fluorescence post- 
hybridisation allows the expression levels of specific proteins to be determined in each 
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sample. Unfortunately, due to the chemical heterogeneity of proteins, incorporation of 
the fluorescent label is difficult to control. Thus, some protein species may fail to label 
whilst other proteins may label excessively. Furthermore, it is possible that the 
fluorescent-labelling of a protein may perturb the conformation such that it is no longer 
recognised by its complementary antibody. The efficiency of dye incorporation must 
also be considered during the subsequent data analysis. The Cy dyes exhibit differing 
chemical structures with the Cy-5 molecule containing an extra pair of carbon atoms 
compared to the Cy-3 molecule. This can lead to differences in labelling efficiency and 
may also alter the affinity of proteins for their corresponding antibodies. Some proteins 
may even develop non-specific affinities towards other antibodies. Furthermore, the Cy- 
3 dye is known to fluoresce more efficiently than the Cy-5 dye. Dye-swapping is an 
accepted method utilised in gene expression microarray experiments and compensates 
for any potential bias in dye incorporation. This involves repeating the microarray 
experiment with the labelling combinations reversed. For example, if in the first 
experiment the control sample was labelled with Cy-3 and the test sample was labelled 
with Cy-5, the dye-swap experiment would comprise of the control sample labelled with 
Cy-5 and the test sample labelled with Cy-3. The differentially expressed proteins 
would therefore appear brighter in one of the scanning channels in the first slide and 
an ear brighter in the second scanning channel in the dye-swapped slide. Other methods IT 
for labelling proteins also exist, however are less widely used. These include radio- 
labelling and the use of fluorescent fusion proteins (Ge, 2000; Kukar et al. 2002). 
8.1.3.2 Sandwich Assays 
Sandwich detection protocols have been used for many years in immunoassays, such as 
enzyme-linked immunosorbent assays (ELISAs). The proteins are captured on the 
microarray by their complementary antibodies and are subsequently 
detected using a 
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cocktail of secondary (detection) antibodies, each one matched to one of the spotted 
antibodies (Haab, 2003). The quantification of bound detection antibody provides a 
measure of protein abundance. The advantage of this detection method is that there is no 
requirement for the target protein to be labelled. In addition, there is minimal cross 
reactivity since a signal is only registered if 2 independent binding events occur; 
immobilised antibody-antigen followed by antigen-detection antibody. Furthermore, 
methods are available to enhance the sensitivity of the antibody microarray technique 
when used in conjunction with this detection method. The rolling circle amplification 
reporter system involves the covalent labelling of the detection antibody with an 
oligonucleotide primer (Schweitzer et al. 2000). Complementary circular DNA initiates 
a PCR reaction resulting in hundreds of copies of replicated DNA, all of which are 
attached to the detection antibody. The use of fluorescently labelled nucleotides during 
PCR leads to increased signal intensity, which allows the more effective analysis of 
lower abundance proteins. A ma or disadvantage to this detection method, however, is j 
the fact that 2 non-competing highly specific antibodies must be available for each 
protein. Furthermore, this method does not work well with highly multiplexed 
microarrays (those which simultaneously analyse the expression levels of >50 proteins). 
This is because there is an increased risk of cross reactivity and precipitation when 
using many different detection antibodies. 
8.1.3.3 Direct Measurement 
Mass spectrometry is invaluable for the analysis of complex proteomes and may also 
prove useful for identifying those proteins, which interact with antibodies on 
microarrays. This strategy may allow the identification of components of multi-protein 
complexes on a large scale, however is not suitable for protein quantification and its use 
for examining protein expression is therefore currently limited. Alternatively. surface 
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plasmon resonance (SPR) provides a sensitive method for the real-time detection of 
unlabelled proteins. This involves the immobilisation of antibodies onto planar gold- 
coated glass microscope slides. A change in the underlying sensor layer is subsequently 
produced upon binding of target proteins to their complementary antibodies on the 
microarray surface. This produces an electrical signal proportional to the amount of 
bound target. Major disadvantages to this detection method include the requirement for 
specialist biosensing instruments and expensive gold-coated sensor slides. 
8.1.4 Commercial versus Custom Antibody Microarrays 
In an idealWOTId a custom antibodyMiCToaffay would be designed to answer the needs 
of individual experiments. Antibodies to be arrayed would be selected based on the 
experiment to be conducted and the most suitable surface chemistry would be chosen to 
complement the antibody selection. However, the arraying of antibodies is fraught with 
problems and as such the use of commercially available antibody microarrays is often 
preferable. Strict quality control measures implemented by the suppliers of such slides 
ensure excellent spot morphology and spot homogeneity. A high level of spot-to-spot 
reproducibility can be observed and batch-to-batch variation is minimised. Suppliers 
also have access to antibody libraries, which offer a large range of biomolecules to be 
arrayed. These antibodies are extensively validated prior to immobilisation to ensure 
high specificity and are tested to ensure their functionality is retained following 
immobilisation. In addition, the production of custom antibody microarrays is time 
consuming and requires many optimisation steps. For each capture molecule and/ or 
surface chemistry the optimal arraying conditions, printing buffers, antibody 
concentrations and storage conditions must be determined. Furthen-nore, a significant 
investment is required due to the cost implications involved with purchasing a 
microarraying robot and antibodies to be arrayed. For the long-term however, such an 
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investment may be beneficial because of the considerable expense of commercially 
available antibody microarrays. For many laboratories however, such an investment 
may not be feasible and as such many researchers are limited to the surface chemistries 
and antibodies available on commercial antibody microarrays. As the technology is 
novel the number of available antibody microarrays on the market is currently limited. 
However, as the field expands this number is sure to grow and a wider choice of 
microarrays will become available to the end-user. The aim of this study was to 
investigate the use of a commercially available antibody microarray from Sigma- 
Aldrich to compare the protein profiles of parental MDA-MB-231 breast cancer cells 
and novel derivative cells (MDA-MB-23 I DR) displaying significant resistance to 
doxorubicin. The Panorarna"m Cell Signalling Antibody Microarray Kit was exploited, 
which detects a wide variety of proteins representing a broad range of biological 
functions including apoptosis, cell cycle, neurobiology, cytoskeleton, signal 
transduction and nuclear proteins. Each array was composed of 224 highly specific 
antibodies spotted in duplicate on three-dimensional nitrocellulose-coated glass 
microscope slides (see section 8.1.1-3). The microarrays contained 32 sub-arrays with 
duplicate spots of 7 antibodies as well as a single positive control for Cy-3 and Cy-5 
fluorescent protein detection (see section 8.1.3.1) and a single negative control. 
Nitrocellulose-coated glass microscope slides are widely used in combination with the 
detection of fluorescently labelled proteins; a combination which offers many 
advantages over alternative surface chemistries and detection methods (see section 
8.1.1.3 and 8.1.3.1). The complete list of antibodies arrayed upon these microarrays can 
be viewed in Appendix I. 
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8.2 Materials and Methods 
8.2.1 Cell Lines 
The MDA-MB-23 I DR cell line was established in collaboration with Dr. Mark Watson 
(University of Hull) from the surviving population of MDA-MB-231 breast cancer cells 
after treatment with a single 24hr dose of 200nM doxorubicin. The concentration of 
doxorubicin. used to select out the resistant cell line was based upon the reported 
clinically achievable plasma concentrations in the range of 1.4-34.4ýM (Moriuchi et al. 
1996; Schondorf et al. 2002), as well as our own observations. This applied a degree of 
clinical relevance to this in-vitro study. 
8.2.2 Assessment of In-Vitro Doxorubicin Resistance 
The relative resistance of MDA-MB-231 and MDA-MB-231DR to doxorubicin over 
the concentration range of 0-400nl\4 was measured using a modified colony counting 
assay as described in section 4.3.2. 
8.2.3 Antibody Microarrays 
The PanoramaTMCell Signalling Antibody Microarray Kit (#CSAAI; Sigma-Aldrich) 
was exploited for analysis. Protein was extracted and quantified as described previously 
in sections 4.7.1.1 and 4.7.1.2. The fluorescent-labelling of proteins was performed as 
described in section 4.7.1.3 and hybridisation of the labelled protein samples to 
antibody microarrays was undertaken as detailed in section 4.7-1.4. Images were 
acquired and analysed as described in section 4.7.1.5. Four biological replicates were 
created in which the MDA-MB-231 protein extracts were 
labelled with Cy-3 and MDA- 
MB-23 I DR protein extracts were labelled with Cy-5. In addition, 2 
dye-swapped 
replicates were created in which the labelling combinations were reversed 
in order to 
account for any bias in dye incorporation. 
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8.2.4 Western Blotting 
Western blotting was exploited for confirmation of results and was performed as 
described in section 4.8. Primary antibodies against p-ERK (#SC-7383; Santa Cruz). 
ERK-2 (#SC- 154; Santa Cruz), cyclin D2 (#SC- 18 1; Santa Cruz), cytokeratin 18 (#SC- 
6259; Santa Cruz) and cyclin Bl (#MS-338; Neomarkers) were added at a concentration 
of 1: 100 for 2 hrs, at RT. The appropriate HRP-conjugated secondary antibody (anti- 
mouse or anti-rabbit, Santa Cruz) was added at a concentration of 1: 1000 and enhanced 
chemiluminescence (ECL) was used for detection as described in section 4.8.3. 
Membranes were subsequently reprobed with GAPDH or beta actin as described in 
4.8.4 and images were analysed as described in section 4.8.5. 
8.3 Results 
8.3.1 Establishment of the MDA-MB-231DR Cell Line 
A modified colony counting assay was used to measure the relative resistance of MDA- 
MB-231 and MDA-MB-231DR to doxorubicin over the concentration range of 0- 
400nM (Figure 8-3). The IC50values for MDA-MD-231 and MDA-MB-231DR were 
25nM and 35nM respectively. MDA-MB-231DR was significantly less sensitive to 
doxorubicin than MDA-MB-231 at 50,100 and 200nM concentrations (p<0.01; 
ANOVA) with a maximal 9-fold increase in resistance observed at I OOnM. Western 
blot, immunocytochemistry or RT-QPCR analysis in collaboration with Dr. Mark 
Watson revealed that both parent and derivative cells demonstrated similar expression 
profiles for p53, P-gp (MDRI), MRPI, BCRP and LRP. 
8.3.2 Antibody Microarrays 
The Panorama Cell Signalling Antibody Microarray Kit (Sigma-Aldrich) was exploited 
in order to analyse the MDA-MB-231 breast cancer cell line and a novel derivative 
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Figure 8-3 Dose response curve demonstrating the relative resistance of MDA-MB-231 
and MDA-MB-231DR cell lines to doxorubicin over the concentration range of 0- 
400nM. Each point represents the mean of 6 replicates and error bars show standard 
error of the mean. The IC5o values for the MDA-MB-231 and MDA-MB-231DR cell 
lines were 25nM and 35nM respectively. MDA-MB-231DR was significantly less 
sensitive to doxorubicin than the MDA-MB-231 parent at 50,100 and 200nM 
concentrations (p<0.01; ANOVA) with a maximal 9-fold increase in resistance 
observed at I OOnM. 
displaying significant resistance to doxorubicin (MDA-MB-231DR). The microarrays 
were composed of 224 different antibodies spotted in duplicate on nitrocellulose-coated 
glass microscope slides. Data from 4 biological replicates were used in which MDA- 
MB-231 protein extracts were labelled with Cy-3 and MDA-MB-231DR protein 
extracts were labelled with Cy-5. Figure 8-4 shows the image of a representative 
microarray after capture in the Cy-3 and Cy-5 channels and after construction of the 
composite image. Although dye-swapping is an accepted method 
for use in gene 
expression microarray experiments, its current utility 
for the interpretation of antibody 
microarray data is currently unknown. Therefore, also 
included in the analysis were the 
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Figure 8-4 A representative antibody microarray post-hybridisation with fluorescently- 
labelled protein. A. Cy-3 image captured at 532nm representing the MDA-MB-231 cell 
line. B. Cy-5 image captured at 63 5nm representing the MDA-MB-23 I DR cell line. C. 
Composite image constructed via the layering of Cy-3 and Cy-5 images. In this 
example, those spots with a high-level of green fluorescence in the composite image 
may represent proteins down-regulated in the MDA-MB-23 I DR cell line. The student's 
Mest was exploited to statistically determine those differentially expressed proteins 
across biological replicates. 
data from 2 replicates in which the samples were dye-swapped. This is the minimum 
number of dve-swapped replicates required in order to apply the appropriate statistical w 
tests. The antibody microarray protocol gave little information regarding data analysis, 
thus differentially expressed proteins were identified following the instructions supplied 
with the Acuity software for the analysis of gene expression microarray data. In order to 
identify those proteins that showed no bias in Cy-3 and Cy-5 dye incorporation a 
students Mest was performed (p<0.05). Figure 8-5 demonstrates an example of a 
successfully dye-swapped feature. Following this selection, those proteins 
demonstrating a >-2 fold change in expression between the cell lines in >50% of 
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Figure 8-5 A representative dye-swapped feature. A. MDA-MB-231 was labelled with 
Cy-3 and MDA-MB-231DR was labelled with Cy-5. B. MDA-MB-231 was labelled 
with Cy-5 and MDA-MB-231DR was labelled with Cy-3. This specific feature shows 
no bias in dye incorporation. 
individual microarrays were deemed as significantly differentially expressed. This cut- 
off was selected because this value is the standard used in the analysis of cDNA 
microarray data (Ghobrial et al. 2005). Analysis revealed a number of differences in 
protein expression levels between cell lines. The down-regulation of MAP kinase- 
activated monopho sphotryo sine (p-ERK; 2.8 fold), cyclin D2 (2.5 fold), cytokeratin 18 
(2.5 fold), cyclin BI (2.4 fold) and heterogeneous nuclear ribonucleoprotein M3-M4 
(HnRNP M3-M4; 2.0 fold) was associated with doxorobucin resistance. A summary of 
the results is displayed in Table 8-2. Interestingly, no proteins were found to be 
significantly over-expressed in MDA- MB-23 I DR compared with the parent. 
8.3.3 Western Blot Analysis 
Western blotting is the standard method used for the confirmation of data obtained from 
antibody microarray experiments. Confirmatory techniques are important due to the 
possibility of false discovery; a potential problem known to be associated with gene 
expression microarrays and also a factor in the antibody microarray technique. Four of 
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Table 8-2 Proteins identified as significantly differentially expressed between the 
MDA-MB-231 and MDA-MB-231DR cell lines from the antibody microarray 
experiments. Expression values (fold-changes) are those identified in the MDA-MB- 
23 1 DR cell line relative to those of the MDA-MB-231 cell line. Bold proteins represent 
those that have been confirmed up to date. 
Protein Antibody Microarray 
Fold-change 
Western Blot 
Status 
Functional 
Category 
p-ERK 12.8 12.9 (p-ERK1) 
ý1.3 (p-ERK2) 
Signal Transduction 
Cyclin D2 ý 2.5 ý 1.8 Cell Cycle 
Cytokeratin 18 12.5 Not Confinned C)ýoskeleton 
Cyclin B1 12.4 ý 1.7 Cell Cycle 
HnRNP m3-m4 12.0 Not Tested Nuclear 
the differentially expressed proteins were selected for further validatation by western 
blotting in 3 biological replicates. Each band was normalised to either GAPDH or beta 
actin and protein expression was quantitated using densitometric analysis (Quantity One 
(version 4.6.1), Bio-Rad; see section 4.8.5). Using this technique the down-regulation of 
p-ERK (p-ERKI; 2.9 fold, p-ERK2; 1.3 fold), cyclin D2 (1.8 fold) and cyclin BI (1.7 
fold) was confinned in the MDA-MB-231DR cell line (Figure 8-6). The decreased 
expression of cytokeratin 18 in MDA-MB-231DR cells was not confirined 
in all 
replicates. 
8.4 Discussion 
Resistance to doxorubicin. represents a major obstacle to the successful treatment of 
patients with breast cancer. In this study, the parental 
NMA-MB-231 cell line and a 
novel derivative displaying significant resistance to 
doxorubicin (MDA-MB-231DR) 
were analysed using novel antibody microarray 
technology. Antibody microarray 
results suggest that the down-regulation of p-ERK 
(2.8 fold), cyclin D2 (2.5 fold), 
cytokeratin 18 (2.5 fold), cyclin B1 (2-4 
fold) and HnRNP M3-M4 (2.0 fold) may be 
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Figure 8-6 Confirmation of the antibody microarray results by western blotting. Lane 
1. MDA-MB-231; Lane 2. MDA-MB-231DR. The down-regulation of p-ERK (p- 
ERK1 (44-kDa); 2.9 fold) and p-ERK2 (42-kDa); 1.3 fold), cyclin D2 (34-kDa; 1.8 
fold) and cyclin BI (62-kDa; 1.7 fold) was confirmed by western blotting. As suggested 
by the antibody microarray data, there was no difference in the expression of 
unphosphorylated ERKI (44-kDa) and ERK2 (42-kDa). Protein bands were visible in 
the correct size ranges in relation to the Cruz Marker molecular weight standards. 
Expression was quantitated by densitometry following normalisation to either GAPDH 
or beta-actin. 
associated with resistance to doxorubicin. In the present study, differentially expressed 
proteins were identified using a >-2.0 fold cut-off value for the antibody microarray. 
This value was selected because this information was not supplied with the kit, however 
it is the standard value used for the analysis of gene expression microarray data. Since 
antibody microarray technology remains in its infancy it is difficult to determine what 
cut-off level constitutes a significant change in expression. Traditional approaches for 
the global analysis of protein expression have a limited ability to detect the lower 
abundance proteins, however antibody microarrays are more amenable to the analysis of 
such proteins. Therefore, any change in the expression of low abundance proteins may 
be subtle, however may still exert a causative effect. The cut-off level must therefore 
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represent a balance to encompass subtle changes in expression levels (which may still 
constitute important functional changes) whilst maximising the specificity of the 
antibody microarray technique. Future work must be conducted in order to determine 
the functional relevance of lower level changes and as such this may help to identify a 
more informative cut-off level. In 2005, Ghobrial et al. exploited antibody microarrays 
for the analysis of Mantle Cell Lymphoma (MCL) and analysed proteins using 2 cut-off 
values (ý2.0 fold and >-t. 3 fold). The ýý13 fold cut-off was determined as a significant 
value for differentially expressed proteins by the manufacturer of their microarray 
analysis software (Genespring software, Silicon Genetics, USA). This group found that 
when using the standard ý! 2 fold cut-off level, 13 proteins were differentially expressed 
in MCL when compared with normal tonsillar B-cells. Cyclin D1 is a protein known to 
be involved in the pathogenesis of MCL, however using the standard -: ýý2 fold cut-off 
level this protein was not identified as differentially expressed. In contrast, cyclin DI 
was readily detected as being over-expressed in these cells by western blotting and 
immunohistochernistry and was therefore classed as a false-negative target from the 
antibody microarray experiment. Using the >1.3 fold cut-off, 77 proteins were identified 
as being over-expressed including cyclin Dl. However, some of these 77 proteins could 
not be validated using alternative techniques therefore representing false-positive targets 
from the antibody microarray experiment and further highlighting the problem with 
false discovery. False discovery is a problem associated with gene expression 
microarrays and is also a factor with antibody microarrays. The confirmation of data 
obtained from antibody microarrays using alternative techniques is therefore of high 
importance. In our study, while the antibody microarrays indicated that cytokeratin 18 
was down-regulated by 2.5 fold in MDA-MB-23 I DR cells, this was not evident on the 
western blots suggesting that this may have been a false-positive target. In contrast, the 
down-regulation of p-ERK, cyclin D2 and cyclin BI in MDA-MB-231DR cells was 
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confirmed by western blotting in 3 biological replicates suggesting that these may be 
potential targets worthy of further studies. The down-regulation of heterogeneous 
nuclear ribonucleoprotein (HnRNP) M3-M4 has yet to be confirmed by western 
blotting. On confirmation by western blotting further studies will be conducted in order 
to deten-nine whether the targets have true functional associations with doxorubicin 
resistance. Gene silencing methods (e. g. RNA interference) and/or pharmacological 
inhibitors will detennine whether the down-regulation of such targets can contribute to 
a doxorabicin resistant phenotype (see section 6.4.7). To the best of our knowledge, this 
is the first study to implicate the down-regulation of these proteins with resistance to 
doxorubicin in human breast cancer cells. Doxorubicin exerts a cytotoxic effect by 
inducing apoptosis. Thus, resistance to apoptosis is possibly the principal mechanism by 
which cells may evade treatment. The properties of these proteins and their possible 
roles in apoptosis and the development of doxorubicin resistance are discussed below. 
8.4.1 Mitogen-Activated Protein Kinase-Activated Monophosphotyrosine 
The mitogen-activated protein kinase (MAPK) super-family of enzymes plays a key 
role in widespread signalling pathways and serves to coordinate key cellular processes 
such as cell proliferation and cell death. MAPKs have been classified into 3 
subfamilies; the extracellular signal-regulated protein kinase (ERK) family, the c-Jun N- 
terminal kinase (JNK) family and the p38 MAPK family. The ERK subfamily consists 
of 2 closely related MAPKs, ERK1 and ERK2 (p44 and p42, respectively). These 
proteins are terminal kinases, which exist in a kinase cascade (Werry et al. 2005). Each 
kinase phosphorylates and thereby activates the next member in sequence. This results 
in the transmission of a message from extracellular stimuli to intracellular target 
molecules. The phosphorylation of ERK1 and ERK2 is regulated 
by MEKI and MEK2, 
which in turn are phosphorylated and activated by Raf-I 
in response to Ras stimulation. 
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MAPK enzymes require the dual phosphorylation of regulatory tyrosine and threonine 
residues to become fully activated, however partially phosphorylated forms do exist 
- (Yao et al. 2000). Phosphorylation of either the tyrosine or threonine residue alone 
increases enzymatic activity by no more than 5-10 fold. In contrast, dual 
phosphorylation of both residues results in a 3000-fold increase (Zhang et al. 1995; 
Khokhlatchev et al. 1997). In the present study, the down-regulation of the 
monophosphorylated tyrosine form of ERK was associated with doxorabicin resistance. 
In contrast, the expression of the monophosphorylated threonine form of ERK remained 
unchanged between cell lines. The MAP-kinase activated diphospho antibody was also 
present on the antibody microarray, however this form was not significantly dye- 
swapped and was therefore not included in the subsequent analyses. Since dual 
phosphorylation is required for full activation, the expression of diphosphorylated ERK 
requires further evaluation. Results from the antibody microarray experiment also 
showed that the expression of unphosphorylated ERK remained unchanged between cell 
lines. This finding was also independently confinned by western blot analysis (Figure 8- 
4). This suggests an alteration in the expression level of an upstream regulator of ERK. 
Raf- 1 was also not significantly dye-swapped and was therefore excluded from 
subsequent analyses. Unfortunately, MEK1 and MEK2 were not represented on the 
microarray and therefore the expression levels of these proteins warrant further 
investigation. Alternatively, the inactivation of ERK occurs through dephosph, orylation 
by specific phosphatase enzymes. It is been suggested that monophosphorylated ERKs 
are the products of such dephosphorylation events (Yao et al. 2000). Thus, it may be 
possible that changes in the expression level of a specific phosphatase(s) may be 
responsible for the down-regulation of p-ERK observed in MDA-MB-231DR cells. 
Such phosphatases may also not have been analysed by the antibody microarray. 
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MAPK pathways are involved with the transmission of many different signals, 
including the apoptotic signal. Therefore, the down-regulation of key players within 
these pathways may be associated with resistance to chemotherapy due to the 
attenuation of pro-apoptotic signalling. In accordance, Yeh et al. (2001) demonstrated 
that p-ERK2 phosphorylates p53 in response to treatment with doxorubicin. The p53 
protein activates DNA repair and/ or apoptosis in response to DNA damage (see section 
2.1.1). Yeh et al. (2001) therefore concluded that p-ERK2 was required for p53- 
dependent apoptosis in response to doxorubicin. Furthermore, the inhibition of ERKI 
and ERK2 activity has been associated with the development of HSP25 mediated- 
radiotherapy-resistance in L929 cells (Cho et at. 2002). The over-expression of the 
HSP25 gene resulted in resistance to radiotherapy by the down-regulation of ERKI and 
ERK2. The subsequent transfection of ERKI and ERK2 cDNA produced increased 
levels of ERK1 and ERK2 proteins as well as their active phosphorylated fonns. 
Clonogenic survival and apoptosis assays were performed and it was found that 
radiosensitivity was restored in ERK2 but not ERKI, transfected cells. Further studies 
showed that reduced basal levels of cdc2 kinase, cyclin DI and cyclin A proteins by 
HSP25 over-expression were restored by ERK2 cDNA transfection. Also, the increased 
induction of the anti-apoptotic protein Bel-2 by HSP25 over-expression was also 
reduced to control levels. Tyrosine phosphorylation precedes threonine phosphorylation 
and in some cases the mono-phosphorylated tyrosine form can accumulate within cells 
(Boulton and Cobb, 1991). It has been suggested that this accumulation may act as a 
store of rapidly activatable enzyme, which may prime the cell for response to 
extracellular stimuli (Cobb, 1999). Thus, the down-regulation of this mono- 
phosphorylated form of ERK may reduce cellular response to doxorubicin manifesting 
as resistance to this agent. 
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8.4.2 Cyclins 
The cyclin proteins are key cell cycle regulators. Cyclin D2 is required for the GI/S- 
phase transition and cyclin B1 regulates progression of cells through G2 into the M- 
phase of the cell cycle. Transient changes in the expression levels of these proteins may 
have been detected due to cell-cycle stage at the time of analysis. However, apoptosis is 
intricately linked with the cell cycle and although the mechanisms remain elusive there 
is accumulating evidence to suggest that cyclins may also play a role in apoptosis. 
8.4.2.1 Cyclin D2 
Cyclin D members have previously been associated with apoptosis (Sofer-Levi and 
Resnitzky, 1996; Qian et al. 1998; Mendelsohn et al. 2002). However, there is 
considerably less evidence to suggest that cyclin D2 plays a role in apoptotic pathways. 
The level of cyclin D2 protein has been shown to be up-regulated in P19 embryonal 
carcinoma cells committed to apoptosis (Glozak and Rogers, 2001). However, the 
possible mechanisms require further investigation. 
8.4.2.2 Cyclin BI 
Cyclin BI has also been implicated with apoptosis induced by several methods, 
including the use of DNA damaging agents (Fotedar et al. 1995; Gao and Zelenka, 
1995; Porter et al. 2000). In a study conducted by Porter et al. (2000) an increase in the 
level of cyclin B1 protein was required for y-radiation-induced apoptosis in 
haematopoietic cells. Furthennore, antisense inhibition of this protein was found to 
inhibit apoptosis induced by this agent. Cyclin B1 may be able to induce apoptosis due 
to the activation of cdc2 kinase; a protein which may also be regulated by p-ERK 
(Porter et al. 2000; Konishi et al. 2002). It has been suggested that the cyclin B1/cdc2 
kinase complex may regulate apoptosis by phosphorylating and activating molecules 
231 
Chapter VIII The Analysis ofDoxorubicin Resistance in Breast Cancer using Antibody Microarrays 
involved in apoptotic pathways (Porter et al. 2000). In support of this mechanism, 
Konishi et al. (2002) discovered that activated cdc2 kinase was able to phosphorylate 
BAD thereby inducing BAD-mediated apoptosis in rat cerebellar granule neurons. This 
suggests that cyclin BI may activate cell death machinery via the cdc2 kinase. 
Furthen-nore, Ling et al. (1996) showed that the cytotoxicity of doxorubicin was cell- 
cycle dependent and was mediated, at least in part, by a disturbance in the regulation of 
the cyclin BI /cdc2 kinase complex. Cdc2 kinase was not represented on the microarray, 
therefore the expression level of this protein requires further investigation. The down 
regulation of cyclin BI was also discovered in a lung cancer cell line (A549/UCN) 
selected for resistance to a novel anticancer compound UCN-01 (Sugiyama et al. 1999). 
Furthermore, cyclin BI has been implicated with response to chemotherapy in clinical 
studies. High expression levels of cyclin B1 were found to predict a good clinical 
outcome in follicular lymphoma patients treated with doxorubicin-containing CHOP 
chemotherapy regimen (Bjorck et al. 2005). This suggests that the down-regulation of 
cyclin B1 observed in the present study may be directly associated with an attenuated 
apoptotic response in MDA-MB-23 I DR cells in response to doxorabicin. 
8.4.3 Heterogeneous Nuclear Ribonucleoprotein M3-M4 
In the present study, results from the antibody microarrays indicated that the down- 
regulation of heterogeneous nuclear ribonucleoprotein (HnRNP) M3-M4 was associated 
with resistance to doxorubicin in MDA-MB-231 breast cancer cells. This group of 
proteins is involved with protein biosynthesis, and specific HnRNPs have been found to 
control the translation of anti-apoptotic proteins (see Appendix G). It may therefore be 
conceivable to speculate that specific HnRNPs may also be involved with the 
translation of pro-apoptotic proteins. However, the down-regulation of HnRNP M3-M4 
in MDA-MB-231DR cells must first be confirmed by western blotting before 
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perfonning the functional studies required to verify any hypotheses. This is because 
HnRNP M3-M4 may represent another false-positive target from the antibody 
microarray experiment. 
8.4.4 Discussion and Conclusion 
High resolution 2DE remains the gold standard for the global analysis of protein 
expression, however is associated with several drawbacks. The technique is time- 
consuming and requires considerable skill to perform reproducibly. More importantly, 
2DE is not suitable for the analysis of certain classes of proteins. Many membrane 
proteins are refractory to gel-based separation due to their hydrophobicity and low 
abundance proteins are often masked by the more abundant species. Furthermore, 2DE 
cannot support the high-throughput that is required for medical applications. 
Nevertheless, 2DE remains unrivalled in its ability to obtain a "snapshot" of whole 
complex proteomes and no prior knowledge is required for target discovery. The 
antibody microarray is a promising new technique designed to overcome many of the 
drawbacks associated with 2DE. However, although the antibody microarray offers an 
approach for the simultaneous analysis of many proteins, studies are limited to the 
number of antibodies present on the microarray slides. As such the antibody microarray 
provides a complementary approach for the analysis of complex proteomes. The 
PanarornaTm Cell Signalling Antibody Microarray Kit exploited in this study allowed 
for the analysis of 224 specific proteins; a relatively small number when taking into 
consideration the fact that the whole proteome may actually consist of over 1,000,000 
different proteins. In fact, several proteins of interest, including MEKI, MEK2 and cdc2 
kinase were not present on the microarray. Furthermore, the antibody microarray 
technique is only suitable for the analysis of known proteins for which highly specific 
antibodies are available. As the field of antibody microarrays expands new commercial 
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antibody microarrays are being introduced, which allow for increasing numbers of 
proteins to be analysed simultaneously. The Labvision antibody microarray is one such 
example, which consists of 720 highly specific antibodies spotted in triplicate (see 
chapter IX). Alternatively, researchers may choose to fabricate their own custom 
antibody microarrays for the analysis of specific proteins (see section 8.1.4). However, 
an ideal antibody microarray for use in biomarker discovery would allow the analysis of 
the complete protein complement expressed by a given genome. This would require the 
production of highly specific antibodies against every protein in the human body and is 
therefore a gigantic task. In the future, the use of recombinant antibody technology may 
allow the fabrication of vast antibody microarrays (Tomlinson and Holt, 2001), however 
at present the use of 2DE in conjunction with antibody microarrays can provide 
complementary data and therefore maximise the analysis of complex proteomes. 
In conclusion, the aims of this chapter were successfully fulfilled. A protocol was 
optimised for the Panorama Cell Signalling Antibody Microarray Kit (Sigrna-Aldrich), 
which has recently been introduced onto the market. In addition, a suitable data analysis 
method was established including use of an appropriate number of replicates, use of the 
dye-swapping method, application of appropriate statistical tests and the use of an 
appropnate cut-off value. This proteomic approach was successfully exploited for the 
identification of molecular markers, which may be associated with doxorubicin 
resistance in human breast cancer cells. Three of these targets were confirmed by 
western blotting, which provides further evidence of the effective protocols established 
for the effective use of this kit. Such targets are worthy of further studies. Furthermore, 
we have published one of the first manuscripts in the field of cancer research using this 
commercial kit. Only a few other manuscripts report the exploitation of this 
kit in the 
field of cancer research. 
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Perhaps the most interesting targets identified in this study are the cyclins since both of 
these proteins were confirmed by western blotting and function in cell cycle control. 
This indicates that defects in cell cycle checkpoints may allow the continous 
proliferation of resistant cells in the presence of doxorabicin and introduces the concept 
of cell-cycle mediated drug resistance. This warrants further investigation. Functional 
studies using gene silencing methods and/ or pharmacological inhibitors will determine 
whether the down-regulation of these proteins can cause resistance to doxorubicin in 
MDA-MB-231 breast cancer cells (see section 6.4.7). In addition, flow cytometry may 
be useful to obtain cell cycle information for both cell populations. These targets must 
also be validated on clinical samples for reasons previously described (see section 
6.4.7). If validated, these proteins may prove useful as biomarkers for the prediction of 
response to doxorabicin treatment in human breast cancer. Those patients unlikely to 
respond to doxorubicin would be spared the serious life-threatening side effects 
for no 
therapeutic gain and may be offered a more appropriate treatment regimen. These 
targets may also provide novel targets for future therapeutic intervention. 
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CHAPTER IX 
THE ANALYSIS OF RADIO-RESISTANCE IN HUMAN 
BREAST CANCER CELLS USING ANTIBODY 
MICROARRAYS 
Aims: 
To optimise a protocol for the recently introduced Labvision Antibody 
Microarray Kit (#TAA-001; Neomarkers) for the analysis of radiotherapy 
resistance in human breast cancer cells. 
To optimise the data analysis method developed in chapter VIII for use with the 
Labvision Antibody Microarray Kit (Neomarkers). 
To assess the efficacy of using the Labvision antibody microarray (Neomarkers) 
comprised of 720 different antibodies, to identify molecular markers associated 
with radiotherapy resistance in human breast cancer cells. 
To conduct a further proteomic analysis of the novel radiotherapy resistant 
breast cancer cell line previously analysed by 2DE-NIALDI-TOF MS (see 
chapter VII) in order to provide complementary infonnation. 
To validate the molecular markers identified by antibody microarrays; using 
western blot analysis. 
To produce one of the first published manuscripts describing the complementary 
use of 2DE-MALDI-TOF MS (see chapter VII) and antibody microarrays (using 
Labvision Antibody Microarray Kit (Neomarkers)) in the field of resistance to 
anticancer therapy. 
236 
Chapter IX The Analysis ofRadio-Resistance in Breast Cancer using Antibody Microarrays 
9.1 Introduction 
Chapter VIII describes the use of a commercially available antibody microarray from 
Sigma-Aldrich. The Panorama Cell Signalling antibody microarray (Sigma-Aldrich) 
was comprised of 224 highly specific antibodies spotted in duplicate onto 
nitrocellulose-coated glass microscope slides. This is a relatively small number of 
antibodies when taking into consideration the fact that the whole proteome may actually 
consist of over 1,000,000 different protein species. In accordance, the results from 
chapter VIII revealed that further analysis is required in order to examine the expression 
levels of several other proteins, which were not represented on the antibody microarray 
(see section 8.4.4). This will further increase both the labour and cost implications 
required to complete this experiment and may also implicate additional proteins also 
requiring further analysis. In an ideal world, antibody microarrays would allow for the 
analysis of the complete protein complement expressed by a given genome. Although 
this would allow a more comprehensive understanding of particular disease phenotypes 
this is not currently possible because specific antibodies against every protein in the 
human body are not yet available. As such antibody microarrays do not currently offer a 
true global approach for the analysis of complex biological systems and therefore many 
important proteins which are associated with particular disease phenotypes may remain 
unknown. Nevertheless, as this technology grows commercial antibody microarrays 
composed of increasing numbers of antibodies are becoming more readily available. 
The aim of this study was to extend the antibody microarray technique utilised in 
chapter VIII in order to analyse the MCF7 breast cancer cell line and the novel 
derivative (MCF740Gy) displaying significant resistance to RT. These cell lines were 
previously analysed by 2DE-NLALDI-TOF MS (see section 7.3). 
The Labvision 
Antibody Microarray Kit (#TAA-001; Neomarkers) was exploited, which detects a 
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larger number of proteins in comparison with the Panorama Cell Signalling Antibody 
Microarray Kit (Sigrna-Aldrich). These proteins represent a broad range of biological 
functions including proteins involved in apoptosis, signal transduction, the regulation of 
transcription, angiogenesis and neurobiology. Each microarray was comprised of 720 
highly specific antibodies spotted in triplicate on derivatized glass microscope slides 
(see section 8.1.1.1 and Figure 8-2). The surface chemistry was proprietary information, 
however the microarray slides were known to be coated with a special polyrner to 
facilitate the immobilisation of antibodies. This is in contrast to the three-dimensional 
surface exploited by the antibody microarrays purchased from Sigma-Aldrich. The 
Labvision antibody microarrays contained 16 sub-arrays each exploiting a number of 
antibodies for the detection of house-keeping proteins for use as positive internal 
controls (e. g. claudins, actins, myosins, tubulin and laminin) and a number of antibodies 
for the detection of mouse, rabbit and viral proteins for use as negative controls (for 
protein extracts from human samples). The complete list of antibodies arrayed upon 
these microarrays can be viewed in Appendix J. The protein profiles of these MCF7 and 
MCF740Gy cell lines were previously compared using 2DE in combination with 
MALDI-TOF MS; the resolution of which remains unrivalled (chapter VII). However, 
antibody microarrays offer several advantages over this technique including a more 
suitable analysis of membrane and low abundance proteins (see section 8.4.4. ). Thus, it 
was expected that the further analysis of these cell lines using antibody microarrays 
would provide complementary data and finiher add to the list of proteins that may be 
associated with resistance to RT in this in-vitro cell culture model. 
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9.2 Materials and Methods 
9.2.1 Cell Lines 
The novel derivative displaying significant resistance to RT (MCF740Gy) was 
previously established as described in section 7.2.1 and the relative resistance of MCF7 
and MCF740Gy to single fractions of ionising radiation (IR) was measured as described 
in sections 4.3.2 and 7.2.2. 
9.2.2 Antibody Microarrays 
The Labvision Antibody Microarray Kit (#TAA-001; Neomarkers) was exploited for 
analysis. Protein was extracted and quantified as described previously in sections 
4.7.2.1 and 4.7.2.2. The fluorescent-labelling of proteins was performed as described in 
section 4.7.2.3 and the hybridisation of labelled protein samples to antibody microarrays 
was undertaken as detailed in section 4.7.2.4. hnages were acquired and analysed as 
described in section 4.7.2.5. Three biological replicates were analysed in which the 
MCF7 protein extracts were labelled with Cy-3 and the MCF740Gy protein extracts 
were labelled with Cy-5. Also included in the analysis were the data from 2 dye- 
swapped replicates in which the MCF7 protein extracts were labelled with Cy-5 and the 
MCF740Gy protein extracts were labelled with Cy-3 (see section 9.3.2.2). This was 
performed in order to overcome any potential bias in dye incorporation. 
9.2.3 Western Blotting 
Western blotting was exploited for confirmation of results and was performed as 
described in section 4.8. Primary antibodies against cyclin C (#RB-009; Neomarkers, 
1: 100), Bak (#RB-1520; Neomarkers, 1: 200), MyD88 (#RB-1735; Neomarkers, 1: 200) 
and L-Plastin (#MS-1326; Neomarkers, 1: 100) were added for 2 hrs at RT The 
appropriate HRP-conjugated secondary antibody (anti-mouse or anti-rabbit, 
#SC-2031 
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or #SC-2030; Santa Cruz) was added at a concentration of 1: 1000 and enhanced 
chemiluminescence (ECL) was used for detection as described in section 4.8.3. 
Membranes were re-probed with GAPDH as described in section 4.8.4 and image 
analysis was undertaken as described in section 4.8.5. 
9.3 Results and Discussion 
9.3.1 Establishment of the MCF740Gy Cell Line 
The relative resistance of MCF7 and MCF740Gy cell lines to single fractions of IR is 
decribed in section 7.3.1. 
9.3.2 Antibody Microarrays 
9.3.2.1 Work in Progress 
The Labvision Antibody Microarray Kit (Neomarkers) was exploited in order to analyse 
the MCF7 breast cancer cell line and a novel derivative displaying significant resistance 
to RT (MCF740Gy). The protocol recommended by the manufacturer of the antibody 
microarray kit was followed but problems were encountered during the experimental 
procedure suggesting further optimisation is required. Problems occurred during the 
final step of the protocol during which the microar-ray slides were dried by 
centrifugation at 1000g. This speed was found to be too rigorous because despite the 
successful drying of the first set of replicate slides, the second set of replicate slides 
shattered during this step. Despite repeated assurances from the supplier that the 
microarray slides were able to tolerate such high speeds a further microarray slide in the 
third set of replicates (a dye-swapped microarray) broke in half directly through the 
block of antibodies. An image was still acquired for this replicate and the required data 
analysis was perfonned. However, 2 of the 16 sub-arrays were unavailable for analysis 
because this was where the break in the microarray slide was positioned. 
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For the final set of replicates the centrifugation speed was reduced to 200g to avoid 
similar problems. This is the speed used to dry gene expression microarray slides prior 
to image acquisition and data analysis. Although these microarray slides remained intact 
water marks were visible on the slide surfaces resulting in a higher level of background 
noise. It also became apparent during analysis that the spot morphology of these 
microarray slides was particularly poor in comparison with the antibody microarray 
slides purchased from Sigma-Aldrich (Figure 9-1). Doughnut-shaped spots were visible 
on the Labvision antibody microarray slides. Doughnut-shapes result from the irregular 
distribution of antibodies within the spots. This can result from a rapid drying of the 
microarray slides following printing. A slow evaporation rate allows time for the 
antibodies to diffuse unifonnly across the spots minimising the formation of doughnut- 
shapes. Alternatively, the force and speed at which the printing pins impact the surface 
of the microarray slide can create this effect. Smearing effects were also visible. 
Excessive humidity (>65%) can cause spots to spread to undesirable sizes and to 
assume irregular shapes (Hegde et al. 2000). During the printing of high-density 
microarrays, adjacent spots can become cross-contaminated as a result of the variability 
in spot size caused by high humidity. Alternatively, an excessive delivery of protein 
during printing can cause large irregular spots. The larger the dwell time during pickup 
in the source plate or during slide contact, the greater the amount of material deposited. 
This may result in cross-contamination of the larger irregular spots in adjacent 
of 
positions. This effect may also be observed if the wells in the source plate are holding 
too much of the antibody solutions or as a result of an excessive vertical acceleration of 
the printing pins. Furthermore, it is also possible that the poor spot morphology 
observed was the result of pin defects including poor pin design, bent pins or darnaged 
pin tips. Pin defects can cause irregular spot morphology and erratic spot-to-spot 
spacing resulting in doughnut-shaped spots and smearing effects. 
Other possible causes 
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Figure 9-1 Poor spot morphology on the Labvision antibody microarrays (A) in 
comparison with the Panorama Cell Signalling antibody microarrays (B). Doughnut- 
shaped spots (examples of which are indicated by arrows) and smearing effects (boxed 
regions) are visible on the Labvision antibody microarrays. These effects are indicative 
of the suboptimal spotting of antibodies onto the surfaces of microarray slides. 
include an inappropriate combination of pins, surface chemistry and/ or printing buffer 
composition. The poor spot morphology indicates that the fabrication of the Labvision 
microarray slides requires further optimisation by the manufacturer. Aspects which may 
need additional optimisation include the humidity and temperature settings, pin 
acceleration speeds, dwell times, the volume of antibody solutions in the source plate, 
pin quality and an assessment of the pin, surface chemistry and/ or printing buffer 
compatibility. 
In addition, the antibody microarray protocol gave little information regarding data 
analysis. Due to the poor spot morphology of these microarray slides a less stringent 
quality control procedure was adopted during data analysis in comparison to that 
utilised for the analysis of the Panorama Cell Signalling antibody microarrays. This is 
because >80% of the features were excluded from the analysis of the Labvision 
antibody microarrays when using the strict quality control criteria described in section 
4.7.1.5. Thus, individual features were manually reviewed in GenePix Pro (version 4.1) 
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and those spots that were not found or were of particularly poor quality were flagged. 
Following the importation of all data into Acuity (version 4.0) a dataset was created to 
include only those features that were not flagged (Flags >0; see section 4.7.2.5). This 
allowed the maximum number of features to be analysed however highlights the 
importance of confirmatory techniques. 
A further problem that was also encountered with one of the dye-swapped replicates 
was an insufficient hybridisation of the Cy-3 labelled protein extract (MCF740Gy). For 
this replicate the level of background fluorescence was higher than that for the 
hybridised Cy-3 labelled proteins giving rise to an inverse image in which the 
background fluoresced green and individual spots remained black. The reasons for this 
result are unknown, however successful hybridisation of the Cy-5 labelled protein 
extract ruled out problems with hybridisation, washing or the quality of the slide. The 
amount of protein and the incubation time for hybridisation were also consistent across 
all replicates and the D/P ratio for this labelled protein sample was acceptable (ý: 2) 
suggesting that the problem was not the result of an insufficient labelling of this extract. 
It was therefore not possible to include this replicate in the subsequent data analysis. 
In total, only 4 replicates were available for a preliminary analysis of the data (3 
biological replicates and 1 dye-swapped replicate). In order to use the student's t-test to 
identify those proteins that showed no bias in dye incorporation each group required at 
least 2 replicate microarrays for comparison. Thus, the dye-swapped microarray that 
was damaged during the centrifugation step was included in the preliminary analysis. 
This is in contrast to the data analysis of the antibody microarrays, purchased from 
Sigma, which included 6 high quality antibody microarrays; 4 biological replicates and 
2 dye-swapped slides. It was accepted that not all antibodies on the Labvision antibody 
243 
Chapter IX The Analysis ofRadio-Resistance in Breast Cancer using Antibody Microarrays 
microarray slides were analysed and that at least one more dye-swapped replicate and a 
higher quality of spot morphology were required in order to obtain a comprehensive 
analysis of all the antibodies represented on these microarray slides. The results from 
the preliminary data analysis are presented below. 
9.3.2.2 Preliminary Data Analysis 
Data from 3 biological replicates were used in which the MCF7 protein extracts were 
labelled with Cy-3 and the MCF740Gy protein extracts were labelled with Cy-5. Also 
included in the analysis were the data from 2 dye-swapped replicates (including the 
damaged replicate described in section 9.3.2.1). In order to identify those proteins that 
showed no bias in dye incorporation a student's Mest was performed (p<0.05). 
Following this selection, those proteins demonstrating a >2 fold change in expression 
between cell lines in >50% of individual microarrays were deemed as significantly 
differentially expressed. This cut-off was selected because this value is the standard 
used in the analysis of cDNA microarray data (Ghobrial et al. 2005) and was 
successfully exploited for the analysis of the Panorama Cell Signalling antibody 
microarrays (Sigma-Aldrich). Preliminary data analysis revealed that the down- 
regulation of cyclin C (3.1 fold) was associated with resistance to RT. However, only 16 
proteins were statistically dye-swapped using this method of data analysis. Therefore, 
only 2% of all the antibodies represented on the microarray were analysed indicating 
many other possible targets may have been overlooked. A good example of this was L- 
Plastin, which was identified as down-regulated in the same MCF740Gy cell line by 
2DE and MALDI-TOF MS (see chapter VII). This result was confirmed independently 
by western blotting, which revealed that the expression of L-Plastin was undetectable in 
MCF740Gy cells in comparison with MCF7 parent cells (Figure 7-6). The L-Plastin 
antibody was the only target from the 2DE-NLkLDI-TOF MS experiment that was also 
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represented on the Labvision antibody microarray. This protein was therefore suitable 
for use as an internal control to ensure the accuracy of the antibody microarray 
technique and to determine the most appropriate cut-off level. However, this protein 
failed to be significantly dye-swapped and was therefore excluded from the analysis. 
This highlighted the potential problems associated with the fluorescent labelling of 
proteins (see section 8.1.3.1) and raised the question as to whether dye-swapping was 
really necessary for data interpretation. In an attempt to answer this question the 
preliminary data analysis was repeated using an alternative method. The dye-swapped 
slides were excluded and an analysis of the 3 biological replicates (all of which were 
labelled in the same direction) was undertaken. A one-tailed student's Mest was 
perfonned (p<0.05) to identify those targets showing little variation in the log ratio 
values across all 3 biological replicates. This yielded 42 potential targets. This statistical 
test was applied because it is used to analyse gene expression microarray data when an 
indirect method is used for the fluorescent labelling of cDNA molecules. This indirect 
labelling method results in no coupling bias between either of the dyes and therefore 
dye-swap replicates are not required. Unfortunately, an indirect method for the 
fluorescent labelling of proteins is not yet available. The application of this statistical 
test was performed to minimise false-discovery. Following this selection, those proteins 
demonstrating a >2 fold change in expression between the cell lines in all 3 biological 
replicates were deemed as significantly differentially expressed. 
A ý! 2 fold change in all 
3 replicates (rather than in >50% of individual replicates) was specified 
because of the 
small number of microarrays analysed. This applied some 
degree of stringency to the 
search parameters to farther reduce the possibility of 
false discovery. Using this method 
the up-regulation of platelet derived growth 
factor receptor alpha (PDGFR; 3.3 fold), 
myoglobin (3.2 fold), myeloid differentiation marker 
88 (MyD88; 3.1 fold) and Bak 
(2.9 fold) was associated with resistance to RT. 
It was interesting to note that both 
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cyclin C and L-Plastin were excluded from this analysis because of a high level of 
variance in the log ratio values between individual microarrays. However, because it 
was known that L-Plastin was differentially expressed between the cell lines this protein 
became a benchmark with which to identify the most suitable method of data analysis 
and to determine an appropriate cut-off value. The Labvision antibody microarrays 
revealed that the expression of L-Plastin was down-regulated in the MCF740Gy cell 
line by 1.1-fold, 1.1-fold and 1.6-fold across the 3 replicate microarrays. The mean 
average fold-change was therefore calculated to be 1.3-fold. A >1.3 fold cut-off level 
was found to be suitable for the analysis of MCL using antibody microarrays (Ghobrial 
et al. 2005). However, in this study L-Plastin remained unidentified using a ý1.3 fold 
cut-off level. This is because a >1.3 fold change in expression was not observed across 
all 3 of the replicates. Altering the parameters to identify the differential expression of 
L-Plastin generated vast amounts of targets many of which may be the result of false 
discovery. Therefore, one method to maximise the specificity of the antibody 
microarray technique in the absence of dye-swapping may be to increase the number of 
replicates. Alternatively, it was hypothesised that these antibody microarrays may not 
have provided an accurate measure of protein expression. In accordance, the expression 
of L-Plastin was re-examined in 3 fresh biological replicates for each cell line by 
western blotting. Results revealed expression profiles similar to those shown in Figure 
7-6. Thus, the fact that such a large change in expression was not detected by the 
Labvision antibody Microarrays indicates that this kit may have provided an inaccurate 
measure of protein expression. 
9.3.3 Western Blot Analysis 
Western blot analysis was used for confirmation of the preliminary results. 
Confirmatory techniques are important due to the possibility of false discovery; a 
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potential problem known to be associated with gene expression microarrays and which 
is also a factor in the antibody microarray technique. Confinnation is particularly 
important in this chapter because the results were obtained through a preliminary 
analysis of the data and the quality of the antibody microarrays was less than optimal. 
Western blotting was also performed to ensure that the identification of some of these 
targets was not the result of a biased incorporation of the fluorescent dyes. The down- 
regulation of cyclin C (3.1 fold) in MCF740Gy cells was identified using the more 
stringent dye-swapping method of data analysis and was selected for western blot 
analysis. The over-expression of MyD88 (3.1 fold) and Bak (2.9 fold) in MCF740Gy 
cells were identified from the less stringent analysis in which the dye-swapped slides 
were excluded. These targets were also selected for western blot confinnation. Bands 
were normalised to GAPDH and protein expression was quantitated in 3 biological 
replicates using densitometric analysis (Quantity One (version 4.6.1), Bio-Rad; see 
section 4.8.5). No changes in the expression levels of these proteins were observed 
between the cell lines suggesting possible false discovery (Figure 9-2) and providing 
further evidence of the inaccuracy of these antibody microarrays. 
9.4 Conclusion 
The Labvision antibody microarrays exploited in this chapter were composed of many 
more antibodies (720) in comparison with the Panorama Cell Signalling antibody 
microarrays (224; see chapter VIII). The use of these antibody microarrays, may 
therefore allow a more comprehensive analysis of complex proteomes in comparison 
with the Panorama Cell Signalling antibody microarrays (Sigma-Aldrich). However, the 
results fTom the present study suggest that further optimisation of this kit 
is required. In 
particular, the spot quality of these microarrays, was poor compared with the antibody 
microarrays purchased from Sigma-Aldrich (see Figure 
9-1). Labvision antibody 
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Figure 9-2 Western blotting revealed that the down-regulation of cyclin C or the up- 
regulation of MyD88 and Bak could not be confirmed suggesting that these proteins are 
false-positive targets from the Labvision antibody microarrays. 
microarrays were composed of triplicate spots of each antibody. This is in comparison 
to duplicate spots of each antibody represented on the Panorama Cell Signalling 
antibody microarrays (Sigma-Aldrich). In addition, although the size of individual 
features was smaller on the Labvision antibody microarrays, (300[im) in comparison to 
the size of individual features on the Panorama Cell Signalling antibody microarrays 
(500ýtm) the size of individual features on high density gene expression microarrays is 
often as small as 100[tm. This allows for the simultaneous analysis of several thousands 
of genes. Therefore, the use of triplicate spots in combination with the relatively large 
feature size on the Labvision antibody microarrays resulted in little space between 
individual features, which may have contributed to the poor spot quality. It is also 
possible that the surface chemistry (see section 8.1.1.1) of Labvision antibody 
microarrays may have played a role in the poor spot morphology. Surface chemistry is 
critical to spot quality and derivatised glass slides, as used in the Labvision Antibody 
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Microarray Kit (Neomarkers), suffer from the inherent disadvantage of low levels of 
spot homogeneity. This is often the result of uneven polymerisation across the slide 
surface. This is in contrast to the antibody microarrays purchased from Sigrna-Aldrich, 
which exploited a three-dimensional surface (nitrocellulose) for the immobilisation of 
antibodies (see Figure 8-2). It must also be determined whether the Labvision antibody 
microarrays can provide an accurate measure of protein expression. In the present study, 
L-Plastin was used as a control protein to assess the accuracy of the Labvision antibody 
microarray. The 2DE-MALDI-TOF MS and western blot analyses revealed that this 
protein was present in MCF7 cells and was undetectable in MCF740Gy cells, however 
this protein was not identified as differentially expressed using antibody microarrays in 
the same cells. In the future, it may be beneficial to perform western blotting with a 
broad selection of the antibodies represented on the microarrays. This will help 
determine the expression levels of several proteins prior to antibody microarray analysis 
and will provide several control proteins (rather than a single control protein) to 
elucidate the accuracy of the antibody microarray. This will also help to determine an 
appropriate cut-off level with which to identify differentially expressed proteins because 
it currently remains unknown as to what fold-change constitutes a significant functional 
change in expression (see section 8.4). In addition, it remains to be determined whether 
dye-swapping is really necessary for data interpretation or whether an alternative 
method of data analysis can be employed to identify potential targets in combination 
with robust confinnatory techniques. In this study, the targets identified using the two 
different data analysis methods failed to be confirmed by western blotting suggesting 
that false discovery will remain an issue (especially with the Labvision Antibody 
Microarray Kit (Neomarkers)) regardless of the method employed. Thus, alternative 
techniques (such as western blotting) will remain an important tool in the confirmation 
of those targets identified by antibody microarrays. 
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In conclusion, the Panorama Cell Signalling antibody microarray was composed of 224 
different antibodies and was successfully utilised to identify potential biomarkers 
associated with resistance to anticancer therapy (see chapter VIII). In order to obtain a 
more comprehensive analysis of complex proteomes an increase in the number of 
antibodies would be desirable. This was attempted using the Labvision antibody 
microarray but despite lengthy discussions with the manufacturer, the poor quality of 
this kit prevented the aims of this chapter from being successfully fulfilled. 
Nevertheless, the problems that were encountered with this kit enabled a further 
investigation into the antibody microarray technique and have demonstrated the 
importance of confirmatory studies. It was also determined that commercial kits are not 
necessarily effective and previous experience with the antibody microarrays from 
Sigma-Aldrich proved invaluable in being able to perform the different methods of data 
analysis and recognise the poor quality of the Labvision antibody microarrays. 
Therefore, at present the Panorama Cell Signalling Antibody Microarray Kit (Sigma- 
Aldrich) is currently the tool of choice with which to complement 2DE-based 
approaches for the discovery of potential biomarkers. However, this kit requires a 
relatively large amount of starting material (ý: I mg/ml of protein) and may be therefore 
unsuitable for the analysis of clinical samples. This is in comparison with 0.25 mg/ml, 
which is minimum amount required for Labvision antibody microarrays. Nevertheless, 
the performance status of Sigma-Aldrich antibody microarrays supersedes that of the 
Labvision antibody microarrays, thus it may be possible to combine this type of kit with 
more sensitive labelling procedures to allow the more effective analysis of clinical 
samples in the future. In addition, other antibody microarray kits are available. BD 
Biosciences is one such company that also supplies antibody microarray kits, however 
these kits are currently much more expensive than those utilised for this thesis. 
Nevertheless, as the field of antibody microarrays expands other technologically 
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advanced kits will become more widely available. Furthermore, it may also be possible 
to collaborate with Sigma-Aldrich in order to further improve their kit and increase the 
number of antibodies represented on their antibody microarrays for a more 
comprehensive analysis of complex proteomes. 
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10.1 Concluding Remarks 
This thesis has generated a list of candidate proteins that may be involved with 
resistance to anticancer therapy. These targets may be clinically relevant and have been 
ranked in order of their importance to prioritise those for further studies (see TablelO- 
1). The possible roles played by these individual targets in the development of 
resistance to anticancer therapy have been discussed and have generated many 
hypotheses. However, it is possible that these targets may act in concert in specific 
cellular pathways. These pathways, rather than the individual targets, may be more 
important in the development of resistance to anticancer therapy; the abrogation or 
stimulation of which may provide novel therapeutic approaches. In support of this 
hypothesis, many of the targets appear to be associated with several specific cellular 
pathways; the ubiquitin/ proteasome pathway, the NF-KB pathway and the MAPK 
pathways. In addition, some of the targets provide cross-links between these pathways. 
The ubiquitin/ proteasome pathway is the main non-lysosomal route for the degradation 
of proteins and is responsible for the turnover of >80% of cellular proteins (Dalton, 
2004). This involves the conjugation of multiple ubiquitin moieties to a protein 
substrate followed by the downstream degradation of the tagged protein by the 26S 
proteasome. Alterations in the expression levels of several 26S proteasome-associated 
subunits (proteasome beta I subunit, PSME1 and PSME2) were implicated with 
resistance to anticancer therapy in this thesis. These alterations may have compromised 
the function of the 26S proteasome resulting in the increased stability of those proteins 
required for the development of resistance to anticancer therapy. In support of this 
hypothesis, a decrease in the expression level of HSP27 was also observed; a protein 
which is responsible for targeting misfolded or short-lived proteins to the proteasome 
for degradation. Furthennore, a decrease in the expression of eIF3 (subunit 2P) was also 
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observed. Links between eIF3 subunits and the 26S proteasome have been previously 
established. Subunit 3 of the eIF3 complex has weak sequence homology to Mov-34; a 
subunit of the 26S proteasome (Asano et al. 1997). Mayeur and Hershey (2002) also 
demonstrated that independent of the eEF3 complex, subunit 6 interacts directly with a 
complex called COP9. CON is a signalosome that regulates protein stability via the 
ubiquitin/ proteasome pathway and may also be involved with the c-jun N-terminal 
kinase (JNK) signalling pathway (Seeger et al. 2001). 
In contrast, the over-expression of the proteasome beta I subunit may have enhanced 
the function of the 26S proteasome resulting in the excessive degradation of those 
proteins required for an effective response to anticancer therapy. This hypothesis 
provides an effective link between the ubiquitin/ proteasome pathway and the NF-rB 
pathway. NF-KB is a transcription factor, which protects cells from apoptosis through 
the induction of survival genes including cIAP1, cW2, XW and Bcl-2. In 
unstimulated cells, an inhibitor of NF-KB (lKB) sequesters this protein in the cytoplasm 
by binding to and masking the nuclear translocation signal (Karin and Ben-Neriah, 
2000). In response to a variety of extracellular stimuli, IKB becomes rapidly 
phosphorylated and ubiquitinylated. Ubiquitinylated I-KB is degraded by the 26S 
proteasome allowing NF-rB to translocate to the nucleus and induce gene transcription. 
Thus, an over-expression of specific proteasome subunits may result in an excessive 
degradation of IKB, which would allow the nuclear translocation of NF-KB stimulating 
an inappropriate transcription of survival genes. It is possible to test this hypothesis by 
detennining the level of proteasome activity in sensitive and resistant cells as previously 
described in section 6.4.7. In addition, the analysis of IrB expression using western 
blotting would help to determine whether differences exist in degradation rate of this 
protein between phenotypes. 
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There is also evidence to suggest that the nuclear translocation of the NF-KB 
transcription factor can also be regulated by post-translational acetylation. The 
acetylation of proteins is regulated by a family of enzymes called acetyltransferases. N- 
acetyltransferase is a member of this family; the down-regulation of which was 
associated with resistance to anticancer therapy. This may have contributed to the de- 
regulation of this pathway. 
Peroxiredoxins are a family of antioxidant enzymes, which use thioredoxin as an 
electron donor for the reduction of H202 (see section 6.4.3). H202 plays a role as a 
secondary messenger in signalling cascades via the oxidation of the cysteine residues of 
protein tyrosine phosphatases. Protein tyrosine phosphatases are responsible for 
dephosphorylation events and therefore the attenuation of signalling cascades. 
Oxidation of the cysteine residues results in the inactivation of these enzymes leading to 
sustained phosphorylation and activation of several key signalling pathways, including 
the NF-icB pathway and MAPK pathways. H202 is produced in response to several 
growth factors, such as PDGF, EGF and TNF-a. TNF-a signalling is regulated via the 
intermediate filament (IF) family of proteins. One member of this family includes CK 
17; the down-regulation of which was associated with resistance to anticancer therapy. 
It is possible that TNF-sipalling increases the production of H202 resulting in the 
sustained phosphorylation and excessive proteasomal degradation of IKB. In support of 
this hypothesis, Caulin and colleagues (2000) observed an increase in NF-rB and JNK 
activation in keratin-deficient endodermal cells in response to treatment with TNF. It 
would also be interesting to examine the expression levels of other members of the CK 
family. in particular, CK 17 interacts with CK 5. Western blot analysis would determine 
whether the expression of CK 5 has been up-regulated in order to compensate for the 
loss of CK 17. 
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GIG5 is a further target with links to the NF-KB pathway. GIG5 is a key component of a 
calcium-dependent multiprotein E3 ubiquitin ligase complex that plays a key role in 
targeting specific proteins for proteasomal. degradation. In particular, the stability of 
beta catenin is regulated via the GIG5-containing E3 ubiquitin ligase complex. This 
protein plays a key role in the Wnt signalling pathway; a pathway also known to 
activate NF-rB (Bournat et al. 2000). In the absence of a Wnt signal, beta catenin is 
effectively degraded by a process involving the GIG5-containing E3 ubiquitin ligase 
complex. In the presence of a Wnt signal, beta catenin is stabilised and translocates to 
the nucleus leading to the transcription of Wnt target genes and the activation of the NF- 
KB pathway. In the present study, a down-regulation of GIG5 was associated with 
resistance to anticancer therapy. This may have increased the stability of beta catenin 
thereby activating the NF-KB pathway. 
Many other targets may also play a role in the regulation of the NF-rB and/ or MAPK 
pathways. In particular, peptidyl prolyl isomerases control protein function following 
phosphorylation and have been shown to stimulate IKB phosphorylation and NF-KB 
activation. Furthermore, these enzymes are also involved in the activation of MAPK 
pathways. Tropomyosin- Ia (TM I) is a protein, which sensitizes cells to anoikis; a fonn 
of apoptosis induced when cells become detached from their local micro environment. 
The down-regulation of TMI results in resistance to anoikis, which confers a survival 
advantage for detached cells allowing the formation of metastatic tumours. Several 
pathways have been implicated with the development of resistance to anoikis, an 
example of which includes the NF-KB pathway (Aplin et al. 1998). Specific HnRNPs 
have also been shown to activate the NF-KB pathway and because the LRPPRC protem 
binds to some of the same RNA molecules as the HnRNPs it is possible that this protein 
may also play a role in the regulation of NF-KB. Furthermore, some ribosomal proteins 
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have also been implicated with the regulation of the NF-KB pathway. Khanna et al. 
(2003) demonstrated that the over-expression of ribosomal protein S29 was able to 
induce apoptosis and augment the effects of cisplatin and etoposide in H520 lung cancer 
cells. This was mediated by the down-regulation of several inhibitors of apoptosis and 
also via a reduction in NF--KB transcriptional activity. It is possible that ribosomal 
protein PO may function in a similar manner; the down-regulation of which would 
presumably increase the activity of NF-rB. It is also possible that L-Plastin may be 
associated with the NF-KB and "K pathways. L-plastin consists of 4 calponin 
homology domains, which is a common feature shared by many signalling molecules. 
In addition, L-plastin is a substrate for protein kinase C (PKC). PKC phosphorylates 
various signalling molecules resulting in the activation of cellular pathways including 
the NF-rB and MAPK pathways. The MAPK super-family of enzymes plays a key role 
in widespread signalling pathways and serves to co-ordinate key cellular processes such 
as cell proliferation and cell death. MAPKs have been classified into 3 subfamilies; the 
extracellular signal-regulated protein kinase (ERK) family, the c-jun N-terminal kinase 
(JNK) family and the p38 MAPK family. Several of the targets described above not 
only appear to regulate the NF-rcB pathway but also regulate the "K pathways. In 
particular, several targets appear to be involved in the JNK signalling pathway (see 
nil aDove); a pathway that ultimately activates the NF-KB pathway. 
The NF-YB pathway can be analysed further in these cell lines using the powerful 
technique of immuno fluorescence (EF) microscopy. IF exploits highly specific 
antibodies, which are labelled with a fluorescent dye. The antibodies capture their 
complementary antigens and, following excitation of the fluorescent dyes, cellular 
localisation can be determined. This technique would therefore allow the localisation of 
NF-r, B to be determined in both sensitive and resistant cells following treatment with 
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cisplatin or RT. It may be possible to observe a shift in staining intensity from the 
cytoplasm to the nucleus in the resistant cells, suggesting nuclear translocation and 
transcriptional activation. This technique would also allow the localisation of other 
targets to be deterrnined as it is possible that alterations in sub-cellular localisation 
(rather than differential expression) may also be responsible for resistance to therapy. 
Many signalling pathways, including the MAPK pathways, are initiated at the cell 
membrane as a result of extracellular signals. This often results in the recruitment of 
signalling molecules to the cell membrane leading to the subsequent initiation of a 
downstream signalling cascade. It is possible that signalling molecules can be 
effectively recruited to the cell membrane in sensitive cells. Unfortunately, such 
proteins would not be amenable to analysis by 2DE due to their increased 
hydrophobicity. However, the results from this thesis suggest that alterations in several 
cytoskeletal proteins may be associated with resistance to anticancer therapy. Thus, it is 
possible that the signalling molecules cannot be recruited to the cell membrane in 
resistant cells. As such, the signalling molecules would retain their nuclear localisation 
and would therefore be visible on 2D gels. It is also possible to abrogate the NF-KB and 
MAPK pathways in an attempt to restore sensitivity to anticancer therapy. Many small 
molecules are available for inhibition of the NF-KB pathway. Common molecules used 
for the inhibition of the NF-KB pathway are the proteasome inhibitors; lactacystin and 
Bortezimib (see section 6.4.7). Small molecules are also available for the inhibition of 
the MAPK pathways, e. g. PD 169316 and PD98059. Unfortunately, the targeting of such 
widespread signalling pathways may lead to a multitude of cellular effects. For 
example, exploiting proteasome inhibitors for the regulation of the NF-rB pathway may 
lead to the abrogation and/ or stimulation of several other pathways. This is because the 
26S proteasome is involved in the turnover of >80% of cellular proteins and inhibition 
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would alter the turnover of many other proteins in addition to IKB. As such, results from 
the use of these inhibitors would be difficult to interpret. 
10.2 Future Perspectives 
10.2.1 Unidentified Proteins 
The identities of some of the differentially expressed proteins that were recognised by 
2DE remain unknown. Thirteen proteins remained unidentified in the analysis of 
cisplatin resistance in human breast cancer cells (see chapter VI). Three proteins 
remained unidentified in the analysis of radiotherapy resistance in human breast cancer 
cells (see chapter VII). This may have been the result of co-migration or an inaccurate 
manual spot excision leading to the digestion and subsequent analysis of peptides from 
multiple proteins in addition to the POI. This issue can be addressed in the future by 
increasing the resolution of the 2DE technique. This can be achieved by using large 
fonnat gels (17cm or 24cm) and/or by using additional prefractionation strategies such 
as multiple overlapping narrow pH range IPG strips and/or subcellular fractionation 
prior to analysis. Alternatively, results from the optimisation procedure revealed that 
some proteins are simply not amenable to identification by PMF alone. The sequences 
of some of these unknown proteins may have had few specific sites for tryptic digestion 
thereby yielding a small number of peptides within the analysed mass range. On the 
other hand, some of these proteins may have been composed of regions with a high 
content of lysine and arginine residues. These proteins may have undergone extensive 
cleavage thereby yielding short peptides which were undetectable in the analysed mass 
range. Additional protease enzymes are available for use in proteomic analyses (e. g. 
Glu-C (V8 protease), Lys-C, Asp-N and chymotrypsin) and may prove useful for the 
subsequent analysis of those proteins unsuitable for tryptic digestion. In the future, these 
unknown proteins may also be analysed using MS/MS. This technique offers several 
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advantages over MALDI-TOF MS (see section 3.4.1.3) including being more suitable 
for the analysis of smaller quantities of proteins. Peptide sequences may also be 
obtained and therefore more confident assignments can be made providing that these 
proteins are present in the NCBInr protein database (see section 3.4.1.4). Thus, further 
proteins associated with resistance to anticancer therapy may be identified. 
10.2.2 The In- Vitro Functional Relevance 
Efforts are now underway to perfonn in-vitro functional studies (such as the use of 
RNA interference and phannacological. inhibitors) to detennine the functional relevance 
of the targets identified in this thesis. Targets will be selected for further studies based 
on a positive confirmatory result using an alternative technique (e. g. western blotting). 
In addition, those targets that were identified by several different techniques (e. g. 2DE- 
MALDI-TOF MS, western blotting, gene expression microarrays and RT-QPCR) or 
those involved in specific cellular pathways (see section 10.1) will be a priority. Targets 
identified by antibody microarrays will also be selected based on the degree of change 
in expression. Further work will also involve the confirmation of the remaining proteins 
(those not yet confinned) in order to generate additional targets for functional studies. 
Those targets for which there are no available antibodies may derive benefit from RT- 
QPCR analysis. This technique allows the expression levels of specific mRNA 
sequences to be determined, which may (or may not) correlate with protein expression. 
However, it is worth noting that those targets which fail to confirm using this method 
may be regulated post translationally and could therefore still prove 
important in the 
development of resistance to anticancer therapy. 
10.2.3 Clinical Samples 
This thesis has analysed novel chemotherapy and radiotherapy resistant cell 
lines. 
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Protein profiles were compared to identify candidate biomarkers associated with 
chemotherapy and/ or RT resistance. Despite problems associated with genetic 
divergence and variability cell lines remain a good in-vitro model for the initial 
identification and assessment of such biornarkers (Burdall et al. 2003). This is due to 
their ready availability, ease of culture and manipulation and their well characterised 
genotypes and phenotypes. Thus, future work will involve the analysis of further 
chemotherapy and/ or radiotherapy resistant cell lines. This will include not only 
additional breast cancer cell lines displaying significant resistance to anticancer therapy 
but also those cell lines originating from other tumour types. This will lead to an 
increased number of targets for prospective evaluation and complement the growing 
search for novel biomarkers associated with resistance to specific treatment modalities. 
However, although cell lines represent a good starting point, the results obtained do not 
always correlate with the in-vivo situation. This is because the microenvironment 
influences the behaviour of tumour cells and cultured cells are not subject to this 
influence. Multicellular spheroid models provide a more realistic three-dimensional in- 
vitro tumour model but the ultimate goal is the screening of clinical samples. 
Unfortunately, the proteomic analysis of primary tumour tissue or serum samples is 
associated with further technical problems. Tumours are heterogeneous in nature and 
may require microdissection. More replicates may also be required in order to draw 
conclusive results. Clinical tissue samples are often small (especially predictive pre- 
treatment biopsies) resulting in limited amounts of starting material for analysis. MS 
instruments are becoming increasingly more sensitive and this will allow smaller 
amounts of protein to be effectively analysed in the future. Recent advances in MS 
instrumentation have also allowed the direct analysis of tumour tissue (Schwartz et al. 
2005) and the identification of proteins from formalin-fixed, paraffin-embedded 
archival tumour samples (Crockett et al. 2005; Hood et al. 2005). Furthennore, clinical 
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investigations will require a more efficient sample collection and data accessibility and 
will also rely on the academic breast oncologist to produce the appropriate specimens 
for analysis. It is also unlikely that one single protein will provide a definitive prediction 
of treatment outcome in breast cancer because of the vast number of mechanisms by 
which response to treatment may be modulated. Therefore, global approaches are 
advantageous because they allow individual and/ or combinations of previously 
unknown proteins to be associated with particular disease phenotypes. However, it is 
unlikely that the proteomic techniques utilised in this thesis will be conducive as a 
routine tool for predicting response to treatment within the clinic. This is because the 
2DE-MS technique is inherently irreproducible and time-consuming to perform. At least 
weeks of experimentation is required prior to the identification of differentially 
expressed proteins. Complex analyses of the gel images are also required and days of 
spot-editing are needed before SOIs can be assigned. This is not practical in a clinical 
setting where rapid results are of utmost importance to allow the immediate 
implementation of the most appropriate treatment strategy. Likewise, high density 
antibody microarrays, (representing hundreds of targets) will also prove fruitless in the 
clinic due to the vast cost implications and complex data analyses required for data 
interpretation. As such it is more likely that a small panel of biomarkers will be the way 
forward for predicting clinical response to treatment because a small panel will provide 
a sufficient level of information whilst remaining simple, rapid and cost effective 
enough to be clinically feasible. hýfitial hunting studies with global approaches (e. g. 
2DE-MS, chapters VI and VII) will be necessary in order to identify the potential 
biomarkers for such small panels. These biomarkers may be subsequently printed upon 
a small custom antibody microarray (as described in chapter VIII), which would provide 
a simple and cheap tool for use within the clinic. Consequently, we are currently 
optimising custom antibody microarrays, within the laboratory in collaboration with the 
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York Technology Facility, University of York. Initial optimisation steps have involved 
the use of different antibodies at various concentrations, different printing buffers and 
different antibody microarray slides with varying surface chemistries. It is hoped that 
some of the targets identified in this thesis may contribute to such an antibody 
microarray; the feasibility of which will be tested in order to detennine whether 
treatment response may be predicted. The ultimate goal is the availability of customised 
antibody microarrays for each major tumour type (e. g. breast cancer), drug (e. g. 
cisplatin, doxorubicin), drug class (e. g. cross-linking agents, anthracyclines) and 
specific treatment modality (e. g. chemotherapy, RT). 
10.3 Conclusion 
In conclusion, resistance to anticancer therapy remains a major barrier to the successful 
treatment of breast cancer. This thesis has successfully established and optimised 
proteomic techniques and has generated a list of candidate biomarkers, which may be 
associated with resistance to anticancer therapy. Further work is now underway to 
detennine the functional relevance of these targets. The identification of novel 
biomarkers that correlate with treatment response would not only increase our 
understanding of resistance mechanisms but may also allow therapy to be tailored on an 
individual patient basis. Those patients unlikely to respond to a particular treatment 
strategy would be spared from the serious life-threatening side effects for no therapeutic 
gain. The immediate implementation of a more appropriate treatment strategy may also 
prevent disease progression. Such biomarkers would also suggest new drug targets 
and/or sensitising agents for future therapeutic intervention. Ultimately, overcoming 
resistance to both chemotherapy and radiotherapy would represent a major advance in 
the effective management of human breast cancer today. 
265 
References 
References 
Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. 
(1996) Specific P53 mutations are associated with de-novo resistance to doxorubicin in breast cancer 
patients. Nat. Med. 2(7); 811-814 
Afanassiev V, Hanemann V, Wolfl S. (2000). Preparation of DNA and protein micro arrays on glass 
slides coated with an agarose film. Nucleic Acids Res. 28(12); E66 
Albertson DG, Pinkel D. (2003). Genomic microarrays in human genetic disease and cancer. Human 
Molecular Genetics 12(2); R145-RI52 
Alfonso P, Nunez A, Madoz-Gurpide J, Lombardia L, Sanchez L, Casal JI. (2005). Proteomic expression 
analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 5(10); 2602- 
2611 
AlIal AS, Kahne T, Reverdin AK, Lippert H, Schlegel W, Reymond MA. (2004). Radioresistance-related 
proteins in rectal cancer. Proteomics 4(8); 2261-2269. 
Allen JD, Schinkel AH. (2002) Multidrug resistance and pharmacological protection mediated by the 
breast cancer resistance protein (BCRP/ ABCG2). Mol. Cancer Ther. 1; 427-434 
Alpy F, Tomasetto C. (2005). Give lipids a START: the StAR-related lipid transfer (START) domain in 
mammals. J Cell Sci. 118; 2791-2801 
Anderson JA. (1977) Lobular carcinoma in situ of the breast. An approach to rational treatment. Cancer 
39(6); 2597-2602 
Aplin AE, Howe A, Alahari SK, Juliano RL. (1998). Signal transduction and signal modulation by cell 
adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and 
selectins. Pharmacol. Rev. 50: 197-264 
Ariga N, Suzuki T, Morlya T, Kimura M, Inoue T, Ohuchi N, Sasano H. (2001) Progesterone receptor A 
and B isoforms in the human breast and its disorders. Jpn J Cancer Res. 92(3); 302-308 
Amesen T, Anderson D, Baldersheini C, Lanotte M, Varhaug JE, Lillehaug JR. (2005). Identification and 
characterization of the human ARDl-NATH protein acetyltransferase complex. Biochem. J. 386; 433-443 
Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kanipinga HH, Van der Zee AG. (1999). 
Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation to response to chemotherapy 
and prognosis. Int J Cancer 84(3): 234-238 
Asano K, Vornlocher HP, Richter-Cook NJ, Merrick WC, Hinnebusch AG, Hershey JW. (1997). 
Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits. Possible roles in RNA 
binding and macromolecular assembly. J Biol. Chem. 272(43); 27042-27052 
Avendano C, Menendez JC. (2002) Inhibitors of multidrug resistance to antiturnour agents (MDR). Curr. 
Med. Chem. 9(2); 159-193 
Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Kadcuri S, DuBois 
RN. (2005). 15-hydroxyprostaglandin dehygrogenase is down-regulated in colorectal cancer. J. Biol. 
Chem. 280(5): 3217-3223 
Bamberger AM, Milde-Langosch K, Schulte HM, Loning T. (2000) Progesterone receptor isoforms, PR- 
A and PR-B in breast cancer: correlations with clinicopathologic turnour parameters and expression of 
AP- I factors. Horm. Res. 54(l); 32-37 
Bannister AJ, Miska EA. (2000). Regulation of gene expression by transcription factor acetylation. CelL 
Mol. Life Sci. 57(8-9); 1184-1192 
266 
References 
Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, Berger SL. (2001). Acetylation 
of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. MoL Cell 
8(6); 1243-1254 
Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. (2001) The role of half-transporters in 
multidrug resistance. J. Bioenerg. Biomembr. 33(6); 503-511 
Beekman JM, Allan GF, Tsai SY, Tsai MJ, O'Malley BW. (1993) Transcriptional activation by the 
estrogen receptor requires a conformational change in the ligand binding domain. MoL Endocrinol. 7(10); 
1266-1274 
Benne R, Hershey JW. (1978). The mechanism of action of protein synthesis initiation factors from rabbit 
reticulocytes. J. Biol. Chem. 253(9); 3078-3087 
Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van 
Putten WL, Inganas M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn 
JG. (2000) Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast 
cancer. Cancer Res. 60; 2155-2162 
Berrieman HK, Cawkwell L, O'Kane SL, Smith L, Lind MJ. (2006) Hsp27 may allow prediction of 
response to single-agent vinorelbine chemotherapy in non-small cell lung cancer. Oncol Rep. 15(l); 283-6 
Beuckmann CT, Fujimori K, Urade Y, Hayaishi 0. (2000). Identification of mu-class glutathione, 
transferases M2-2 and M3-3 as cytosolic prostaglandin E synthases in the human brain. Neurochem. Res. 
25(5); 733-738 
Bjellqvist B, Ek K, Righetti PG, Gianazza E, Gorg A, Westermeier R, Postel W. (1982). Isoelectric 
focusing in immobilised pH gradients: Principle, methodology and some applications. J Biochem. 
Biophys. Methods 6; 317-339 
Bjorck E, Ek S, Landgren 0, Jerkeman M, Ehinger M, Bjorkholm M, Borrebaeck CA, Porwit-MacDonald 
A, Nordenskjold M. (2005). High expression of cyclin Bl predicts a favorable outcome in patients with 
follicular lymphorna. Blood 105(7); 2908-2915 
Block KL, Vornlocker HP, Hershey JWB. (1998). Characterisation of cDNAs encoding the p44 and p35 
subunits of human translation initiation factor eIF3. J BW Chem. 273(48); 31901-31908 
Boulton TG, Cobb MH. (1991). Identification of multiple extracellular signal-regulated kinases (ERKs) 
with antipeptide antibodies. Cell Regul. 2; 357-371 
Bournat JC, Brown AM, Soler AP. (2000). Wnt-1 dependent activation of survival factor NF-kappaB in 
PC12 cells. J Neurosci. Res. 61(l); 21-32 
Boyes J, Byfield P, Nakatani Y, Ogryzko V. (1998). Regulation of activity of the transcription factor 
GATA- 1 by acetylation. Nature 396(6711); 594-598 
Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Anal Biochem 72; 248-254 
Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast 
cancers in carriers of BRCAI or BRCA2tumours; and sporadic cases. The Lancet 349; 1505-1510 
Breitschopf K, Zeiher AM, Dirnmeler S. (2000). Ubiquitin-mediated degradation of the proapoptotic 
active form of bid. A functional consequence on apoptosis induction. J BioL Chem. 275(28): 21648-52 
Brennan M, Wilcken N, French J, Ung 0, Boyages J. (2005) Management of early breast cancer. Aust. 
Fam. Phys. 34(9); 755-759 
Britten RA, Kuny S, Perdue S. (1999) Modification of non-conservative double-strand break (DSB) 
rejoining activity after the induction of cisplatin resistance in human turnour cells. Br. J Cancer 79(5/6); 
843-849 
267 
References 
Brodin 0, Arnberg H, Bergh J, Nilsson S. (1995). Increased radioresistance of an in-vitro transformed 
human small cell lung cancer cell line. Lung Cancer 12; 183-198 
Burdall SE, Hanby AM, Lansdown MRJ, Speirs V. (2003). Breast cancer cell lines: friend or foe? Breast 
Cancer Res. 5; 89-95 
Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JGM, Wierner EAC, Stoter G, Nooter K. 
(2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug 
resistance-associated proteins I and 2, and multidrug resistance gene 1 in breast cancer: correlation with 
chemotherapeutic response. Clin. Cancer. Res. 9; 827-836 
Buzdar AU, Hortobagyi G. (1998) Update on endocrine therapy for breast cancer Clin. Cancer Res. 4; 
527-534 
Capano M, Virji S, Cromptom M. (2002). Cyclophilin A is involved in excitotoxin-induced caspase 
activation in rat neuronal B50 cells. Biochem. J 363: 29-36 
Caprioli RM. (2005). Deciphering protein molecular signatures in cancer tissues to aid in diagnosis, 
prognosis, and therapy. Cancer Res. 65; 10642-5. 
Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. (2002) Mechanisms of growth arrest by c-myc 
antisense oligonucleotides in MCF7 breast cancer cells: implications for the antiproliferative effects of 
antiestrogens. Cancer Res. 62; 3126-3131 
Cary RB, Peterson SR, Wang J, Bear DG, Bradbury EM, Chen DJ. (1997) DNA looping by ku and the 
DNA-dependent protein kinase. Proc. NatI. Acad Sci. USA 94; 4267-4272 
Caulin C, Ware CF, Magin TM, Oshima RG. (2000) Keratin-dependent, epithelial resistance to tumour 
necrosis factor-induced apoptosis. J. Cell Biol. 149(l); 17-22 
Chauhan D, Hideshima T, Anderson KC. (2005). Proteasome inhibition in multiple myeloma: therapeutic 
implication. Annu Rev Pharmacol Toxicol 45: 465-476 
Chehal A, Taher A, Khalil M, Shameseddine A. (2004). Cisplatin plus vinorelbine (PVn) as a salvage 
regimen for reEractory breast cancer. The Breast 13: 421-424 
Chevillard S, Lebeau J, Pouillart P, de Toma C, Beldjord C, Asselain B, Klijanienko J, Fourquet A, 
Magdelenat H, Vielh P. (1997) Biological and clinical significance of concurrent p53 gene alterations, 
MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary 
chemotherapy or radiotherapy. Clin. Cancer Res. 3; 2471-2478 
Cho Y, Gorina S, Jeffrey PD, Pavletich NP. (1994) Crystal structure of a p53 tumour-suppressor-DNA 
complex: understanding tumorigenic mutations. Science 265; 346-355 
Cho HN, Lee YJ, Cho CK, Lee SJ, Lee YS. (2002). Downregulation of ERK2 is essential for the 
inhibition of radation-induced cell death in HSP25 overexpressed L929 cells. Cell Death Diff 9: 448456 
Choi Y, Pinto M (2005). Estrogen receptor 0 in breast cancer: associations between ERP, hormonal 
receptors, and other prognostic biomarkers. Appl. Immunohistochem. Mol. Morphol. 13(l); 19-24 
Christian MC, McCabe MS, Kom EL, Abrams JS, Kaplan RS, Friedman MA. (1995) The National 
Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. N. 
EngL J Med. 333; 1469-1474 
Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ. (2001). Increased expression of peroxiredoxin 11 
confers resistance to cisplatin. Anticancer Res. 21(2A): 1129-1133 
Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, 
Sahmoud TM, van de Vijver MJ. (1998). p53 protein accumulation and response to adjuvant 
chemotherapy in premenopausal women with node-negative early 
breast cancer. J Clin. Oncol. 16(2); 
470-479 
268 
References 
Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson 
PA, Chilton FH. (1999). Influence of J series prostaglandins; on apoptosis and tumorigenesis of breast 
cancer cells. Carcinogenesis 20(10); 1905-1911 
Cobb MH. (1999). MAP kinase pathways. Prog. Biophys. Mol. Biol. 71; 479-500 
Condon LT, Ashman JN, Ell SP, Stafford ND, Greenman J, Cawkwell L. (2002). Overexpression of Bcl- 
2 in squamous cell carcinoma of the larynx: a marker of radioresistance. Int. J Cancer 100(4); 472-5 
Cory S, Adams KM. (2002) The bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. 
Cancer 2(9); 647-656 
Couture C, Raybaud-Diogene H, Tetu B, Bairati I, Murry D, Allard J, Fortin A. (2002) p53 and ki-67 as 
markers of radioresistance in head and neck carcinoma. Cancer 94; 713-722 
Crockett DK, Lin Z, Vaughn CP, Lim MS, ElenitobaJohnson KS. (2005). Identification of proteins from 
formalin-fixed paraffin-embedded cells by LC-MS/MS. Lab Invest. 85; 1405-15. 
Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr. (2001). Enhanced 
chemo sensitivity to CPT- 11 with proteasome inhibitor PS-34 1: implications for systemic nuclear factor- 
kappaB, inhibition. Cancer Res. 61(9); 3535-3540 
Dalton WS. (2004). The proteasome. Semin. Oncol. 31; 3-9 
Das S, Maiti T, Das K, Maitra U. (1997). Specific interaction of eukaryotic translation initiation factor 5 
(eIF5) with the beta-subunit of eIF2. J Biol. Chem. 272(50); 31712-31718 
Davidson SD, Cherry JP, Choudhury MS, Tazaki H, Mallouh C, Konno S. (1999). Glyoxalase I activity 
in human prostate cancer: a potential marker and importance in chemotherapy. J. UroL 161(2); 690-691 
De Brouwer AP, Westerman J, Kleinnijenhuis A, Bevers LE, Roelofsen B, Wirtz KW. (2002). Clofibrate- 
induced relocation of phosphatidy1choline transfer protein to mitochondria in endothelial cells. Exp. Cell 
Res. 274(l); 100- 111 
Delanote V, Vandekerckhove J, Gettemans J. (2005). Plastins: versatile modulators of actin organisation 
in (patho)physiological cellular processes. Acta Pharmacol. Sin. 26(7); 769-779 
Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. (2000) Cisplatin resistance and oncogenes -a 
review. Anticancer Drugs 11(4); 225-236 
De Placido S, De Laurentiis M, Carlornagno, C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, 
Pagliarulo C, Panico L, Pettinato G, Petrella G, Bianco AR. (2003) Twenty-year results of the Naples 
GUN randornised trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin. 
Cancer Res. 9; 1039-1046 
Di Ilio C, Angelucci S, Pennelli A, Zezza A, Tenaglia R, Sacchetta P. (1995). Glyoxalase activities in 
tumor and non-tumor human urogenital tissues. Cancer Lett. 96(2); 189-193 
Ding Y, Tong M, Liu S, Moscow JA, Tai HE (2005). NAD+-Iinked 15-hydroxyprostaglandin 
dehydrogenase (I 5-PGDH) behaves as a turnour suppressor in lung cancer. Carcinogenesis 26(l): 65-72 
Dirven HAAM, van Ommen B, van Bladeren PJ. (1994) Involvement of human glutathione-s-transferase 
isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 54; 6215- 
6220 
Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. (2005). Early prediction of 
response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl. Med 
46(7); 1144-1150 
Doyle LA. Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. (1998) A multidrug 
resistance transporter from human MCF-7 breast cancer cells. Proc. Nad. Acad Sci. USA 
95; 15665- 
15670 
269 
References 
Doyle LA, Ross DD. (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP 
(ABCG2). Oncogene 22(47); 7340-7358 
Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV. (2005). Description of paclitaxel resistance- 
associated genes in ovarian and breast cancer cell lines. Cancer Chemother. Pharmacol. 55(3); 277-285 
Duell EJ, Millikan RC, Pittman GS, Winkel S, Lunn RM, Tse CK, Eaton A, Mohrenweiser HW, Newman 
B, Bell DA. (2001) Polymorphisms in the DNA repair gene XRM and breast cancer. Cancer 
Epidemiol. Biomarkers Prev. 10; 217-222 
Dun-ýitrescu RG, Cotarla 1. (2005) Understanding breast cancer risk - where do we stand in 2005? J CeIL MoL Med. 9(l); 208-221 
Dunn MJ, Gorg A. (2001). Two-dimensional gel electrophoresis for proteome analysis. In Proteomics: 
From Protein sequence to junction. (Pennington SR, Dunn MJ, Ed). BIOS Scientific Publishers Limited, 
Oxford, UK; 43-63 
Duraker N, Caynak ZC. (2005) Prognostic value of the 2002 TNM classification for breast carcinoma 
with regard to the number of metastatic axillary lymph nodes. Cancer 104; 700-707 
Durand S, Angeletti S, Genti-Raimondi S. (2004). GTTI/StarD7, a novel phosphatidylchohne transfer 
protein-like highly expressed in gestational trophoblastic turnour: cloning and characterization. Placenta 
25(l); 37-44 
Dykxhoom DM, Novina, CD, Sharp PA. (2003). Killing the messenger: short RNAs that silence gene 
expression. Nat. Rev. MoL Cell BioL 4; 457-467 
Early Breast Cancer Trialists Collaborative Group. (2000). Favourable and unfavourable effects on long- 
term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355; 
1757-1770 
Elston CW, Ellis 10. (1991) Pathological prognostic factors in breast cancer. I. The value of histological 
grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5); 
403-410 
Emi M, Kim R, Tanabe K, Uchida Y, Toge T. (2005) Targeted therapy against B62-related proteins in 
breast cancer cells. Br. Cancer Res. 7; R940-R952 
Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, 
Repasky EA, Gabrielson E, Schutte, M, Baylin SB, Herman JG. (2000) Promoter hypermethylation and 
BRCA 1 inactivation in sporadic breast and ovarian tumours. J NatI. Cancer Inst. 92; 564-5 69 
Faneyte IF, Kristel PMP, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JIB4, van de Vijver MJ. 
(2002) Expression of the breast cancer resistance protein in breast cancer. Clin. Cancer Res. 8; 1068-1074 
Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D. (2001) Resistance to topoisomerase 
poisons due to loss of DNA mismatch repair. Int. J. Cancer 93(4); 571-576 
Filipits M, Malayeri R, Suchomel RW, Pohl G, Stranzl T, Dekan G, Kaider A, Stiglbauer W, Depisch D, 
Pirker R. (1999) Expression of multidrug resistance protein (MRPI) in breast cancer. Anticancer Res, 
19(6B); 5043-5049 
Finkel T. (1998). Oxygen radicals and signalling. Curr Opin Cell Biol. 10: 248-253 
Foley EF, Jazaeri AA, Shupnik MA, Jazaeri 0, Rice LW. (2000). Selective loss of estrogen receptor 0 in 
malignant human colon. Cancer Res. 60; 245-248 
Fotedar R, Flatt J, Gupta S, Margolis RL, Fitzgerald P, Messier H, Fotedar A. (1995). Activation-induced 
T-cell death is cell cycle dependent and regulated by cychn B. Mol Cell Biol. 15(2): 932-942 
270 
References 
Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM. (2004). Proteomic 
analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass 
spectrometry. Proteomics 4(3); 793-811 
Frit P, Canitrot Y, Muller C, Foray N, Calsou P, Marangoni E, Bourhis J, Salles B. (1999) Cross- 
resistance to ionising radiation in a murine leukaernic cell line resistant to cis-dichlorodiammineplatinum (11): role of Ku autoantigen. MoL Pharmacol. 56; 141-146 
Fu Z, Fenselau C. (2005). Proteornic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase 
in drug-resistance. J Proteome Res. 4(5): 1583-1591 
Fuentes H, Calderillo G, Alexander F, Ramirez M, Avila E, Perez L, AgunTe G, Onate-Ocana LF, 
Gallardo D, Otero J. (2006). Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. 
Anticancer Drugs 17(5); 565-570 
Fujii K, Nakano T, Kanazawa M, Akimoto S, Hirano T, Kato H, Nishimura T. (2005). Clinical-scale 
high-throughput human plasma proteome analysis: lung adenocarcinoma. Proteomics. 5; 1150-9. 
Galper S, Recht A, Silver B, Bernardo MV, Geh-nan R, Wong J, Schnitt SJ, Connolly JL, Harris JR. 
(2000). Is radiation alone adequate treatment to the axilla for patients with limited axillary surgery? 
Implications for treatment after a positive sentinel node biopsy. Int. J. Radiat. Oncol. BioL Phys. 48(l); 
125-132 
Gao CY, Zelenka PS. (1995). Induction of cyclin B and HI kinase activity in apoptotic PC12 cells. Exp 
Cell Res 219(2): 612-618 
Garfin DE. (2003). Two-dimensional gel electrophoresis: an overview. Trends in Analytical ChemistrY 
22(5); 263-272 
Ge H. (2000). UPA, a universal protein array system for quantitative detection of protein-protein, protein- 
DNA, protein-RNA and protein-ligand interactions. Nucleic Acids Res. 28; E3 
Gehrmann ML, Fenselau C, Hathout Y. (2004)a. Highly altered protein expression profile in the 
adriamycin resistant MCF7 cell line. J Proteome Res. 3; 403-409 
Gehrmann ML, Hathout Y, Fenselau C. (2004)b. Evaluation of metabolic labelling for comparative 
proteornics in breast cancer cells. J Proteome Res. 3(5); 1063-1068 
Geisler S, Lonning PE, Aas T, Johnsen H, Fluge 0, Haugen DF, Lillehaug JP, Akslen LA, Borresen-Dale 
AL. (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with 
doxorubicin in locally advanced breast cancer. Cancer Res. 61; 2505-2512 
Ghobrial IM, McCormick DJ, Kauftnann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, 
Stenson MJ, Melhem MF, Novak AJ, Ansell. SM, Witzig TE. (2005). Proteomic analysis of mantle-cell 
lymphoma. by protein microarray. Blood 105; 3722-3730 
Globocan (2002). LTRL: www-dep. iarc. frlglobocanldatabase. htm [Accessed on 18.08.06] 
Glozak MA, Rogers MB. (2001). Retinoic acid- and bone morphogenetic protein 4-induced apoptosis in 
P 19 embryonal carcinoma cells requires p27. Exp Cell Res. 268(2): 128-13 8 
Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, 
Buzdar AU, Hortobagyi GN, Arun B. (2005) Women age : 53 5 years with primary breast cancer. Cancer 
103; 2466-2472 
Gorg A, Obermaier C, Boguth G, Harder A, Schreibe B, Wildgruber R. Weiss W. (2000). The current 
state of two-dimensional electrophoresis with inimobilised pH gradients. Electrophoresis 21; 1037-1053 
Gorg A, Boguth G, Drews 0, Kopf A, Luck C, Reil G, Weiss W. (2003). Two-dimensional 
electrophoresis with immobilised pH gradients for proteorne analysis. URL: 
www. weihenstephan-delblmldegl2D-ManuaLpdf [Accessed on 29.03.06] 
271 
References 
Graves PR, Haystead TAJ. (2002). Molecular Biologist's guide to proteon-&s. MicrobioL MoL BioL Rev. 
66(l); 39-63 
Graves PR, Haystead TAJ (2003). Proteomics and the molecular biologist. In Handbook of Proteomic Methods (Conn PM, Ed. ) Humana Press Inc, Totowa, New Jersey: 3-17 
Gu S, Liu Z, Pan S, Jiang Z, Lu H, Amit 0. (2004). Global investigation of p53-induced apoptosis 
through quantitative proteomic profiling using comparative amino acid-coded tagging. MoL Cell 
Proteomics 3(10); 998-1008 
Guo JY, Xu J, Mao Q, Fu LL, Gu JR, De Zhu 1 (2002). The promoter analysis of the human C17orf25 
gene, a novel chromosome 17pl3.3 gene. Cell. Res. 12(5-6); 339-352 
Gupta VK, Jaskowiak NT, Beckett MA, Mauceri HJ, Grunstein J, Johnson RS, Calvin DA, Nodzenski E, 
Pejovic M, Kufe DW, Posner MC, Weichselbaum RR. (2002). Vascular endothelial growth factor 
enhances endothelial cell survival and tumor radioresistance. Cancer J 8(l); 47-54 
Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. (1999). Quantitative analysis of complex 
protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17(10); 994-9. 
Haab BB. (2003). Methods and applications of antibody microarrays in cancer research. Proteomics 
3(l 1); 2116-2122 
Haab BB, Dunham MJ, Brown PO. (2001). Protein microarrays for highly parallel detection and 
quantitation of specific proteins and antibodies in complex solutions. Genome BioL 2(2); 0004.1-0004.13. 
Hanna E, Schrieve DC, Ratanatharathorn V, Xia X, Breau R, Suen J, Li S. (2001). A novel alternative 
approach for prediction of radiation response of squamous cell carcinoma of the head and neck. Cancer 
Res. 61(6); 2376-2380 
Harris Al, Hochhauser D. (1992) Mechanisms of multidrug resistance in cancer treatment. Acta. Oncol. 
31(2); 205-213 
Hathout Y, Riordan K, Gehrmann M, Fenselau C. (2002). Differential protein expression in the cytosol 
fraction of an MCF-7 breast cancer cell line selected for resistance to melphalan. J. Proteome Res. 1(5); 
435-442 
Haupt Y, Maya R, Kazaz A, Oren M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 
387(6630): 296-299 
Hayes JD, Pulford DJ. (1995). The glutathione s-transferase supergene family: regulation of GST and the 
contribution of the isoenzymes to cancer chernoprotection and drug resistance. Crit. Rev. Biochem. Mol. 
Biol. 30(6); 445-600 
Hegde P, Qi R, Abernathy K, Gay C, Dharap S, Gaspard R, Hughes JE, Snesrud E, Lee N, Quackenbush 
J. (2000). A concise guide to cDNA microarray analysis. Biotechniques 29(3); 548-550 
Hennessy BT, Pusztai L. (2005) Adjuvant therapy for breast cancer. Minerva Ginecol. 57(3); 305-326 
Herbert BR. (1999). Advances in protein solubilisation for two dimensional electrophoresis. 
Electrophoresis 20; 660-663 
Herbert BR, Galvani M, Hamdan M, Olivieri E, MacCarthy J, Pederson S, Righetti PG. (2001). 
Reduction and alkylation of proteins in preparation of two-dimensional map analysis: why, when and 
how? Electrophoresis 22; 2046-2057 
Herbomel P, Ninio J. (1980). Fidelity of a polymerization reaction according to the proximity to 
equilibrium. C. R. Seances Acad. Sci. D. 291(11); 881-884 
Hettinga JV, Lemstra W, Meijer C, Los G, de Vries EG, Konings AW, Kampinga HH. (1996). Heat- 
shock protein expression in cisplatin-sensitive and -resistant human turnour cells. Int. 
J Cancer 67(6); 
800-807 
272 
References 
Hewitt SC, Harrell JC, Korach KS. (2005) Lessons in estrogen biology from knockout and transgenic 
animals. Annu. Rev. Physiol. 67; 285 
Hilf R, Savlov ED, Rector WD, Wittliff JL. (1976). Relationship of glycolytic enzyme activities and 
response of breast cancer patients to chemotherapy: a preliminary report. Cancer 38(2): 695-700 
Hirano T, Kato H, Maeda M, Gong Y, Shou Y, Nakamura M, Maeda J, Yashima K, Kato Y, Akimoto S, 
Ohira T, Tsuboi M, Ikeda N. (2005). Identification of postoperative adjuvant chemotherapy responders in 
non-small cell lung cancer by novel biomarker. Int J Cancer 117(3): 460-468 
Hoch, strasser DF, Sanchez JC, Appel RD. (2002). Proteornics and its trends facing nature's complexity. Proteomics 2(7); 807-812 
Hofmann WA, StojiIjkovic L, Fuchsova B, Vargas GM, Mavrommatis E, Philimonenko V, Kysela K, 
Goodrich JA, Lessard JL, Hope TJ, Hozak P, de Lanerolle P. (2004). Actin is part of pre-initiation 
complexes and is necessary for transcription by RNA polymerase II. Nat. Cell Biol. 6(11); 1094-1101 
Holcik M, Gordon BW, Korneluk RG. (2003). The internal ribosome entry site-mediated translation of 
antiapoptotic protein XIAP is modulated by the heterogeneous nuclear ribonucleoproteins CI and C2. 
Mol Cell Biol 23(l): 280-288 
Hollstein M, Sidransky D, Vogelstein B, Harris CC. (1991) p53 mutations in human cancers. Science 
253; 49-53 
Holm C. (1994) Coming undone: how to untangle a chromosome. Cell 77; 955-957 
Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, Kikuchi S, Endo M, Tsuchida A, Aoki T, Itoi T, 
Moriyasu F, Hirohashi S, Yamada T. (2005). Possible detection of pancreatic cancer by plasma protein 
profiling. Cancer Res. 65; 10613-22. 
Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, Sesterhenn IA, Conrads TP, 
Veenstra TD, Krizman DB. (2005). Proteornic analysis of formalin-fixed prostate cancer tissue. Mol Cell 
Proteomics. 4; 1741-53. 
Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SAW. (2004). Low levels of estrogen receptor 
P protein predict resistance to tamoxifen therapy in breast cancer. Clin. Cancer Res. 10; 7490-7599 
Hou CL, Tang C, Roffler SR, Tang TK. (2000). Protein 4.1R binding to eIF3-p44 suggests an interaction 
between the cytoskeletal network and the translation apparatus. Blood 96(2); 747-753 
Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case DL. (2001) Amino acid substitution 
variants of APEI and XRCCI genes associated with ionising radiation sensitivity. Carcinogenesis 22(6); 
917-922 
Hu P, Wu S, Hernandez N. (2004). A role for beta-actin in RNA polymerase III transcription. Genes Dev. 
18(24); 3010-3015 
Hu Y, Benedict MA, Wu D, Inohara, N, Nunez G. (1998) Bcl-xL interacts with Apaf-l and inhibits Apaf- 
1 -dependent caspase-9 activation. Proc. NatI. Acad Sci. USA 95; 4386-4391 
Hu ZB, Minden MD, McCulloch EA. (2000). Regulation of drug sensitivity by ribosomal protein S3a. 
Blood 95(3): 1047-1055 
Huang H, Joazeiro CA, Bonfocco E, Kamada S, Leverson JD, Hunter T. (2000). The inhibitor of 
apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of 
caspase 3 and 7. JBiol Chem. 275(35): 26661-4 
Hudis C. (2005) The best use of adjuvant chemotherapy: new drugs and the new use of old drugs. The 
Breast 14; 570-575 
273 
References 
Hurley J, Doliny P, Reis 1, Silva 0, Gomez-Fernandez C. Velez P, Pauletti G, Pegram MD, Slamon DJ. 
(2006). Docetaxel, cisplatin and trastuzumab as primary systemic therapy for human epidermal growth 
factor receptor 2-positive locally advanced breast cancer. J Clin. Oncol. 24(12); 1831-1838 
Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H. (1995). Lactacystin, a 
specific inhibitor of the protesome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. 
Res. Commun. 217(3); 1070-1077 
Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido, M, Saijo N. (1998). Preferential binding 
of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines. Jpn J 
Cancer Res 89(9): 954-962 
Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S. (2000). Quantitative analysis of estrogen receptor- 
beta mRNA and its variants in human breast cancers. Int. J Cancer 88(5); 733-736 
Jameel JKA, Rao VSR,, Cawkwell L, Drew PJ. (2004). Radioresistance in carcinoma of the breast. The 
Breast 13; 452-460 
Jelinsky SA, Estep P, Church GM, Samson LD. (2000). Regulatory networks revealed by transcriptional 
profiling of damaged Saccharomyces cerevisiae cells: Rpn4 links base excision repair with proteasomes. 
MoL Cell. Biol. 20(21); 8157-8167 
Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW. 
(2002). Regulation and destabilization of HIF- 1 alpha by ARD I -mediated acetylation. Cell 111; 709-720 
Jha MK, Avlonitis VS, Griffith CD, Lennard TW, Wilson RG, McLean LM, Dawes PD, Shrimankar J. 
(2001). Aggressive local treatment for screen-detected DCIS results in very low rates of recurrence. Eur. 
J Surg. OncoL 27; 454-458 
Kang HC, Kim IJ, Park JH, Shin Y, Ju JL, Jung MS, Yoo BC, Kim HK, Park JG. (2004). Identification of 
genes with differential expression in acquired drug-resistant gastric cancer cells using high-denisty 
oligonucleotide microarrays. Clin. Cancer Res. 10; 272-284 
Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. (1998). Mammalian peroxiredoxin isoforms 
can reduce hydrogen peroxide generated in response to growth factors and tumour necrosis factor-a. J 
Biol Chem 273: 6297-6302 
Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y. (2001) 
Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn. J Cancer Res. 
92(4); 452-458 
Karin M, Ben-Nariah Y. (2000). Phosphorylation meets ubiquitination: the control of NF-[kappa]B 
activity. Annu Rev Immunol 18: 621-663 
Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronerneyer H, Chambon P. (1990) Two distinct 
estrogen-regulated promoters generate transcripts encoding the two functionally different human 
progesterone receptor isoforms, A and B. EMBO J 9(5); 1603-1614 
Katabami M, Fujita H, Honke K, Makita A, Akita H, Miyamoto H, Kawakami Y, Kuzumaki N. (1993). 
Marked reduction of type I keratin (K14) in cisplatin-resistant human lung squarnous-carcinoma cell 
lines. Biochem Pharmacol. 45(8): 1703-17 10 
Kearns PR, Chrzanowska-Lightowlers ZMA, Pieters F, Veerman A, Hall AG. (2003). Mu class 
glutathione S-transferase mRNA isoform expression in acute lyniphoblastic leukaemia. Br J Haematol. 
120: 80-88 
Keen JC, Davidson NE. (2003) The biology of breast carcinoma. Cancer 97(3 Suppl); 825-833 
Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. (199 1) Identification of 
p53 as a sequence- specific DNA-binding protein. Science 252; 1708-1711 
274 
References 
Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. (1992) Oncogenic forms 
of p53 inhibit p53-regulated gene expression. Science 256; 827-830 
Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A. (2002) Waf-1 (P2 I) and p53 polymorphisnis 
in breast cancer. Cancer Epidemiol. Biomarkers Prev. 11; 127-130 
Khan S, van den Broek M, Schwarz K, de Giuli R, Diener PA, Groettrup M. (2001). Immunoproteasomes 
largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the 
liver. J. Immunol. 167(12); 6859-6868 
Khanna N, Sen S, Sharma H, Singh N. (2003). S29 ribosomal protein induces apoptosis in H520 cells and 
sensitizes them to chemotherapy. Biochem Biophys Res Commun. 304: 26-35 
Khil MS, Kim SH, Pinto JT, Kim JH. (1996). Ethacrynic acid: a novel radiation enhancer in human 
carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. 34(2); 375-380 
Khokhlatchev A, Xu S, English J, Wu P, Schaefer E, Cobb MIH. (1997). Reconstitution of rrýitogen- 
activated protein kinase phosphorylation cascades in bacteria. J BioL Chem 272: 11057-11062 
Kim CH, Park SJ, Lee SH. (2002) A targeted inhibition of DNA-dependent protein kinase sensitises 
breast cancer cells following ionising radiation. J Pharmacol. Exp. Ther. 303; 753-759 
King RJ13. (2000) Growth: a balance of cell proliferation, death and differentiation. In Cancer Biology, 
2 nd Edition. Pearson Education, Harlow, UK; 146-173 
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, 
Wickerham L, Wolmark N, Fisher B. (2001) Tamoxifen and breast cancer incidence among women with 
inherited mutations in BRCAI and BRCA2. JAMA 286; 2251-2256 
Knudson AG, Jr. (1987) A two mutation model for human cancer. Adv. ViraL Oncol. 27; 1-17 
Konishi Y, Lehtinen M, Donovan N, Bonni A. (2002). Cdc2 phosphorylation of BAD links the cell cycle 
to the cell death machinery. Mol Cell 9(5): 1005-1016 
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, 
Sauter G, Kallioniemi OP. (1998). Tissue n-licroarrays for high-throughput molecular profiling of turnour 
specimens. Nat. Med. 4(7); 844-847 
Kouzarides T. (2000). Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19(6); 
1176-1179 
Kukar T, Eckenrode S, Gu Y, Lian W, Megginson M, She JX, Wu D. (2002). Protein microarrays to 
detect protein-protein interactions using red and green fluorescent proteins. Anal. Biochem. 306(l); 50-54 
Kunz-, Schughart LA, Freyer JP, Hofstaedter F, Ebner R. (2004). The use of 3-D cultures for high- 
throughput screening: the multicellular spheroid model. JBiomol Screen 9; 273-85. 
Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P. (2000) Estrogen receptor 
pathways to AP- 1. J. Steroid Biochem. Mol. Biol. 74; 311-317 
Kusnezow W, Hoheisel JD. (2003). Soldis supports for microarray immunoassays. J Mol. Recognit. 16; 
165-176 
Kusnezow W, Jacob A, Walijew A, Diehl F, Hoheisel JD. (2003) Antibody microarrays: an evaluation of 
production parameters. Proteomics 3(3): 254-64. 
Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J, Baggetto LG. (2004). New invMED I element cis- 
activates human multidrug-related MDRI and MVP genes, involving the LRP130 protein. 
Nucleic Acids 
Res. 32(13); 3864-3876 
Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. (2001). ERP inhibits proliferation and invasion 
of breast cancer cells. EndocrinoL 142; 4120-4130 
275 
References 
Leavitt J. (1994). Discovery and characterization of two novel human cancer-related proteins using two- dimensional gel electrophoresis. Electrophoresis 15(3-4); 345-357 
Lee SH, Kim CH. (2002) DNA-dependent protein kinase complex: a multifunctional protein in DNA 
repair and damage checkpoint. Mol. Cells 13(2); 159-166 
Lee YN, Nechushtan H, Figov N, Razin E. (2004). The function of lysyl-tRNA synthetase and Ap4A as 
signaling regulators of MITF activity in FcepsilonRI-activated mast cells. Immunity 20; 145-151 
Lee YN, Razin E. (2005). Nonconventional involvement of LysRS in the molecular mechanism of USF2 
transcriptional activity in FcepsilonRI-activated mast cells. MoL Cell. Bid 25(20); 8904-8912 
Leonessa F, Clarke R. (2003) ATP binding cassette transporters and drug resistance in breast cancer. 
Endocr. Relat. Cancer 10; 43-73 
Levy E, Baroche C, Barret JM, Alapetite C, Salles B, Averbeck D, Moustacchi E. (1994) Activated ras 
oncogenes and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction 
of DNA cross-links and their repair. Carcinogenesis 15(5); 845-850 
Li B, Dou QP. (2000). Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in 
tumour survival and progression. Proc. NatI. Acod Sci. USA 97(11): 3850-3855 
Li Z, Stanelle J, Leurs C, Hanenberg H, Putzer BM. (2005). Selection of novel mediators of E2Fl- 
induced apoptosis through retroviral expression of an antisense cDNA library. Nucleic Acids Res. 33(9); 
2813-21 
Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan Z. (2003). Targeting the 
phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. MoL Cancer 
Ther. 2(4); 353-360 
Lieber MR, Grawunder U, Wu X, Yaneva M. (1997) Tying loose ends: roles of Ku and DNA-dependent 
protein kinase in the repair of double-strand breaks. Curr. Opin. Genet. Dev. 7(l); 99-104 
Liebler DC. (2002). Protein digestion techniques. In Introduction to Proteomics (Liebler DC, Ed. ). 
Humana Press, Totowa, NJ; 49-54 
Lilley KS, Razzaq A, Dupree P. (2002). Two-dimensional gel electrophoresis: recent advances in sample 
preparation, detection and quantitation. Curr. Opin. Chem. Biol. 6; 46-50 
Lin L, Holbro T, Alonso G, Gerosa D, Burger MM. (2001). Molecular interaction between human tumor 
marker protein p 150, the largest subunit of eIF3, and intermediate filament protein K7. J Cell Biochem. 
80(4); 483-490 
Ling YH, EI-Naggar AK, Priebe W, Perez-Soler R. (1996). Cell cycle-dependent cytotoxicity, G2/m 
phase arrest, and disruption of p34 ldc2/CyClin B1 activity induced by doxorubicin in synchronised P388 
cells. MoL Pharmacol. 49; 832-841 
Liu QY, Lei JX, LeBlanc J, Sodja C, Ly D, Charlebois C, Walker PR, Yamada T, Hirohashi S, Sikorska 
M. (2004). Regulation of DNaseY activity by actinin-alpha4 during apoptosis. Cell Death Diff. 11(6); 
645-654 
Liu Y, Liu H, Han B, Zhang JT. (2006). Identification of 14-3-3(y as a contributor to drug resistance in 
human breast cancer cells using functional proteomic analysis. Cancer Res. 66(6); 3248-3255 
Lowe SW, Ruley HE, Jacks T, Housman DE. (1993) p53-dependent apoptosis modulates the cytoxicity of 
anticancer agents. Cell 74(6); 957-967 
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. (1994) 
p5 3 status and the efficacy of cancer therapy in vivo. Science 266; 807-8 10 
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the folin phenol 
reagent. J. BioL Chem. 193; 265-275 
276 
References 
Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. (1998) Bid, a bcl2 interacting protein, mediates 
cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94; 481-490 
Mallon E, Osin P, Nasiri N, Blain 1, Howard B, Gusterson B. (2000). The basic pathology of human breast cancer. J Mammary Gland Biol Neoplasia 5(2); 139-163 
Malmstrom P, Holmberg L, Anderson H, Mattsson J, Jonsson PE, Tennvall-Nittby L, Balldin G, Loven 
L, Svensson JH, Ingvar C, Moller T, Holmberg E, Wallgren A; Swedish Breast Cancer Group. (2003). 
Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast 
cancer: a randomised clinical trial in a population with access to public mammography screening. Eur. J Cancer 39(12); 1690-1697 
Mandic R, Schamberger CJ, Muller JF, Geyer M, Zhu L, Carey TE, Grenman R, Dunne AA, Werner JA. 
(2005) Reduced cisplatin sensitivity of head and neck squarnous cell carcinoma cell lines correlates with 
mutations affecting the COOH-terminal nuclear localisation signal of p53. Clin. Cancer Res. 11; 6845- 
6852 
Mann CJ, Stephens SK, Burke JF. (2004). Production of protein microarrays. In Protein Microarray 
Technology (Kambhampati D, Ed). Wiley-VCH Verlag GmbH & Co KGaA, Weinheim, Germany; 165- 
194 
Mao Q, Unadkat JD. (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. 
AAPS J. 7(l); EI 18-E 133 
Marshansky V, Wang X, Bertrand R, Luo H, Duguid W, Chinnadurai G, Kanaan N, Vu MD, Wu J. 
(2001). Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and 
compromise functioning of the electron transport chain in leukaemia cells. J Immunol 166(5): 3130-3142 
Martin M. (2001). Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 
2(3): 190-208 
Martinis SA, Plateau P, Cavarelli J, Florentz C. (1999). Aminoacyl-tRNA synthetases: a family of 
expanding functions. Mittelwihr, France, October 10- 15,1999. EMBO J. 18(17); 4591-4596 
Matsuzawa SI, Reed JC. (200 1). Siah- 1, SIP, and Ebi collaborate in a novel pathway for beta-catenin 
degradation linked to p53 responses. MoL Cell 7(5); 915-926 
Mayeur GL, Hershey VVB. (2002). Malignant transformation by the eukaryotic translation initiation factor 
3 subunit p48 (eIF3e). FEBS Lett. 514; 49-54 
McCartney BM, Peifer M. (2000). Teaching tumour supressors new tricks. Nat Cell Biol 2(4): E58-60 
McPherson K, Steel CM, Dixon JM. (2000) Breast cancer- epidemiology, risk factors and genetics. BMJ 
321; 624-628 
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the 
NCI-EORTC Working Group on Cancer Diagnostics. (2005). REporting recommendations for tumor 
MARKer prognostic studies (REMARK). Nat Clin Pract UroL 2; 416-22. 
Mendelsohn AR, Hamer JD, Wang ZB, Brent R. (2002). Cyclin D3 activates Caspase 2, connecting cell 
proliferation with cell death. Proc Natl Acad Sci USA 99(10): 6871-6876 
Merril CR. (1990). Silver staining of proteins and DNA. Nature 343; 779-780 
Meyer E, Vollrner J-Y, Bovey R, Stamenkovic 1. (2005). Matrix metalloproteinase 9 and 10 inhibit 
protein-kinase c-potentiated, p53-mediated apoptosis. Cancer Res. 65(10): 4261-4272 
Mezi S, Primi F, Capoccetti F, Scopinaro F, Modesti M, Schillaci 0. (2003). In vivo detection of 
resistance to anthracycline based neoadjuvant chemotherapy in locally advanced breast cancer and 
inflammatory breast cancer with technetium-99m sestamibi scintimarnmography. Int. J. Oncol. 22(6); 
1233-1240 
277 
References 
Mian S, Ball G, Hornbuckle J, Holding F, Carmicheal J, Ellis 1, Ali S, Li G, McArdle S, Creaser C, Rees 
R. (2003). A prototype methodology combining surface-enhanced laser desorption/ionization protein chip 
technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer 
cell lines exposed to paclitaxel and doxorubicin under in vitro conditions. Proteomics 3(9); 1725-1737 
Mili S, Pinol-Roma S. (2003). LRP130, a pentatricopeptide motif protein with a noncanonical RNA- 
binding domain, is bound in vivo to mitochondrial and nuclear RNAs. Mol. Cell. Biol. 23(14); 4972-4982 
Miura K, Suzuki S, Tanita J, Shinkawa H, Satoh K, Tsuchida S. (1997). Correlated expression of 
glutathione S -trans ferase-pi and c-Jun or other oncogene products in human squamous cell carcinomas of 
the head and neck: relevance to relapse after radiation therapy. Jpn. J. Cancer Res. 88(2); 143-151 
Mokbel K. (2003). Current management of ductal carcinoma in situ of the breast Int. J. Clin. OncoL 8; 
18-22 
Montague JW, Gaido ML, Frye C, Cidlowski JA. (1994). A calcium-dependent nuclease from rat 
thymocytes is homologous with cyclophilin: recombinant cyclophilins, A, B and C have nuclease activity. 
J. Biol. Chem. 269(29): 18877-18880 
Moriuchi S, Shimizu K, Miyao Y, Yamada M, Ohkawa M, Hayakawa T. (1996). In vitro assessment for 
neurotoxicity of antiturnour agents before local administration into central nervous system. Anticancer 
Res. 16(l); 135-140 
Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. J ImmunoL Methods 65; 55-63 
Mosser DD, Morimoto RI. (2004). Molecular chaperones and the stress of oncogenesis. Oncogene 23: 
2907-2918 
Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall 1 (2003) Polymorphisms in the DNA 
repair gene XRCCI, breast cancer risk and response to radiotherapy. Cancer EpidemioL Biomarkers 
Prev. 12; 1168-1174 
Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Sternmel 
W, Oren M, Krammer PH. (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage 
by anticancer agents. J. Exp. Med. 188(l 1); 2003-2045 
Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. (1998) An induced proximity model for 
caspase-8 activation. J BioL Chem. 273(5); 2926-2930 
Nass SJ, Dickson RB. (1997) Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res. 
Treat. 44(l); 1-22 
Neumann F, Krawinkel U. (1997). Constitutive expression of human ribosomal protein U arrests the cell 
cycle in GI and induces apoptosis in jurkat T-lymphoma cells. Exp. Cell Res. 230: 252-261 
Nicholson RI, McClelland RA, Robertson JFR, Gee JMW. (1999) Involvement of steroid hormone and 
growth factor cross-talk in endocrine response in breast cancer. Endocr. Relat. Cancer 6; 373-387 
Nishizuka Y. (1992). Intracellular signaling by hydrolysis of phospholipids and activation of protein 
kinase C. Science 258(5082); 607-614 
Nix P, Lind M, Greenman J, Stafford N, Cawkwell L. (2004). Expression of Cox-2 protein in 
radioresistant laryngeal cancer. Annals of Oncology 15; 797-801 
Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N. (2005). Bcl-2 expression predicts radiotherapy 
failure in laryngeal cancer. Br J. Cancer 92(12); 2185-2189 
Noguchi A (2002). Does regional treatment improve the survival in patients with operable breast cancer? 
Breast Cancer Res. Treat. 76(3); 269-282 
278 
References 
Nonn L, Berggren M, Powis G. (2003). Increased expression of mitochondrial peroxiredoxm-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide- dependent apoptosis. Mol Cancer Res 1(9): 682-689 
Olayioye M, Hoffmann P, Pomorski T, Armes J, Simpson RJ, Kemp BE, Lindeman GJ, Visvader JE. 
(2004). The phosphoprotein StarDlO is overexpressed in breast cancer and cooperates with ErbB 
receptors in cellular transformation. Cancer Res. 64(10); 3 53 8-3 544 
Olayioye M, Neve RM, Lane HA, Hynes NE. (2000) The erbB signalling network: receptor heterodimerisation in development and cancer. EMBO J 19(13); 3159-3167 
Osborne C. (1998). Steriod hormone receptors in breast cancer management. Breast Cancer Res. Treat. 
51(3); 227-238 
Osborne C, Wilson P, Tripathy D. (2004) Oncogenes and turnour suppressor genes in breast cancer: 
potential diagnostic and therapeutic applications. The Oncologist 9; 361-377 
Ouwerkerk-Mahadevan S, van Boom JH, Dreef-Tromp MC, Ploeman JHTM, Meyer DJ, Mulder GJ. 
(1995). Glutathione analogues as novel inhibitors of rat and human glutathione s-transferase isoenzymes, 
as well as of glutathione conjugation in isolated rat hepatocytes and in the rat in-vivo. Biochem. J 308; 
283-290 
Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW. (1991) Lobular neoplasia of the breast: 
higher risk for subsequent invasive breast cancer predicted by more extensive disease. Hum. Pathol. 
22(12); 1232-1239 
Palacios J, Honrado, E, Osorio, A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez 0, 
Alonso C, Lerma E, Sanchez L, Rivas C, Benitez J. (2003) Immunohistochemical characteristics defined 
by tissue microarray of hereditary breast cancer not attributable to BRCA1 and BRCA2 mutations: 
differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin. Cancer Res. 9; 
3606-3614 
Parekh HK, Simpkins H. (1995). The differential expression of cytokeratin 18 in cisplatin-sensitive and - 
resistant human ovarian adenocarcinoma cells and its association with drug sensitivity. Cancer Res. 
55(22): 5203-5206 
Park SH, Cho EK, Bang SM, Shin DB, Lee JH, Lee YD. (2005) Docetaxel plus cisplatin is effective for 
patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical 
trial. BMC Cancer 5: 21-26 
Parry D, Steinert PM. (1999). Intermediate filaments: molecular architecture, assembly, dynamics and 
polymorphism. Q Rev Biophys 32: 99-187 
Patry C, Bouchard L, Labrecque P, Gendron D, Lemieux B, Toutant J, Lapointe E, Wellinger R, Chabot 
B. (2003). Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule 
Al/A2 proteins induces apoptosis in human cancer cells but not in non-nal mortal cell lines. Cancer Res 
63: 7679-7688 
Peluso P, Wilson DS, Do D, Tran H, Venkatasubbaiah M, Quincy D, Heidecker B, Poindexter K, Tolani 
N, Phelan M, Witte K, Jung LS, Wagner P, Nock S. (2003). Optimizing antibody immobilization 
strategies for the construction of protein microarrays. Anal. Biochem. 312(2); 113-124 
Philimonenko VV, Zhao J, Then S, Dingova H, Kysela K, Kahle M, Zentgraf H, Hoftnann WA, de 
Lanerolle P, Hozak P, Grummt 1. (2004). Nuclear actin and myosin I are required for RNA polymerase I 
transcription. Nat. Cell Biol. 6(12); 1165-1172 
Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. (2005). Role of dynamic contrast enhanced 
MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast 
Cancer Res. Treat. 91; 1- 10 
Pierce LJ. (2005) The use of radiotherapy after mastectomy: a review of the literature. J. Clin. Oncol. 23; 
1706-1717 
279 
References 
Porter LA, Singh G, Lee JM. (2000). Abundance of cyclin BI regulates gannna-radiation-induced 
apoptosis. Blood 95(8); 2645-2650 
Prados J, Melguizo C, Marchal JA, Velez C, Alvarez L, Aranega A. (1998). Therapeutic differentiation in 
a human rhabdomyosarcoma cell line selected for resistance to actinomycin. D. Int. J. Cancer 75(3); 379- 
383 
Pusztai L, Asmar L, Smith TL, Hortobagyi GN. (1999). Relapse after complete response to anthracycline- 
based combination chemotherapy in metastatic breast cancer. Breast Cancer Res. Treat 55; 1-8 
Qian HR, Huang S. (2005). Comparison of false discovery rate methods in identifýýing genes with 
differential expression. Genomics. 86; 495-503. 
Qian X, Kulig E, Jin L, Lloyd RV. (1998). Expression of D-type cyclins in nomial and neoplastic rat 
pituitary. Endocrinology 139(4); 2058-2067 
Rabilloud T, Adessi C, Giraudel A, Lunardi J. (1997). Improvement of the solubilization of proteins in 
two-dimensional electrophoresis with immobilised pH gradients. Electrophoresis 18; 307-316 
Radetzki S, Kohne CH, von Haefen C, Gillissen B, Sturm I, Dorken B, Daniel PT. (2002) The apoptosis 
promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-l- 
overexpressing breast cancer cell lines. Oncogene 21(2); 227-238 
Rahman SM, Shyr Y, Yildiz PB, Gonzalez AL, Li H, Zhang X, Chaurand P, Yanagisawa K, Slovis BS, 
Miller RF, Ninan M, Miller YE, Franklin WA, Caprioli RM, Carbone DP, Massion PP. (2005). Proteomic 
patterns of preinvasive bronchial lesions. Am JRespir Crit Care Med. 172; 1556-62. 
Rajagopal A, Simon SM. (2003) Subcellular localisation and activity of multidrug resistance proteins. 
Mol. BioL Cell 14; 3389-3399 
Ranganathan S, Tew KD. (1993). Analysis of glyoxalase-I from normal and tumor tissue from human 
colon. Biochim Biophys Acta. 1182(3); 311-316 
Ranganathan S, Walsh ES, Tew KD. (1995). Glyoxalase I in detoxification: studies using a glyoxalase I 
transfectant cell line. Biochem. J 309; 127-131 
Rawal RM, Patel PS, Vyas RK, Sainger RN, Shah MH, Peshavariya HM, Patel DD, Bhatavdekar JM. 
(2001). Role of pretherapeutic biomarkers in predicting postoperative radiotherapy response in patients 
with advanced squamous cell carcinoma. Int. J Radiat. BioL 77(l 1); 1141-1146 
Rechsteiner M, Hill CP- (2005). Mobilising the proteolytic machine: cell biological roles of proteasome 
activators and inhibitors. Trends Cell Biol. 15(l); 27-33 
Reis-Filho JS, Westbury C, Pierga JY. (2006). The impact of expression profiling on prognostic and 
predictive testing in breast cancer. J Clin Pathol. 59; 225-3 1. 
Rhee SG, Bae YS, Lee SR, Kwon J. (2000). Hydrogen peroxide: a key messenger that modulates protein 
phosphorylation through cysteine oxidation. Sci STKE 2000: PEI 
Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. (2004). Oestrogen receptor status, pathological 
complete response and prognosis in patients receiving neoadjuvant chemotherapy for early 
breast cancer. 
Br. J Cancer 91; 2012-2017 
Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J, Brambilla C. (1995). Differential c-myc, c-jun, c-raf 
and p53 expression in squamous cell carcinoma of the head and neck: 
implication in drug and 
radioresistance. Eur. J. Cancer B. Oral Oncol. 31B(6); 384-391 
Robain M, Pierga JY, Jouve M, Asselain B, Dieras V, Beuzeboc P, Palangie T, Dorval T, Extra JM, 
Scholl S, Pouillart P. (2000). Predictive factors of response to first-line chemotherapy in 1426 women 
with metastatic breast cancer. Eur. J Cancer 36; 2301-2312 
280 
References 
Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer F, Rodel C. (2005). Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 65(l 1); 4881-4887 
Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. (2001). Decreased expression of estrogen receptor P protein in proliferative preinvasive mammary tumors. Cancer Res. 61; 2537-2541 
Rosati G, Riccardi F, Tucci A, De Rosa P, Pacilio G. (2000). A phase 11 study of paclitaxel/cisplatin 
combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy. Tumori. 86(3); 207-210 
Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A, Mor G. (2000). Absence of estrogen 
receptor-P expression in metastatic ovarian cancer. Obstet. Gynecol. 96; 417-421 
Sakamoto H, Mashima. T, Kizaki A, Dan S, Hashimoto Y, Naito M, Tsuruo T. (2000). Glyoxalase I is 
involved in resistance of human leukaernia cells to antitumor agent-induced apoptosis. Blood 95(10); 3214-3218 
Salvadori B, Bartoli C, Zurrida S, Delledonne V, Squicciarini P, Rovini D, Barletta L. (1991) Risk of invasive breast cancer in women with lobular carcinoma of the breast/ Eur. J Cancer 27(l); 35-37 
Santoni V, Molloy M, Rabilloud T. (2000). Membrane proteins and proteomics: un amour impossible? 
Electrophoresis 21; 1054-1070 
Schondorf T, Kurbacher CM, Gohring UJ, Benz C, Becker M, Sartorius J, Kolhagen H, Mallman P, 
Neumann R. (2002). Induction of MDR1 -gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res. 22; 2199-203 
Schreck R. Rieber P. Baeuerle PA. (1991). Reactive oxygen intermediates as apparently widely used 
messengers in the activation of the NF-kappa B transcription factor and HIV- 1. EMBO J 10: 2247-225 8 
Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD, Caprioli RM. (2005). 
Proteornic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption 
ionization mass spectrometry. Cancer Res. 65; 7674-8 1. 
Schweitzer B, Wiltshire S, Lambert J, O'Malley S, Kukanskis K, Zhu Z, Kingsmore SF, Lizardi PM, 
Ward DC. (2000). Inaugural article: iminunoassays with rolling circle DNA amplification: a versatile 
platform for ultrasensitive antigen detection. Proc. Natl. Acad. Sci. USA 97(18); 10113-10119 
Seeger M, Gordon C, Dubiel W. (2001). Protein stability: the CON signalosome gets in on the act. Curr. 
Biol. 11(16); R643-R646 
Semenza GL. (2003). Targeting HIF- 1 for cancer therapy. Nat. Rev. Cancer 3(l 0); 721-732 
Shalli K, Brown I, Heys SD, Schofield AC. (2005). Alterations of beta-tubulin isotypes in breast cancer 
cells resistant to docetaxel. FASEB J. 19(10): 1299-301 
Shaw MM, Riederer BM. (2003). Sample preparation for two-dimensional gel electrophoresis. 
Proteomics 3; 1408-1417 
Shen DW, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S, Pastan 1, Gottesman MM. (1986). 
Multiple drug-resistant human KB carcinoma cells independently selected for high level resistance to 
colchicine, adriamycin or vinblastine show changes in expression of specific proteins. J BioL Chem. 
261(17); 7762-7770 
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998). Modulation of apoptosis and bcl-2 
expression by prostaglandin E2 I human colon cancer cells. Cancer Res. 58(2): 362-366 
Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS, Lim Sj, Park JG. (2005). Down-regulation of 
nutochondrial FlFO-ATP Synthase in human colon cancer cells with induced 5-Fluorouracil resistance. 
Cancer Res. 65(8); 3162-3170 
281 
References 
Silverstein MJ, Poller DN, Waisman M Colbum WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P, 
Slamon DJ. (1995) Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345; 1154-115 7 
Silvestrini R, Veneroni S, Benini E, Daidone MG, Luisi A, Leutner M, Maucione A, Kenda R, Zucali F, 
Veronesi U. (1997). Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from 
adjuvant radiotherapy in breast cancer. J Nad. Cancer Inst. 89(9); 639-645 
Singh B, Kim SH, Carew JF, Yu I, Shaha AF, Wolden S, Boyle J, Shah JP, Rao PH. (2000). Genome- 
wide screening for radiation response factors in head and neck cancer. Laryngoscope 110(8); 1251-1256 
Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. (1998) Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach 
cancer cells. J Biochem. Biophys. Methods 37(3): 105-116 
Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. (1999)a. Increased expression of 
epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel 
electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the 
pancreas. Electrophoresis 20(14): 2952-60 
Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. (1999)b. Search for novel proteins 
involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using 
two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 20(14): 2961- 
69 
Sinha P, Kohl S, Fischer J, Hutter G, Kern M, Kottgen E, Dietel M, Lage H, Schnolzer M, Schadendorf 
D. (2000) Identification of novel proteins associated with the development of chemoresistance in 
malignant melanoma using two-dimensional electrophoresis. Electrophoresis 21(14): 3048-57 
Sinha P, Poland J, Schnolzer M, Celis JE, Lage H. (2001). Characterisation of the differential protein 
expression associated with thermoresistance in human gastric carcinoma cell lines. Electrophoresis 
22(14); 2990-3000 
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987) Human breast cancer: 
correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235; 177-182 
Sofer-Levi Y, Resnitzky D. (1996). Apoptosis induced by ectopic expression of cyclin Dl but not cyclin 
E. Oncogene 13(11): 2431-2437 
Somiari RI, Sullivan A, Russell S, Somiari S, Hu H, Jordan R, George A, Katenhusen R, Buchowiecka A, 
Arciero C, Brzeski H, HookeJ, Shriver C. (2003). High-throughput proteomic analysis of human 
infiltrating ductal carcinoma of the breast. Proteomics 3(10); 1863-1873 
Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP. 
(1992). Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine- 
resistant human breast cancer cell lines. Cancer Res. 52(19): 5190-5197 
Spataro V, Simmen K, Realini CA. (2002). The essential 26S proteasome subunit RpnI I confers 
multidrug resistance to mammalian cells. Anticancer Res. 22(6C): 3905-3909 
Spengler B. (1997). Post-source decay analysis in matrix-assisted laser desorption/ ionisation mass 
spectrometry of biornolecules. J. Mass Spectrom 32; 1019-1036 
Sreekumar A, Nyati MK, Varambally S, Barrette TR, Ghosh D, Lawrence TS, Chinnaiyan AM. (2001). 
Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. 
Cancer Res 61(20); 7585-93. 
Stamenkovic 1. (2003). Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 
200: 448-464 
Stochaj VvIR, Berkeh-nan T, Laird N. (2003). Preparative two-dimensional gel electrophoresis with 
immobilised pH gradients. In Proteins and proteomics: a laboratory manual. (Simpson RJ, Ed). Cold 
Spring Harbour Laboratory Press, New York, USA; 143-215 
282 
References 
Struski S, Doco-Fenzy M, Koehler M, Chudoba I, Levy F, Masson L, Michel N, Ulrich E, Gruson N, 
Benard J, Potron G, Comillet-Lefebvre P. (2003). Cytogenetic evolution of human ovarian cell lines 
associated with chemoresistance and loss of tumorigenicity. Anal. Cell Pathol. 25(3); 115-122 
Su F, Hu X, Jia W, Gong C, Song E, Hamar P. (2003). Glutathione s transferase pi indicates 
chemotherapy resistance in breast cancer. J Surg Res. 1 13(l): 102-108 
Sugiyama K, Akiyama T, Shimizu M, Tamaoki T, Courage C, Gescher A, Akinaga S. (1999). Decrease in 
susceptibility toward induction of apoptosis and alteration in GI checkpoint function as determinants of 
resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine). 
Cancer Res 59(17): 4406-4412 
Sun J, Chen Y, Li M, Ge Z. (1998). Role of antioxidant enzymes on ionizing radiation resistance. Free Radic Biol. Med. 24(4); 586-593 
SusIn SA, Lorenzo HK, Zarnzanii N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini 
P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. 
(1999). Molecular characterisation of mitochondrial apoptosis-inducing factor. Nature 397: 441-446 
Suzuki Y, Nakabayashi Y, Takahashi R. (2001). Ubiquitin-protein ligase activity of x-linked inhibitor of 
apoptosis protein promotes proteasomal degradation of caspase 3 and enhances its anti-apoptotic effect in 
Fas-induced cell death. Proc. Nad. Acad Sci. USA 98(15): 8662-8667 
Tai IT, Dai M, Owen DA, Chen LB. (2005). Genome-wide expression analysis of therapy-resistant 
turnours reveals SPARC as a novel target for cancer therapy. J Clin. Invest. 115(6); 1492-1502 
Takahashi K, Inuzuka M, Ingi T. (2004). Cellular signalling mediated by calphoglin-induced activation of 
IPP and PGM. Biochem. Biophys. Res. Commun. 325; 203-214 
Tanahashi N, Murakami Y, Minami Y, Shimbara N, Hendil KB, Tanaka K. (2000). Hybrid proteasomes. 
Induction by interferon-ganuna and contribution to ATP-dependent proteolysis. J BioL Chem. 275(19); 
14336-14345 
Tannock IF, Lee CM, Tunggal JK, Cowan DSM, Egorin MJ. (2002) Limited penetration of anticancer 
drugs through turnour tissue: a potential cause of resistance of solid turnours to chemotherapy. Clin. 
CancerRes. 8; 878-884 
Tanveer A, Virji S, Andreeva L, Totty NF, Hsuan JJ, Ward JM, Crompton M. (1996). Involvement of 
cyclophilin D in the activation of a mitochondrial pore by Ca2+ and oxidant stress. Eur. J. Biochem. 
238(l): 166-172 
Tetu B, Brisson J. (1994) Prognostic significance of HER-2/neu oncoprotein expression in node-positive 
breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73(9); 2359- 
2365 
Tomlinson IM, Holt U. (2001). Protein profiling comes of age. Genome Biol. 2(2); 1004.1-1004.3 
Towbin H, Staehelin T, Gordon J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels 
to nitrocellulose sheets: procedure and some applications. Proc. NatI. Acad Sci. USA 76(9); 4350-4354 
Townsend AJ, Tu CP, Cowan KH. (1992). Expression of human mu or alpha class glutathione S- 
transferases in stably transfected human MCF-7 breast cancer cells: effect on cellular sensitivity to 
cytotoxic agents. MoL PharmacoL 41(2); 230-236 
Townsend DM, Tew KD. (2003). The role of glutathione-s-transferase in anti-cancer drug resistance. 
Oncogene 22(47): 7369-75 
Trachsel H, Erni B, Schreier MH, Staehelin T. (1977). Initiation of mammalian protein synthesis. II. The 
assembly of the initiation complex with purified initiation factors. J MoL BioL 116(4); 755-767 
283 
References 
Tsunoda T, Koga H, Yokomizo A, Tatsugami K, Eto M, Inokuchi J, Hirata A, Masuda K, Okumura K, 
Naito S. (2005). Inositol 1,4,5-trisphosphate (IP3) receptor typel (IP3RI) modulates the acquisition of 
ciSplatin resistance in bladder cancer cell lines. Oncogene 24(8); 1396-1402 
Tulub AA, Stefanov VE. (2001). Cisplatin stops tubulin assembly into microtubules. A new insight into 
the mechanism of antiturnour activity of platinum complexes. Int J Biol. MacromoL 28: 191-198 
Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, 
Baserga R, Glazer PM. (1997). Insulin-like growth factor-I receptor overexpression mediates cellular 
radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57(15); 
3079-3083 
Urbani A, Poland J, Bernardini S, Bellincanipi L, Biroccio A, Schnolzer M, Sinha P, Federici G. (2005) 
A proteornic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 5(3): 
796-804 
Vallat L, Magdelenat H, Merle-Beral H, Masdehors P, Potocki de Montalk G, Davi F, Kruhoffer M, 
Sabatier L, Orntoft TF, Delic J. (2003). The resistance of B-CLL cells to DNA damage-induced apoptosis 
defined by DNA microarrays. Blood 101 (11); 4598-4606 
Van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallionierni 0, Kononen J, Torhorst J, Sauter G, Zuber 
M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. (2002). Expression of 
cytokeratins; 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J Pathol. 
161(6); 1991-1996 
Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans, J, Dalesio 0, Nusse R. (1988) Neu-protein 
overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited 
prognostic value in stage 11 breast cancer. N. EngL J Med 319(19); 1239-1245 
Vargas-Roig LM, Gago FE, Tello 0, Martin de Civetta, MT, Ciocca DR. (1999) c-erbB-2 (HER-2/neu) 
protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J Cancer 
84(2); 129-134 
Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA. (1987) Alterations to either c-erb-2 
(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 
1(4); 423-430 
Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Panopoulos C, Chrissohoou M. Apostolikas 
N, Efremidis AP. (2005). First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. 
The Breast 14: 136-141 
Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Pateras H, Efremidis AP. (2000). 
Vinorelbine, and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann. 
Oncol. 11(9); 1155-1160 
Vassilomanolakis M, Koumakis G, Demiri M, Missitzis J, Barbounis V, Efremidis AP. (2003). 
Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after 
docetaxel and anthracycline treatment. Cancer Invest. 21(4); 497-504 
Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M. (2003). Proteorne analysis of vinca alkaloid 
response and resistance in acute lymphoblastic leukaernia reveals novel cytoskeleton alterations. J BioL 
Chem. 278(46); 45082-45093 
Voges D, Zwickl P, Baumeister W. (1999). The 26S proteasome: a molecular machine designed for 
controlled proteolysis. Annu. Rev. Biochem. 68; 1015-1068. 
Walsh BJ, Herbert BR. (1998). Setting up two-dimensional gel electrophoresis for proteome projects. 
URL: www. abrf-orgIABRFNewsl]998IMarch981mar982D. htmI [Accessed on 29.03.06] 
Wang X. (2002). The expanding role of mitochondria in apoptosis. Genes Dev. 15: 2922-2933 
284 
References 
Warnberg F, Nordgren H, Bergh J, Holmberg L. (1999). Ductal carcinoma in situ of the breast from a 
population-defined cohort: an evaluation of new histopathological classification systems. Eur. J Cancer 35(5); 714-720 
Watson MB, Cawkwell L. (2004) Breast cancer cytogenetics, chromosomal abnormalities and 
comparative genomic hybridisation. In: Molecular Oncology ofBreast Cancer: (Ross JS, Hortobagyi GN, 
Eds). Jones and Bartlett Publishers Inc, Sudbury. 
Watson MB, Smith L, Drew PJ, Lind MJ, Cawkwell L. Expression micorarray analysis reveals genes 
associated with in-vitro resistance to cisplatin in a cell line model of advanced breast cancer. Manuscript Submitted 
Wehbe H, Kearney CM, Pinney KG. (2005). Combretastatin A-4 resistance in H460 human lung 
carcinoma demonstrates distinctive alterations in beta tubulin isotype expression. Anticancer Res 25(6B): 
3865-70 
Werry TD, Sexton PM, Christopoulos A (2005) 'Ins and outs' of seven-transmembrane receptor 
signalling to ERK. Trends Endocrinol. Metab. 16; 26-33. 
Whelan RD, Waring 0, Wolf CR, Hayes JD, Hosking LK, Hill BT. (1992). Over-expression of p- 
glycoprotein and glutathione s-transferase pi in MCF7 cells selected for vincristine resistance in vitro. Int 
J Cancer 52(5): 241-246 
Wijnholds J. (2002) Drug resistance caused by multidrug resistance-associated proteins. Novartis Found 
Symp. 243; 69-79 
Wilkins MR, Appel RD, Van Eyk JE, Chung MC, Gorg A, Hecker M, Huber LA, Langen H, Link AJ, 
Paik YK, Patterson SD, Pennington SR, Rabilloud T, Simpson RJ, Weiss W, Dunn MJ. (2006). 
Guidelines for the next 10 years of proteornics. Proteomics. 6: 4-8. 
Wilkins MR, Sanchez JC, Gooley AA, Appel AD, Humphrey-Smith 1, Hochstrasser DF, Williams KL. 
(1996). Progress with proteome projects: why all proteins expressed by a given genome should be 
identified and how to do it. BiotechnoL Genet. Eng. Rev. 13; 19-50 
Wilson C, Yang J, Strefford JC, Surnmersgill B, Young BD, Shipley J, Oliver T, Lu YJ. (2005). 
Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell turnour cell 
lines. Genes Chromosomes Cancer 43(2); 211-216 
Winer EP. (2005) Optimising endocrine therapy for breast cancer. J Clin. Oncol. 23(8); 1609-16 10 
Wollman R, Yahalorn J, Maxy R, Pinto J, Fuks Z. (1994). Effect of epidermal growth factor on the 
growth and radiation sensitivity of human breast cancer cells in vitro. Int. J Radiat. OncoL BioL Phys. 
30(l); 91-98 
Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, Lin Y, Liao J, Shih JW, Cheung TH, Lo 
KW, Yim. SF, Yip SK, Ngong DT, Siu N, Chan LK, Chan CS, Kong T, Kutlina E, McKinnon RD, 
Denhardt DT, Chin KV, Chung TK. (2003). Expression genomics of cervical cancer: molecular 
classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res. 9(15); 5486- 
5492 
Wool IG, Chan YL, Gluck A. (1995). Structure and evolution of mannnalian ribosomal proteins. 
Biochem. Cell Biol. 73: 933-947 
Wulf G, Ryo A, Liou YC, Lu KP. (2003). The proply isomerase Pinl in breast development and cancer. 
Breast Cancer Res. 5(2): 76-82 
Yamanaka M, Koga M, Tanaka H, Nakamura Y, Ohta H, Yornogida K, Tsuchida J, Iguchi N, Nojima H, 
Nozaki M, Matsun-fiya K, Okuyama A, Toshimori K, Nishimune Y. (2000). Molecular cloning and 
characterization of phosphatidylcholine transfer protein-like protein gene expressed in murine haploid 
germ cells. BioL Reprod. 62(6); 1694-1701 
285 
References 
Yao Q, Li M, Yang H, Chai H, Fisher W, Chen C. (2005). Roles of cyclophilMS in cancers and other 
organ systems. World J. Surg. 29: 276-280 
Yao Z, Dolginov Y, Hanoch T, Yung Y, Ridner G, Lando Z, Zharhary D, Seger R (2000) Detection of 
partially phosphorylated forms of ERK by monoclonal antibodies reveals spatial regulation of ERK 
activity by phosphatises. FEBS Letters 468; 37-42. 
Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Obtake. (2001). Heat shock protein 27 was upregulated 
in cisplatin resistant human ovarian turnour cell line and associated with cisplatin resistance. Cancer Lett 
168(2): 173-181 
Yates JR. (2000). Mass spectrometry; from genomics to proteornics. TIG 16(l); 5-8 
Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL. (1998). High expression of 
thyrnidylate synthase is associated with drug resistance of gastric carcinoma to high dose 5-fluorouracil- 
based systemic chemotherapy. Cancer 82(9); 1626-1631 
Yeh PY, Chaung SE, Yeh KH, Song YC, Cheng AL. (2001). Nuclear extracellular signal-regulated 
kinase 2 phosphorylates p53 at Thr 55 in response to doxorubicin. Biochem Biophys Res Commun 284: 
880-886 
Yoo BC, Ku JL, Hong SH, Shin YK, Park SY, Kim HK, Park JG- (2004)a. Decreased pyruvate kinase 
M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int. J Cancer 108; 532- 
539 
Yoo BC, Jeon E, Hong SH, Shin YK, Chang HJ, Park JG. (2004)b. Metabotropic glutamate receptor 4- 
mediated 5-fluorouracil resistance in a human colon cancer cell line. Clin Cancer Res. 10; 4176-4184 
Yoon HJ, Donahue TF. (1992). The suil suppressor locus in Saccharomyces cerevisiae encodes a 
translation factor that functions during tRNA(iMet) recognition of the start codon. Mol. Cell Biol. 12(l); 
248-260 
Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung ME, You HJ. (2004) Oncogenic h-ras up- 
regulates expression of ERCCI to protect cells from platinum-based anticancer agents. Cancer Res. 64; 
4849-4857 
Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES. (2005). Proteomic study reveals that proteins 
involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast 
cancer. Mol Cell Proteomics. 4; 1686-96. 
Zhang J, Zhang F, Ebert D, Cobb MH, Goldsmith EJ. (1995). Activity of the MAP Kinase ERK2 is 
controlled by a flexible surface loop. Structure 3: 299-307 
Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L, Tang X, Lu KP, Xiao ZX (2002). The 
prolyl isomerase pinI is a regulator of p53 in genotoxic response. Nature 419: 849-853 
Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, Zhang QH, Xiao DK, Shen SH, Imbeaud S, Eveno 
E, Zhao CJ, Chen YL, Fan HY, Waxman S, Auffiray C, Jin G, Chen SJ, Chen Z, Zhang J. (2005). Systems 
analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell 
differentiation/apoptosis ofpromyelocytic leukemia. ProcNatlAcadSci USA. 102; 7653-8. 
Zhongkui L, Liqun X, Lee LM, Khaletskiy A, Jianyi W, Wong JYC, Li JJ. (2001). Effector genes altered 
in MCF-7 human breast cancer cells after exposure to fractionated ionising radiation. Radiat. Res. 155(4); 
543-553 
Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor Cl. (2004). Effects of the EGFRJHER2 kinase 
inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, 
radio sensitization, and resistance. Int. J Radiat. Oncol. Biol. Phys. 58(2); 
344-352 
286 
Appendices 
Appendix A: Suppliers and contact details 
Abeam Ple 
332 Cambridge Science Park, Milton Road, Cambridge, CB4 OFW, UK. 
Amersharn Biosciences 
Amersham place, Little Chalfont, Buckinghamshire, HP7 9NA, UK. 
Biochrom Ltd 
Cambridge Science Park, Milton Road, Cambridge, CB4 OFJ, UK. 
Bio-Rad Laboratories 
1000 Alfred Nobel Drive, Hercules, CA 94547, USA. 
Bruker Daltonics Ltd 
Banner Lane, Coventry, CV4 9GH, UK. 
Invitrogen Life Technologies Ltd 
3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, UK. 
Kodak Ltd 
Headstone Drive, Harrow, Middlesex, HAI 4TY, UK. 
Lab Vision (U. K. ) Ltd (Neomarkers) 
The Pines, Fordham Road, Newmarket, Suffolk, CB8 MG, LTK. 
Merck Ltd (BDH Laboratory Supplies) 
Seldown Lane, Poole, Dorset, BH15 1TD, UK. 
Millipore (U. K. ) Ltd 
Units 3&5, The Courtyards, Hatters Lane, Watford, WD18 8YH, UK. 
Molecular Devices Corporation (Axon Instruments) 
1311 Orleans Drive, Sunnyvale, CA 94089-1136, USA. 
MWG Biotech AG 
Anzingerstr. 7a, 85560 Ebersberg, Germany 
Pierce Biotechnology 
PO Box 117, Rockford, IL 61105, USA. 
Promega Corporation 
Delta House, Southampton Science Park, Southampton, SO 16 7NS, UK. 
Santa Cruz Biotechnology Inc. 
2145 DelawaTe Avenue, Santa Cruz, CA 95060, USA. 
Sartorius Ltd (Vivascience) 
Longmead Business Park, Blenheim Road, Epsorn, Surrey, KT19 9QQ, UK. 
Scientific Laboratory Supplies 
Wilford Industrial Estate, Ruddington Lane, Wilford, Nottingham, NG1 1 7EP, LTK. 
Sigma-Aldrich Ltd. 
Fancy Road, Poole, Dorset, BH12 4QH, UK. 
Thermo Electron Corporation 
81 Wyman Street, Waltham, MA 02454, USA. 
Ultrawave Ltd. 
oxford Street, Cardiff, CF24 3WY, UK. 
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UniEquip 
Fraunhoferstrasse 11, Martinsried, Munich, D-82152, Germany. 
WPA Ltd 
Unit 22, Cambridge Science Park, Milton Road, Cambridge, CB4 OFJ 
Appendix B: The calculation used for cell counting 
each small division Is 
0.06 rnm 
-i 
shadc4 arta 
is otle **Cc I r, 
The haemocytometer 
The number of cells per ml was calculated as follows: 
[(Y_(l +2+3 +4+5)/5) x 2] x 10 4= cells/ n-d 
Appendix C: Equations used to calculate the D/P ratio for the PanoramaTM Cell Signalling 
Antibody Microarrays 
The [tmolar extinction coefficients (E): 
Cy3: E5 52=0.15 ýM 1 crff 1 
Cy5: E650 = 0.25 [Ml cnf 1 
Cy3 concentration (pM) = A55210-15 
Cy5 concentration (ptM) = A65WO. 25 
Y (mg/n-fl) = protein concentration after labelling 
Protein concentration (ýM) = [Y (mg/n-A)/60,000] x 106 
D/P = Cy3 or Cy5 concentration/Protein concentration of sample (RM) 
Appendix D: Equations used to calculate the D/P ratio for the Labvision Antibody Microarrays 
Cy3/Protein Ratio: 
Cy3 concentration = 
A55211 
.5x 
105 
Protein concentration = 
[A280 
-(0.08 x 
A552)1/1 
.7x 
105 
D/P ratio = Cy3 concentration/Protein concentration 
Cy5/Protein Ratio: 
Cy5 concentration = A65o/2.5 x 
105 
Protein concentration = 
[A280 
-(0.05 x 
A650)1/1.7 x 105 
D/P ratio = Cy5 concentration/Protein concentration 
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Appendix E: Result sheets obtained from the successful identification of cytochrome C 
At the head of the report are a few lines identifying the search uniquely. The infon-nation provided 
includes the search title, date, and user name. The database is also specified and is identified by a release 
number and timestarrip. In addition, one or more of the top scoring proteins are listed. Following the 
header is a histogram showing the distribution of protein scores. The best matching proteins are divided 
into groups and the heights of the bars represent the number of matches in each group. The protein score 
is a measure of significance. The shaded area of the histogram indicates the region where random matches 
may be expected. This region extends to the significance threshold. A match in the un-shaded region of 
the histogram has a less than 5% probability of being a random event and is therefore significant 
(p<0.05). The main body of the report contains a tabular summary of the best matching proteins. Proteins 
that match the same set (or a subset) of mass values are grouped into a single hit. The table contains an 
accession string (which provides a link to the protein view), the molecular weight and protein (MOWSE) 
score. MOWSE scores >61 were significant (p<0.05). Expect is the number of times we would expect to 
obtain an equal or higher score purely by chance. Therefore, a more significant result is obtained from a 
lower expectation. Also displayed is the number of peptides matched to the protein and at the foot of the 
report the search parameters are summarised. 
I RIX Mascot Search Results 
User XJ Welha3n 
Email X. J. Welham0hull. ac. uk 
Search title z PZV Search Bovine Cytochrome C Tryptic digest (LSmith P8) 
Database : SwissProt 43.2 (191643 sequences; $7132023 residues) 
Taxonomy : Mammalia (mammals) (64471 sequences) 
Timestamp : 21 May 2004 at 12: 43: 55 GMT 
Top Score : 87 for P00006, (CYC_BOVIN) Cytochrome c Cytochrome c 
Probability Based Mowse Score 
Tons score is -10*Log(P), where P is the probability that the observed match is a random event. 
Protein scores greater than 61 are significant (p<0.05). 
lo 
0 
Concise Protein Summary Report 
Format As ]FConcis. e Protein Summary 
Significancc threshold p< 10.0.15 Max. number of hits 
Re-Search All Search Unmatched 
P00006 Mass: 11565 Score: 87 
(CYC-BOVIN) Cytochrome c Cytochrome c 
P00011 Masss 11494 Score: 87 
(CYC_CANFA) Cytochrome c Cytochrome c 
Expect% 0.00014 Queries ml 
Expectt 0.00014 QuerieS rag 
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P00012 Maass 11479 
(CYC-MIRLE) Cytochrome c Cytochrome c 
P00005 Mass: 11680 
(CYC-EQUAS) Cytochrome c Cytochrome c 
P09013 Mass-. 11436 
(CYC-MINSC) Cytochrome c Cytochrome c 
P00007-00-01-00 Mass: 11537 
(CYC-HIPAM) Splice isoform Displayed; 
P00007-00-00-00 Mass: 11523 
..... ..... I-...... ....... ....... (CYC-HIPAM) Splice isoforin Displayed; 
Scores 86 Expects 0.00016 Queries ma 
Score: 52 Expect: 0.38 Queries matcl 
Score: 52 Expects 0.4 Queries =tchi 
Score: 42 Expect: 4.2 Queries match( 
Variant Unnamed variant isoform 1; Conf] 
Score: 42 Expect: 4.2 Queries matche 
Variant Displayed; Conflict Displayed; f 
Q8YýlMj-03-00-00 Mass: 8301 Scoret 27 Expects 1.2e+02 Queries me 
(VML3_HUMAN) Splice isoform 4; Variant Displayed; Conflict Displayed; from QU 
043439-01-00-00 Maass 63861 Score: 22 Expect: 4.4e+02 Queries me 
(MT8R_IIUMAN) Splice iBOform, 2; Variant Displayed; Conflict Displayed; from 042 
Qalý, Tz Mass: 24133 Scoret 21 Expect: 4.7e+02 Queries me 
(RNS9-MACA, S) Ribonuclease -like protein 9 precursor Ribonuclease -like protein 5 
P00015 Masst 11575 Score: 21 Expect: 5e+02 Queries matc 
(CYC2_MOUSE) Cytochrome c, testis-specific Cytochrome c, testis-specific 
P10715 Mass: 11604 Score: 21 Expect: 5.2e+02 Queries me 
(CYC2-RAT) Cytochrome c, testis-specific Cytochrome c, testis-specific 
2. P00010 Mass% 11509 Score: 86 Expects 0.00014 Queries me 
(CYC-ESCGI) Cytochrome c Cytochrome c 
P00008 Mass: 11553 Score: 52 Expects 0.4 Queries matcht 
(CYC-RABIT) Cytochrome 6 Cytochrome c 
3. P00377 
(DYR_PIG) 
Mass- 21441 Score: 31 Expects 55 Queries matched 
Dihydrofolate reductase (EC 1.5.1.3) Dihydrofolate reductase (EC I. E 
4. Q9XS77 Mass: 31121 Score: 31 Expects 56 Queries matched 
(ILlB_TRIVU) Interleukin-1 beta precursor (IL-1 beta) Interleukin-1 beta precl 
Q9TUI5 Mass: 6244 Scores 28 Expects le+02 Queries matc 
(MT4_CANFA) Metallothionein-IV (MT-IV) Metal lothionein- IV (MT-IV) 
P20930 Mass: 44080 Score: 22 Expects 4.4e+02 Queries zu 
(FILA_HUMA N) Filaggrin precursor (Fragment) Filaggrin precursor (Fragment) 
Q29119 Mass: 3464 Score: 21 Expects 5e+02 Queries matc 
(IAPP_PIG) Islet amyloid polypeptide (Amylin) (Fragment) Islet amyloid polype; 
QBIVH4-00-00-00 Mass: 46509 Score: 30 Expect: 57 Queries matchee 
(MMAA-HUMAN) Splice isoformi Displayed; Variant Displayed; Conflict Displayed; 
Q9BDR7 Mass: 9457 Scores 24 Expect: 2.3e+02 Queries zu 
(FCEG_BOVIN) High affinity immunoglobulin epsilon receptor gamma-subunit prect 
QBIVH4-00-01-00 Mass: 46448 Scores 21 Expects 4.8e+02 Queries = 
(MMAA-HUMAN) Splice isoform Displayed; Variant MMAA-VAR_017202; Conflict Disp] 
6. P80295 Mass: 6035 Score: 30 Expect: 71 Queries matchee 
(MT1I_HUMAN) Metallothionei n-II (MT-1I) Metallothionein-II (MT-11) 
7. Q61382 Mass: 53383 Score: 28 Expects 91 Queries matcheý 
(TRA4_MOUSE) TNF receptor a ssociated factor 4 (Cysteine rich motif associated 
8. P42695 Mass: 169610 Score: 28 Expect: 
I. Ie+02 Queries me 
HUMAN) (Y056 Hypothetical protein KIAA0056 (Fragment) Hypot hetical protein 
KI; 
_ 
P19957 Mass% 12261 Score: 22 Expect: 3.9e+02 
Queries me 
HUMAN) (ELAF Elafin precursor (Elastase-spe cific inhibitor) (ESI) 
(Skin-derive 
_ 
P02624 Masss 11926 Score: 22 Expects 4.2e+02 
Queries zu 
(PRVA_RABIT) Parvalbumin alpha Parvalbumin alpha 
P33435 Mass: 54148 Score: 21 Expects 5.2e+02 Queries me 
(MM13_MOUSE) Collagenase 3 precursor (EC 3. 4.24. -) (Matrix metalloproteinase-3 
9. P28288-00-01-00 Mass: 75486 Scores 27 
zxpect: 1.2e+02 Queries NR 
(A. BD3_HUMAN) Splice isoform Displayed; Variant ZWS-2-VAR_000091; 
Conflict DiSr 
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P59041 Mass: 24747 Score: 22 EXPOCtl 4. le+02 Queries zu 
(WS18-MOUSE) Williams-Beuren syndrome chromosome region 18 protein homolog Wil 
10. P48774 Mass: 26617 Scores 27 Expects 1.3e+02 Queries ru 
(GTM5_MOUSE) Glutathione S-transferase Mu 5 (RC 2.5.1.18) (GST class-mu 5) (Fj 
11.09NPC3 Mass: 31524 Scores 27 Expect: 1.4e+02 Queries zu 
(Hilo-HUMAN) Human enhancer of invasion 10 (EC 6.3.2. -) (E3 ubiquitin protein 
12. Q9QZH2 Mass: 84495 Score: 26 Expect: 1.6e+02 Queries zu 
(BARI-RAT) BRCAI -associated RING domain protein I (BARD-1) BRCA1 -associated RI 
13. Q9ULKO Masse 112060 Score: 25 Expect: 2.2e+02 Queries ru 
(GRDI_HUMAN ) Glutamate receptor delta-1 subunit precursor (GluR delta-1) Glutz 
14. P51648-00-07-00 Mass: 54868 Score: 24 Expect: 2.6e+02 Queries mg 
(DHA4_HUMAN ) Splice isoform 1; Variant SLS-VAR_ 017515; Con flict Displayed; frc 
P51648-01-07-00 Maass 57688 Score: 23 Expect, 3.5e+02 Queries zu 
(DRA4_HUMAN ) Splice isoform 2; Variant SLS-VAR_ 017515; Conflict Displayed; frc 
15. P10765 Mass: 22658 Scores 24 Expect: 2.7e+02 Queries inz 
(PRL_LOXAF) Prolactin (PRL) Prolactin (PRL) 
16. P98156 Mass: 96310 Score: 23 Expects 3e+02 Queries matc 
(LDVR_MOUSE) Very low-density lipoprotein receptor precursor (VLDL receptor) 1 
17. Q15599-01-00-00 Masai 36130 Score: 23 Expect: 3.5e+02 Queries vu 
(NHR2_HUMAN) Splice isoform 2; Variant Displayed; Conflict Displayed; from QIE 
is. P51648-00-15-00 Mass: 54764 Score% 22 Expecti 3.9e+02 Queries me 
(DHA4_HUMAN) Splice isoform, 1; Variant SLS-VAR_01 7520; Conflict Displayed; frc 
P51648,01-15-00 Mass: 57584 Score: 21 Expect: 5.1e+02 Queries me 
(DHA4_HUMAN) Splice isoform 2; Variant SLS-VAR_017520; Conflict Displayed; frc 
19. P23097 Masai 53341 Score: 22 Expect: 4e+02 Queries matc 
(MM13_RAT) Collagenase 3 precursor (EC 3.4.24. -) (Matrix metal loproteinase - 13) 
20. QBHZM6 Mass: 38582 Scores 22 Expects 4. le+02 Queries 
(ANXI-HORSE) Annexin Al (Annexin I) (LipoCortin I) (Calpactin II) Annexin Al 
Search Parameters 
Type of search t Peptide Mass Fingerprint 
Enzyme : Trypsin 
mass values : Monoisotopic 
Protein Mass : Unrestricted 
Peptide Mass Tolerance Sj0.1 
Peptide Charge State : I+ 
Max Missed Cleavages :I 
Number of queries : 20 
Mascot: htW: matrixscience. com/ 
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The protein view is obtained through the accession string in the tabular view of best matching proteins. At 
the head of this report infori-nation about the specific protein, the enzyme used for digestion and any 
modifications used in the search are provided. A formatted sequence of the protein in I letter code 
subsequently follows with the matched peptides highlighted in bold red (underlined with red in this 
example). The sequence block is followed by a detailed table of the peptide matches and unmatched 
peptides are also specified. A scatter graph is also presented displaying the mass differences between the 
calculated and experimental mass values for the matched protein. 
fMATRIX' v 
(sciETME) Mascot Search Results 
Protein View 
Match to: P00006 Score: 87 Expect: 0.00014 
(CYC-BOVIN) Cytochrome c Cytochrome c 
Nominal mass (Mr): 11565; Calculated pI value; 9.52 
NCBI BLAST search of P00006 against nr 
Unformatted seq! ý_qjLqe__§triRg for pasting into other applications 
Taxonomy: Bos taurus 
Links to retrieve other entries containing this sequence from NCBI Entrez: 
POOOOG from Sus scrofa 
P00006 from Ovis aries 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is 
Number of mass values searched: 20 
Number of mass values matched: 11 
Sequence Coverage: 46% 
Matched peptides shown in Bold Red 
I GDVEKGKKIF VQKCAQCHTV EKGGKHKTGP NIHGLFGRKT GQAPGFSYTD 
51 ANKNKGITWG EETLMEYLEN PKKYIPGTKM IFAGIKKKGE REDLIAYLKK 
101 ATNE 
Shwvpý, e 
(-'ý Residue Number () Increasing Mass C Decreasing Mass 
Start - End observed Mr(expt) Mr(calc) Delta Miss Sequence 
26 - 38 1434.63 1433.63 1432.77 0.86 1 HKTGPNLHGLFGR 
28 - 38 1169.47 1168.46 1167.61 0.85 0 TGPNLHGLFGR 
28 - 39 1297.60 1296.60 1295.71 0.89 1 TGPNLHGLFGRK 
39 - 53 1585.67 1584.66 1583.76 0.90 1 KTGQAPGFSYTDANK 
40 - 53 1457.58 1456.57 1455.66 0.91 0 TGQAPGFSYTDANK 
40 - 55 1698.64 1697.63 1697-80 -0.17 1 TGQAPGFSYTDANKNY, 
40 - 55 1699.73 1698.72 1697.80 0.92 1 TGQAPGFSYTDANKNK 
56 72 2010.94 2009.93 2008.95 0.98 0 GITWGEETLMEYLENPK 
56 72 2011.92 2010.92 2008.95 1.97 0 GITWGRETLMIKYLENPK 
56 73 2139-04 2138.03 2137.04 0.99 1 GITWGRETLMEYLENPKK 
56 73 2140.01 2139.00 2137.04 1.96 1 GITWGRETLMEYLENPrK 
No match to: 823.87,824.88,1435.67,1458.60,1562.77,1563.80,1691.88,1827.84, 
0.1 
ýtl 
L L 
L- 0.05 -------------------- 0 ------------------------- 
ui 
-4 ----------------------------------------------- 
VýO 1500 1750 2000 
RMS' error 648 ppm Mass (Da) 
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Appendix F: The database of contaminants used to edit the PMFs prior to database searching 
Cleavages were performed using trypsin and up to I missed cleavage was considered. The modifications 
considered were carbamidomethylation (CAM), proprionamide (PAM) and oxidation of methionine 
residues (MSO). The table includes only those peptides within the m/z range of 900-2500 (see sections 5.2.3.3 and 5.2.3.5). 
CONTAMINANT F ON i ý M/Z VALUE MODIFICATION MODIFIED M/Z VALUE 
Por 
rcine 
Trypsin 
po 2457.2000 CAM PAM 2571.2429 2599.2742 
2283.1801 mso 2299.1750 
2211.1040 
2158.0307 CAM 
PAM 
mso 
2215.0522 
2229.0678 
2174.0256 
1869.0552 
1768.7992 CAM 
PAM 
1882.8422 
1910.8735 
1736.8424 CAM 
PAM 
1793-8639 
1807.8796 
1469.7304 CAM 
PAM 
1526.7519 
1540.7676 
1045.5636 
1006.4873 CAM 
PAM 
1063.5088 
1077.5245 
906.5043 
Keratin 1 2400.2115 mso 2416.2064 
2383.9518 
2349.2183 
2329.1742 
2292.2081 
2286.1248 
2236.9536 CAM 
PAM 
2293.9751 
2307.9907 
2150.0777 
2121.0108 
2079.9146 
2021.9886 
1993.9766 
1985.8943 mso 2017.8841 
1941.9876 
1881.9705 
1844.9461 
1830.9093 
1813.8939 
1751.8266 
1730.9548 
1716.8511 
1708.7132 CAM 
PAM 
1765.7346 
1779.7503 
1687.9701 
1657.7928 
1653.8152 mso 1669.8101 
1638.8598 
1599.8336 
1542.6675 mso 1574-6574 
1523.7886 mso 1539.7835 
1482.7143 
1475.7852 
1475.7489 
1469.8434 
1421.7383 
1393.7321 
1383.6903 
1357.6957 
1340.6692 
1302.7151 
1302.7012 
1300.5296 mso 1332.5195 
1280.6481 
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1277.6332 
1265.6372 
1217.6161 
1179.6004 
1175.6015 
1159.6542 
1152.5531 
1141.5194 mso 1157.5143 
1127.5401 mso 1143.5350 
1125.5422 
1092.5028 
1087.5279 
1073.5949 
1066.5163 
1065.5211 
1033.5160 
1006.4296 
999.4966 
999.4451 mso 1015.4401 
998.4836 mso 1014.4785 
985.5789 
973.5313 
945.4999 
932.5047 
ý 
910.4152 
Keratin 17 24M 1640 
2367,2626 
2285,9628 CAM 
PAM 
2342.9843 
2356.9999 
2283.0921 CAM 
PAM 
2340.1136 
2354.1292 
2212.0979 
2210.0472 
2176.0992 
2013.9070 CAM 
PAM 
2070.9284 
2084.9441 
1996.9709 
1953.1127 
1880.9534 mso 1896.9484 
1797.0116 
1707.7721 
1640.7735 
1636.8176 
1622.8271 
1543.6996 
1520.7452 
1495.6983 
1450.7244 
1434.7699 
1392.6502 
1390.6808 
1381.6481 
1357.7182 
1350.6284 
1324.6168 
1262.5971 
1261.5668 
1237.5847 
1234.6790 
1201.6171 
1185.5229 
1165.5848 
1158.6041 
1131.5463 mso 1147.5412 
1109.4898 
1090.5310 mso 1106.5259 
1079.5116 
1071.5251 mso 1087.5200 
1064.6098 
1048.5785 
1003.5531 
993.5000 
9/0.4, Z. J 1 
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966.4567 
948.4493 
935.4251 mso 951.4200 
Keratin 9 2377.1881 
2357.2306 
2329.1816 mso 2345.1765 
2325.1577 CAM 
PAM 
mso 
2382.1792 
2396.1948 
2341.1526 
2299.1196 mso 2331.1094 
2271.1291 
2205.0716 mso 2221.0666 
2171.0246 mso 2203.0144 
2146.0159 
2091.8822 
2038.0161 CAM 
PAM 
2095-0376 
2109.0532 
1966.0603 
1938-9589 mso 1954.9538 
1855.9218 mso 1871-9167 
1851.9269 mso 1867.9218 
1837.9654 
1791.7276 
1650.7289 CAM 
PAM 
1707.7503 
1721.7660 
1619.7156 
1605.7431 
1586.7656 
1391.7277 
1350.6872 
1315.6852 
1307.6776 mso 1323.6725 
1277.5869 
1235.5287 
1206.6147 mso 1222.6096 
1204.6419 
1190.6085 mso 1206.6034 
1157.5909 
1138.5925 mso 1154.5874 
1121.5837 
1097-5082 
1095.5469 
1091.5133 
1066.4986 mso 1082.4935 
1065.4993 mso 1081.4942 
1060.5633 
967.4519 
P 
962.4901 
Type 1 Hair Keratin 1 T el T el 2463.2838 
2338.2361 
2331.1074 CAM 
PAM 
2388.1288 
2402.1445 
2307.1826 
2298.1506 CAM 
PAM 
2355.1721 
2369.1877 
2247.1788 CAM 
PAM 
2304.2002 
2318.2159 
2234.1775 
2155.0812 CAM 
PAM 
2212.1026 
2226.1183 
2105.0621 
2047,0627 CAM 
PAM 
2104.0842 
2118.0998 
2045.9637 CAM 
PAM 
2102.9851 
2117.0008 
2037.9876 
2022.0250 
2005.0937 
1998.9410 CAM 
PAM 
2055.9624 
2069.9781 
1957.9688 mso 1973.9637 
1881.8865 
1848.9926 
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1787.9650 
1731.9136 
1712.8925 
1625.8493 
1556.8391 
1546.8509 CAM 
PAM 
1603.8723 
1617-8880 
1530.6902 CAM 
PAM 
mso 
1644.7331 
1672.7644 
1546.6851 
1504.7754 
1471.7499 
1465.7394 
1464.6812 
1399.7652 
1367.6736 CAM 
PAM 
1424.6950 
1438.7107 
1326.6396 
1309.6382 
1243.6641 
1238.6739 
1218.6212 
1203.6765 CAM 
PAM 
1260-6980 
1274.7137 
1186.6062 
1153.5306 mso 1169.5255 
1140.5354 CAM 
PAM 
1197.5568 
1211.5725 
1134.5935 CAM 
PAM 
1191.6150 
1205.6307 
1078.6255 
1047.5754 CAM 
PAM 
1104.5969 
1118.6125 
1036.5421 
1009.5313 
999.5833 
988.5309 
982.4233 CAM 
PAM 
1096.4662 
1124.4976 
Background Peaks 1107.8 
1133.5 
1153.7 
1223.4 
1320.1 
1494.5 
1537.4 
1639.7 
1794.9 
1839.1 
1853.9 
1994.7 
2225.3 
Appendix G: The potential relevance of those additional targets, which may be involved in 
cisplatin-resistance but require confirmation (see chapter VI). 
Beta Tubulin Type 3 
Microtubules play an important role in mitosis by forming the mitotic spindle that allows chromosomes to 
separate during cell division. The main components of these structures are tubulin heterodimers. The 
heterodimers consist of 1 molecule of alpha tubulin and I molecule of beta tubulin. Microtubules are very 
dynamic and the ability to rapidly assemble and disassemble is critical to their function. The beta tubulin 
family is composed of 6 isotypes, all of which have related amino acid sequences. In the present study, 
the down-regulation of beta tubulin type 3 was associated with resistance to cisplatin. Reduced expression 
levels of beta tubulin isotypes have previously been implicated with resistance to chemotherapy (Iwamoto 
et al. 1998; Shalli et al. 2005; Wehbe et al. 2005). In 2005, Wehbe and colleagues analysed resistance to 
specific anti-tubulin agents in Non Small Cell Lung Cancer 
(NSCLC). H460 cells resistant to 
combretastatin A4 (CA4) and vinblastine demonstrated a reduction of 
beta tubulin type 3 expression. A 
reduction in beta tubulin type 3 has also been observed in E7010-resistant tumour cells 
(Iwamoto et al. 
1998). E70 10 is a sulphonamide anti-mitotic agent, which binds to this beta tubulin isotype. To the best of 
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our knowledge, this is the first study which implicates the down-regulation of beta tubuhn type 3 with 
resistance to cisplatin. Cisplatin is a cross-linking agent, which primarily acts by targeting the DNA. 
However, in a study conducted by Tulub and Stefanov (2001) cisplatin was able to bind beta tubulin with 
a similar affmity as that reported for cisplatin-DNA interactions. Thus, it is plausible that the down- 
regulation of one of the drug targets may increase resistance to cisplatin. 
Electron Transfer Flavoprotein Beta 
Electron transfer flavoprotein beta polypeptide isoform I (ETFB) is localised to the initochondrial 
membrane and shuttles electrons from several dehydrogenases to the main respiratory chain via 
ubiquinone oxidoreductase. In the present study, the over-expression of ETFB was associated with 
resistance to cisplatin. The over-expression of ETF has also been associated with resistance to 
doxorubicin in MCF7 breast cancer cells (Liu et al. 2006). This indicates that this protein may have a 
finiher function in addition to its role in ATP production. In support of this hypothesis, apoptosis- 
inducing factor (AIF) and cytochrorne C are not only involved in apoptosis but also function as 
flavoproteins in the respiratory chain within the mitochondria (Susin et al. 1999; Wang et al. 2002). 
Although further studies are required to elucidate other possible functions, the fact that some components 
of the respiratory chain are also involved with apoptosis indicates an association between the 2 biological 
processes. 
Heterogeneous Nuclear Ribonucleoprotein A3 
Heterogeneous nuclear ribonucleoproteins (HnRNPs) are abundant nuclear proteins, which bind RNA. In 
this study the over-expression of HnRNP A3 was implicated with resistance to cisplatin. In 2005, Urbani 
et al. found that the over-expression of HnRNP K was associated with resistance to etoposide in 
neuroblastoma. cell lines. Evidence suggests that this family of proteins may play an anti-apoptotic role in 
mammalian cells. Holcik et al. (2003) demonstrated that HnRNPC I and -C2 were able to modulate the 
expression of XIAP. XIAP is a potent inhibitor of specific caspases. Holcik et al. found that the 
translation of XIAP was controlled by an internal ribosome entry site (IRES) element located in the 5' 
untranslated region of XIAP mRNA. HnRNPC1 and -C2 formed part of a complex at the XIAP IRES, 
which allowed the translation of this anti-apoptotic protein to proceed. Furthermore, the over-expression 
of HnRNPC1 and -C2 led to enhanced translation of XIAP. Thus, it is conceivable to speculate that the 
over-expression of specific HnRNPs could attenuate apoptosis in response to cisplatin through the 
enhanced translation of survival transcripts, such as XIAP. It has also been postulated that HnRNPs are 
able to prevent apoptosis through a telomeric capping function. Telomere length becomes progressively 
shorter at each round of DNA synthesis. Eventually cell cycle arrest and apoptosis result. Telomeric 
capping is a mechanism, which maintains telomere length and allows cells to continue growing. Patry et 
al. (2003) showed that inhibition of HnRNPA1 and -A2 was sufficient to induce apoptosis in human 
cancer cells by interfering with this capping function. 
Hydroxyprostaglandin Dehydrogenase 
Hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) catalyses the oxidation of the 15(S)-hydroxyl 
groups of prostaglandins (PGs). This results in the production of 15-keto-prostaglandins, which have 
greatly reduced biological activity. Thus, HPGD is considered a key metabolic enzyme in the inactivation 
of PGs. Conflicting evidence exists as to the role played by HPGD in tumorigenesis. The down-regulation 
of HPGD has been demonstrated in the progression of both lung and colorectal turnours (Backlund et al. 
2005; Ding et al. 2005). This was attributed to the resulting increase in the levels of PGs, which can 
stimulate turnour progression by modulating several pro-neoplastic pathways including proliferation, 
angiogenesis, cell migration, invasion and apoptosis. In particular, PGE2 has been shown prevent 
apoptosis by the stimulating the expression of Bcl-2; an anti-apoptotic protein (Sheng et al. 1998). In 
contrast, the present study suggests that over-expression of HPGD may be associated with resistance to 
cisplatin in this in-vitro cell culture model. Clay et al. (1999) demonstrated that J series prostaglandins 
triggered apoptosis through the activation of peroxisome proliferator-activated receptor 
(PPAR)-y in both 
MCF7 and MDA-MB-231 breast cancer cell lines. The group concluded that the prostanoids may 
represent an important group of molecules that have the capacity to induce apoptosis 
in certain neoplastic 
cells. Taken together with results from the present study these 
data suggest that the over-expression of 
HPGD may result in the increased catabolism of PGs, which are subsequently unable to 
induce apoptosis. 
This may manifest as resistance to chemotherapy in breast cancer cells. 
isocitrate Dehydrogenase 3 
Mitochondria are the powerhouses of a cell and are involved in the production of 
ATP. Apoptosis is an 
energy-dependent process. In 2005, Shin et al. implicated the 
down-regulation of ATP synthase subunits 
with resistance to 5-fluorouracil resistance in 
human colon cancer cells. The authors postulated that a 
defect in ATP synthase may result in chemotherapy resistance because the oxidative phosphorylation 
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capability of the cell is diminished and thus, the apoptotic potential is hampered. Isocitrate dehydrogenase 
3 is an enzyme, which functions in the tricarboxylic acid (TCA) cycle. In the present study a down- 
regulation of this enzyme was associated with resistance to cisplatin, therefore it is possible that a 
reduction in ATP production may have caused this resistant phenotype. The activity of this enzyme was 
also found to be lower in breast cancer patients failing to respond to various chemotherapy regimens (Hilf 
et al. 1976). 
Matrix Metalloproteinase 9 
Matrix metalloproteinases (MMPs) constitute a family of zinc endopeptidases, which are involved in the degradation of the extracellular matrix along with many other biological processes. In the present study, 
the up-regulation of MMP9 was associated with cisplatin-resistance. This result requires ftirther 
confirmation due to the relatively low sequence coverage and a pl value that differed somewhat from the 
predicted value. Initial western blots have proved in-conclusive due to non-specific binding by the 
antibody exploited. Further attempts using alternative antibodies must therefore be performed for 
confirmation of differential expression. However, the expression of MMP9 has Previously been implicated in resistance to protein kinase c-potentiated p53-mediated apoptosis in colon cancer cells (Meyer et al. 2005). A potential mechanism to explain this effect is the MUT9-dependent release and 
activation of transforming growth factor (TGF)-p and cleavage of various other chemokines including 
interleukin (IL)-8. TGF-P and IL8 can promote the survival of transformed cells (Stamenkovic, 2003). 
Peptidyl-Prolyl Isornerases 
The peptidyl-prolyl isomerase (PPIase) family of enzymes catalyse the cis-trans isomerisation of the 
peptide bond N-terminal to proline. These proteins help fold newly synthesised proteins and also help the 
repair of damaged proteins in response to environmental stresses. Furthermore, these enzymes are also 
involved in the prolyl isomerisation of phosphorylated serine/ threonine residues preceding a proline. This 
is a post-phosphorylation regulatory mechanism that induces conformational changes to control proteln 
function following phosphorylation and is a key signalling mechanism in breast cancer (Wulf et al. 2003). 
Evidence suggests that these enzymes play a role in many biological processes including maintenance of 
mitochondrial function and apoptosis (Yao et al. 2005). However, whether these enzymes exhibit anti- or 
pro-apoptotic properties remains to be determined. Interestingly, in the present study PPIA was down- 
regulated in the MCF7CR cell line whilst PPIB was up-regulated. It has been suggested that PPIA is 
involved with apoptosis, however the molecular mechanisms remain unclear. The inhibition of PPIA 
expression by antisense RNA or inhibition of function by cyclosporin A significantly inhibited 
excitotoxin-induced activation of caspases in rat neuronal B50 cells (Capano et al. 2002). This suggested 
that this protein was necessary for induction of apoptosis and is in accordance with the present results 
since the down-regulation of this protein was observed in the MCF7CR cell line. PPIA has also been 
shown to bind and change the conformation of phosphorylated p53 (Zheng et al. 2002). This stabilises 
and activates p53, which is a protein involved in initiating DNA repair or inducing apoptosis in response 
to damage. Furthermore, both PPIA and PPIB have been shown to possess nuclease activity similar to the 
activity of apoptotic endonucleases, independent of their PPIase function. This suggests involvement in 
apoptotic genome degradation (Montague et al. 1994). In contrast however, our results suggest that PPIB 
may have exerted a protective effect in the MCF7CR cell line; the over-expression of which prevented 
these cells from the induction of apoptosis. Other members of this family have also been shown to exert a 
protective effect. The over-expression of PPID was shown to desensitise HEK293 and rat glioma C6 cells 
to apoptotic stimuli (Tanveer et al. 1996). This was attributed to conformational changes associated with 
the formation of the mitochondrial permeability transition pores (MPTPs), which are required for 
apoptosis. Thus, it is possible that PPIB may function in a similar manner. Over-expression may therefore 
manifest as resistance to apoptosis. 
Tropomyosin 1-alpha 
Tropornyosins are a family of actin-binding proteins that are known to function in the regulation of 
muscle contraction. However, in nonmuscle cells it is thought that the tropornyosins regulate actin 
polyrnerisation and stabilise microfilaments in the cytoskeleton. The down-regulation of tropornyosins in 
malignantly transformed cells has widely been reported and this is thought to contribute to a 
disorganised 
cytoskeleton; a prominent feature in many neoplastic cells. In the present study, a 
down-regulation of 
tropomyosin I-alpha was associated with cisplatin-resistance. In accordance, Fu and Fenselau (2005) 
observed the decreased expression of this same isoform. in 3 drug resistant breast cancer cell 
lines selected 
by exposure to etoposide, mitoxantrone or adriamycin in the presence of verapamil. However, the 
mechanism by which this down-regulation may confer resistance to chemotherapy remains unclear. 
Tropomyosin 1 (TM1) is a turnour suppressor gene, the down-regulation of which has been associated 
with a metastatic phenotype. This is because this protein sensitizes cells to anoikis; a 
form of apoptosis 
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induced when cells become detached from their local microenvironment. The down-regulation of TMI 
results in resistance to anoikis, which confers a survival advantage for detached cells. This allows cells to 
migrate to more distant sites and form metastastic turnours. Several molecules and signalling pathways have been implicated in the regulation of anoikis (Aplin et al. 1998). One example is the NF-KB pathway; 
an anti-apoptotic signalling pathway, which has previously been associated with resistance to 
chemotherapy-induced apoptosis. Thus, it is possible that the down-regulation of TMI may also play a 
role in resistance to chemotherapy-induced apoptosis, thereby resulting in treatment failure. 
Appendix H: The potential relevance of those additional targets, which may be involved in radio- 
resistance but require confirmation (see chapter VII). 
Actinin Alpha 4 
Actinin-alpha 4 (ACTN4) also belongs to the subclass of actin-bundling proteins. In the present study an 
up-regulation of this protein was associated with radio-resistance. The increased expression of actinin- 
alpha has previously been associated with multi-drug resistance (MDR) in a human rhabdomyosarcoma 
cell line (Prados et al. 1998). This indicates that over-expression may attenuate an apoptotic response to 
external stimuli. In contrast, the ACTN4 isoform has been shown to be involved in the induction of 
apoptosis (Liu et al 2004; Li et al. 2005). Therefore, confirmation of the result from our study is of high importance. If confirmation is achieved subsequent functional studies may be conducted in order to 
elucidate how an over-expression of this protein may contribute to a RT resistant phenotype. 
Chromosome 17 Open Reading Frame 25 
The results from the present study also suggest that the down-regulation of chromosome 17 open reading 
frame 25 (C170RF25) may be associated with radio-resistance. Bioinformatic analysis has revealed that 
this protein may belong to the glyoxalase family of proteins (Guo et al. 2002). This family consists of 2 
enzymes; glyoxalase I (GLOI) and glyoxalase II (GLOII) and, using glutathione (GSH) as a co-factor, is 
involved in the detoxification of methylglyoxal (MG) and other a-oxoaldehydes. MG is a toxic by- 
product of the glycolytic pathway and can modify macromolecules causing cellular damage. GLOI 
catalyses the formation of S-D-lactoylglutathione from MG and GSH and GLOII subsequently 
metabolises this product to D-lactic acid regenerating GSH. The aberrant expression of GLO enzymes has 
previously been associated with human cancers (Ranganathan and Tew, 1993; Di Ilio et al. 1995; 
Ranganathan et al. 1995; Davidson et al. 1999). Furthermore, the over-expression of these enzymes has 
previously been implicated with resistance to various chemotherapeutic agents (Ranganathan et al. 1995; 
Sakamoto et al. 2000) indicating a possible link between the expression of these enzymes and apoptosis. 
Sakamoto et al. (2000) showed that GLOI was over-expressed in human leukaemia cells resistant to 
doxorubicin-induced apoptosis. This group found that the activation of caspase-3 in GLOI over- 
expressing cells was suppressed and therefore hypothesised that this enzyme was able to block a 
signalling pathway leading to doxorubicin-induced cell death. The confirmation of a down-regulation of 
this target in MCF740Gy cells is therefore crucial. 
Eukaryotic Translation Initiation Factor 3 
Translational control plays an important role in the regulation of gene expression in eukaryotes. Initiation 
of translation begins with dissociation of the 80S ribosome into 40S and 60S subunits. The 40S subunit 
binds a ternary complex comprising eukaryotic translation initiation factor (eIF) 2, GTP and methionyl- 
tRNAi (met-tRNAi). This pre-initiation complex recognises and binds mRNA forming a stable complex 
at the first AUG initiation codon (Block et al. 1998). Subsequently, the 60S subunit joins to form the 80S 
initiation complex. A large eIF3 complex plays a central role in this process, which is composed of at 
least 12 subunits. This complex binds to the 40S ribosomal subunit promoting dissociation of the 80S 
ribosome. It also acts to stabilise the binding of met-tRNAi to the 40S subunit and contributes to mRNA 
binding (Trachsel et al. 1977; Benne and Hershey, 1978). It may also be involved in recognition of the 
initiation codon (Yoon and Donahue, 1992) and the GTPase activity of eIF2 activated by eIF5 (Das et al. 
1997). Results from the present study suggest that a down-regulation of eIF3 subunit 2 beta may be 
associated with radio-resistance. Because translation is a target of signal transduction pathways it is 
possible that inefficient translation would prevent cells from responding to RT in an appropriate manner. 
Subunits of the eIF3 complex are also able to function independently of translational machinery. Several 
subunits of the eIF3 complex have been shown to interact with cytoskeletal proteins 
(Hou et al. 2000; Lin 
et al. 2001). Subunit 3 of the eIF3 complex also has weak sequence 
homology to Mov-34; a subunit of 
26S proteasome (Asano et al. 1997). Further links between eIF3 subunits and the proteasome 
have also 
been established. Mayeur and Hershey (2002) demonstrated that independent of the eIF3 complex, 
subunit 6 can interact directly with a complex called COP9. CON 
is a signalosome that regulates protein 
stability via the ubiquitin/ proteasome pathway and may also 
be involved in the c-jun signalling pathway 
(Seeger et al. 2001). Therefore, the down-regulation of eIF3 subunits may interfere with these functions 
299 
Appendices 
leading to the development of radio-resistance. Links between eIF3, cytoskeletal proteins and 
proteasomal degradation suggests a multitude of mechanisms may contribute to radio-resistance including 
protein stability and cell signalling. 
Growth Inhibiting Gene 5 Protein 
Growth-inhibiting gene 5 (GIG5) protein (also known as siah-interacting protein) is a key component of a 
calcium-dependent multiprotein E3 ubiquitin ligase complex that targets specific proteins, such as beta 
catenin, for proteasomal degradation. This complex also comprises Siah-1, SKP IA and the F-box protein Ebi (Matsuzawa and Reed, 2001). In the present study, a down-regulation of GIG5 was associated with 
radio-resistance. This may have been the result of a decrease in beta catenin degradation because this 
protein is involved in the Wnt signalling pathway. In the absence of a Wnt signal, beta catenin is 
effectively degraded by a process involving the GIG5-containing E3 ubiquitin ligase complex. In the 
presence of a Writ signal, beta catenin is stabilised and translocates to the nucleus. Within the nucleus this 
protein binds to members of the T-cell factor (Tcf)/ Lymphoid enhancing factor (Lef) family of DNA binding proteins leading to the transcription of Wnt target genes. A number of Wnt target genes have 
been defined including c-myc, c-jun, survivin and members of the matrix metalloproteinase (MMP) 
family. The over-expression of several of these genes has previously been associated with resistance to 
RT (Riva et al. 1995; Vallat et al. 2003; Rodel et al. 2005). The down-regulation of GIG5 must first be 
confirmed by an alternative technique. However, should confirmation be achieved it would be interesting 
to test whether the down-regulation of GIG5 could lead to the stabilisation of beta catenin causing the 
inappropriate transcription of Writ target genes thereby contributing to radio-resistance. 
Leucin-Rich Pentatricopeptide Repeat Motif-Containing Protein 
Leucine-rich pentatricopeptide repeat motif-containing protein (LRPPRC but previously called LRP130) 
is an mRNA-binding protein involved in the regulation of both mitochondrial and nuclear gene 
expression (Mili and Pinol-Roma, 2003). Results from the present study indicate that an up-regulation of 
LRPPRC may be associated with radio-resistance. In the nucleus, this protein binds to some of the same 
RNA molecules as the heterogeneous nuclear ribonucleoprotein (HnRNP) Al (Mili and Pinol-Roma, 
2003). The over-expression of some members of the HnRNP family has previously been implicated with 
resistance to anticancer therapy (see chapter VI; Urbani et al. 2005; Holcik et al. 2003). The over- 
expression of these proteins has been implicated in the enhanced translation of survival transcripts (see 
appendix G). Moreover, the LRPPRC protein is required for the accurate transcriptional activity of the 
multidrug-resistance genes; MDRI and LRP (Labialle et al. 2004). Thus, following confirmation of the 
result using an alternative technique, further studies will be required to determine whether an up- 
regulation of this protein can enhance the transcription and/ or translation of survival genes leading to 
reduced apoptosis and contributing to radio-resistance. 
Lysyl-tRNA Synthetase 
Aminoacyl-tRNA synthetases (aaRSs) play an important role in translation during protein biosynthesis. 
Each of the 20 different enzymes catalyses the aminoacylation of the 20 specific tRNAs, thus providing 
the building blocks for protein biosynthesis. Our study has demonstrated that an up-regulation of lysyl- 
tRNA synthetase (LysRS) may be associated with radio-resistance. Although the mechanisms remain 
unclear, these proteins have acquired additional purposes throughout evolution. Specific aaRSs are now 
involved in a broad repertoire of cellular functions including tRNA processing, RNA splicing, RNA 
trafficking and transcriptional and translational regulation (Martinis et al. 1999). In particular, LysRS has 
been shown to play a role in the regulation of gene expression by activating transcription factors in 
response to intracellular signalling pathways (Lee et al. 2004; Lee and Razin, 2005). LysRS forms part of 
a multiprotein complex with Upstream Stimulatory Factor 2 (US172) and Hint; a protein acting to suppress 
the transcriptional activity of USF2. In response to external stimuli, LysRS synthesises AP4A, which 
binds to Hint leading to the dissociation of Hint from USF2 and allowing the transactivation of US172- 
responsive genes (Lee and Razin, 2005). US172 plays a significant role in a variety of cellular functions 
and the target genes have been associated with the onset of physiological processes such as 
carcinogenesis. Further studies will therefore be required in order to determine whether an up-regulation 
of LysRS can increase the activity of transcription factors (such as USF2) and lead to an 
inappropriate 
transcription of the genes involved with the development of radio-resistance. 
N-Acetyltransferase 
Protein acetylation is an important post-translational modification, which is catalysed by a family of 
proteins called acetyltransferases. The results from the present study suggest that a 
down-regulation of N- 
acetyltransferase (the human hornolog of the S. cerevisiae arrest 
defective-1 protein (ARDI)) may be 
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associated with radio-resistance. Human ARD 1 (hARD 1) expresses N-terminal a-acetylation activity in a 
complex with human N-acetyltransferase I (NATH). Protein N-acetylation is a co-translational process 
and studies have shown that the hARDl-NATH complex associates with the ribosome and facilitates 
acetylation by interacting with ribosomal proteins including PI and P2 (Amesen et al. 2005). These 
ribosomal proteins interact directly with ribosomal protein PO, which may also be down-regulated in MCF740Gy cells. The down-regulation of these proteins may therefore result in the insufficient 
acetylation of target proteins thereby altering their function. In support of this hypothesis, several 
transcription factors including EM, MyoD, GATA-1 and p53 are modified by acetylation (Boyes et al. 1998; Kouzarides, 2000). This regulates their DNA binding activity and interactions with other proteins including co-activator proteins and transcriptional regulator proteins (Bannister and Miska, 2000; Barlev 
et al. 2001). Furthermore, although conflicting evidence exists hARDI may act independently of the hARDl-NATH complex. Jeong and colleagues (2002) demonstrated that mARD I (the mouse homolog of S. cerevisiae ARDI) mediated the r:, -acetylation of the hypoxia-inducible factor (HIF) I-a transcription factor, which subsequently enhanced its ubiquitination and degradation. This resulted in the decreased 
expression of HIF-la target genes, which are involved in the regulation of angiogenesis, apoptosis, cell 
proliferation and glucose metabolism (Semenza, 2003). 
Pyrophosphatase 1 
Inorganic pyrophosphate represents a by-product of many important anabolic pathways such as those 
producing RNA, DNA and oligosaccharides macromolecules. The hydrolysis of inorganic pyrophosphate 
to orthophosphate is catalysed by the enzyme pyrophosphatase (PPase). It has been proposed that PPases 
may also be required for ensuring DNA fidelity following DNA replication (Herbomel and Ninio, 1980). 
The PPase enzyme functions as a homodimer of 30-36-kDa and requires Mg" for full activation. The 
results from our study suggest that the down-regulation of PPase I may be associated with resistance to 
RT but this finding requires confirmation. The potential mechanisms remain elusive, however a link 
between this enzyme and cell signalling pathways has previously been established. PPase was shown to 
form a complex with calphoglin and phosphoglucomutase (PGM). Calphoglin enhanced the activity of 
PPase, which subsequently activated PGM (Takahashi et al. 2004). PGM is an enzyme required for the 
anaerobic production of ATP and is involved in both glycolysis and gluconeogenesis. Perhaps more 
significantly however, this complex was also found to mediate the Ca 2+ -dependent calmodulin/ 
calcineurin cell signalling pathway via an interaction with cyclophilin A (Takahashi et al. 2004). The 
calmodulin/ calcineurin pathway is involved in the induction of apoptosis by promoting nuclear 
translocation of the NFAT transcription factor thereby activating transcription of the pro-apoptotic FasL 
gene. Furthermore, this pathway also results in the mitochondrial translocation of BAD, which stimulates 
the release of cytochrome C triggering apoptosis. It may be reasonable to speculate therefore that down- 
regulation of PPase may interfere with signalling pathways reducing apoptosis in response to RT 
treatment, however the verification of this hypothesis requires further studies (including first and 
foremost confirmation of the result). 
STARD 10 
The steroidogenic acute regulatory protein (STAR)-related lipid transfer (START) domain is a protein 
domain, which is found in 15 distinct human proteins (Alpy and Tomasetto, 2005). Recent work has 
implicated these START proteins (also known as START domain-containing (STARD) proteins) in the 
control of several aspects of lipid biology including lipid metabolism, lipid trafficking and lipid-mediated 
cell signalling. Results from the present study have associated the down-regulation of STARDIO with 
resistance to RT. This protein is a member of the STARD2/ Phosphatidy1choline Transfer Protein (PCTP) 
subfamily of STARD proteins and binds phosphatidy1choline (PC) and phosphatidylethanolamine (PE). It 
has been proposed that members of this subfamily may have mitochondrial functions or may play a role 
in phospholipid cell-signalling (de Brouwer et al. 2002; Durand et al. 2004). However, the mechanisms 
by which a down-regulation of STARDIO may contribute to radio-resistance remains elusive. It has been 
postulated that this protein may be involved in energy metabolism (Yamanaka et al. 2000). Apoptosis is 
an ATP-dependent process. The down-regulation of STARD 10 may therefore reduce the availability of 
free energy decreasing the apoptotic potential of a cell. Furthermore, it has also 
been proposed that this 
protein may function as a co-factor for receptor-mediated signalling. 
This is because in co-transfected 
NIH3T3 cell lines STARDIO was able to co-operate with Erb-Bl to promote anchorage independent 
growth (Olayioye et al. 2004). Lipids are used within cells 
by phospholipases to generate secondary 
messengers, such as phosphatidic acid and diacylglycerol (Nishizuka, 
1992). STARDIO may play a role 
in replenishing membranes with the specific lipids required by these phospholipases. 
Should a down- 
regulation of this target be confirmed in MCF740Gy cells, 
functional studies will be required in order to 
determine the functional relevance of this finding. It is possible that a down-regulation of STARDIO may 
result in aberrant cell-signalling in response to external stimuli. 
301 
.0 
-11ý 
.E r 
v 
0 ,= ý, -0 
0 
Q 
ýg 
x C'. 
;a 
0 
-a M 
0 
9-- 
a 
C) 
J-- 
0 
> 
U 
> 
0 U 
s = n 
U 
C 
u 0 
U U U 
.0 . 15 
13 
C, ) tn RI ý 
z - - 
Uý4 
0 D (-. 3 c n V 1 w 0. 0. 
ý4 Ej -. 2 , -1 -E -E - 
0 
- 
ý 3 
, ,1 
-0. -. 
ýI -, o 
U E b . z 8E ý o. 2. . 
- ý 
5 " 
8 - 
C) 0 
= 
D in. Aý U 
r_ 
'= C ) -Ei 
Pý 
I 
*ý` *ý, - o6 - oo - Do - . I u 
TU 
Ic 
0 0 0 13 CD U U U lu U U U U U U U U 
15ý V X 
0, 
ro- 
.ý 
1 
. C: 
S F ý. 
00 -L 
0. 0. <R < 
0 0 m U U 4L 0 W W WI 
E_ 
C, U 0 
0ý 
' 
U 
- M L L I) U U U U U w U U L ) 4 4 , 
00 
00 
Cý 
I' M L; ý 
I U 
0 2 z 
im 
;m 
zm 
10 
W 
90 
.M .m 
, *. 0 
0 c ýz 
u - 1 u I u u 0 u u . 4 u 
F. S 
m C, 4 0 = 
u lu 
CI 
r4 Q 
(J u u <7ý U -< U U W ,ý 
0 u w 
S 
C. ) C, 
u 
.< 
" Z (3 3 - u ý: ý ýz u 
W Q. iz ý ý- 0 
ý2 oij 0 .0 
r 
< Z > g= M " :ý M ý, 0 : L, * la 0 t 0. ý i2 r- c 4 ý ý4 Z 1u ýR go V) c: 1. 
0 
u ta ý: 
It - 'O g g r. . - 10 C 6 
u x .4 
u xQ 
0 
k > 
-0 
A, CIO 
> 00 1- 
u z 04 U ý, 4 ce C-) C < 
4 1 
- - 
C14 
5 
r 
r 
v 
9 
_ 
I , I u t m R =ý C 1 :e 9 , u A. Z CJ 0 JE ý4 u -) C-) C-) xý - 
J? a co 
ajý 
00 
t 
R 
ý , 5 
.0 ý4 < 
. 
- - - - - - - - - - 
a- u a 
vi 00 00 
ý, U ' "a 0 
' 2' `6 >' u ;F u cn CL 04 0. I. 
u S s 0 2 u w 
r 
u 
0 
vi 
a 
u F- u ý u 
ýT. -0: 3 
F. U 0 ý4 -Z U 
i U U . g . - 
43 
u 
' z z 
D '40 
ý 'm v 
u 'n 
8 
3 7 rq r- m 
ý, IT 3 u u 0 ' ý4 u > Z F- ý u . " , cl 9 < w u ý 8 -ý- m:, u < ý I Cl I . . 
0 cq 
m 
0 
0 
u - 0 
< r- 0 
00 U m T r- 't) C'ý 
r 
, 
< 
C4 
0 
a = r_ 
.0 
CA 
0 r- ý ll c c, S + 
'j 
E 
9 D. ý6 
00 00 O'D 
u 4L C ) u u u E 
i 
A 
5i 
I p 
0 
, - u u 0 U u w 
u 
l l 
M 
-2 
5, 
-4 
C) 0 lý Q ) -4 r 
E 
') ý ý2 
7 
(z) ýE ý 
E C) r r 
8 
iz ý-d ý 4 ,I 
Cý 
P 
OL 
C) 
14 
;ý 
u CLý -a Cý u a v , ýý - C: ý 2 c) n F. a 
2 ý ýD ýD u U-1 
F m 
Ln - < 
p 
u 
g 
< U (D A ? o 0 m < 1 I 1 Ic T I I L 
M 
x 
0 
CD 00 
u u DO T 
4. ) r 4j 
(2 Ei 
-Fi < o -c4 c), 9 - u u u & G ;F ýF 0 t: U u U 
0 U C) 0 
ý 
r 
W 
0 
.2 < 
U 
JD 
ca 
00 
r- 
a 
V) 110 
L 
g k- ý 0 
00 r 
9 
= 
0 c - - " -- 0 
0 1 r- 
a 2 
' 
r- ,, _ t:: 
"0 
Ez f i m .9 V) 
2 m 1 5, a E 
< 
P. ý4 u 4 ; 'a u w -n C) d V) u 0. W m u u u 
0 
0 
b V) 4) m 
u 
> 0 , C 0 
. 0 
0 N = V) rz - " 1ý ý E :2 to c 0 L ý2 -; ý k 0 =3 ý . 11 v 
u u u A. U r- gn. u u 
:3 V) 6 u z m z z u iz u x u 
E 
0 
00 
> 'IT 
ca 
F- 
< 
m 
ýý 
0 .. 
> 
< 
m 
< - 
LZ 
< 
u z 
p 
4i u z al u 
4j < t 1 l I 1 I I I 
In 
ýx 0. u 0 > 
E cý < u .' , A I ý2 c) C, Z X u 
u t > 
0 cli gý. 
92 
v 2 
ý3 0 
c , 
gz 
s 
= v 
4) -0 E ý r- , 
u 
.0 ý U -0 ý ý :i = 
S: ' 
lý 
1 
, 
2 
0 2 :1 u 
U ci. u 
0. 92. 2 - ci . (D 
.0 LI 
c9 
0 Z 4 Z '-, 
CD 
- Z < . < 
hd 
4) 
Ei 
< 
0= 
- 2 
ow 
= 0 
2 u t A- 2 lý: ý rZ ý 
zz 
U. ý x t4 - p4 ' 
f2 
1? 
< 
cl L2- 2 
0 
'ti 0 Z 
< im 
0 
:2 
j < 
vi 
r: 
